(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 03/070902 A2

(51) International Patent Classification[7]: C12N

(21) International Application Number: PCT/US03/04902

(22) International Filing Date: 18 February 2003 (18.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/358,279	20 February 2002 (20.02.2002)	US
60/364,338	13 March 2002 (13.03.2002)	US
60/375,657	25 April 2002 (25.04.2002)	US
60/376,669	29 April 2002 (29.04.2002)	US
60/379,837	10 May 2002 (10.05.2002)	US
60/379,853	10 May 2002 (10.05.2002)	US

(71) Applicant *(for all designated States except US)*: **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CHAWLA, Narinder, K.** [US/US]; 33 Union Square, #712, Union City, CA 94587 (US). **YUE, Henry** [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). **RICHARDSON, Thomas, W.** [US/US]; 616 Canyon Road, #107, Redwood City, CA 94062 (US). **MARQUIS, Joseph, P.** [US/US]; 4428 Lazy Lane, San Jose, CA 95135 (US). **LEHR-MASON, Patricia, M.** [US/US]; 360 Clarke Lane, Morgan Hill, CA 95014 (US). **GORVAD, Ann, E.** [US/US]; 369 Marie Common, Livermore, CA 94550 (US). **BECHA, Shanya, D.** [US/US]; 21062 Gary Drive # 117, Castro Valley, CA 94546 (US). **KABLE, Amy, E.** [US/US]; 2345 Polk Street #4, San Francisco, CA 94109 (US). **SWARNAKAR, Anita** [CA/US]; 8 Locksley Avenue # 5D, San Francisco, CA 94122 (US). **JIN, Pei** [US/US]; 320 Curtner Avenue #D, Palo Alto, CA 94306 (US). **HAWKINS, Phillip, R.** [US/US]; 750 North Shorline Boulevard #115, Mountain View, CA 94043 (US). **CHIEN, David** [US/US]; 444 Yerba Buena Avenue, Los Altos, CA 94022 (US). **RAMKUMAR, Jayalaxmi** [IN/US]; 34359 Maybird Circle, Fremont, CA 94555 (US). **TRAN, Uyen, K.** [US/US]; 2638 Mabury Square, San Jose, CA 95133 (US). **HAFALIA, April, J., A.** [US/US]; 2227 Calle de Primavera, Santa Clara, CA 95054 (US). **BAUGHN, Mariah, R.** [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). **LEE, Soo, Yeun** [KR/US]; 40 Westdale Avenue, Daly City, CA 94015 (US). **JIANG, Xin** [US/US]; 14371 Elva Avenue, Saratoga, CA 95070 (US). **JACKSON, Alan, A.** [US/US]; 1541 Elwood Drive, Los Gatos, CA 95032 (US). **KHARE, Reena** [US/US]; 12650 Orella Court, Saratoga, CA 95070 (US). **BULLOCH, Sean, A.** [US/US]; 175 Calvert Drive #B-102, Cupertino, CA 95014 (US).

(74) Agents: **HAMLET-COX, Diana** et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RECEPTORS AND MEMBRANE-ASSOCIATED PROTEINS

(57) Abstract: Various embodiments of the invention provide human receptors and membrane-associated proteins (REMAP) and polynucleotides which identify and encode REMAP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of REMAP.

WO 03/070902 A2

RECEPTORS AND MEMBRANE-ASSOCIATED PROTEINS

TECHNICAL FIELD

The invention relates to novel nucleic acids, receptors and membrane-associated proteins encoded by these nucleic acids, and to the use of these nucleic acids and proteins in the diagnosis, treatment, and prevention of cell proliferative, autoimmune/inflammatory, neurological, metabolic, developmental, and endocrine disorders. The invention also relates to the assessment of the effects of exogenous compounds on the expression of nucleic acids and receptors and membrane-associated proteins.

BACKGROUND OF THE INVENTION

Signal transduction is the general process by which cells respond to extracellular signals. Signal transduction across the plasma membrane begins with the binding of a signal molecule, e.g., a hormone, neurotransmitter, or growth factor, to a cell membrane receptor. The receptor, thus activated, triggers an intracellular biochemical cascade that ends with the activation of an intracellular target molecule, such as a transcription factor. This process of signal transduction regulates all types of cell functions including cell proliferation, differentiation, and gene transcription.

Biological membranes surround organelles, vesicles, and the cell itself. Membranes are highly selective permeability barriers made up of lipid bilayer sheets composed of phosphoglycerides, fatty acids, cholesterol, phospholipids, glycolipids, proteoglycans, and proteins. Membranes contain ion pumps, ion channels, and specific receptors for external stimuli which transmit biochemical signals across the membranes. These membranes also contain second messenger proteins which interact with these pumps, channels, and receptors to amplify and regulate transmission of these signals.

Plasma Membrane Proteins

Plasma membrane proteins (MPs) are divided into two groups based upon methods of protein extraction from the membrane. Extrinsic or peripheral membrane proteins can be released using extremes of ionic strength or pH, urea, or other disruptors of protein interactions. Intrinsic or integral membrane proteins are released only when the lipid bilayer of the membrane is dissolved by detergent.

The majority of known integral membrane proteins are transmembrane proteins (TM) which are characterized by an extracellular, a transmembrane, and an intracellular domain. TM domains are typically comprised of 15 to 25 hydrophobic amino acids which are predicted to adopt an α-helical conformation. TM proteins are classified as bitopic (Types I and II) and polytopic (Types III and IV)

(Singer, S.J. (1990) Annu. Rev. Cell Biol. 6:247-296). Bitopic proteins span the membrane once while polytopic proteins contain multiple membrane-spanning segments. TM proteins carry out a variety of important cellular functions, including acting as cell-surface receptor proteins involved in signal transduction. These functions are represented by growth and differentiation factor receptors, and receptor-interacting proteins such as *Drosophila* pecanex and frizzled proteins, LIV-1 protein, NF2 protein, and GNS1/SUR4 eukaryotic integral membrane proteins. TM proteins also act as transporters of ions or metabolites, such as gap junction channels (connexins), and ion channels, and as cell anchoring proteins, such as lectins, integrins, and fibronectins. TM proteins may be vesicle organelle-forming molecules, such as caveolins, or cell recognition molecules, such as cluster of differentiation (CD) antigens, glycoproteins, and mucins.

Many MPs contain amino acid sequence motifs that serve to localize proteins to specific subcellular sites. Examples of these motifs include PDZ domains, KDEL, RGD, NGR, and GSL sequence motifs, von Willebrand factor A (vWFA) domains, and EGF-like domains. RGD, NGR, and GSL motif-containing peptides have been used as drug delivery agents in targeted cancer treatment of tumor vasculature (Arap, W. et al. (1998) Science, 279:377-380). Furthermore, MPs may also contain amino acid sequence motifs that serve to interact with extracellular or intracellular molecules, such as carbohydrate recognition domains (CRD).

Chemical modification of amino acid residue side chains alters the manner in which MPs interact with other molecules, for example, phospholipid membranes. Examples of such chemical modifications to amino acid residue side chains are covalent bond formation with glycosaminoglycans, oligosaccharides, phospholipids, acetyl and palmitoyl moieties, ADP-ribose, phosphate, and sulphate groups.

RNA encoding membrane proteins may have alternative splice sites which give rise to proteins encoded by the same gene but with different messenger RNA and amino acid sequences. Splice variant membrane proteins may interact with other ligand and protein isoforms.

Receptors

The term receptor describes proteins that specifically recognize other molecules. The category is broad and includes proteins with a variety of functions. The bulk of receptors are cell surface proteins which bind extracellular ligands and produce cellular responses in the areas of growth, differentiation, endocytosis, and immune response. Other receptors facilitate the selective transport of proteins out of the endoplasmic reticulum and localize enzymes to particular locations in the cell. The term may also be applied to proteins which act as receptors for ligands with known or unknown chemical composition and which interact with other cellular components. For example, the steroid hormone receptors bind to and regulate transcription of DNA.

Cell surface receptors are typically integral plasma membrane proteins. These receptors recognize hormones such as catecholamines; peptide hormones; growth and differentiation factors; small peptide factors such as thyrotropin-releasing hormone; galanin, somatostatin, and tachykinins; and circulatory system-borne signaling molecules. Cell surface receptors on immune system cells recognize antigens, antibodies, and major histocompatibility complex (MHC)-bound peptides. Other cell surface receptors bind ligands to be internalized by the cell. This receptor-mediated endocytosis functions in the uptake of low density lipoproteins (LDL), transferrin, glucose- or mannose-terminal glycoproteins, galactose-terminal glycoproteins, immunoglobulins, phosphovitellogenins, fibrin, proteinase-inhibitor complexes, plasminogen activators, and thrombospondin (Lodish, H. et al. (1995) Molecular Cell Biology, Scientific American Books, New York NY, p. 723; Mikhailenko, I. et al. (1997) J. Biol. Chem. 272:6784-6791).

Receptor Protein Kinases

Many growth factor receptors, including receptors for epidermal growth factor, platelet-derived growth factor, fibroblast growth factor, as well as the growth modulator α-thrombin, contain intrinsic protein kinase activities. When growth factor binds to the receptor, it triggers the autophosphorylation of a serine, threonine, or tyrosine residue on the receptor. These phosphorylated sites are recognition sites for the binding of other cytoplasmic signaling proteins. These proteins participate in signaling pathways that eventually link the initial receptor activation at the cell surface to the activation of a specific intracellular target molecule. In the case of tyrosine residue autophosphorylation, signaling proteins can bind these motifs using several common domains, for example Src homology-2 (SH2) domains, phosphotyrosine-binding (PTB) domains, and forkhead-associated (FHA) domains. These domains, alone or in combination, are found in many signaling proteins, such as phospholipase C-γ (PLC-γ), the p85 regulatory subunit of PI-3 kinase, $pp60^{c\text{-}src}$,Ras-GTPase activating protein, Chk2, AF-6, insulin receptor substrate-1 (IRS-1), and Shc (Li, J. et al. (2000) J. Cell Sci. 113:4143-4149; Guy, G.R. et al. (2002) Cell Signal. 14:11-20; Vidal, M. et al. (2001) Crit. Rev. Oncol. Hematol. 40:175-186; Lowenstein, E.J. et al. (1992) Cell 70:431-442). The cytokine family of receptors share a different common binding domain and include transmembrane receptors for growth hormone (GH), interleukins, erythropoietin, and prolactin.

Other receptors and second messenger-binding proteins have intrinsic serine/threonine protein kinase activity. These include activin/TGF-β/BMP-superfamily receptors, calcium- and diacylglycerol-activated/phospholipid-dependant protein kinase (PK-C), and RNA-dependant protein kinase (PK-R). In addition, other serine/threonine protein kinases, including nematode Twitchin, have fibronectin-like, immunoglobulin C2-like domains.

G-protein coupled receptors

The G-protein coupled receptors (GPCRs), encoded by one of the largest families of genes

yet identified, play a central role in the transduction of extracellular signals across the plasma membrane. GPCRs have a proven history of being successful therapeutic targets.

GPCRs are integral membrane proteins characterized by the presence of seven hydrophobic transmembrane domains which together form a bundle of antiparallel alpha (α) helices. GPCRs range in size from under 400 to over 1000 amino acids (Strosberg, A.D. (1991) Eur. J. Biochem. 196:1-10; Coughlin, S.R. (1994) Curr. Opin. Cell Biol. 6:191-197). The amino-terminus of a GPCR is extracellular, is of variable length, and is often glycosylated. The carboxy-terminus is cytoplasmic and generally phosphorylated. Extracellular loops alternate with intracellular loops and link the transmembrane domains. Cysteine disulfide bridges linking the second and third extracellular loops may interact with agonists and antagonists. The most conserved domains of GPCRs are the transmembrane domains and the first two cytoplasmic loops. The transmembrane domains account, in part, for structural and functional features of the receptor. In most cases, the bundle of α helices forms a ligand-binding pocket. The extracellular N-terminal segment, or one or more of the three extracellular loops, may also participate in ligand binding. Ligand binding activates the receptor by inducing a conformational change in intracellular portions of the receptor. In turn, the large, third intracellular loop of the activated receptor interacts with a heterotrimeric guanine nucleotide binding (G) protein complex which mediates further intracellular signaling activities, including the activation of second messengers such as cyclic AMP (cAMP), phospholipase C, and inositol triphosphate, and the interaction of the activated GPCR with ion channel proteins. (See, e.g., Watson, S. and S. Arkinstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 2-6; Bolander, F.F. (1994) Molecular Endocrinology, Academic Press, San Diego CA, pp. 162-176; Baldwin, J.M. (1994) Curr. Opin. Cell Biol. 6:180-190.)

GPCRs include receptors for sensory signal mediators (e.g., light and olfactory stimulatory molecules); adenosine, γ-aminobutyric acid (GABA), hepatocyte growth factor, melanocortins, neuropeptide Y, opioid peptides, opsins, somatostatin, tachykinins, vasoactive intestinal polypeptide family, and vasopressin; biogenic amines (e.g., dopamine, epinephrine and norepinephrine, histamine, glutamate (metabotropic effect), acetylcholine (muscarinic effect), and serotonin); chemokines; lipid mediators of inflammation (e.g., prostaglandins and prostanoids, platelet activating factor, and leukotrienes); and peptide hormones (e.g., bombesin, bradykinin, calcitonin, C5a anaphylatoxin, endothelin, follicle-stimulating hormone (FSH), gonadotropic-releasing hormone (GnRH), neurokinin, and thyrotropin-releasing hormone (TRH), and oxytocin). GPCRs which act as receptors for stimuli that have yet to be identified are known as orphan receptors.

GPCR mutations, which may cause loss of function or constitutive activation, have been associated with numerous human diseases (Coughlin, *supra*). For instance, retinitis pigmentosa may arise from mutations in the rhodopsin gene. Furthermore, somatic activating mutations in the

thyrotropin receptor have been reported to cause hyperfunctioning thyroid adenomas, suggesting that certain GPCRs susceptible to constitutive activation may behave as protooncogenes (Parma, J. et al. (1993) Nature 365:649-651). GPCR receptors for the following ligands also contain mutations associated with human disease: luteinizing hormone (precocious puberty); vasopressin V_2 (X-linked nephrogenic diabetes); glucagon (diabetes and hypertension); calcium (hyperparathyroidism, hypocalcuria, hypercalcemia); parathyroid hormone (short limbed dwarfism); β_3-adrenoceptor (obesity, non-insulin-dependent diabetes mellitus); growth hormone releasing hormone (dwarfism); and adrenocorticotropin (glucocorticoid deficiency) (Wilson, S. et al. (1998) Br. J. Pharmocol. 125:1387-1392; Stadel, J.M. et al. (1997) Trends Pharmacol. Sci. 18:430-437). GPCRs are also involved in depression, schizophrenia, sleeplessness, hypertension, anxiety, stress, renal failure, and several cardiovascular disorders (Horn, F. and G. Vriend (1998) J. Mol. Med. 76:464-468).

In addition, within the past 20 years several hundred new drugs have been recognized that are directed towards activating or inhibiting GPCRs. The therapeutic targets of these drugs span a wide range of diseases and disorders, including cardiovascular, gastrointestinal, and central nervous system disorders as well as cancer, osteoporosis and endometriosis (Wilson et al., *supra*; Stadel et al., *supra*). For example, the dopamine agonist L-dopa is used to treat Parkinson's disease, while a dopamine antagonist is used to treat schizophrenia and the early stages of Huntington's disease. Agonists and antagonists of adrenoceptors have been used for the treatment of asthma, high blood pressure, other cardiovascular disorders, and anxiety; muscarinic agonists are used in the treatment of glaucoma and tachycardia; serotonin 5HT1D antagonists are used against migraine; and histamine H1 antagonists are used against allergic and anaphylactic reactions, hay fever, itching, and motion sickness (Horn et al., *supra*).

Nuclear Receptors

Nuclear receptors bind small molecules such as hormones or second messengers, leading to increased receptor-binding affinity to specific chromosomal DNA elements. In addition the affinity for other nuclear proteins may also be altered. Such binding and protein-protein interactions may regulate and modulate gene expression. Examples of such receptors include the steroid hormone receptors family, the retinoic acid receptors family, and the thyroid hormone receptors family.

Ligand-Gated Receptor Ion Channels

Ligand-gated receptor ion channels fall into two categories. The first category, extracellular ligand-gated receptor ion channels (ELGs), rapidly transduce neurotransmitter-binding events into electrical signals, such as fast synaptic neurotransmission. ELG function is regulated by post-translational modification. The second category, intracellular ligand-gated receptor ion channels (ILGs), are activated by many intracellular second messengers and do not require post-translational modification(s) to effect a channel-opening response.

ELGs depolarize excitable cells to the threshold of action potential generation. In non-excitable cells, ELGs permit a limited calcium ion-influx during the presence of agonist. ELGs include channels directly gated by neurotransmitters such as acetylcholine, L-glutamate, glycine, ATP, serotonin, GABA, and histamine. ELG genes encode proteins having strong structural and functional similarities. ILGs are encoded by distinct and unrelated gene families and include receptors for cAMP, cGMP, calcium ions, ATP, and metabolites of arachidonic acid.

Macrophage Scavenger Receptors

Macrophage scavenger receptors with broad ligand specificity may participate in the binding of low density lipoproteins (LDL) and foreign antigens. Scavenger receptors types I and II are trimeric membrane proteins with each subunit containing a small N-terminal intracellular domain, a transmembrane domain, a large extracellular domain, and a C-terminal cysteine-rich domain. The extracellular domain contains a short spacer domain, an α-helical coiled-coil domain, and a triple helical collagenous domain. These receptors have been shown to bind a spectrum of ligands, including chemically modified lipoproteins and albumin, polyribonucleotides, polysaccharides, phospholipids, and asbestos (Matsumoto, A. et al. (1990) Proc. Natl. Acad. Sci. USA 87:9133-9137; Elomaa, O. et al. (1995) Cell 80:603-609). The scavenger receptors are thought to play a key role in atherogenesis by mediating uptake of modified LDL in arterial walls, and in host defense by binding bacterial endotoxins, bacteria, and protozoa.

T-Cell Receptors

T cells play a dual role in the immune system as effectors and regulators, coupling antigen recognition with the transmission of signals that induce cell death in infected cells and stimulate proliferation of other immune cells. Although a population of T cells can recognize a wide range of different antigens, an individual T cell can only recognize a single antigen and only when it is presented to the T cell receptor (TCR) as a peptide complexed with a major histocompatibility molecule (MHC) on the surface of an antigen presenting cell. The TCR on most T cells consists of immunoglobulin-like integral membrane glycoproteins containing two polypeptide subunits, α and β, of similar molecular weight. Both TCR subunits have an extracellular domain containing both variable and constant regions, a transmembrane domain that traverses the membrane once, and a short intracellular domain (Saito, H. et al. (1984) Nature 309:757-762). The genes for the TCR subunits are constructed through somatic rearrangement of different gene segments. Interaction of antigen in the proper MHC context with the TCR initiates signaling cascades that induce the proliferation, maturation, and function of cellular components of the immune system (Weiss, A. (1991) Annu. Rev. Genet. 25:487-510). Rearrangements in TCR genes and alterations in TCR expression have been noted in lymphomas, leukemias, autoimmune disorders, and immunodeficiency disorders (Aisenberg, A.C. et al. (1985) N. Engl. J. Med. 313:529-533; Weiss, *supra*).

Netrin Receptors:

The netrins are a family of molecules that function as diffusible attractants and repellants to guide migrating cells and axons to their targets within the developing nervous system. The netrin receptors include the *C. elegans* protein UNC-5, as well as homologues recently identified in vertebrates (Leonardo, E.D. et al. (1997) Nature 386:833-838). These receptors are members of the immunoglobulin superfamily, and also contain a characteristic domain called the ZU5 domain. Mutations in the mouse member of the netrin receptor family, Rcm (rostral cerebellar malformation) result in cerebellar and midbrain defects as an apparent result of abnormal neuronal migration (Ackerman, S.L. et al. (1997) Nature 386:838-842).

VPS10 Domain Containing Receptors

The members of the VPS10 domain containing receptor family all contain a domain with homology to the yeast vacuolar sorting protein 10 (VPS10) receptor. This family includes the mosaic receptor SorLA, the neurotensin receptor sortilin, and SorCS, which is expressed during mouse embryonal and early postnatal nervous system development (Hermey, G. et al. (1999) Biochem. Biophys. Res. Commun. 266:347-351; Hermey, G. et al. (2001) Neuroreport 12:29-32). A recently identified member of this family, SorCS2, is highly expressed in the developing and mature mouse central nervous system. Its main site of expression is the floor plate, and high levels are also detected transiently in brain regions including the dopaminergic brain nuclei and the dorsal thalamus (Rezgaoui, M. (2001) Mech. Dev. 100:335-338).

Membrane-Associated Proteins

Tetraspan Family Proteins

The transmembrane 4 superfamily (TM4SF) or tetraspan family is a multigene family encoding type III integral membrane proteins (Wright, M.D. and M.G. Tomlinson (1994) Immunol. Today 15:588-594). The TM4SF is comprised of membrane proteins which traverse the cell membrane four times. Members of the TM4SF include platelet and endothelial cell membrane proteins, melanoma-associated antigens, leukocyte surface glycoproteins, colonal carcinoma antigens, tumor-associated antigens, and surface proteins of the schistosome parasites (Jankowski, S.A. (1994) Oncogene 9:1205-1211). Members of the TM4SF share about 25-30% amino acid sequence identity with one another. A number of TM4SF members have been implicated in signal transduction, control of cell adhesion, regulation of cell growth and proliferation, including development and oncogenesis, and cell motility, including tumor cell metastasis. Expression of TM4SF proteins is associated with a variety of tumors and the level of expression may be altered when cells are growing or activated.

Tumor Antigens

Tumor antigens are surface molecules that are differentially expressed in tumor cells relative to normal cells. Tumor antigens distinguish tumor cells immunologically from normal cells and provide diagnostic and therapeutic targets for human cancers (Takagi, S. et al. (1995) Int. J. Cancer 61:706-715; Liu, E. et al. (1992) Oncogene 7:1027-1032).

Ion Channels

Ion channels are found in the plasma membranes of virtually every cell in the body. For example, chloride channels mediate a variety of cellular functions including regulation of membrane potentials and absorption and secretion of ions across epithelial membranes. When present in intracellular membranes of the Golgi apparatus and endocytic vesicles, chloride channels also regulate organelle pH. (See, e.g., Greger, R. (1988) Annu. Rev. Physiol. 50:111-122.) Electrophysiological and pharmacological properties of chloride channels, including ion conductance, current-voltage relationships, and sensitivity to modulators, suggest that different chloride channels exist in muscles, neurons, fibroblasts, epithelial cells, and lymphocytes. Many channels have sites for phosphorylation by one or more protein kinases including protein kinase A, protein kinase C, tyrosine kinase, and casein kinase II, all of which regulate ion channel activity in cells. Inappropriate phosphorylation of proteins in cells has been linked to changes in cell cycle progression and cell differentiation. Changes in the cell cycle have been linked to induction of apoptosis or cancer. Changes in cell differentiation have been linked to diseases and disorders of the reproductive system, immune system, and skeletal muscle.

Cerebellar granule neurons possess a non-inactivating potassium current which modulates firing frequency upon receptor stimulation by neurotransmitters and controls the resting membrane potential. Potassium channels that exhibit non-inactivating currents include the *ether a go-go* (EAG) channel. A membrane protein designated KCR1 specifically binds to rat EAG by means of its C-terminal region and regulates the cerebellar non-inactivating potassium current. KCR1 is predicted to contain 12 transmembrane domains, with intracellular amino and carboxyl termini. Structural characteristics of these transmembrane regions appear to be similar to those of the transporter superfamily, but no homology between KCR1 and known transporters was found, suggesting that KCR1 belongs to a novel class of transporters. KCR1 appears to be the regulatory component of non-inactivating potassium channels (Hoshi, N. et al. (1998) J. Biol. Chem. 273:23080-23085).

ABC Transporters

ATP-binding cassette (ABC) transporters, also called the "traffic ATPases", are a superfamily of membrane proteins that mediate transport and channel functions in prokaryotes and eukaryotes (Higgins, C.F. (1992) Annu. Rev. Cell Biol. 8:67-113). ABC proteins share a similar overall structure and significant sequence homology. All ABC proteins contain a conserved domain of approximately two hundred amino acid residues which includes one or more nucleotide binding

domains. Mutations in ABC transporter genes are associated with various disorders, such as hyperbilirubinemia II/Dubin-Johnson syndrome, recessive Stargardt's disease, X-linked adrenoleukodystrophy, multidrug resistance, celiac disease, and cystic fibrosis.

Semaphorins and Neuropilins

Semaphorins are a large group of axonal guidance molecules consisting of at least 30 different members and are found in vertebrates, invertebrates, and even certain viruses. All semaphorins contain the sema domain which is approximately 500 amino acids in length. Neuropilin, a semaphorin receptor, has been shown to promote neurite outgrowth *in vitro*. The extracellular region of neuropilins consists of three different domains: CUB, discoidin, and MAM domains. The CUB and the MAM motifs of neuropilin have been suggested to have roles in protein-protein interactions and are thought to be involved in the binding of semaphorins through the sema and the C-terminal domains (reviewed in Raper, J.A. (2000) Curr. Opin. Neurobiol. 10:88-94).

Membrane Proteins Associated with Intercellular Communication

Intercellular communication is essential for the development and survival of multicellular organisms. Cells communicate with one another through the secretion and uptake of protein signaling molecules. The uptake of proteins into the cell is achieved by endocytosis, in which the interaction of signaling molecules with the plasma membrane surface, often via binding to specific receptors, results in the formation of plasma membrane-derived vesicles that enclose and transport the molecules into the cytosol. The secretion of proteins from the cell is achieved by exocytosis, in which molecules inside of the cell are packaged into membrane-bound transport vesicles derived from the *trans* Golgi network. These vesicles fuse with the plasma membrane and release their contents into the surrounding extracellular space. Endocytosis and exocytosis result in the removal and addition of plasma membrane components, and the recycling of these components is essential to maintain the integrity, identity, and functionality of both the plasma membrane and internal membrane-bound compartments.

Nogo has been identified as a component of the central nervous system myelin that prevents axonal regeneration in adult vertebrates. Cleavage of the Nogo-66 receptor and other glycophosphatidylinositol-linked proteins from axonal surfaces renders neurons insensitive to Nogo-66, facilitating potential recovery from CNS damage (Fournier, A.E. et al. (2001) Nature 409:341-346).

The slit proteins are extracellular matrix proteins expressed by cells at the ventral midline of the nervous system. Slit proteins are ligands for the repulsive guidance receptor Roundabout (Robo) and thus play a role in repulsive axon guidance (Brose, K. et al. (1999) Cell 96:795-806).

Lysosomes are the site of degradation of intracellular material during autophagy and of extracellular molecules following endocytosis. Lysosomal enzymes are packaged into vesicles which

bud from the *trans*-Golgi network. These vesicles fuse with endosomes to form the mature lysosome in which hydrolytic digestion of endocytosed material occurs. Lysosomes can fuse with autophagosomes to form a unique compartment in which the degradation of organelles and other intracellular components occurs.

Protein sorting by transport vesicles, such as the endosome, has important consequences for a variety of physiological processes including cell surface growth, the biogenesis of distinct intracellular organelles, endocytosis, and the controlled secretion of hormones and neurotransmitters (Rothman, J.E. and F.T. Wieland (1996) Science 272:227-234). In particular, neurodegenerative disorders and other neuronal pathologies are associated with biochemical flaws during endosomal protein sorting or endosomal biogenesis (Mayer, R.J. et al. (1996) Adv. Exp. Med. Biol. 389:261-269).

Three classes of molecular motors – kinesins, dyneins and myosins – are involved in a variety of biological movements, such as mitosis, axoplasmic transport and secretion. Structurally, motor proteins consist of two functional parts: a motor domain that reversibly binds to the cytoskeleton and converts chemical energy into motion; and the rest of the molecule, often referred to as the tail, that interacts with cargo directly or through accessory light chains. These movements are required for the spatial organization of cytoplasm and, as a consequence, are crucial for cell division, embryonic development, and the formation of specialized areas of cytoplasm such as cilia and flagella. The ability of these proteins to transport a wide array of cargo is due, in part, to the fact that the tail domains are quite divergent from one another. This has allowed them to evolve into adaptors, linking themselves to cargo through interactions with receptor proteins on the cargo surface (Karcher, R.L. et al. (2002) TRENDS in Cell Biology Vol.12 No.1).

Kinesin is the most abundant motor in many cell types and is responsible for movement of a variety of different cargoes. The best characterized of kinesin receptors is kinectin, a receptor isolated as an endoplasmic-reticulum specific protein (Kumar, J. et al. (1995) Science 267, 1834–1837). Kinesin exists as a tetramer of two heavy chains, which contain the N-terminal motor domain and C-terminal tail, as well as two light chains, which bind to the heavy chain tail. Kinectin binds to the heavy chain of kinesin and is considered an ER-specific receptor for this motor protein. Interactions between motor proteins and corresponding receptors may be verified using a yeast two-hybrid system or co-immunoprecipitation assays.

Peroxisomes are organelles independent from the secretory pathway. They are the site of many peroxide-generating oxidative reactions in the cell. Peroxisomes are unique among eukaryotic organelles in that their size, number, and enzyme content vary depending upon organism, cell type, and metabolic needs (Waterham, H.R. and J.M. Cregg (1997) BioEssays 19:57-66). Genetic defects in peroxisome proteins which result in peroxisomal deficiencies have been linked to a number of

human pathologies, including Zellweger syndrome, rhizomelic chonrodysplasia punctata, X-linked adrenoleukodystrophy, acyl-CoA oxidase deficiency, bifunctional enzyme deficiency, classical Refsum's disease, DHAP alkyl transferase deficiency, and acatalasemia (Moser, H.W. and A.B. Moser (1996) Ann. NY Acad. Sci. 804:427-441). In addition, Gartner, J. et al. (1991; Pediatr. Res. 29:141-146) found a 22 kDa integral membrane protein associated with lower density peroxisome-like subcellular fractions in patients with Zellweger syndrome.

Normal embryonic development and control of germ cell maturation is modulated by a number of secretory proteins which interact with their respective membrane-bound receptors. Cell fate during embryonic development is determined by members of the activin/TGF-β superfamily, cadherins, IGF-2, and other morphogens. In addition, proliferation, maturation, and redifferentiation of germ cell and reproductive tissues are regulated, for example, by IGF-2, inhibins, activins, and follistatins (Petraglia, F. (1997) Placenta 18:3-8; Mather, J.P. et al. (1997) Proc. Soc. Exp. Biol. Med. 215:209-222). Transforming growth factor beta (TGFβ) signal transduction is mediated by two receptor Ser/Thr kinases acting in series, type II TGFβ receptor and (TβR-II) phosphorylating type I TGFβ receptor (TβR-I). Signaling is initiated when the ligand binds to the TβR-II which is followed by recruitment of TβR-I into a heteromeric complex. Within the complex, TβR-II transphosphorylates and activates TβR-I kinase, which phosphorylates and activates downstream signaling components of the pathway. TβR-I-associated protein-1 (TRECAP-1), which distinguishes between quiescent and activated forms of the type I transforming growth factor beta receptor, has been associated with TGFβ signaling (Charng, M.J. et al. (1998) J. Biol. Chem. 273:9365-9368).

Retinoic acid receptor alpha (RAR alpha) mediates retinoic-acid induced maturation and has been implicated in myeloid development. Genes induced by retinoic acid during granulocytic differentiation include E3, a hematopoietic-specific gene that is an immediate target for the activated RAR alpha during myelopoiesis (Scott, L.M. et al. (1996) Blood 88:2517-2530).

The μ-opioid receptor (MOR) mediates the actions of analgesic agents including morphine, codeine, methadone, and fentanyl as well as heroin. MOR is functionally coupled to a G-protein-activated potassium channel (Mestek A. et al. (1995) J. Neurosci. 15:2396-2406). A variety of MOR subtypes exist. Alternative splicing has been observed with MOR-1 as with a number of G protein-coupled receptors including somatostatin 2, dopamine D2, prostaglandin EP3, and serotonin receptor subtypes 5-hydroxytryptamine4 and 5-hydroxytryptamine7 (Pan, Y.X. et al. (1999) Mol. Pharm. 56:396-403).

Peripheral and Anchored Membrane Proteins

Some membrane proteins are not membrane-spanning but are attached to the plasma membrane via membrane anchors or interactions with integral membrane proteins. Membrane anchors are covalently joined to a protein post-translationally and include such moieties as prenyl,

myristyl, and glycosylphosphatidyl inositol groups. Membrane localization of peripheral and anchored proteins is important for their function in processes such as receptor-mediated signal transduction. For example, prenylation of Ras is required for its localization to the plasma membrane and for its normal and oncogenic functions in signal transduction.

Expression profiling

Microarrays are analytical tools used in bioanalysis. A microarray has a plurality of molecules spatially distributed over, and stably associated with, the surface of a solid support. Microarrays of polypeptides, polynucleotides, and/or antibodies have been developed and find use in a variety of applications, such as gene sequencing, monitoring gene expression, gene mapping, bacterial identification, drug discovery, and combinatorial chemistry.

One area in particular in which microarrays find use is in gene expression analysis. Array technology can provide a simple way to explore the expression of a single polymorphic gene or the expression profile of a large number of related or unrelated genes. When the expression of a single gene is examined, arrays are employed to detect the expression of a specific gene or its variants. When an expression profile is examined, arrays provide a platform for identifying genes that are tissue specific, are affected by a substance being tested in a toxicology assay, are part of a signaling cascade, carry out housekeeping functions, or are specifically related to a particular genetic predisposition, condition, disease, or disorder.

Breast Cancer

Breast cancer is the most frequently diagnosed type of cancer in American women and the second most frequent cause of cancer death. There are more than 180,000 new cases of breast cancer diagnosed each year, and the mortality rate for breast cancer approaches 10% of all deaths in females between the ages of 45-54 (K. Gish (1999) AWIS Magazine 28:7-10). The lifetime risk of an American woman developing breast cancer is 1 in 8, and one-third of women diagnosed with breast cancer die of the disease. However the survival rate based on early diagnosis of localized breast cancer is extremely high (97%), compared with the advanced stage of the disease in which the tumor has spread beyond the breast (22%). A number of risk factors have been identified, including hormonal and genetic factors. Current procedures for clinical breast examination are lacking in sensitivity and specificity, and efforts are underway to develop comprehensive gene expression profiles for breast cancer that may be used in conjunction with conventional screening methods to improve diagnosis and prognosis of this disease (Perou CM et al. (2000) Nature 406:747-752).

Breast cancer evolves through a multi-step process whereby premalignant mammary epithelial cells undergo a relatively defined sequence of events leading to tumor formation. An early event in tumor development is ductal hyperplasia. Cells undergoing rapid neoplastic growth gradually progress to invasive carcinoma and become metastatic to the lung, bone, and potentially

other organs. Variables that may influence the process of tumor progression and malignant transformation include genetic factors, environmental factors, growth factors, and hormones.

Breast cancer is a genetic disease commonly caused by mutations in cellular disease. One genetic defect associated with breast cancer results in a loss of heterozygosity (LOH) at multiple loci such as p53, Rb, BRCA1, and BRCA2. Another genetic defect is gene amplification involving genes such as c-myc and c-erbB2 (Her2-neu gene). Steroid and growth factor pathways are also altered in breast cancer, notably the estrogen, progesterone, and epidermal growth factor (EGF) pathways. Mutations in two genes, BRCA1 and BRCA2, are known to greatly predispose a woman to breast cancer and may be passed on from parents to children (Gish, supra). However, this type of hereditary breast cancer accounts for only about 5% to 9% of breast cancers, while the vast majority of breast cancer is due to noninherited mutations that occur in breast epithelial cells.

A good deal is already known about the expression of specific genes associated with breast cancer. For example, the relationship between expression of epidermal growth factor (EGF) and its receptor, EGFR, to human mammary carcinoma has been particularly well studied. (See Khazaie et al., supra, and references cited therein for a review of this area.) Overexpression of EGFR, particularly coupled with down-regulation of the estrogen receptor, is a marker of poor prognosis in breast cancer patients. In addition, EGFR expression in breast tumor metastases is frequently elevated relative to the primary tumor, suggesting that EGFR is involved in tumor progression and metastasis. This is supported by accumulating evidence that EGF has effects on cell functions related to metastatic potential, such as cell motility, chemotaxis, secretion and differentiation. Changes in expression of other members of the erbB receptor family, of which EGFR is one, have also been implicated in breast cancer. The abundance of erbB receptors, such as HER-2/neu, HER-3, and HER-4, and their ligands in breast cancer points to their functional importance in the pathogenesis of the disease, and may therefore provide targets for therapy of the disease (Bacus, SS et al. (1994) Am J Clin Pathol 102:S13-S24). Other known markers of breast cancer include a human secreted frizzled protein mRNA that is downregulated in breast tumors; the matrix G1a protein which is overexpressed is human breast carcinoma cells; Drg1 or RTP, a gene whose expression is diminished in colon, breast, and prostate tumors; maspin, a tumor suppressor gene downregulated in invasive breast carcinomas; and CaN19, a member of the S100 protein family, all of which are down regulated in mammary carcinoma cells relative to normal mammary epithelial cells (Zhou Z et al. (1998) Int J Cancer 78:95-99; Chen, L et al. (1990) Oncogene 5:1391-1395; Ulrix W et al (1999) FEBS Lett 455:23-26; Sager, R et al. (1996) Curr Top Microbiol Immunol 213:51-64; and Lee, SW et al. (1992) Proc Natl Acad Sci USA 89:2504-2508).

Cell lines derived from human mammary epithelial cells at various stages of breast cancer provide a useful model to study the process of malignant transformation and tumor progression as it

has been shown that these cell lines retain many of the properties of their parental tumors for lengthy culture periods (Wistuba II et al. (1998) Clin Cancer Res 4:2931-2938). Such a model is particularly useful for comparing phenotypic and molecular characteristics of human mammary epithelial cells at various stages of malignant transformation.

Prostate cancer

As with most tumors, prostate cancer develops through a multistage progression ultimately resulting in an aggressive tumor phenotype. The initial step in tumor progression involves the hyperproliferation of normal luminal and/or basal epithelial cells. Androgen responsive cells become hyperplastic and evolve into early-stage tumors. Although early-stage tumors are often androgen sensitive and respond to androgen ablation, a population of androgen independent cells evolve from the hyperplastic population. These cells represent a more advanced form of prostate tumor that may become invasive and potentially become metastatic to the bone, brain, or lung. A variety of genes may be differentially expressed during tumor progression. For example, loss of heterozygosity (LOH) is frequently observed on chromosome 8p in prostate cancer. Fluorescence *in situ* hybridization (FISH) revealed a deletion for at least 1 locus on 8p in 29 (69%) tumors, with a significantly higher frequency of the deletion on 8p21.2-p21.1 in advanced prostate cancer than in localized prostate cancer, implying that deletions on 8p22-p21.3 play an important role in tumor differentiation, while 8p21.2-p21.1 deletion plays a role in progression of prostate cancer (Oba, K. et al. (2001) Cancer Genet. Cytogenet. 124: 20-26). As with breast cancer, there is a need for diagnostic and therapeutic agents that will improve treatment options for prostate cancer patients that can be fulfilled by the use of microarray expression analysis.

Colon Cancer

While soft tissue sarcomas are relatively rare, more than 50% of new patients diagnosed with the disease will die from it. The molecular pathways leading to the development of sarcomas are relatively unknown, due to the rarity of the disease and variation in pathology. Colon cancer evolves through a multi-step process whereby pre-malignant colonocytes undergo a relatively defined sequence of events leading to tumor formation. Several factors participate in the process of tumor progression and malignant transformation including genetic factors, mutations, and selection.

To understand the nature of gene alterations in colorectal cancer, a number of studies have focused on the inherited syndromes. The first, Familial Adenomatous Polyposis (FAP), is caused by mutations in the Adenomatous Polyposis Coli gene (APC), resulting in truncated or inactive forms of the protein. This tumor suppressor gene has been mapped to chromosome 5q. The second known inherited syndrome is hereditary nonpolyposis colorectal cancer (HNPCC), which is caused by mutations in mismatch repair genes.

Although hereditary colon cancer syndromes occur in a small percentage of the population,

and most colorectal cancers are considered sporadic, knowledge from studies of the hereditary syndromes can be applied broadly. For instance, somatic mutations in APC occur in at least 80% of sporadic colon tumors. APC mutations are thought to be the initiating event in disease progression. Other mutations occur subsequently. Approximately 50% of colorectal cancers contain activating mutations in ras, while 85% contain inactivating mutations in p53. Changes in all of these genes lead to gene expression changes in colon cancer. Less is understood about downstream targets of these mutations and the role they may play in cancer development and progression.

Lung Cancer

Lung cancer is the leading cause of cancer death in the United States, affecting more than 100,000 men and 50,000 women each year. Nearly 90% of the patients diagnosed with lung cancer are cigarette smokers. Tobacco smoke contains thousands of noxious substances that induce carcinogen metabolizing enzymes and covalent DNA adduct formation in the exposed bronchial epithelium. In nearly 80% of patients diagnosed with lung cancer, metastasis has already occurred. Most commonly lung cancers metastasize to pleura, brain, bone, pericardium, and liver. The decision to treat with surgery, radiation therapy, or chemotherapy is made on the basis of tumor histology, response to growth factors or hormones, and sensitivity to inhibitors or drugs. With current treatments, most patients die within one year of diagnosis. Earlier diagnosis and a systematic approach to identification, staging, and treatment of lung cancer could positively affect patient outcome.

Lung cancers progress through a series of morphologically distinct stages from hyperplasia to invasive carcinoma. Malignant lung cancers are divided into two groups comprising four histopathological classes. The Non Small Cell Lung Carcinoma (NSCLC) group includes squamous cell carcinomas, adenocarcinomas, and large cell carcinomas and accounts for about 70% of all lung cancer cases. Adenocarcinomas typically arise in the peripheral airways and often form mucin secreting glands. Squamous cell carcinomas typically arise in proximal airways. The histogenesis of squamous cell carcinomas may be related to chronic inflammation and injury to the bronchial epithelium, leading to squamous metaplasia. The Small Cell Lung Carcinoma (SCLC) group accounts for about 20% of lung cancer cases. SCLCs typically arise in proximal airways and exhibit a number of paraneoplastic syndromes including inappropriate production of adrenocorticotropin and anti-diuretic hormone.

Lung cancer cells accumulate numerous genetic lesions, many of which are associated with cytologically visible chromosomal aberrations. The high frequency of chromosomal deletions associated with lung cancer may reflect the role of multiple tumor suppressor loci in the etiology of this disease. Deletion of the short arm of chromosome 3 is found in over 90% of cases and represents one of the earliest genetic lesions leading to lung cancer. Deletions at chromosome arms 9p and 17p

are also common. Other frequently observed genetic lesions include overexpression of telomerase, activation of oncogenes such as K-ras and c-myc, and inactivation of tumor suppressor genes such as RB, p53 and CDKN2.

Genes differentially regulated in lung cancer have been identified by a variety of methods. Using mRNA differential display technology, Manda et al. (1999; Genomics 51:5-14) identified five genes differentially expressed in lung cancer cell lines compared to normal bronchial epithelial cells. Among the known genes, pulmonary surfactant apoprotein A and alpha 2 macroglobulin were down regulated whereas nm23H1 was upregulated. Petersen et al.. (2000; Int J. Cancer, 86:512-517) used suppression subtractive hybridization to identify 552 clones differentially expressed in lung tumor derived cell lines, 205 of which represented known genes. Among the known genes, thrombospondin-1, fibronectin, intercellular adhesion molecule 1, and cytokeratins 6 and 18 were previously observed to be differentially expressed in lung cancers. Wang et al. (2000; Oncogene 19:1519-1528) used a combination of microarray analysis and subtractive hybridization to identify 17 genes differentially overexpresssed in squamous cell carcinoma compared with normal lung epithelium. Among the known genes they identified were keratin isoform 6, KOC, SPRC, IGFb2, connexin 26, plakofillin 1 and cytokeratin 13.

Ovarian Cancer

Ovarian cancer is the leading cause of death from a gynecologic cancer. The majority of ovarian cancers are derived from epithelial cells, and 70% of patients with epithelial ovarian cancers present with late-stage disease. As a result, the long-term survival rates for this disease is very low. Identification of early-stage markers for ovarian cancer would significantly increase the survival rate. Genetic variations involved in ovarian cancer development include mutation of p53 and microsatellite instability. Gene expression patterns likely vary when normal ovary is compared to ovarian tumors.

Immune Response

Tumor cells stimulate the formation of stroma that secretes various mediators, such as growth factors, cytokines, and proteases, all of which are pivotal for tumor growth. One such cytokine, interferon gamma (IFN-γ) induces growth arrest in normal human mammary epithelial cells by establishing a block during mid-G1 phase. IFN-γ inhibits the kinase activities of cdk2, cdk4 and cdk6 within 24 h of treatment. IFN-γ -mediated growth inhibition requires signal transducers and activators of transcrip-tion (STAT)-1 activation and may require induction of the cyclin-dependent kinase inhibitor p21. IFN-γ , maybe through the elevation of caspase-8 levels, sensitizes human breast tumor cells to a death receptor-mediated, mitochondria-operated pathway of apoptosis.

IFN-γ , also known as Type II interferon or immune interferon, is produced primarily by T-lympho-cytes and natural killer cells. IFN-γ was originally characterized based on its antiviral characteristics. The protein exhibits antiproliferative, immunoregulatory and proinflammatory

activities and is thus important in host defense mechanisms. IFN-γ induces the production of cytokines, upregulates the expression of class I and II MHC antigens, Fc receptor, and leukocyte adhesion molecules. It modulates macrophage effector functions, influences isotype switching and potentiates the secretion of immunoglobulins by B cells. IFN-γ also augments TH1 cell expansion and may be required for TH1 cell differentiation. The IFN-γ receptor has been cloned and characterized, and is structurally related to the recently cloned IL-10 receptor. It is present on almost all cell types except mature erythrocytes.

Human peripheral blood mononuclear cells (PBMCs)

Human peripheral blood mononuclear cells (PBMCs) represent the major cellular components of the immune system. PBMCs contain about 52% lymphocytes (12% B lymphocytes, 40% T lymphocytes {25% CD4+ and 15% CD8+}), 20% NK cells, 25% monocytes, and 3% various cells that include dendritic cells and progenitor cells. The proportions, as well as the biology of these cellular components tend to vary slightly between healthy individuals, depending on factors such as age, gender, past medical history, and genetic background. These cells are responsible for immune responses and fighting infections, and thus represent a crucial system designed to maintain human health. Understanding the factors that activate and maintain this system requires analysis of cellular responses to stimuli, examining differences in the gene expression patterns of the various cell types, and determination of potential therapeutic targets that could be exploited for bolstering the immune response in individuals with deficiencies in this system. Microarray expression analysis can play an important role in achieving these goals.

Leukocytes comprise lymphocytes, granulocytes, and monocytes. Lymphocytes include T and B cells, which specifically recognize and respond to foreign pathogens. T cells fight viral infections and activate other leukocytes, while B cells secrete antibodies that neutralize bacteria and other microbes. Lymphoblast cell lines can be used to study signaling in human B cells and identify factors produced by those cells. An example is the RPMI 6666 B cell lymphoblast cell line derived from the peripheral blood of a male donor with Hodgkin's disease, which produces immunoglobulins and presents cell-associated Epstein-Barr virus (EBV) particles. Granulocytes and monocytes are primarily migratory, phagocytic cells that exit the bloodstream to fight infection in tissues. Monocytes, which are derived from immature promonocytes, further differentiate into macrophages that engulf and digest microorganisms and damaged or dead cells. Monocytes and macrophages modulate the immune response by secreting signaling molecules such as growth factors and cytokines. Tumor necrosis factor-α (TNF-α), for example, is a macrophage-secreted protein with anti-tumor and anti-viral activity. In addition, monocytes and macrophages are recruited to sites of infection and inflammation by signaling proteins secreted by other leukocytes. The differentiation of the monocyte blood cell lineage can be studied *in vitro* using cultured cell lines. For example, THP-1

is a human promonocyte cell line that can be activated by treatment with both phorbol ester such as phorbol myristate acetate (PMA) and ionomycin, a calcium ionophore that permits the entry of calcium in the cell, which increases the intracellular concentration of calcium. PMA is a broad activator of the protein kinase C-dependent pathways. The combination of PMA and ionomycin activates two of the major signaling pathways used by mammalian cells to interact with their environment. In T cells, the combination of PMA and ionomycin mimics the type of secondary signaling events elicited during optimal B cell activation. THP-1 can also be activated by treatment with both phorbol ester such as phorbol myristate acetate (PMA), and lipopolysaccharide (LPS). In another example, K-562 is a myeloid precursor cell line derived from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia. The K-562 cell line has been extensively used to study differentiation of the erythrocytic, granulocytic, and monocytic lineage in humans. In addition, the K-562 cell line is widely used as an extremely sensitive target to the cytolytic activity of human natural killer cells *in vitro.* Another cell line, Jurkat, is an acute T cell leukemia cell line that grows actively in the absence of external stimuli and has been extensively used to study signaling in human T cells. In T cells, the combination of PMA and ionomycin mimics the type of secondary signaling events elicited during optimal B cell activation.

Monocytes are involved in the initiation and maintenance of inflammatory immune responses. The outer membrane of gram-negative bacteria expresses lipopolysaccharide (LPS) complexes called endotoxins. Toxicity is associated with the lipid component (Lipid A) of LPS, and immunogenicity is associated with the polysaccharide components of LPS. LPS elicits a variety of inflammatory responses, and because it activates complement by the alternative (properdin) pathway, it is often part of the pathology of gram-negative bacterial infections. For the most part, endotoxins remain associated with the cell wall until the bacteria disintegrate. LPS released into the bloodstream by lysing gram-negative bacteria is first bound by certain plasma proteins identified as LPS-binding proteins. The LPS-binding protein complex interacts with CD14 receptors on monocytes, macrophages, B cells, and other types of receptors on endothelial cells. Activation of human B cells with LPS results in mitogenesis as well as immunoglobulin synthesis. In monocytes and macrophages three types of events are triggered during their interaction with LPS: 1) Production of cytokines, including IL-1, IL-6, IL-8, TNF-α , and platelet-activating factor, which stimulate production of prostaglandins and leukotrienes that mediate inflammation and septic shock; 2) Activation of the complement cascade; and 3) Activation of the coagulation cascade. Thus, LPS stimulation of lymphocytic cells can be used to examine changes in gene expression that occur in response to infectious stimuli, and can be analyzed by microarray expression analysis.

Functional interaction of the cell types involved in immune responses involves transfer of signals via soluble messenger molecules known as cytokines. Both hematopoietic cells and non-

hematopoietic cells produce cytokines, which stimulate the activation, differentiation and proliferation of T cells, B cells, macrophages, and granulocytes during an active immune response. Cytokines bind to specific receptors expressed on cellular membranes and transduce a signal through the cell. Depending on the type of cytokine and the cell to which it binds, this signal initiates activation, differentiation, growth, and/or apoptosis. IL-10 is a pleiotrophic cytokine that can exert either immunostimulatory or immunosupressive effects on a variety of cell types. IL-10 suppresses the accessory cell function of macrophages and dendritic cells in part by downregulating class II MHC expression, preventing antigen presentation. IL-10 directly suppresses macrophage and monocyte production of inflammatory molecules such as tumor necrosis factor alpha (TNF-α), IL-1α, and IL-6, while maintaining production of transforming growth factor beta (TGF-β) which curbs Th1 responses. In contrast to its suppressive activities on T cells and macrophages, IL-10 boosts proliferation and differentiation of activated B cells into plasma cells.

Staphylococcal exotoxins specifically activate human T cells, expressing an appropriate TCR-Vbeta chain. Although polyclonal in nature, T cells activated by Staphylococcal exotoxins require antigen presenting cells (APCs) to present the exotoxin molecules to the T cells and deliver the costimulatory signals required for optimum T cell activation. Although, Staphylococcal exotoxins must be presented to T cells by APCs, these molecules are not required to be processed by APC. Indeed, Staphylococcal exotoxins directly bind to a non-polymorphic portion of the human MHC class II molecules, bypassing the need for capture, cleavage, and binding of the peptides to the polymorphic antigenic groove of the MHC class II molecules.

There is a need in the art for new compositions, including nucleic acids and proteins, for the diagnosis, prevention, and treatment of cell proliferative, autoimmune/inflammatory, neurological, metabolic, developmental, and endocrine disorders.

SUMMARY OF THE INVENTION

Various embodiments of the invention provide purified polypeptides, receptors and membrane-associated proteins, referred to collectively as 'REMAP' and individually as 'REMAP-1,' 'REMAP-2,' 'REMAP-3,' 'REMAP-4,' 'REMAP-5,' 'REMAP-6,' 'REMAP-7,' 'REMAP-8,' 'REMAP-9,' 'REMAP-10,' 'REMAP-11,' 'REMAP-12,' 'REMAP-13,' 'REMAP-14,' 'REMAP-15,' 'REMAP-16,' 'REMAP-17,' 'REMAP-18,' 'REMAP-19,' 'REMAP-20,' 'REMAP-21,' 'REMAP-22,' 'REMAP-23,' 'REMAP-24,' 'REMAP-25,' 'REMAP-26,' 'REMAP-27,' 'REMAP-28,' 'REMAP-29,' 'REMAP-30,' 'REMAP-31,' 'REMAP-32,' 'REMAP-33,' 'REMAP-34,' 'REMAP-35,' 'REMAP-36,' 'REMAP-37,' and 'REMAP-38,' and methods for using these proteins and their encoding polynucleotides for the detection, diagnosis, and treatment of diseases and medical conditions. Embodiments also provide methods for utilizing the purified receptors and

membrane-associated proteins and/or their encoding polynucleotides for facilitating the drug discovery process, including determination of efficacy, dosage, toxicity, and pharmacology. Related embodiments provide methods for utilizing the purified receptors and membrane-associated proteins and/or their encoding polynucleotides for investigating the pathogenesis of diseases and medical conditions.

An embodiment provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38. Another embodiment provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO:1-38.

Still another embodiment provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38. In another embodiment, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-38. In an alternative embodiment, the polynucleotide is selected from the group consisting of SEQ ID NO:39-76.

Still another embodiment provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38. Another embodiment provides a cell transformed with the recombinant polynucleotide. Yet another embodiment provides a transgenic organism comprising the recombinant polynucleotide.

Another embodiment provides a method for producing a polypeptide selected from the group

consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Yet another embodiment provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38.

Still yet another embodiment provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical or at least about 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In other embodiments, the polynucleotide can comprise at least about 20, 30, 40, 60, 80, or 100 contiguous nucleotides.

Yet another embodiment provides a method for detecting a target polynucleotide in a sample, said target polynucleotide being selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical or at least about 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76; c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe

specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex. In a related embodiment, the method can include detecting the amount of the hybridization complex. In still other embodiments, the probe can comprise at least about 20, 30, 40, 60, 80, or 100 contiguous nucleotides.

Still yet another embodiment provides a method for detecting a target polynucleotide in a sample, said target polynucleotide being selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical or at least about 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof. In a related embodiment, the method can include detecting the amount of the amplified target polynucleotide or fragment thereof.

Another embodiment provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, and a pharmaceutically acceptable excipient. In one embodiment, the composition can comprise an amino acid sequence selected from the group consisting of SEQ ID NO:1-38. Other embodiments provide a method of treating a disease or condition associated with decreased or abnormal expression of functional REMAP, comprising administering to a patient in need of such treatment the composition.

Yet another embodiment provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, and d) an immunogenic fragment of a polypeptide having an amino acid sequence

selected from the group consisting of SEQ ID NO:1-38. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. Another embodiment provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. Yet another embodiment provides a method of treating a disease or condition associated with decreased expression of functional REMAP, comprising administering to a patient in need of such treatment the composition.

Still yet another embodiment provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. Another embodiment provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. Yet another embodiment provides a method of treating a disease or condition associated with overexpression of functional REMAP, comprising administering to a patient in need of such treatment the composition.

Another embodiment provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

Yet another embodiment provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an

amino acid sequence selected from the group consisting of SEQ ID NO:1-38, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

Still yet another embodiment provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

Another embodiment provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical or at least about 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical or at least about 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide can comprise a fragment of a polynucleotide selected

from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for full length polynucleotide and polypeptide embodiments of the invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog, and the PROTEOME database identification numbers and annotations of PROTEOME database homologs, for polypeptide embodiments of the invention. The probability scores for the matches between each polypeptide and its homolog(s) are also shown.

Table 3 shows structural features of polypeptide embodiments, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide embodiments, along with selected fragments of the polynucleotides.

Table 5 shows representative cDNA libraries for polynucleotide embodiments.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze polynucleotides and polypeptides, along with applicable descriptions, references, and threshold parameters.

Table 8 shows single nucleotide polymorphisms found in polynucleotide sequences of the invention, along with allele frequencies in different human populations.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleic acids, and methods are described, it is understood that embodiments of the invention are not limited to the particular machines, instruments, materials, and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention.

As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one

or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with various embodiments of the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"REMAP" refers to the amino acid sequences of substantially purified REMAP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of REMAP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of REMAP either by directly interacting with REMAP or by acting on components of the biological pathway in which REMAP participates.

An "allelic variant" is an alternative form of the gene encoding REMAP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding REMAP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as REMAP or a polypeptide with at least one functional characteristic of REMAP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding REMAP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide encoding REMAP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent REMAP. Deliberate amino acid substitutions may be made on the basis of one or more

similarities in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of REMAP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" can refer to an oligopeptide, a peptide, a polypeptide, or a protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid. Amplification may be carried out using polymerase chain reaction (PCR) technologies or other nucleic acid amplification technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of REMAP. Antagonists may include proteins such as antibodies, anticalins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of REMAP either by directly interacting with REMAP or by acting on components of the biological pathway in which REMAP participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, $F(ab')_2$, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind REMAP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures

on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "aptamer" refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an *in vitro* evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Patent No. 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2'-OH group of a ribonucleotide may be replaced by 2'-F or 2'-NH_2), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system. Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker (Brody, E.N. and L. Gold (2000) J. Biotechnol. 74:5-13).

The term "intramer" refers to an aptamer which is expressed *in vivo*. For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl. Acad. Sci. USA 96:3606-3610).

The term "spiegelmer" refers to an aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a polynucleotide having a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic"

refers to the capability of the natural, recombinant, or synthetic REMAP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide" and a "composition comprising a given polypeptide" can refer to any composition containing the given polynucleotide or polypeptide. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotides encoding REMAP or fragments of REMAP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (Accelrys, Burlington MA) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

Original Residue	Conservative Substitution
Ala	Gly, Ser
Arg	His, Lys
Asn	Asp, Gln, His
Asp	Asn, Glu
Cys	Ala, Ser
Gln	Asn, Glu, His
Glu	Asp, Gln, His
Gly	Ala
His	Asn, Arg, Gln, Glu
Ile	Leu, Val
Leu	Ile, Val

Lys	Arg, Gln, Glu
Met	Leu, Ile
Phe	His, Met, Leu, Trp, Tyr
Ser	Cys, Thr
Thr	Ser, Val
Trp	Phe, Tyr
Tyr	His, Phe, Trp
Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

"Differential expression" refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

"Exon shuffling" refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

A "fragment" is a unique portion of REMAP or a polynucleotide encoding REMAP which can be identical in sequence to, but shorter in length than, the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from about 5 to about 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500

contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:39-76 can comprise a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:39-76, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:39-76 can be employed in one or more embodiments of methods of the invention, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:39-76 from related polynucleotides. The precise length of a fragment of SEQ ID NO:39-76 and the region of SEQ ID NO:39-76 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-38 is encoded by a fragment of SEQ ID NO:39-76. A fragment of SEQ ID NO:1-38 can comprise a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-38. For example, a fragment of SEQ ID NO:1-38 can be used as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-38. The precise length of a fragment of SEQ ID NO:1-38 and the region of SEQ ID NO:1-38 to which the fragment corresponds can be determined based on the intended purpose for the fragment using one or more analytical methods described herein or otherwise known in the art.

A "full length" polynucleotide is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

"Homology" refers to sequence similarity or, alternatively, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of identical nucleotide matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using one or more computer algorithms or programs known in the art or described herein. For example, percent identity can be determined using the default parameters of the CLUSTAL V algorithm as incorporated into

the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989; CABIOS 5:151-153) and in Higgins, D.G. et al. (1992; CABIOS 8:189-191). For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms which can be used is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2.html. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of identical residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide. The phrases "percent similarity" and "% similarity," as applied to polypeptide sequences, refer to the percentage of residue matches, including identical residue matches and conservative substitutions, between at least two polypeptide sequences aligned using a standardized algorithm. In contrast, conservative substitutions are not included in the calculation of percent identity between polypeptide sequences.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for

instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 μg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. and D.W. Russell (2001; Molecular Cloning: A Laboratory Manual, 3rd ed., vol. 1-3, Cold Spring Harbor Press, Cold Spring Harbor NY, ch. 9).

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC

concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 μg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acids by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid present in solution and another nucleic acid immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or polynucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of REMAP which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of REMAP which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, antibodies, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, antibody, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of REMAP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of REMAP.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or

synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an REMAP may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of REMAP.

"Probe" refers to nucleic acids encoding REMAP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acids. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in, for example, Sambrook, J. and D.W. Russell (2001; Molecular Cloning: A Laboratory Manual, 3rd ed., vol. 1-3, Cold Spring Harbor Press, Cold Spring Harbor NY), Ausubel, F.M. et al. (1999; Short Protocols in Molecular Biology, 4th ed., John Wiley & Sons, New York NY), and Innis, M. et al. (1990; PCR

Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA). PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a nucleic acid that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook and Russell (*supra*). The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a

vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An "RNA equivalent," in reference to a DNA molecule, is composed of the same linear sequence of nucleotides as the reference DNA molecule with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing REMAP, nucleic acids encoding REMAP, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably at least about 75% free, and most preferably at least about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters,

chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" or "expression profile" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. In another embodiment, the nucleic acid can be introduced by infection with a recombinant viral vector, such as a lentiviral vector (Lois, C. et al. (2002) Science 295:868-872). The term genetic manipulation does not include classical cross-breeding, or *in vitro* fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook and Russell (*supra*).

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater

sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotides that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity or sequence similarity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity or sequence similarity over a certain defined length of one of the polypeptides.

THE INVENTION

Various embodiments of the invention include new human receptors and membrane-associated proteins (REMAP), the polynucleotides encoding REMAP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, autoimmune/inflammatory, neurological, metabolic, developmental, and endocrine disorders.

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide embodiments of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown. Column 6 shows the Incyte ID numbers of physical, full length clones corresponding to the

polypeptide and polynucleotide sequences of the invention. The full length clones encode polypeptides which have at least 95% sequence identity to the polypeptide sequences shown in column 3.

Table 2 shows sequences with homology to polypeptide embodiments of the invention as identified by BLAST analysis against the GenBank protein (genpept) database and the PROTEOME database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (GenBank ID NO:) of the nearest GenBank homolog and the PROTEOME database identification numbers (PROTEOME ID NO:) of the nearest PROTEOME database homologs. Column 4 shows the probability scores for the matches between each polypeptide and its homolog(s). Column 5 shows the annotation of the GenBank and PROTEOME database homolog(s) along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Accelrys, Burlington MA). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are receptors and membrane-associated proteins. For example, SEQ ID NO:6 is 100% identical, from residue M1 to residue S208, to human tumor necrosis factor receptor 1 (GenBank ID g339750) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 4.5e-119, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:6 also has homology to proteins that are localized to the plasma membrane, function as receptors, and are tumor necrosis factor receptors, type 1, as determined by BLAST analysis using the PROTEOME database. SEQ ID NO:6 also contains a TNF-receptor internal cysteine rich domain, a TNFR/NGFR cysteine-rich region domain, and a tumor necrosis factor receptor/nerve domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM, INCY, and SMART databases of conserved protein family domains. (See Table 3.) Data from

BLIMPS, MOTIFS, and other BLAST analyses provide further corroborative evidence that SEQ ID NO:6 is a type 1 tumor necrosis factor receptor. In another example, SEQ ID NO:8 is 99% identical, from residue M1 to residue A272, to human gastrin receptor (GenBank ID g406076) as determined by the Basic Local Alignment Search Tool (BLAST). The BLAST probability score is 3.2e-206, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:8 also has homology to cholecystokinin B (gastrin) receptors that are localized to the basolateral plasma membrane, as determined by BLAST analysis using the PROTEOME database. These receptors are G protein-coupled receptors. They are involved in stimulating phospholipase C and intracellular calcium flux, regulating digestion, gastric mucosal cell proliferation, and opioidergic and dopaminergic signaling. The human CCKBR variant is associated with colorectal cancer. SEQ ID NO:8 also contains a 7 transmembrane receptor (rhodopsin family) domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein families/domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:8 is a G-protein coupled gastrin receptor. In another example, SEQ ID NO:22 is 99% identical, from residue M1 to residue G187, to human CDw40 (GenBank ID g29851) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 2.7e-107, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:22 is also a member of the tumor necrosis factor receptor superfamily, binds the ligand CD40L, and is expressed specifically in B lymphocytes. It also has a role in B lymphocyte maturation, as determined by BLAST analysis using the PROTEOME database. SEQ ID NO:22 also contains a TNF-receptor internal cysteine rich, Tumor necrosis factor receptor / nerve, and TNFR/NGFR cysteine-rich region domains as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM, SMART, and INCY databases of conserved protein families/domains. (See Table 3.) Data from BLIMPS and MOTIFS analyses, and BLAST analyses against the PRODOM and DOMO databases, provide further corroborative evidence that SEQ ID NO:22 is a CDw40. In another example, SEQ ID NO:27 is 100% identical, from residue M1 to residue M224, to *Homo sapiens* ocular melanoma-associated antigen (GenBank ID g246539) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.8e-115, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:27 also has homology to proteins that are members of the tetraspanning superfamily and specifically CD63 antigen, form complexes with integrins and MHC class II molecules, and act to limit the invasion and progression of melanoma, as determined by BLAST analysis using the PROTEOME database. SEQ ID NO:27 also contains a tetraspanin family

domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein families/domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses, and BLAST analyses against the PRODOM and DOMO databases, provide further corroborative evidence that SEQ ID NO:27 is a transmembrane 4 family or tetraspanning family member. In another example, SEQ ID NO:31 is 85% identical, from residue F6 to residue I786, to human CD97 (GenBank ID g1685051) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:31 also has homology to proteins that are localized to the plasma membrane and are members of the EGF TM7 family of class II seven-span transmembrane receptors, as determined by BLAST analysis using the PROTEOME database. SEQ ID NO:31 also contains a 7 transmembrane receptor (secretin family) domain, an EGF-like domain, a G-protein coupled receptor proteolytic site domain, and a latrophilin/CL-1-like GPS domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM and SMART databases of conserved protein families/domains. (See Table 3.) Data from BLIMPS, MOTIFS, and TMHMMER analyses, and BLAST analyses against the PRODOM and DOMO databases, provide further corroborative evidence that SEQ ID NO:31 is a CD97 antigen. In another example, SEQ ID NO:38 is 99% identical, from residue M1 to residue K792, to *H. sapiens* CD97 (GenBank ID g1685051) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:38 also has homology to proteins that are localized to the plasma membrane, are receptors for the complement cascade regulator, CD55 (Daf1), may play a role in lymphocyte activation, and are CD97 antigens as determined by BLAST analysis using the PROTEOME database. SEQ ID NO:38 also contains a 7 transmembrane receptor domain, an EGF-like domain, and a Latrophilin/CL-1-like GPS domain, as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM and SMART databases of conserved protein families/domains. (See Table 3.) Data from BLIMPS and MOTIFS analyses, and BLAST analyses against the PRODOM and DOMO databases, provide further corroborative evidence that SEQ ID NO:38 is a CD97 antigen. SEQ ID NO:1-5, SEQ ID NO:7, SEQ ID NO:9-21, SEQ ID NO:23-26, SEQ ID NO:28-30, and SEQ ID NO:32-37 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-38 are described in Table 7.

As shown in Table 4, the full length polynucleotide embodiments were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of

these two types of sequences. Column 1 lists the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:), the corresponding Incyte polynucleotide consensus sequence number (Incyte ID) for each polynucleotide of the invention, and the length of each polynucleotide sequence in basepairs. Column 2 shows the nucleotide start (5') and stop (3') positions of the cDNA and/or genomic sequences used to assemble the full length polynucleotide embodiments, and of fragments of the polynucleotides which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:39-76 or that distinguish between SEQ ID NO:39-76 and related polynucleotides.

The polynucleotide fragments described in Column 2 of Table 4 may refer specifically, for example, to Incyte cDNAs derived from tissue-specific cDNA libraries or from pooled cDNA libraries. Alternatively, the polynucleotide fragments described in column 2 may refer to GenBank cDNAs or ESTs which contributed to the assembly of the full length polynucleotides. In addition, the polynucleotide fragments described in column 2 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (*i.e.*, those sequences including the designation "ENST"). Alternatively, the polynucleotide fragments described in column 2 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (*i.e.*, those sequences including the designation "NM" or "NT") or the NCBI RefSeq Protein Sequence Records (*i.e.*, those sequences including the designation "NP"). Alternatively, the polynucleotide fragments described in column 2 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, a polynucleotide sequence identified as FL_*XXXXXX*_N_1_N_2_*YYYYY*_N_3_N_4 represents a "stitched" sequence in which *XXXXXX* is the identification number of the cluster of sequences to which the algorithm was applied, and *YYYYY* is the number of the prediction generated by the algorithm, and $N_{1,2,3...}$, if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the polynucleotide fragments in column 2 may refer to assemblages of exons brought together by an "exon-stretching" algorithm. For example, a polynucleotide sequence identified as FL*XXXXXX*_g*AAAAA*_g*BBBBB*_1_*N* is a "stretched" sequence, with *XXXXXX* being the Incyte project identification number, g*AAAAA* being the GenBank identification number of the human genomic sequence to which the "exon-stretching" algorithm was applied, g*BBBBB* being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and *N* referring to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the "exon-stretching" algorithm, a RefSeq identifier (denoted by "NM," "NP," or "NT") may be used in place of the GenBank identifier (*i.e.*, g*BBBBB*).

Alternatively, a prefix identifies component sequences that were hand-edited, predicted from

genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V).

Prefix	Type of analysis and/or examples of programs
GNN, GFG, ENST	Exon prediction from genomic sequences using, for example, GENSCAN (Stanford University, CA, USA) or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK).
GBI	Hand-edited analysis of genomic sequences.
FL	Stitched or stretched genomic sequences (see Example V).
INCY	Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.

In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in Table 4 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotides which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotides. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

Table 8 shows single nucleotide polymorphisms (SNPs) found in polynucleotide sequences of the invention, along with allele frequencies in different human populations. Columns 1 and 2 show the polynucleotide sequence identification number (SEQ ID NO:) and the corresponding Incyte project identification number (PID) for polynucleotides of the invention. Column 3 shows the Incyte identification number for the EST in which the SNP was detected (EST ID), and column 4 shows the identification number for the SNP (SNP ID). Column 5 shows the position within the EST sequence at which the SNP is located (EST SNP), and column 6 shows the position of the SNP within the full-length polynucleotide sequence (CB1 SNP). Column 7 shows the allele found in the EST sequence. Columns 8 and 9 show the two alleles found at the SNP site. Column 10 shows the amino acid encoded by the codon including the SNP site, based upon the allele found in the EST. Columns 11-14 show the frequency of allele 1 in four different human populations. An entry of n/d (not detected) indicates that the frequency of allele 1 in the population was too low to be detected, while n/a (not available) indicates that the allele frequency was not determined for the population.

The invention also encompasses REMAP variants. Various embodiments of REMAP variants can have at least about 80%, at least about 90%, or at least about 95% amino acid sequence identity to the REMAP amino acid sequence, and can contain at least one functional or structural characteristic of REMAP.

Various embodiments also encompass polynucleotides which encode REMAP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:39-76, which encodes REMAP. The polynucleotide sequences of SEQ ID NO:39-76, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses variants of a polynucleotide encoding REMAP. In particular, such a variant polynucleotide will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a polynucleotide encoding REMAP. A particular aspect of the invention encompasses a variant of a polynucleotide comprising a sequence selected from the group consisting of SEQ ID NO:39-76 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:39-76. Any one of the polynucleotide variants described above can encode a polypeptide which contains at least one functional or structural characteristic of REMAP.

In addition, or in the alternative, a polynucleotide variant of the invention is a splice variant of a polynucleotide encoding REMAP. A splice variant may have portions which have significant sequence identity to a polynucleotide encoding REMAP, but will generally have a greater or lesser number of polynucleotides due to additions or deletions of blocks of sequence arising from alternate splicing during mRNA processing. A splice variant may have less than about 70%, or alternatively less than about 60%, or alternatively less than about 50% polynucleotide sequence identity to a polynucleotide encoding REMAP over its entire length; however, portions of the splice variant will have at least about 70%, or alternatively at least about 85%, or alternatively at least about 95%, or alternatively 100% polynucleotide sequence identity to portions of the polynucleotide encoding REMAP. For example, a polynucleotide comprising a sequence of SEQ ID NO:69 and a polynucleotide comprising a sequence of SEQ ID NO:76 are splice variants of each other. Any one of the splice variants described above can encode a polypeptide which contains at least one functional or structural characteristic of REMAP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding REMAP, some bearing minimal

similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring REMAP, and all such variations are to be considered as being specifically disclosed.

Although polynucleotides which encode REMAP and its variants are generally capable of hybridizing to polynucleotides encoding naturally occurring REMAP under appropriately selected conditions of stringency, it may be advantageous to produce polynucleotides encoding REMAP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding REMAP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of polynucleotides which encode REMAP and REMAP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic polynucleotide may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a polynucleotide encoding REMAP or any fragment thereof.

Embodiments of the invention can also include polynucleotides that are capable of hybridizing to the claimed polynucleotides, and, in particular, to those having the sequences shown in SEQ ID NO:39-76 and fragments thereof, under various conditions of stringency (Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-511). Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Biosciences, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Invitrogen, Carlsbad CA). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ

Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Amersham Biosciences), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art (Ausubel et al., *supra*, ch. 7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853).

The nucleic acids encoding REMAP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119). In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art (Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-

specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotides or fragments thereof which encode REMAP may be cloned in recombinant DNA molecules that direct expression of REMAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other polynucleotides which encode substantially the same or a functionally equivalent polypeptides may be produced and used to express REMAP.

The polynucleotides of the invention can be engineered using methods generally known in the art in order to alter REMAP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent No. 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of REMAP, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, polynucleotides encoding REMAP may be synthesized, in whole or in part, using one or more chemical methods well known in the art (Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232). Alternatively, REMAP itself or a fragment thereof may be synthesized using chemical methods known in the art. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques (Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; Roberge, J.Y. et al. (1995) Science 269:202-204). Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of REMAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography (Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421). The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing (Creighton, *supra*, pp. 28-53).

In order to express a biologically active REMAP, the polynucleotides encoding REMAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotides encoding REMAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of polynucleotides encoding REMAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where a polynucleotide sequence encoding REMAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

Methods which are well known to those skilled in the art may be used to construct expression vectors containing polynucleotides encoding REMAP and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques,

synthetic techniques, and *in vivo* genetic recombination (Sambrook and Russell, *supra*, ch. 1-4, and 8; Ausubel et al., *supra*, ch. 1, 3, and 15).

A variety of expression vector/host systems may be utilized to contain and express polynucleotides encoding REMAP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems (Sambrook and Russell, *supra*; Ausubel et al., *supra*; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355). Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of polynucleotides to the targeted organ, tissue, or cell population (Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5:350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90:6340-6344; Buller, R.M. et al. (1985) Nature 317:813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31:219-226; Verma, I.M. and N. Somia (1997) Nature 389:239-242). The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotides encoding REMAP. For example, routine cloning, subcloning, and propagation of polynucleotides encoding REMAP can be achieved using a multifunctional *E. coli* vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Invitrogen). Ligation of polynucleotides encoding REMAP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for *in vitro* transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509). When large quantities of REMAP are needed, e.g. for the production of antibodies, vectors which direct high level expression of REMAP may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of REMAP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH

promoters, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign polynucleotide sequences into the host genome for stable propagation (Ausubel et al., *supra*; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; Scorer, C.A. et al. (1994) Bio/Technology 12:181-184).

Plant systems may also be used for expression of REMAP. Transcription of polynucleotides encoding REMAP may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection (The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196).

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, polynucleotides encoding REMAP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses REMAP in host cells (Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes (Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355).

For long term production of recombinant proteins in mammalian systems, stable expression of REMAP in cell lines is preferred. For example, polynucleotides encoding REMAP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be

propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk*⁻ and *apr*⁻ cells, respectively (Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823). Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14). Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites (Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051). Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β-glucuronidase and its substrate β-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding REMAP is inserted within a marker gene sequence, transformed cells containing polynucleotides encoding REMAP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding REMAP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the polynucleotide encoding REMAP and that express REMAP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of REMAP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on REMAP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art

(Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding REMAP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, polynucleotides encoding REMAP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Biosciences, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with polynucleotides encoding REMAP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode REMAP may be designed to contain signal sequences which direct secretion of REMAP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted polynucleotides or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant polynucleotides encoding REMAP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric REMAP protein

containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of REMAP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the REMAP encoding sequence and the heterologous protein sequence, so that REMAP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel et al. (*supra*, ch. 10 and 16). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In another embodiment, synthesis of radiolabeled REMAP may be achieved *in vitro* using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ^{35}S-methionine.

REMAP, fragments of REMAP, or variants of REMAP may be used to screen for compounds that specifically bind to REMAP. One or more test compounds may be screened for specific binding to REMAP. In various embodiments, 1, 2, 3, 4, 5, 10, 20, 50, 100, or 200 test compounds can be screened for specific binding to REMAP. Examples of test compounds can include antibodies, anticalins, oligonucleotides, proteins (e.g., ligands or receptors), or small molecules.

In related embodiments, variants of REMAP can be used to screen for binding of test compounds, such as antibodies, to REMAP, a variant of REMAP, or a combination of REMAP and/or one or more variants REMAP. In an embodiment, a variant of REMAP can be used to screen for compounds that bind to a variant of REMAP, but not to REMAP having the exact sequence of a sequence of SEQ ID NO:1-38. REMAP variants used to perform such screening can have a range of about 50% to about 99% sequence identity to REMAP, with various embodiments having 60%, 70%, 75%, 80%, 85%, 90%, and 95% sequence identity.

In an embodiment, a compound identified in a screen for specific binding to REMAP can be closely related to the natural ligand of REMAP, e.g., a ligand or fragment thereof, a natural substrate,

a structural or functional mimetic, or a natural binding partner (Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2):Chapter 5). In another embodiment, the compound thus identified can be a natural ligand of a receptor REMAP (Howard, A.D. et al. (2001) Trends Pharmacol. Sci.22:132-140; Wise, A. et al. (2002) Drug Discovery Today 7:235-246).

In other embodiments, a compound identified in a screen for specific binding to REMAP can be closely related to the natural receptor to which REMAP binds, at least a fragment of the receptor, or a fragment of the receptor including all or a portion of the ligand binding site or binding pocket. For example, the compound may be a receptor for REMAP which is capable of propagating a signal, or a decoy receptor for REMAP which is not capable of propagating a signal (Ashkenazi, A. and V.M. Divit (1999) Curr. Opin. Cell Biol. 11:255-260; Mantovani, A. et al. (2001) Trends Immunol. 22:328-336). The compound can be rationally designed using known techniques. Examples of such techniques include those used to construct the compound etanercept (ENBREL; Amgen Inc., Thousand Oaks CA), which is efficacious for treating rheumatoid arthritis in humans. Etanercept is an engineered p75 tumor necrosis factor (TNF) receptor dimer linked to the Fc portion of human IgG_1 (Taylor, P.C. et al. (2001) Curr. Opin. Immunol. 13:611-616).

In one embodiment, two or more antibodies having similar or, alternatively, different specificities can be screened for specific binding to REMAP, fragments of REMAP, or variants of REMAP. The binding specificity of the antibodies thus screened can thereby be selected to identify particular fragments or variants of REMAP. In one embodiment, an antibody can be selected such that its binding specificity allows for preferential identification of specific fragments or variants of REMAP. In another embodiment, an antibody can be selected such that its binding specificity allows for preferential diagnosis of a specific disease or condition having increased, decreased, or otherwise abnormal production of REMAP.

In an embodiment, anticalins can be screened for specific binding to REMAP, fragments of REMAP, or variants of REMAP. Anticalins are ligand-binding proteins that have been constructed based on a lipocalin scaffold (Weiss, G.A. and H.B. Lowman (2000) Chem. Biol. 7:R177-R184; Skerra, A. (2001) J. Biotechnol. 74:257-275). The protein architecture of lipocalins can include a beta-barrel having eight antiparallel beta-strands, which supports four loops at its open end. These loops form the natural ligand-binding site of the lipocalins, a site which can be re-engineered *in vitro* by amino acid substitutions to impart novel binding specificities. The amino acid substitutions can be made using methods known in the art or described herein, and can include conservative substitutions (e.g., substitutions that do not alter binding specificity) or substitutions that modestly, moderately, or significantly alter binding specificity.

In one embodiment, screening for compounds which specifically bind to, stimulate, or inhibit

REMAP involves producing appropriate cells which express REMAP, either as a secreted protein or on the cell membrane. Preferred cells can include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing REMAP or cell membrane fractions which contain REMAP are then contacted with a test compound and binding, stimulation, or inhibition of activity of either REMAP or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with REMAP, either in solution or affixed to a solid support, and detecting the binding of REMAP to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

An assay can be used to assess the ability of a compound to bind to its natural ligand and/or to inhibit the binding of its natural ligand to its natural receptors. Examples of such assays include radio-labeling assays such as those described in U.S. Patent No. 5,914,236 and U.S. Patent No. 6,372,724. In a related embodiment, one or more amino acid substitutions can be introduced into a polypeptide compound (such as a receptor) to improve or alter its ability to bind to its natural ligands (Matthews, D.J. and J.A. Wells. (1994) Chem. Biol. 1:25-30). In another related embodiment, one or more amino acid substitutions can be introduced into a polypeptide compound (such as a ligand) to improve or alter its ability to bind to its natural receptors (Cunningham, B.C. and J.A. Wells (1991) Proc. Natl. Acad. Sci. USA 88:3407-3411; Lowman, H.B. et al. (1991) J. Biol. Chem. 266:10982-10988).

REMAP, fragments of REMAP, or variants of REMAP may be used to screen for compounds that modulate the activity of REMAP. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for REMAP activity, wherein REMAP is combined with at least one test compound, and the activity of REMAP in the presence of a test compound is compared with the activity of REMAP in the absence of the test compound. A change in the activity of REMAP in the presence of the test compound is indicative of a compound that modulates the activity of REMAP. Alternatively, a test compound is combined with an *in vitro* or cell-free system comprising REMAP under conditions suitable for REMAP activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of REMAP may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding REMAP or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease (see, e.g., U.S. Patent No. 5,175,383 and U.S. Patent No. 5,767,337). For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (*neo*; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding REMAP may also be manipulated *in vitro* in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding REMAP can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding REMAP is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress REMAP, e.g., by secreting REMAP in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of REMAP and receptors and membrane-associated proteins. In addition, examples of tissues expressing REMAP can be found in Table 6 and can also be found in Example XI.

Therefore, REMAP appears to play a role in cell proliferative, autoimmune/inflammatory, neurological, metabolic, developmental, and endocrine disorders. In the treatment of disorders associated with increased REMAP expression or activity, it is desirable to decrease the expression or activity of REMAP. In the treatment of disorders associated with decreased REMAP expression or activity, it is desirable to increase the expression or activity of REMAP.

Therefore, in one embodiment, REMAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of REMAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, colon, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system

disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a metabolic disorder such as Addison's disease, cerebrotendinous xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalism, hypoadrenalism, hyperparathyroidism, hypoparathyroidism, hypercholesterolemia, hyperthyroidism, hypoglycemia, hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage diseases, mannosidosis, neuraminidase deficiency, obesity, osteoporosis, phenylketonuria, pseudovitamin D-deficiency rickets, disorders of carbohydrate metabolism such as congenital type II dyserythropoietic anemia, diabetes, insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, galactose epimerase deficiency, glycogen storage diseases, lysosomal storage diseases, fructosuria, pentosuria, and inherited abnormalities of pyruvate metabolism, disorders of lipid metabolism such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid storage disorders such Fabry's disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy, adrenoleukodystrophy, GM_2 gangliosidosis, and ceroid lipofuscinosis, abetalipoproteinemia, Tangier disease, hyperlipoproteinemia, lipodystrophy, lipomatoses, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipoid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with hypertriglyceridemia, primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease, hyperlipidemia, hyperlipemia, and lipid myopathies, and disorders of copper metabolism such as Menke's disease, Wilson's disease, and Ehlers-Danlos syndrome type IX diabetes; a developmental

disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, a seizure disorder such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; and an endocrine disorder such as a disorder of the hypothalamus and/or pituitary resulting from lesions such as a primary brain tumor, adenoma, infarction associated with pregnancy, hypophysectomy, aneurysm, vascular malformation, thrombosis, infection, immunological disorder, and complication due to head trauma, a disorder associated with hypopituitarism including hypogonadism, Sheehan syndrome, diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and dwarfism, a disorder associated with hyperpituitarism including acromegaly, giantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma, a disorder associated with hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection, subacute thyroiditis associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism, a disorder associated with hyperthyroidism including thyrotoxicosis and its various forms, Grave's disease, pretibial myxedema, toxic multinodular goiter, thyroid carcinoma, and Plummer's disease, a disorder associated with hyperparathyroidism including Conn disease (chronic hypercalemia), a pancreatic disorder such as Type I or Type II diabetes mellitus and associated complications, a disorder associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis, amyloidosis, hypokalemia, Cushing's disease, Liddle's syndrome, and Arnold-Healy-Gordon syndrome, pheochromocytoma tumors, and Addison's disease, a disorder associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbation of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis, and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, a hypergonadal disorder associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5 α-reductase, and gynecomastia.

In another embodiment, a vector capable of expressing REMAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of REMAP including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified REMAP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of REMAP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of REMAP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of REMAP including, but not limited to, those listed above.

In a further embodiment, an antagonist of REMAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of REMAP. Examples of such disorders include, but are not limited to, those cell proliferative, autoimmune/inflammatory, neurological, metabolic, developmental, and endocrine disorders described above. In one aspect, an antibody which specifically binds REMAP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express REMAP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding REMAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of REMAP including, but not limited to, those described above.

In other embodiments, any protein, agonist, antagonist, antibody, complementary sequence, or vector embodiments may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of REMAP may be produced using methods which are generally known in the art. In particular, purified REMAP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind REMAP. Antibodies to REMAP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. In an embodiment, neutralizing antibodies (i.e., those which inhibit dimer formation) can be used therapeutically. Single chain antibodies (e.g., from camels or llamas) may be potent enzyme inhibitors and may have application in the design of peptide mimetics, and in the development of immuno-adsorbents and biosensors (Muyldermans, S. (2001) J. Biotechnol. 74:277-302).

For the production of antibodies, various hosts including goats, rabbits, rats, mice, camels, dromedaries, llamas, humans, and others may be immunized by injection with REMAP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and *Corynebacterium parvum* are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to REMAP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are substantially identical to a portion of the amino acid sequence of the natural protein. Short stretches of REMAP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to REMAP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120).

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used (Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; Takeda, S. et al. (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce REMAP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137).

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

Antibody fragments which contain specific binding sites for REMAP may also be generated.

For example, such fragments include, but are not limited to, $F(ab')_2$ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W.D. et al. (1989) Science 246:1275-1281).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between REMAP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering REMAP epitopes is generally used, but a competitive binding assay may also be employed (Pound, *supra*).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for REMAP. Affinity is expressed as an association constant, K_a, which is defined as the molar concentration of REMAP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple REMAP epitopes, represents the average affinity, or avidity, of the antibodies for REMAP. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular REMAP epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the REMAP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of REMAP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of REMAP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available (Catty, *supra*; Coligan et al., *supra*).

In another embodiment of the invention, polynucleotides encoding REMAP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding REMAP. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding REMAP (Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press, Totawa NJ).

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein (Slater, J.E. et al. (1998) J. Allergy Clin. Immunol. 102:469-475; Scanlon, K.J. et al. (1995) 9:1288-1296). Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors (Miller, A.D. (1990) Blood 76:271; Ausubel et al., *supra*; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63:323-347). Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art (Rossi, J.J. (1995) Br. Med. Bull. 51:217-225; Boado, R.J. et al. (1998) J. Pharm. Sci. 87:1308-1315; Morris, M.C. et al. (1997) Nucleic Acids Res. 25:2730-2736).

In another embodiment of the invention, polynucleotides encoding REMAP may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as *Candida albicans* and *Paracoccidioides brasiliensis*; and protozoan parasites such as *Plasmodium falciparum* and *Trypanosoma cruzi*). In the

case where a genetic deficiency in REMAP expression or regulation causes disease, the expression of REMAP from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in REMAP are treated by constructing mammalian expression vectors encoding REMAP and introducing these vectors by mechanical means into REMAP-deficient cells. Mechanical transfer technologies for use with cells *in vivo* or *ex vitro* include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J.-L. and H. Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of REMAP include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). REMAP may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and H.M. Blau, *supra*)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding REMAP from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to REMAP expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding REMAP under the control of an independent promoter or the retrovirus long

terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent No. 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., $CD4^+$ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In an embodiment, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding REMAP to cells which have one or more genetic abnormalities with respect to the expression of REMAP. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent No. 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999; Annu. Rev. Nutr. 19:511-544) and Verma, I.M. and N. Somia (1997; Nature 18:389:239-242).

In another embodiment, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding REMAP to target cells which have one or more genetic abnormalities with respect to the expression of REMAP. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing REMAP to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res.

169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent No. 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999; J. Virol. 73:519-532) and Xu, H. et al. (1994; Dev. Biol. 163:152-161). The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another embodiment, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding REMAP to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for REMAP into the alphavirus genome in place of the capsid-coding region results in the production of a large number of REMAP-coding RNAs and the synthesis of high levels of REMAP in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of REMAP into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of

polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177). A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of RNA molecules encoding REMAP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA molecules encoding REMAP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

In other embodiments of the invention, the expression of one or more selected polynucleotides of the present invention can be altered, inhibited, decreased, or silenced using RNA

interference (RNAi) or post-transcriptional gene silencing (PTGS) methods known in the art. RNAi is a post-transcriptional mode of gene silencing in which double-stranded RNA (dsRNA) introduced into a targeted cell specifically suppresses the expression of the homologous gene (i.e., the gene bearing the sequence complementary to the dsRNA). This effectively knocks out or substantially reduces the expression of the targeted gene. PTGS can also be accomplished by use of DNA or DNA fragments as well. RNAi methods are described by Fire, A. et al. (1998; Nature 391:806-811) and Gura, T. (2000; Nature 404:804-808). PTGS can also be initiated by introduction of a complementary segment of DNA into the selected tissue using gene delivery and/or viral vector delivery methods described herein or known in the art.

RNAi can be induced in mammalian cells by the use of small interfering RNA also known as siRNA. SiRNA are shorter segments of dsRNA (typically about 21 to 23 nucleotides in length) that result *in vivo* from cleavage of introduced dsRNA by the action of an endogenous ribonuclease. SiRNA appear to be the mediators of the RNAi effect in mammals. The most effective siRNAs appear to be 21 nucleotide dsRNAs with 2 nucleotide 3' overhangs. The use of siRNA for inducing RNAi in mammalian cells is described by Elbashir, S.M. et al. (2001; Nature 411:494-498).

SiRNA can either be generated indirectly by introduction of dsRNA into the targeted cell, or directly by mammalian transfection methods and agents described herein or known in the art.(such as liposome-mediated transfection, viral vector methods, or other polynucleotide delivery/introductory methods). Suitable SiRNAs can be selected by examining a transcript of the target polynucleotide (e.g., mRNA) for nucleotide sequences downstream from the AUG start codon and recording the occurrence of each nucleotide and the 3' adjacent 19 to 23 nucleotides as potential siRNA target sites, with sequences having a 21 nucleotide length being preferred. Regions to be avoided for target siRNA sites include the 5' and 3' untranslated regions (UTRs) and regions near the start codon (within 75 bases), as these may be richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP endonuclease complex. The selected target sites for siRNA can then be compared to the appropriate genome database (e.g., human, etc.) using BLAST or other sequence comparison algorithms known in the art. Target sequences with significant homology to other coding sequences can be eliminated from consideration. The selected SiRNAs can be produced by chemical synthesis methods known in the art or by *in vitro* transcription using commercially available methods and kits such as the SILENCER siRNA construction kit (Ambion, Austin TX).

In alternative embodiments, long-term gene silencing and/or RNAi effects can be induced in selected tissue using expression vectors that continuously express siRNA. This can be accomplished using expression vectors that are engineered to express hairpin RNAs (shRNAs) using methods

known in the art (see, e.g., Brummelkamp, T.R. et al. (2002) Science 296:550-553; and Paddison, P.J. et al. (2002) Genes Dev. 16:948-958). In these and related embodiments, shRNAs can be delivered to target cells using expression vectors known in the art. An example of a suitable expression vector for delivery of siRNA is the PSILENCER1.0-U6 (circular) plasmid (Ambion). Once delivered to the target tissue, shRNAs are processed *in vivo* into siRNA-like molecules capable of carrying out gene-specific silencing.

In various embodiments, the expression levels of genes targeted by RNAi or PTGS methods can be determined by assays for mRNA and/or protein analysis. Expression levels of the mRNA of a targeted gene, can be determined by northern analysis methods using, for example, the NORTHERNMAX-GLY kit (Ambion); by microarray methods; by PCR methods; by real time PCR methods; and by other RNA/polynucleotide assays known in the art or described herein. Expression levels of the protein encoded by the targeted gene can be determined by Western analysis using standard techniques known in the art.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding REMAP. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased REMAP expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding REMAP may be therapeutically useful, and in the treatment of disorders associated with decreased REMAP expression or activity, a compound which specifically promotes expression of the polynucleotide encoding REMAP may be therapeutically useful.

In various embodiments, one or more test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding REMAP is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an *in vitro* cell-free or

reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding REMAP are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding REMAP. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a *Schizosaccharomyces pombe* gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use *in vivo*, *in vitro*, and *ex vivo*. For *ex vivo* therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art (Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466).

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of REMAP, antibodies to REMAP, and mimetics, agonists, antagonists, or inhibitors of REMAP.

In various embodiments, the compositions described herein, such as pharmaceutical compositions, may be administered by any number of routes including, but not limited to, oral,

intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery allows administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising REMAP or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, REMAP or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example REMAP or fragments thereof, antibodies of REMAP, and agonists, antagonists or inhibitors of REMAP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is

preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind REMAP may be used for the diagnosis of disorders characterized by expression of REMAP, or in assays to monitor patients being treated with REMAP or agonists, antagonists, or inhibitors of REMAP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for REMAP include methods which utilize the antibody and a label to detect REMAP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring REMAP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of REMAP expression. Normal or standard values for REMAP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to REMAP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of REMAP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for

diagnosing disease.

In another embodiment of the invention, polynucleotides encoding REMAP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotides, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of REMAP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of REMAP, and to monitor regulation of REMAP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotides, including genomic sequences, encoding REMAP or closely related molecules may be used to identify nucleic acid sequences which encode REMAP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding REMAP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the REMAP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:39-76 or from genomic sequences including promoters, enhancers, and introns of the REMAP gene.

Means for producing specific hybridization probes for polynucleotides encoding REMAP include the cloning of polynucleotides encoding REMAP or REMAP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotides encoding REMAP may be used for the diagnosis of disorders associated with expression of REMAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, colon, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory

distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a metabolic disorder such as Addison's disease, cerebrotendinous xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalism, hypoadrenalism, hyperparathyroidism, hypoparathyroidism, hypercholesterolemia, hyperthyroidism, hypoglycemia,

hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage diseases, mannosidosis, neuraminidase deficiency, obesity, osteoporosis, phenylketonuria, pseudovitamin D-deficiency rickets, disorders of carbohydrate metabolism such as congenital type II dyserythropoietic anemia, diabetes, insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, galactose epimerase deficiency, glycogen storage diseases, lysosomal storage diseases, fructosuria, pentosuria, and inherited abnormalities of pyruvate metabolism, disorders of lipid metabolism such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid storage disorders such Fabry's disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy, adrenoleukodystrophy, GM_2 gangliosidosis, and ceroid lipofuscinosis, abetalipoproteinemia, Tangier disease, hyperlipoproteinemia, lipodystrophy, lipomatoses, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipoid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with hypertriglyceridemia, primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease, hyperlipidemia, hyperlipemia, and lipid myopathies, and disorders of copper metabolism such as Menke's disease, Wilson's disease, and Ehlers-Danlos syndrome type IX diabetes; a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, a seizure disorder such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; and an endocrine disorder such as a disorder of the hypothalamus and/or pituitary resulting from lesions such as a primary brain tumor, adenoma, infarction associated with pregnancy, hypophysectomy, aneurysm, vascular malformation, thrombosis, infection, immunological disorder, and complication due to head trauma, a disorder associated with hypopituitarism including hypogonadism, Sheehan syndrome, diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and dwarfism, a disorder associated with hyperpituitarism including acromegaly, giantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma, a disorder associated with hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection,

subacute thyroiditis associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism, a disorder associated with hyperthyroidism including thyrotoxicosis and its various forms, Grave's disease, pretibial myxedema, toxic multinodular goiter, thyroid carcinoma, and Plummer's disease, a disorder associated with hyperparathyroidism including Conn disease (chronic hypercalemia), a pancreatic disorder such as Type I or Type II diabetes mellitus and associated complications, a disorder associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis, amyloidosis, hypokalemia, Cushing's disease, Liddle's syndrome, and Arnold-Healy-Gordon syndrome, pheochromocytoma tumors, and Addison's disease, a disorder associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbation of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis, and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, a hypergonadal disorder associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5 α-reductase, and gynecomastia. Polynucleotides encoding REMAP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered REMAP expression. Such qualitative or quantitative methods are well known in the art.

In a particular embodiment, polynucleotides encoding REMAP may be used in assays that detect the presence of associated disorders, particularly those mentioned above. Polynucleotides complementary to sequences encoding REMAP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of polynucleotides encoding REMAP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of REMAP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding REMAP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from

normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier, thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding REMAP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced *in vitro*. Oligomers will preferably contain a fragment of a polynucleotide encoding REMAP, or a fragment of a polynucleotide complementary to the polynucleotide encoding REMAP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from polynucleotides encoding REMAP may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from polynucleotides encoding REMAP are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP

(isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

SNPs may be used to study the genetic basis of human disease. For example, at least 16 common SNPs have been associated with non-insulin-dependent diabetes mellitus. SNPs are also useful for examining differences in disease outcomes in monogenic disorders, such as cystic fibrosis, sickle cell anemia, or chronic granulomatous disease. For example, variants in the mannose-binding lectin, MBL2, have been shown to be correlated with deleterious pulmonary outcomes in cystic fibrosis. SNPs also have utility in pharmacogenomics, the identification of genetic variants that influence a patient's response to a drug, such as life-threatening toxicity. For example, a variation in N-acetyl transferase is associated with a high incidence of peripheral neuropathy in response to the anti-tuberculosis drug isoniazid, while a variation in the core promoter of the ALOX5 gene results in diminished clinical response to treatment with an anti-asthma drug that targets the 5-lipoxygenase pathway. Analysis of the distribution of SNPs in different populations is useful for investigating genetic drift, mutation, recombination, and selection, as well as for tracing the origins of populations and their migrations (Taylor, J.G. et al. (2001) Trends Mol. Med. 7:507-512; Kwok, P.-Y. and Z. Gu (1999) Mol. Med. Today 5:538-543; Nowotny, P. et al. (2001) Curr. Opin. Neurobiol. 11:637-641).

Methods which may also be used to quantify the expression of REMAP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves (Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotides described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the

activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, REMAP, fragments of REMAP, or antibodies specific for REMAP may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time (Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent No. 5,840,484; hereby expressly incorporated by reference herein). Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression *in vivo*, as in the case of a tissue or biopsy sample, or *in vitro*, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with *in vitro* model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important

as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity (see, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm). Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In an embodiment, the toxicity of a test compound can be assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another embodiment relates to the use of the polypeptides disclosed herein to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, *supra*). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences

of interest. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for REMAP to quantify the levels of REMAP expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoze, L.G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art (Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA

93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/25116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662). Various types of microarrays are well known and thoroughly described in Schena, M., ed. (1999; DNA Microarrays: A Practical Approach, Oxford University Press, London).

In another embodiment of the invention, nucleic acid sequences encoding REMAP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries (Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; Trask, B.J. (1991) Trends Genet. 7:149-154). Once mapped, the nucleic acid sequences may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP) (Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357).

Fluorescent *in situ* hybridization (FISH) may be correlated with other physical and genetic map data (Heinz-Ulrich, et al. (1995) in Meyers, *supra*, pp. 965-968). Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding REMAP on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation (Gatti, R.A. et al. (1988) Nature 336:577-580). The nucleotide sequence of the

instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, REMAP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between REMAP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest (Geysen, et al. (1984) PCT application WO84/03564). In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with REMAP, or fragments thereof, and washed. Bound REMAP is then detected by methods well known in the art. Purified REMAP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding REMAP specifically compete with a test compound for binding REMAP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with REMAP.

In additional embodiments, the nucleotide sequences which encode REMAP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, including U.S. Ser. No. 60/358,279, U.S. Ser. No. 60/364,338, U.S. Ser. No. 60/375,657, U.S. Ser. No. 60/376,669, U.S. Ser. No. 60/379,837, and U.S. Ser. No. 60/379,853, are hereby expressly incorporated by reference.

EXAMPLES

I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database

(Incyte Genomics, Palo Alto CA). Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Invitrogen), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Invitrogen), using the recommended procedures or similar methods known in the art (Ausubel et al., *supra*, ch. 5). Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Biosciences) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Invitrogen, Carlsbad CA), PCDNA2.1 plasmid (Invitrogen), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto CA), pRARE (Incyte Genomics), or pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Invitrogen.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by *in vivo* excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1

ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Biosciences or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Amersham Biosciences); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (Ausubel et al., *supra*, ch. 7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM; PROTEOME databases with sequences from *Homo sapiens*, *Rattus norvegicus*, *Mus musculus*, *Caenorhabditis elegans*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, and *Candida albicans* (Incyte Genomics, Palo Alto CA); hidden Markov model (HMM)-based protein family databases such as PFAM, INCY, and TIGRFAM (Haft, D.H. et al. (2001) Nucleic Acids Res. 29:41-43); and HMM-based protein domain databases such as SMART (Schultz, J. et al. (1998) Proc. Natl. Acad. Sci. USA 95:5857-5864; Letunic, I. et al. (2002) Nucleic Acids Res. 30:242-244). (HMM is a probabilistic approach which analyzes consensus

primary structures of gene families; see, for example, Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, the PROTEOME databases, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, hidden Markov model (HMM)-based protein family databases such as PFAM, INCY, and TIGRFAM; and HMM-based protein domain databases such as SMART. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (MiraiBio, Alameda CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:39-76. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 2.

IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative receptors and membrane-associated proteins were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and

gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94; Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode receptors and membrane-associated proteins, the encoded polypeptides were analyzed by querying against PFAM models for receptors and membrane-associated proteins. Potential receptors and membrane-associated proteins were also identified by homology to Incyte cDNA sequences that had been annotated as receptors and membrane-associated proteins. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data

"Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals

thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

"Stretched" Sequences

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of REMAP Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:39-76 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:39-76 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between

chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook and Russell, *supra*, ch. 7; Ausubel et al., *supra*, ch. 4).

Analogous computer techniques applying BLAST were used to search for identical or related molecules in databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum}\{\text{length(Seq. 1)}, \text{length(Seq. 2)}\}}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotides encoding REMAP are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding REMAP. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

VIII. Extension of REMAP Encoding Polynucleotides

Full length polynucleotides are produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+}, $(NH_4)_2SO_4$, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Biosciences), ELONGASE enzyme (Invitrogen), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2:

94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Biosciences). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Biosciences), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Biosciences) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Biosciences) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, full length polynucleotides are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Identification of Single Nucleotide Polymorphisms in REMAP Encoding Polynucleotides

Common DNA sequence variants known as single nucleotide polymorphisms (SNPs) were identified in SEQ ID NO:39-76 using the LIFESEQ database (Incyte Genomics). Sequences from the same gene were clustered together and assembled as described in Example III, allowing the identification of all sequence variants in the gene. An algorithm consisting of a series of filters was used to distinguish SNPs from other sequence variants. Preliminary filters removed the majority of basecall errors by requiring a minimum Phred quality score of 15, and removed sequence alignment errors and errors resulting from improper trimming of vector sequences, chimeras, and splice variants. An automated procedure of advanced chromosome analysis analysed the original chromatogram files in the vicinity of the putative SNP. Clone error filters used statistically generated algorithms to identify errors introduced during laboratory processing, such as those caused by reverse transcriptase, polymerase, or somatic mutation. Clustering error filters used statistically generated algorithms to identify errors resulting from clustering of close homologs or pseudogenes, or due to contamination by non-human sequences. A final set of filters removed duplicates and SNPs found in immunoglobulins or T-cell receptors.

Certain SNPs were selected for further characterization by mass spectrometry using the high throughput MASSARRAY system (Sequenom, Inc.) to analyze allele frequencies at the SNP sites in four different human populations. The Caucasian population comprised 92 individuals (46 male, 46 female), including 83 from Utah, four French, three Venezualan, and two Amish individuals. The African population comprised 194 individuals (97 male, 97 female), all African Americans. The Hispanic population comprised 324 individuals (162 male, 162 female), all Mexican Hispanic. The Asian population comprised 126 individuals (64 male, 62 female) with a reported parental breakdown of 43% Chinese, 31% Japanese, 13% Korean, 5% Vietnamese, and 8% other Asian. Allele frequencies were first analyzed in the Caucasian population; in some cases those SNPs which showed no allelic variance in this population were not further tested in the other three populations.

X. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:39-76 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μCi of [γ-^{32}P] adenosine triphosphate (Amersham Biosciences), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Biosciences). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of

human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

XI. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing; see, e.g., Baldeschweiler et al., *supra*), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena, M., ed. (1999) DNA Microarrays: A Practical Approach, Oxford University Press, London). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements (Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31).

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and

poly(A)$^+$ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)$^+$ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/μl RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Biosciences). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)$^+$ RNA with GEMBRIGHT kits (Incyte Genomics). Specific control poly(A)$^+$ RNAs are synthesized by *in vitro* transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (Clontech, Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μl 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Biosciences).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma-Aldrich, St. Louis MO) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in U.S. Patent No. 5,807,522, incorporated herein by reference. 1 μl of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in

0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μl of sample mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm^2 coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the

two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte Genomics). Array elements that exhibit at least about a two-fold change in expression, a signal-to-background ratio of at least about 2.5, and an element spot size of at least about 40%, are considered to be differentially expressed.

Expression

For example, T-47D is a breast carcinoma cell line isolated from a pleural effusion obtained from a 54-year-old female with an infiltrating ductal carcinoma of the breast. T-47D cells were treated with interferon gamma for from one hour to three days and then compared to untreated T-47D cells. Expression of SEQ ID NO:39 was decreased from 2- to 5.8-fold in treated T-47D cells when compared to untreated T-47D cells. Therefore, SEQ ID NO:39 is useful as a diagnostic marker or as a potential therapeutic target for breast cancer and inflammatory and immune diseases.

In another example, SEQ ID NO:65 demonstrated differential expression in a number of breast cancer and prostate cancer cell lines, as determined by microarray expression analysis. Normal breast cancer cells were represented by the HMEC (human mammary epithelial cells) cell line, and the fibrocystic cell line MCF-10A, derived from a donor with fibrocystic breast disease, was also used as a control, non-cancerous cell line. SEQ ID NO:65 showed at least a 2-fold decrease in expression in Sk-Br-3 cells, a Her2-positive cell line derived from a malignant adenocarcinoma of the breast, when compared to expression levels in either HMEC or MCF-10A cells. In addition, the BT-20 cell line, a cell line that forms stage II adenocarcinomas in mice derived from a donor with malignant adenocarcinoma of the breast, had at least a 2-fold decrease in SEQ ID NO:65 gene expression levels when compared to MCF-10A expression levels. Interestingly, the MCF-10A cell line showed at least a 2-fold decrease in expression of SEQ ID NO:65 when compared to the expression profile in HMEC normal epithelial cell line.

In another example, expression levels of SEQ ID NO:65 were compared in prostate cancer cell lines and in the normal prostate epithelial cell line PrEC. SEQ ID NO:9 showed a 2-fold increase in expression in PC3 cells (an adenocarcinoma cell line isolated from a bone metastasis of a donor with grade IV prostate cancer) when compared to starved PrEC cells. In other experiments, there was a 2-fold decrease in expression in DU 145 cells (derived from a brain metastasis of a donor with metastatic prostatic carcinoma), and a 2-fold decrease in expression in LNCaP cells (derived from a metastatic site in the lymph node of a prostate cancer donor), when compared to gene expression levels in PrEC cells grown in defined media. LNCaP cells also showed at least a 2-fold decrease in SEQ ID NO:65 gene expression levels when compared to levels in another control prostate cell line, PZ-HPV-7. Additionally, treatment of LNCaP cells with PMA and ionomycin, activating PKC and calcium influx into the cells, lead to a time-dependent increase in expression of SEQ ID NO:65 (at least 2-fold after 4 hours, and at least 3-fold after 8 hours) when compared to untreated cells. Therefore, SEQ ID NO:65 is useful for staging of, monitoring treatment of, and diagnostic assays for breast and prostate cancer.

In another example, SEQ ID NO:62 and SEQ ID NO:65 were shown to have differential expression patterns in a number of lymphocyte cell models upon treatment with various stimuli, as determined by microarray expression analysis. Human peripheral blood mononuclear cells (PBMCs) were treated with PMA and ionomycin, to activate PKC- and calcium-dependent signaling pathways, and SEQ ID NO:62 expression levels were compared to levels in untreated cells. SEQ ID NO:62 showed a time-dependent increase in expression, at least 2.5-fold above untreated cell levels at 1 hour, peaking at 4.8-fold after 2 hours, then declining back to at least 2.5-fold at the 4 hour time point. Also, PBMCs from a number of different donors were treated with LPS for 4 to 24 hours, and these cells showed a general decrease in expression of SEQ ID NO:65 of between 2- and 4.5-fold when compared to untreated cells. In addition, RPMI 6666 cells (B cells derived from a donor with Hodgkin's disease) showed at least a 2-fold decrease in expression of SEQ ID NO:65 upon LPS treatment for 8 hours, when compared to expression levels in untreated RPMI 6666 cells. Treatment of donor PBMCs with SEB (staphylococcal endotoxin), however, resulted in a 2- to 4-fold increase in expression after 24 to 72 hours of SEQ ID NO:65, when compared to untreated cells.

In another example, THP-1 cells, a monocytic cell line, demonstrated differential expression of SEQ ID NO:62 and SEQ ID NO:65 upon differentiation into macrophage-like cells or foam cells, as determined by microarray expression analysis. Stimulation of THP-1 cells with PMA induces differentiation into a macrophage-like cell that displays many characteristics of peripheral human macrophages. The gene expression levels of SEQ ID NO:65 were shown to increase in PMA-treated cells from 2- to 6-fold, when compared to untreated THP-1 cells. Further treatment of THP-1 cells

with oxidized LDL (oxLDL) induces differentiation into foam cells. Upon LPS treatment of macrophage-like or foam cells , the expression of SEQ ID NO:62 increased at least 2-fold when compared to untreated cells. Therefore, SEQ ID NO:62 and SEQ ID NO:65 are useful for study of activated immune system cells, and for monitoring treatment of and diagnostic assays for diseases of the immune system.

In another example, SEQ ID NO:70 and SEQ ID NO:73 showed differential expression in association with breast cancer, as determined by microarray analysis. Gene expression profiles were obtained by comparing the results of competitive hybridization experiments. The gene expression profile of cells isolated from a tumor in the right breast was compared to the gene expression profile of cells originating from grossly uninvolved breast tissue from the same donor, a 43-year-old female diagnosed with invasive lobular carcinoma (Huntsman Cancer Institute, Salt Lake City, UT). The tumor was described as well differentiated and metastatic to 2 out of 13 lymph nodes. SEQ ID NO:73 showed decreased gene expression by at least two-fold in the tumorous tissue sample as compared to the uninvolved tissue sample from the same donor. In another example, the gene expression profile of a breast carcinoma cell line treated with interferon gamma (IFN-γ) was compared to the gene expression profile of untreated cells from the same line. T-47D is a breast carcinoma cell line isolated from a pleural effusion obtained from a 54-year-old female with an infiltrating ductal carcinoma of the breast. T-47D cells were treated with IFN-γ for 1, 4, 8, 24, 48 hours and 3 days. The expression of SEQ ID NO:70 was decreased by at least two-fold in the treated breast carcinoma cell lines as compared to the untreated T-47D population. Thus, SEQ ID NO:70 and SEQ ID NO:73 are useful as diagnostic markers for breast cancer, as well as for monitoring the progression and treatment of breast cancer.

In another example, SEQ ID NO:73 and SEQ ID NO:76 showed differential expression in association with colon cancer, as determined by microarray analysis. Gene expression profiles were obtained by comparing the results of competitive hybridization experiments between normal colon tissue and tumorous rectal tissue from the same donor. Different pieces of normal tissue were also compared against a pool of normal tissue from the same donor to determine gene expression variation in normal colon tissue. The expression of SEQ ID NO:73 was decreased by at least two-fold in tumorous rectal tissue as compared to normal rectal tissue from the same donor. In addition, the gene expression profiles of 6 different colon cancer tissues were analyzed by comparing one individual sample to 5 others, keeping one element in common between the various pairs of comparisons. The reference tissue sample is a metastatic adenocarcinoma of ovarian origin, which distinguishes this sample from the others and may be of special interest. The other five samples include tumorous colon tissue collected from an 85-year-old male, an 81-year-old male, an 83-year-old female, as well

as a mucinous adenocarcinoma from a 58-year-old female, and a poorly differentiated metastatic adenocarcinoma from a 56-year-old female. The gene expression of SEQ ID NO:76 was decreased by two-fold in the tumorous rectal tissue samples as compared to the reference tissue. Therefore, SEQ ID NO:73 and SEQ ID NO:76 are useful as diagnostic markers for colon cancer, as well as for monitoring the progression and treatment of colon cancer.

In another example, SEQ ID NO:73 showed differential expression in association with lung cancer. Gene expression profiles were obtained by comparing the results of competitive hybridization experiments. Messenger RNA isolated from grossly uninvolved lung tissue with no visible abnormalities, from a 73-year-old male, was compared to lung squamous cell adenocarcinoma tissue from the same donor (Roy Castle International Centre for Lung Cancer Research, Liverpool, UK). The expression of SEQ ID NO:73 was decreased by at least two-fold in tumorous lung tissue as compared to normal lung tissue from the same donor. Therefore, SEQ ID NO:73 is useful as a diagnostic marker for lung cancer, as well as for monitoring the progression and treatment of lung cancer.

In another example, SEQ ID NO:73 showed differential expression in association with inflammatory and immune responses, as determined by microarray analysis. Gene expression profiles were obtained by comparing the results of competitive hybridization experiments. Human peripheral blood mononuclelar cells (PBMCs) from seven healthy donors were stimulated in vitro with Staphylococal extoxin B (SEB) for 24 and 72 hours. The SEB treated PBMCs from each donor were compared to PBMCs from the same donor, kept in culture for 24 hours, in the absence of SEB. The gene expression of SEQ ID NO:73 was decreased by at least two-fold in SEB treated PBMCs as compared to untreated PBMCs from the same donors. In another example, SEQ ID NO:73 showed differential expression in treated versus untreated cells in a promonocyte cell line. THP-1 was isolated from the peripheral blood of a 1-year-old male with acute monocytic leukemia. PMA is a broad activator of the protein kinase C-dependent pathways. Upon stimulation with PMA, THP-1 differentiates into a macrophagelike cell that displays many characteristics of peripheral human macrophages. Promonocytes and monocytes to LPS, PMA-activated THP-1 cells (monocytic) and untreated THP-1 cells (promonocytic) were stimulated *in vitro* with LPS for 4 hours. LPS-treated THP-1 cells were compared to untreated THP-1 cells. In addition, PMA-activated THP-1 cells were compared to untreated THP-1 cells. The expression of SEQ ID NO:73 was decreased by at least two-fold in treated cells as compared to untreated cells. Therefore, SEQ ID NO:73 is useful as a diagnostic marker for inflammatory and immune response diseases, as well as for monitoring the progression and treatment of inflammatory and immune response diseases.

XII. Complementary Polynucleotides

Sequences complementary to the REMAP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring REMAP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of REMAP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the REMAP-encoding transcript.

XIII. Expression of REMAP

Expression and purification of REMAP is achieved using bacterial or virus-based expression systems. For expression of REMAP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express REMAP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of REMAP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant *Autographica californica* nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding REMAP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect *Spodoptera frugiperda* (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus (Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945).

In most expression systems, REMAP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from *Schistosoma japonicum*, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Biosciences). Following purification, the GST moiety can be proteolytically cleaved from REMAP at

specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel et al. (*supra*, ch. 10 and 16). Purified REMAP obtained by these methods can be used directly in the assays shown in Examples XVII, XVIII, and XIX, where applicable.

XIV. Functional Assays

REMAP function is assessed by expressing the sequences encoding REMAP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT plasmid (Invitrogen, Carlsbad CA) and PCR3.1 plasmid (Invitrogen), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994; Flow Cytometry, Oxford, New York NY).

The influence of REMAP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding REMAP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake

Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding REMAP and other genes of interest can be analyzed by northern analysis or microarray techniques.

XV. Production of REMAP Specific Antibodies

REMAP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize animals (e.g., rabbits, mice, etc.) and to produce antibodies using standard protocols.

Alternatively, the REMAP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art (Ausubel et al., *supra*, ch. 11).

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity (Ausubel et al., *supra*). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-REMAP activity by, for example, binding the peptide or REMAP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XVI. Purification of Naturally Occurring REMAP Using Specific Antibodies

Naturally occurring or recombinant REMAP is substantially purified by immunoaffinity chromatography using antibodies specific for REMAP. An immunoaffinity column is constructed by covalently coupling anti-REMAP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Biosciences). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing REMAP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of REMAP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/REMAP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and REMAP is collected.

XVII. Identification of Molecules Which Interact with REMAP

REMAP, or biologically active fragments thereof, are labeled with ^{125}I Bolton-Hunter reagent (Bolton, A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled REMAP, washed, and any

wells with labeled REMAP complex are assayed. Data obtained using different concentrations of REMAP are used to calculate values for the number, affinity, and association of REMAP with the candidate molecules.

Alternatively, molecules interacting with REMAP are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989; Nature 340:245-246), or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

REMAP may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

XVIII. Demonstration of REMAP Activity

An assay for REMAP activity measures the expression of REMAP on the cell surface. cDNA encoding REMAP is transfected into an appropriate mammalian cell line. Cell surface proteins are labeled with biotin as described (de la Fuente, M.A. et al. (1997) Blood 90:2398-2405). Immunoprecipitations are performed using REMAP-specific antibodies, and immunoprecipitated samples are analyzed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of REMAP expressed on the cell surface.

In the alternative, an assay for REMAP activity is based on a prototypical assay for ligand/receptor-mediated modulation of cell proliferation. This assay measures the rate of DNA synthesis in Swiss mouse 3T3 cells. A plasmid containing polynucleotides encoding REMAP is added to quiescent 3T3 cultured cells using transfection methods well known in the art. The transiently transfected cells are then incubated in the presence of [^{3}H]thymidine, a radioactive DNA precursor molecule. Varying amounts of REMAP ligand are then added to the cultured cells. Incorporation of [^{3}H]thymidine into acid-precipitable DNA is measured over an appropriate time interval using a radioisotope counter, and the amount incorporated is directly proportional to the amount of newly synthesized DNA. A linear dose-response curve over at least a hundred-fold REMAP ligand concentration range is indicative of receptor activity. One unit of activity per milliliter is defined as the concentration of REMAP producing a 50% response level, where 100% represents maximal incorporation of [^{3}H]thymidine into acid-precipitable DNA (McKay, I. and I. Leigh, eds. (1993) Growth Factors: A Practical Approach, Oxford University Press, New York NY, p. 73.)

In a further alternative, the assay for REMAP activity is based upon the ability of GPCR family proteins to modulate G protein-activated second messenger signal transduction pathways (e.g.,

cAMP; Gaudin, P. et al. (1998) J. Biol. Chem. 273:4990-4996). A plasmid encoding full length REMAP is transfected into a mammalian cell line (e.g., Chinese hamster ovary (CHO) or human embryonic kidney (HEK-293) cell lines) using methods well-known in the art. Transfected cells are grown in 12-well trays in culture medium for 48 hours, then the culture medium is discarded, and the attached cells are gently washed with PBS. The cells are then incubated in culture medium with or without ligand for 30 minutes, then the medium is removed and cells lysed by treatment with 1 M perchloric acid. The cAMP levels in the lysate are measured by radioimmunoassay using methods well-known in the art. Changes in the levels of cAMP in the lysate from cells exposed to ligand compared to those without ligand are proportional to the amount of REMAP present in the transfected cells.

To measure changes in inositol phosphate levels, the cells are grown in 24-well plates containing $1x10^5$ cells/well and incubated with inositol-free media and [^{3}H]myoinositol, 2 μCi/well, for 48 hr. The culture medium is removed, and the cells washed with buffer containing 10 mM LiCl followed by addition of ligand. The reaction is stopped by addition of perchloric acid. Inositol phosphates are extracted and separated on Dowex AG1-X8 (Bio-Rad) anion exchange resin, and the total labeled inositol phosphates counted by liquid scintillation. Changes in the levels of labeled inositol phosphate from cells exposed to ligand compared to those without ligand are proportional to the amount of REMAP present in the transfected cells.

In a further alternative, the ion conductance capacity of REMAP is demonstrated using an electrophysiological assay. REMAP is expressed by transforming a mammalian cell line such as COS7, HeLa or CHO with a eukaryotic expression vector encoding REMAP. Eukaryotic expression vectors are commercially available, and the techniques to introduce them into cells are well known to those skilled in the art. A small amount of a second plasmid, which expresses any one of a number of marker genes such as β-galactosidase, is co-transformed into the cells in order to allow rapid identification of those cells which have taken up and expressed the foreign DNA. The cells are incubated for 48-72 hours after transformation under conditions appropriate for the cell line to allow expression and accumulation of REMAP and β-galactosidase. Transformed cells expressing β-galactosidase are stained blue when a suitable colorimetric substrate is added to the culture media under conditions that are well known in the art. Stained cells are tested for differences in membrane conductance due to various ions by electrophysiological techniques that are well known in the art. Untransformed cells, and/or cells transformed with either vector sequences alone or β-galactosidase sequences alone, are used as controls and tested in parallel. The contribution of REMAP to cation or anion conductance can be shown by incubating the cells using antibodies specific for either REMAP. The respective antibodies will bind to the extracellular side of REMAP, thereby blocking the pore in

the ion channel, and the associated conductance.

In a further alternative, REMAP transport activity is assayed by measuring uptake of labeled substrates into *Xenopus laevis* oocytes. Oocytes at stages V and VI are injected with REMAP mRNA (10 ng per oocyte) and incubated for 3 days at 18 °C in OR2 medium (82.5 mM NaCl, 2.5 mM KCl, 1 mM $CaCl_2$, 1 mM $MgCl_2$, 1 mM Na_2HPO_4, 5 mM Hepes, 3.8 mM NaOH , 50 μg/ml gentamycin, pH 7.8) to allow expression of REMAP protein. Oocytes are then transferred to standard uptake medium (100 mM NaCl, 2 mM KCl, 1 mM $CaCl_2$, 1 mM $MgCl_2$, 10 mM Hepes/Tris pH 7.5). Uptake of various substrates (e.g., amino acids, sugars, drugs, and neurotransmitters) is initiated by adding a ^3H substrate to the oocytes. After incubating for 30 minutes, uptake is terminated by washing the oocytes three times in Na^+-free medium, measuring the incorporated ^3H, and comparing with controls. REMAP activity is proportional to the level of internalized ^3H substrate.

In a further alternative, REMAP protein kinase (PK) activity is measured by phosphorylation of a protein substrate using gamma-labeled [^{32}P]-ATP and quantitation of the incorporated radioactivity using a gamma radioisotope counter. REMAP is incubated with the protein substrate, [^{32}P]-ATP, and an appropriate kinase buffer. The ^{32}P incorporated into the product is separated from free [^{32}P]-ATP by electrophoresis and the incorporated ^{32}P is counted. The amount of ^{32}P recovered is proportional to the PK activity of REMAP in the assay. A determination of the specific amino acid residue phosphorylated is made by phosphoamino acid analysis of the hydrolyzed protein.

XIX. Identification of REMAP Ligands

REMAP is expressed in a eukaryotic cell line such as CHO (Chinese Hamster Ovary) or HEK (Human Embryonic Kidney) 293 which have a good history of GPCR expression and which contain a wide range of G-proteins allowing for functional coupling of the expressed REMAP to downstream effectors. The transformed cells are assayed for activation of the expressed receptors in the presence of candidate ligands. Activity is measured by changes in intracellular second messengers, such as cyclic AMP or Ca^{2+}. These may be measured directly using standard methods well known in the art, or by the use of reporter gene assays in which a luminescent protein (e.g. firefly luciferase or green fluorescent protein) is under the transcriptional control of a promoter responsive to the stimulation of protein kinase C by the activated receptor (Milligan, G. et al. (1996) Trends Pharmacol. Sci. 17:235-237). Assay technologies are available for both of these second messenger systems to allow high throughput readout in multi-well plate format, such as the adenylyl cyclase activation FlashPlate Assay (NEN Life Sciences Products), or fluorescent Ca^{2+} indicators such as Fluo-4 AM (Molecular Probes) in combination with the FLIPR fluorimetric plate reading system (Molecular Devices). In cases where the physiologically relevant second messenger pathway is not known, REMAP may be coexpressed with the G-proteins $G_{\alpha 15/16}$ which have been demonstrated to couple to a wide range of

G-proteins (Offermanns, S. and M.I. Simon (1995) J. Biol. Chem. 270:15175-15180), in order to funnel the signal transduction of the REMAP through a pathway involving phospholipase C and Ca^{2+} mobilization. Alternatively, REMAP may be expressed in engineered yeast systems which lack endogenous GPCRs, thus providing the advantage of a null background for REMAP activation screening. These yeast systems substitute a human GPCR and G_{α} protein for the corresponding components of the endogenous yeast pheromone receptor pathway. Downstream signaling pathways are also modified so that the normal yeast response to the signal is converted to positive growth on selective media or to reporter gene expression (Broach, J.R. and J. Thorner (1996) Nature 384 (supp.):14-16). The receptors are screened against putative ligands including known GPCR ligands and other naturally occurring bioactive molecules. Biological extracts from tissues, biological fluids and cell supernatants are also screened.

Various modifications and variations of the described compositions, methods, and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. It will be appreciated that the invention provides novel and useful proteins, and their encoding polynucleotides, which can be used in the drug discovery process, as well as methods for using these compositions for the detection, diagnosis, and treatment of diseases and conditions. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Nor should the description of such embodiments be considered exhaustive or limit the invention to the precise forms disclosed. Furthermore, elements from one embodiment can be readily recombined with elements from one or more other embodiments. Such combinations can form a number of embodiments within the scope of the invention. It is intended that the scope of the invention be defined by the following claims and their equivalents.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Incyte Full Length Clones
3048626	1	3048626CD1	39	3048626CB1	
2684425	2	2684425CD1	40	2684425CB1	
7505960	3	7505960CD1	41	7505960CB1	
7507021	4	7507021CD1	42	7507021CB1	90122224CA2
7509099	5	7509099CD1	43	7509099CB1	90137914CA2
7509361	6	7509361CD1	44	7509361CB1	90134650CA2
7506815	7	7506815CD1	45	7506815CB1	90115637CA2
7506814	8	7506814CD1	46	7506814CB1	90115621CA2
7506852	9	7506852CD1	47	7506852CB1	90123356CA2, 90123372CA2, 90123380CA2, 90123571CA2
7503782	10	7503782CD1	48	7503782CB1	
7504647	11	7504647CD1	49	7504647CB1	6352669CA2, 90036485CA2, 90036561CA2, 95121338CA2, 95121529CA2, 95121605CA2, 95121637CA2, 95121653CA2, 95121693CA2, 95121745CA2, 95121761CA2, 95121812CA2, 95121868CA2, 95121884CA2, 95121905CA2
7500424	12	7500424CD1	50	7500424CB1	90030465CA2, 90030473CA2, 90030573CA2, 90030581CA2
7500449	13	7500449CD1	51	7500449CB1	
7503281	14	7503281CD1	52	7503281CB1	90041241CA2, 90041301CA2, 90041317CA2, 90041341CA2
7503292	15	7503292CD1	53	7503292CB1	
7503311	16	7503311CD1	54	7503311CB1	
7510384	17	7510384CD1	55	7510384CB1	
7509976	18	7509976CD1	56	7509976CB1	
7510454	19	7510454CD1	57	7510454CB1	55062756CA2, 90005113CA2, 90005121CA2, 90005137CA2, 90005145CA2, 90005205CA2, 90005213CA2, 90005221CA2, 90005237CA2, 90082826CA2, 90208706CA2, 90208714CA2, 90208785CA2, 90208793CA2
8017335	20	8017335CD1	58	8017335CB1	
7510197	21	7510197CD1	59	7510197CB1	3833001CA2
7510055	22	7510055CD1	60	7510055CB1	95110475CA2
7501754	23	7501754CD1	61	7501754CB1	3576444CA2

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Incyte Full Length Clones
7510517	24	7510517CD1	62	7510517CB1	
7511014	25	7511014CD1	63	7511014CB1	90115446CA2
7506687	26	7506687CD1	64	7506687CB1	
7510621	27	7510621CD1	65	7510621CB1	
7505533	28	7505533CD1	66	7505533CB1	95136216CA2, 95136264CA2
7511220	29	7511220CD1	67	7511220CB1	
7510967	30	7510967CD1	68	7510967CB1	
7511298	31	7511298CD1	69	7511298CB1	90171160CA2
7510937	32	7510937CD1	70	7510937CB1	90051283CA2
7511852	33	7511852CD1	71	7511852CB1	95001926CA2
7511077	34	7511077CD1	72	7511077CB1	1929803CA2
7511576	35	7511576CD1	73	7511576CB1	
7511492	36	7511492CD1	74	7511492CB1	
7511141	37	7511141CD1	75	7511141CB1	2776443CA2, 95021920CA2
7511300	38	7511300CD1	76	7511300CB1	

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
1	3048626CD1	g6523391	8.1E-210	[Mus musculus] phtf protein Manuel, A. et al. (2000) Molecular characterization of a novel gene family (PHTF) conserved from drosophila to mammals. Genomics 64:216-220
		587245|Phtf	6.8E-211	[Mus musculus][Transcription factor; DNA-binding protein] Putative homeodomain transcription factor; expressed in testis Manuel, A. et al. (2000) Molecular characterization of a novel gene family (PHTF) conserved from drosophila to mammals. Genomics 64:216-220
		432628| PHTF1	2.1E-209	[Homo sapiens][Transcription factor; DNA-binding protein] Putative homeodomain transcription factor; may play role in development Raich, N. et al. (1999) PHTF, A novel atypical homeobox gene on chromosome 1p13, is evolutionarily conserved. Genomics 59:108-109
2	2684425CD1	g8439531	0.0	[Homo sapiens] transmembrane molecule with thrombospondin module
		599850| LOC55901	0.0	[Homo sapiens] Protein containing a type 1 thrombospondin domain
3	7505960CD1	g4529890	0.0	[Homo sapiens] NG22
		692052|NG22	0.0	[Homo sapiens] Protein of unknown function, has strong similarity to uncharacterized mouse 2210409B01Rik
		664607|2210409 B01Rik	2.3E-294	[Mus musculus] RIKEN cDNA 2210409B01 gene
4	7507021CD1	g2338292	1.4E-78	[Homo sapiens] proline-rich Gla protein 2 Kulman, J.D. et al. (1997) Primary structure and tissue distribution of two novel proline-rich gamma-carboxyglutamic acid proteins. Proc. Natl. Acad. Sci. U.S.A. 94: 9058-9062
5	7509099CD1	g307046	2.4E-274	[Homo sapiens] interleukin 1 receptor precursor

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
		336000|IL1R1	2.0E-275	[Homo sapiens][Receptor (signalling)][Plasma membrane] Type I interleukin-1 receptor, a member of the IL1R like protein family regulated by IL1R associated kinase IRAK1, involve in immune and inflammatory responses, involved in leukemia, atherosclerosis, sepsis and growth of solid tumors Chen, G. et al. (2000) Selection of insulinoma cell lines with resistance to interleukin-1beta- and gamma-interferon-induced cytotoxicity. Diabetes 49:562-570
		583367|Il1r1	2.4E-193	[Mus musculus][Receptor (signalling)][Plasma membrane] Type I interleukin-1 receptor, a member of the IL1R like protein family regulated by IL1R associated kinase IRAK (Il1rak), involved in immune and inflammatory resposes and signal transduction Parnet, P. et al. (1994) Expression of type I and type II interleukin-1 receptors in mouse brain. Brain Res. Mol. Brain Res. 27: 63-70
6	7509361CD1	g339750	4.5E-119	[Homo sapiens] tumor necrosis factor receptor 1 Fuchs, P. et al. (1992) Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13 [corrected] [published erratum appears in (1992) Genomics 13:1384] Genomics 13:219-224
		338586|TNFRSF1A	3.8E-120	[Homo sapiens][Receptor (signalling)][Plasma membrane] FPF Type I tumor necrosis factor receptor, mediates proinflammatory cellular responses, juxtamembrane domain interacts with phosphatidylinositol-4-phosphate 5-kinase Baranzini, S. E. et al. (2000) Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J. Immunol. 165:6576-6582
		723062|1ext_A	3.0E-95	[Protein Data Bank] Tumor Necrosis Factor Receptor

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
		590719| Tnfrsf1a	1.1E-85	[Rattus norvegicus][Receptor (signalling)] Type I tumor necrosis factor receptor, a glycoprotein that mediates proinflammatory cellular responses, contains an extracellular domain that is proteolytically cleaved to yield a tumor necrosis factor binding protein Laabich, A. et al. (2001) Characterization of apoptosis-genes associated with NMDA mediated cell death in the adult rat retina. Brain Res. Mol. Brain Res. 91:34-42
7	7506815CD1	g12653895	1.1E-194	[Homo sapiens] cholecystokinin B receptor
		334486| CCKBR	9.0E-196	[Homo sapiens][Regulatory subunit; Receptor (signalling)] [Basolateral plasma membrane; Cytoplasmic; Plasma membrane] Cholecystokinin B (gastrin) receptor, G protein-coupled receptor stimulating phospholipase C and intracellular calcium flux, associated with anxiety and likely digestion and dopamine signaling, constitutively active form is expressed in colorectal cancers Smith, A. M. and Watson, S. A. (2000) Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence. Gut 4: 820-824
		589913|Cckbr	1.3E-170	[Rattus norvegicus][Receptor (signalling)] [Nuclear; Cytoplasmic; Plasma membrane] Cholecystokinin B (gastrin) receptor, G protein-coupled receptor stimulating phospholipase C and intracellular calcium flux, associated with digestion and opioidergic and dopaminergic signaling; a human CCKBR variant is associated with colorectal cancer Coudore-Civiale, M. A. et al. (2000) Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats. Pain 88:15-22
8	7506814CD1	g12653895	3.20E-206	[Homo sapiens] cholecystokinin B receptor

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
	7506814CD1	334486| CCKBR	2.70E-207	[Homo sapiens][Regulatory subunit; Receptor (signalling)][Basolateral plasma membrane; Cytoplasmic; Plasma membrane] Cholecystokinin B (gastrin) receptor, G protein-coupled receptor stimulating phospholipase C and intracellular calcium flux, associated with anxiety and likely digestion and dopamine signaling, constitutively active form is expressed in colorectal cancers (Desbois, C. et al. (1999) Eur J Biochem 266, 1003-10)
	7506814CD1	589913|Cckbr	3.50E-194	[Rattus norvegicus][Receptor (signalling)][Nuclear; Cytoplasmic; Plasma membrane] Cholecystokinin B (gastrin) receptor, G protein-coupled receptor stimulating phospholipase C and intracellular calcium flux, associated with digestion and opioidergic and dopaminergic signaling; a human CCKBR variant is associated with colorectal cancer (Wank, S. A. et al. (1992) Proc Natl Acad Sci U S A 89, 8691-5)
9	7506852CD1	g400450	1.80E-53	[Homo sapiens] A1 adenosine receptor
	7506852CD1	334066| ADORA1	1.50E-54	[Homo sapiens][Receptor (signalling)][Cytoplasmic; Plasma membrane] Adenosine A1 receptor, a glycoprotein and G protein-coupled receptor that selectively binds adenosine; stimulates cell death of thymocytes and phagocytosis; density is reduced in hippocampus from Alzheimer's disease patients; may play a role in obesity (Libert, F. et al. (1992) Biochem Biophys Res Commun 187, 919-26)
	7506852CD1	590847| Adora1	6.40E-54	[Rattus norvegicus][Receptor (signalling)][Plasma membrane] Adenosine A1 receptor, a G protein-coupled receptor that selectively binds adenosine; modulates adenosine effects in neural and endocrine systems; may play a role in inherited obesity (Mahan, L. C. et al. (1991) Mol Pharmacol 40, 1-7)
10	7503782CD1	g7209574	4.20E-19	[Homo sapiens] LAK-4p
11	7504647CD1	g533184	3.60E-23	[Homo sapiens] 50 kD dystrophin-associated glycoprotein (McNally, E. et al. (1994) Proc. Natl. Acad. Sci. U.S.A. 11;91(21):9690-4)

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
	7504647CD1	337978|SGCA	3.00E-24	[Homo sapiens][Anchor Protein][Extracellular matrix (cuticle and basement membrane); Basement membrane (extracellular matrix); Plasma membrane] Alpha-sarcoglycan (adhalin), a dystrophin-associated glycoprotein required for normal striated muscle development, protects against contraction-induced sarcolemmal damage; mutations in the corresponding gene cause limb girdle muscular dystrophy type 2D (Barresi, R. et al. (2000) J Biol Chem 275, 38554-60)
	7504647CD1	581329|Sgca	5.80E-15	[Mus musculus][Structural protein][Extracellular matrix (cuticle and basement membrane); Basement membrane (extracellular matrix); Cytoplasmic;Plasma membrane] Alpha-sarcoglycan (adhalin), a dystrophin-associated glycoprotein required for normal striated muscle development, protects against contraction-induced sarcolemmal damage; mutations in the human SGCA gene cause limb girdle muscular dystrophy type 2D (Coral-Vazquez, R. et al. (1999) Cell 98, 465-74).
12	7500424CD1	g14250620	4.50E-66	[Homo sapiens] G protein-coupled receptor 56
	7500424CD1	342484| GPR56	3.70E-67	[Homo sapiens][Receptor (signalling)][Plasma membrane] G protein-coupled receptor 56, a putative G protein-coupled receptor that may function in cell adhesion, cell-cell signaling, and is differentially expressed during metastatic progression of melanomas (Zendman, A. J. et al. (1999) FEBS Lett 446, 292-8)
	7500424CD1	732759| Gpr56	6.10E-38	[Mus musculus][Receptor (signalling)][Plasma membrane] G protein-coupled receptor 56
13	7500449CD1	g456353	1.50E-131	[Homo sapiens] intestinal VIP receptor related protein (Couvineau, A. et al. (1994) Biochem. Biophys. Res. Commun. 200, 769-776)
	7500449CD1	749162| VIPR1	4.80E-97	[Homo sapiens][Receptor (signalling)][Plasma membrane] Vasoactive intestinal activating polypeptide receptor 1, a stimulatory G protein coupled receptor; mediates gastrointestinal, nervous system, pulmonary, vascular and immune functions, inhibits inflammation (Sreedharan, S. P. et al. (1995) Proc Natl Acad Sci U S A 92, 2939-43)

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
	7500449CD1	590753|Vipr1	3.50E-78	[Rattus norvegicus][Receptor (signalling)][Plasma membrane] Vasoactive intestinal activating polypeptide receptor 1, a stimulatory G protein coupled receptor; inhibits inflammatory responses and may mediate central and peripheral nervous system functions (Ishihara, T. et al (1992). Neuron 8, 811-9)
14	7503281CD1	g178198	1.40E-112	[Homo sapiens] alpha-2-adrenergic receptor (alpha-2 C2) old gene name 'ADRA2RL1' (Lomasney, J. W. et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 5094-5098)
	7503281CD1	343936| ADRA2B	1.10E-113	[Homo sapiens][Receptor (signalling)][Plasma membrane] Adrenergic alpha-2B receptor, a G protein-coupled receptor that binds epinephrine and norepinephrine, signals through regulation of adenylyl cyclase and MAPK pathways to mediate cell-cell signaling, may have a role in fat metabolism (Smith, M. S. et al. (1995) Brain Res Mol Brain Res 34, 109-17)
	7503281CD1	429618| Adra2b	3.90E-102	[Mus musculus][Receptor (signalling)][Endosome/Endosomal vesicles; Cytoplasmic; Plasma membrane] Adrenergic receptor alpha 2b, a G protein-coupled receptor that binds epinephrine and norepinephrine, signals through regulation of adenylyl cyclase activity, involved in blood pressure regulation, sensory perception, synaptic transmission, and analgesia (Link, R. E. et al. (1996) Science 273, 803-5)
15	7503292CD1	g3901028	1.70E-144	[Homo sapiens] neurotensin receptor 2 (Vita, N. et al. (1998) Eur. J. Pharmacol. 360, 265-272)
	7503292CD1	428880| NTSR2	1.40E-145	[Homo sapiens][Receptor (signalling)][Plasma membrane] Levocabastine-sensitive neurotensin receptor, a low affinity putative G protein-coupled receptor that binds, but is not activated by, neurotensin; activation by SR48692 and SR142948A stimulates IP formation, Ca2+ mobilization, and arachidonic acid release (Mazella, J. et al. (1996) J Neurosci 16, 5613-20)

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
	7503292CD1	659258|Ntsr2	7.10E-119	[Rattus norvegicus][Receptor (signalling)][Plasma membrane] Levocabastine-sensitive neurotensin receptor, a G protein-coupled receptor that binds neurotensin, and the H1 antihistaminic drug levocabastine, activation by SR48692 induces Ca2+ mobilization, may help modulate neuronal osmosensitivity (Botto, J. M. et al. (1998) Biochem Biophys Res Commun 243, 585-90)
16	7503311CD1	g1785516	3.50E-146	[Homo sapiens] gastric inhibitory polypeptide receptor (Yamada, Y. et al. (1995) Genomics 29, 773-776)
	7503311CD1	335524|GIPR	2.80E-147	[Homo sapiens][Receptor (signalling)][Plasma membrane] Gastric inhibitory polypeptide receptor, a G protein-coupled receptor that increases intracellular cAMP levels and MAPK kinase activity, may be associated with Gushing's syndrome (Lacroix, A. et al. (1998) Endocr Res 24, 835-43)
	7503311CD1	590141|Gipr	5.70E-117	[Rattus norvegicus][Receptor (signalling)][Plasma membrane] Gastric inhibitory polypeptide receptor, a G protein-coupled receptor that increases intracellular cAMP and calcium levels, mediates effects of glucose-dependent insulinotropic polypeptide (GIP) on insulin secretion, may be associated with type 2 diabetes (Usdin, T. B. et al. (1993) Endocrinology 133, 2861-70)
17	7510384CD1	g3242762	1.10E-110	[Homo sapiens] growth hormone-releasing hormone receptor
	7510384CD1	335522| GHRHR	3.00E-111	[Homo sapiens][Receptor (signalling)][Plasma membrane] Growth hormone releasing hormone receptor, a G protein-coupled receptor that regulates pituitary growth hormone synthesis and secretion, may act through increasing intracellular cAMP levels; deficiency is a cause of dwarfism (Wajnrajch, M. P. et al. (1996) Nat Genet 12, 88-90)
	7510384CD1	590139|Ghrhr	3.10E-86	[Rattus norvegicus][Receptor (signalling)][Plasma membrane] Growth hormone releasing hormone receptor, a member of the G protein-coupled receptor family expressed primarily in pituitary, has probable roles in regulating growth; has strong similarity to human GHRHR, deficiency of which is associated with dwarfism (Zeitler, P. et al. (1998) J Mol Endocrinol 21, 363-71)
18	7509976CD1	g1200235	0	[Homo sapiens] SEX protein

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
	7509976CD1	599756| HSSEXGENE	0	[Homo sapiens][Receptor (signalling)][Plasma membrane] Protein with strong similarity to murine Plxn3, which is a member of the plexin family of semaphorin receptors involved in cell guidance (Kameyama, T. et al. (1996) Biochem Biophys Res Commun 226, 396-402)
	7509976CD1	582527|Plxn3	0	[Mus musculus][Receptor (signalling)][Plasma membrane] Plexin 3, a member of the plexin family of semaphorin receptors, may play a role in the regulation of neuronal development (Kameyama, T. et al. (supra))
19	7510454CD1	g17481324	1.10E-21	[Mus musculus] vomeronasal receptor 1 E9
	7510454CD1	613285| V1RL1	2.50E-11	[Homo sapiens][Receptor (signalling)] V1R-like 1, a predicted member of the G-protein coupled receptor family and a putative olfactory mucosal pheromone receptor (Rodriguez, I. et al. (2000) Nat Genet 26, 18-9)
20	8017335CD1	g15082375	6.7E-81	[Homo sapiens] Similar to transmembrane 7 superfamily member 1 (upregulated in kidney)
	8017335CD1	338556| TM7SF1	5.5E-82	[Homo sapiens][Plasma membrane] Transmembrane 7 superfamily member 1, may be a member of the G protein-coupled receptor family, contains seven alpha helical transmembrane domains; expression is upregulated during kidney development
				Spangenberg, C. et al.
				Cloning and characterization of a novel gene (TM7SF1) encoding a putative seven-pass transmembrane protein that is upregulated during kidney development.
				Genomics 48, 178-85 (1998).
	8017335CD1	746563| Tm7sf1	1E-80	[Mus musculus] Transmembrane 7 superfamily member 1, may be a member of the G protein-coupled receptor family, contains seven alpha helical transmembrane domains; expression is upregulated during kidney development
22	7510055CD1	g29851	2.7E-107	[Homo sapiens] CDw40
				Stamenkovic, I. et al.

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
				A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas
				EMBO J. 8, 1403-1410 (1989)
	7510055CD1	338592| TNFRSF5	2.2E-108	[Homo sapiens][Receptor (signalling)][Plasma membrane] Member of the tumor necrosis factor receptor superfamily, binds the ligand CD40L and is expressed specifically in B lymphocytes, has a role in B lymphocyte maturation
				Stamenkovic, I. et al.
				A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas.
				Embo Journal 8, 1403-10 (1989).
				Mach, F. et al.
				Reduction of atherosclerosis in mice by inhibition of CD40 signalling.
				Nature 394, 200-3 (1998).
	7510055CD1	586037| Tnfrsf5	4.1E-68	[Mus musculus][Receptor (signalling)][Plasma membrane] Member of the tumor necrosis factor receptor superfamily, binds the ligand CD40L and is expressed specifically in B lymphocytes, has a role in B lymphocyte maturation
				Torres, R. M. et al.
				Differential increase of an alternatively polyadenylated mRNA species of murine CD40 upon B lymphocyte activation.
				J Immunol 148, 620-6 (1992).
23	7501754CD1	g9944291	2.5E-223	[Homo sapiens] TTYH1
				Campbell, H. D. et al.
				Human and mouse homologues of the drosophila melanogaster tweety (tty) gene: A novel gene family encoding predicted transmembrane proteins
				Genomics 68, 89-92 (2000)
	7501754CD1	613379| TTYH1	2E-224	[Homo sapiens][Active transporter, secondary;Transporter] Tweety homolog 1 (Drosophila), a member of a family of putative membrane proteins with five potential transmembrane domains

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
				Campbell, H. D. et al.
				Human and mouse homologues of the drosophila melanogaster tweety (tty) gene: A novel gene family encoding predicted transmembrane proteins
				Genomics 68, 89-92 (2000).
	7501754CD1	618612| Ttyh1	4E-203	[Mus musculus] Tweety homolog 1 (Drosophila), a member of a family of putative membrane proteins with five potential transmembrane domains
				Campbell, H. D. et al. (supra)
24	7510517CD1	g1359731	1.0E-98	[Homo sapiens] EP4 prostaglandin receptor
				Foord, S.M. et al. (1996) The structure of the prostaglandin EP4 receptor gene and related pseudogenes. Genomics 35:182-188.
		337370| PTGER4	8.6E-100	[Homo sapiens][Receptor (signaling)][Plasma membrane] Prostaglandin E receptor 4, a G protein-coupled receptor that signals through stimulatory G-protein, mediates a variety of physiological effects including inflammatory response and cell motility, may increase invasive growth of colorectal carcinoma cells
				Bastien, L. et al. (1994) Cloning, functional expression and characterization of the human Prostaglandin E2 receptor EP2 subtype. J. Biol. Chem. 269:11873-11877.
				An, S. et al. (1993) Cloning and expression of the EP2 subtype of human receptors for prostaglandin E2. Biochem. Biophys. Res. Commun. 197:263-270.
				Dumais, N. et al. (1998) Prostaglandin E2 up-regulates HIV-1 long terminal repeat-driven gene activity in T cells via NF-kappaB-dependent and -independent signaling pathways. J. Biol. Chem. 273:27306-27314.
				Pai, R. et al. (2002) Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8:289-293.
				Mutoh, M. et al. (2002) Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 62:28-32.

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
				Sheng, H. et al. (2001) Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 276:18075-18081.
		582643| Ptger4	8.8E-91	[Mus musculus][Receptor (signaling)][Plasma membrane] Prostaglandin E receptor 4, a G protein-coupled receptor that signals through a stimulatory G-protein, mediates a variety of physiological and pathophysiological effects including immune and inflammatory responses and heart and skeletal development
				Honda, A. et al. (1993) Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J. Biol. Chem. 268:7759-7762.
				Suzawa, T. et al. (2000) The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective Eps. Endocrinology 141:1554-1559.
				Miyaura, C. et al. (2000) Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J. Biol. Chem. 275:19819-19823.
25	7511014CD1	g456564	9.9E-140	[Homo sapiens] prostanoid FP receptor
				Abramovitz, M. et al. (1994) Cloning and expression of a cDNA for the human prostanoid FP receptor. J. Biol. Chem. 269:2632-2636.
		337372| PTGFR	8.5E-141	[Homo sapiens][Receptor (signaling)][Plasma membrane] Prostanoid FP receptor (prostaglandin F2-alpha receptor), activation induces calcium flux, regulates smooth muscle contraction, and predicted to be necessary for luteolysis; mutations in the corresponding gene are associated with breast cancer
				Sossey-Alaoui, K. et al. (2001) Fine mapping of the PTGFR gene to 1p31 region and mutation analysis in human breast cancer. Int. J. Mol. Med 7:543-546.
				Sugimoto, Y. et al. (1997) Failure of parturition in mice lacking the prostaglandin F receptor. Science 277:681-683.

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
		582645|Ptgfr	4.3E-130	[Mus musculus][Receptor (signaling)][Plasma membrane] Prostanoid FP receptor (prostaglandin F2-alpha receptor), a G protein-coupled receptor that mediates intracellular signaling, necessary for luteolysis; mutations in human PTGFR gene are associated with breast cancer
				Sugimoto, Y. et al. (1994) Cloning and expression of a cDNA for mouse prostaglandin F receptor. J. Biol. Chem. 269:1356-1360.
26	7506687CD1	g6010211	0.0	[Homo sapiens] semaphorin receptor
				Tamagnone, L. et al. (1999) Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 99:71-80.
		568412| PLXNB1	0.0	[Homo sapiens][Receptor (signaling)][Plasma membrane] Plexin 5, member of the plexin family of semaphorin receptors involved in mediating cell guidance, expressed in the brain
				Maestrini, E. et al. (1996) A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc. Natl. Acad. Sci. USA 93:674-678.
		608600|Plxn6	2.5E-149	[Mus musculus] Protein containing a plexin repeat, a Sema domain, and three IPT/TIG domains, all of which are found in receptors
27	7510621CD1	g246539	1.8E-115	[Homo sapiens] ocular melanoma-associated antigen; OMA81H
				Wang, M. X. et al. (1992) An ocular melanoma-associated antigen. Molecular characterization. Arch. Ophthalmol. 110:399-404.
		344036|CD63	1.6E-116	[Homo sapiens][Lysosome/vacuole; Cytoplasmic; Plasma membrane] Melanoma 1 antigen, a member of the tetraspanning superfamily (TM4SF), forms multicomponent complexes with beta 1 integrins, associates with peptide-loaded MHC class II molecules; acts to limit the invasion and progression of melanoma
				Metzelaar, M. J. et al. (1991) CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J. Biol. Chem. 266:3239-3245.

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
				Gwynn, B. et al. (1996) Genetic localization of Cd63, a member of the transmembrane 4 superfamily, reveals two distinct loci in the mouse genome. Genomics 35:389-391.
				Radford, K. J. et al. (1996) CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta 1 integrins in human melanoma. Biochem. Biophys. Res. Commun. 222:13-18.
				Smith, D. A. et al. (1995) Antibodies against human CD63 activate transfected rat basophilic leukemia (RBL-2H3) cells. Mol. Immunol. 32:1339-1344.
		583753|Cd63	2.3E-92	[Mus musculus][Plasma membrane] Melanoma 1 antigen, a member of the tetraspanning superfamily (TM4SF), may play a role in maintaining normal renal function, highly expressed in activated macrophages
				Miyamoto, H. et al. (1994) Molecular cloning of the murine homologue of CD63/ME491 and detection of its strong expression in the kidney and activated macrophages. Biochim. Biophys. Acta 1217:312-316.
28	7505533CD1	g7768496	6.9E-13	[Schizosaccharomyces pombe] putative ER-derived vesicles protein similar to yeast erv14
		569856| HSPC163	8.9E-43	[Homo sapiens] Protein of unknown function, has moderate similarity to S. cerevisiae Erv14p, which is a protein of ER-derived vesicles that is required for efficient degradation of soluble ER quality control substrates
		6677|ERV14	4.0E-15	[Saccharomyces cerevisiae][Vesicle coat protein; Docking protein][Endoplasmic reticulum; Other vesicles of the secretory/endocytic pathways] Protein of ER-derived vesicles that is required for efficient degradation of soluble ER quality control substrates, has similarity to Drosophila melanogaster cni protein
				Powers, J. et al. (1998) Transport of Axl2p depends on Erv14p, an ER-vesicle protein related to the Drosophila cornichon gene product. J. Cell Biol. 142:1209-1222.
29	7511220CD1	g7259234	1.0E-75	[Mus musculus] contains transmembrane (TM) region
				Inoue, S. et al.

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
				Growth suppression of Escherichia coli by induction of expression of mammalian genes with transmembrane or ATPase domains
				Biochem. Biophys. Res. Commun. 268, 553-561 (2000)
30	7510967CD1	g14091952	0.0	[Rattus norvegicus] KIDINS220
				Iglesias, T. et al.
				Identification and cloning of Kidins220, a novel neuronal substrate of protein kinase D
				J. Biol. Chem. 275, 40048-40056 (2000)
	7510967CD1	735217| KIDINS220	0.0	[Homo sapiens] Protein containing eleven ankyrin (Ank) repeats, which may mediate protein-protein interactions, has a region of low similarity to a region of ankyrin 1 (human ANK1), which is a a cytoskeletal anchor protein and is associated with hereditary spherocytosis
	7510967CD1	244565| F36H1.2	9.6E-181	[Caenorhabditis elegans] Ankyrin repeat-containing protein with similarity to C. elegans UNC-44 and human and D. melanogaster ankyrins
				Iglesias, T. et al. (supra)
31	7511298CD1	g1685051	0.0	[Homo sapiens] CD97
				Gray, J. X. et al.
				CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation
				J Immunol 157, 5438-47 (1996).
	7511298CD1	762597|CD97	0.0	[Homo sapiens][Receptor (signalling)][Plasma membrane] CD97 antigen, a leukocyte activation antigen that binds CD55 (DAF), may be involved in cell-cell signaling, cell adhesion, immune and inflammatory responses, expressed in thyroid and gastrointestinal tract cancer
				Zendman, A. J. et al.
				TM7XN1, a novel human EGF-TM7-like cDNA, detected with mRNA differential display using human melanoma cell lines with different metastatic potential.
				FEBS Lett 446, 292-8 (1999).

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
				Aust, G. et al.
				CD97: a dedifferentiation marker in human thyroid carcinomas.
				Cancer Res 57, 1798-806 (1997).
	7511298CD1	584465|Cd97	5.4E-213	[Mus musculus][Adhesin/agglutinin;Receptor (signalling)][Plasma membrane] CD97 antigen, a member of the EGF TM7 family that is a group of class II seven-span transmembrane receptors, receptor for the complement cascade regulator, CD55(Daf1), plays a role in cell adhesion, may play a role in lymphocyte activation
				Qian, Y. M. et al.
				Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55).
				Immunology 98, 303-11 (1999).
32	7510937CD1	g3766232	0.0	[Vulpes vulpes] kinectin
		341688| KTN1	0.0	[Homo sapiens][Anchor Protein; Activator][Endoplasmic reticulum; Cytoplasmic] Kinectin, functions as a receptor for the microtubule-motor protein kinesin and plays a role in intracellular movement of organelles; mutations in the corresponding gene are associated with childhood papillary thyroid carcinoma.
				Salassidis, K. et al. Translocation t(10;14)(q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma. Cancer Res 60, 2786-9. (2000).
		581915|Ktn1	0.0	[Mus musculus][Anchor Protein][Endoplasmic reticulum; Cytoplasmic; Plasma membrane] Kinectin, functions as a receptor for the microtubule-motor protein kinesin and plays a role in intracellular movement of organelles; mutations in the human KTN1 gene are associated with childhood papillary thyroid carcinoma.
				Leung, E. et al. Cloning of novel kinectin splice variants with alternative C-termini: structure, distribution and evolution of mouse kinectin. Immunol Cell Biol 74, 421-33 (1996).

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
33	7511852CD1	g189186	8.1E-149	[Homo sapiens] tumor necrosis factor receptor
				Smith, C. A. et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248, 1019-1023 (1990).
		338588| TNFRSF1B	6.5E-150	[Homo sapiens][Receptor (signalling)][Plasma membrane] Tumor necrosis factor receptor 1b, a receptor for tumor necrosis factor (TNF), mediates proinflammatory responses associated with wounding and immunity; mutation in gene is associated familial combined hyperlipidemia and narcolepsy.
				Chan, F. K. et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288, 2351-4 (2000).
		586035| Tnfrsf1b	1.5E-81	[Mus musculus][Receptor (signalling)][Extracellular (excluding cell wall); Plasma membrane] Tumor necrosis factor receptor 1b, a receptor for tumor necrosis factor (TNF), mediates proinflammatory responses; mutation in human TNFRSF1B gene is associated familial combined hyperlipidemia and narcolepsy.
				Kurrelmeyer, K. M., Michael, L. H., Baumgarten, G., Taffet, G. E., Peschon, J. J., Sivasubramanian, N., Entman, M. L., and Mann, D. L. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A 97, 5456-61 (2000).
				Azuma, Y., Kaji, K., Katogi, R., Takeshita, S., and Kudo, A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275, 4858-64. (2000).
34	7511077CD1	g15079236	3.3E-81	[Mus musculus] Similar to tumor differentially expressed 1
		585979|Tde1	3.0E-81	[Mus musculus] Tumor differentially expressed 1, a putative membrane protein that is overexpressed in testicular tumor cells.
				Bossolasco, M. et al. The human TDE gene homologue: localization to 20q13.1-13.3 and variable expression in human tumor cell lines and tissue. Mol Carcinog 26, 189-200 (1999).

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
		428528| TDE1	3.7E-76	[Homo sapiens] Tumor differentially expressed 1, a putative membrane protein that is overexpressed in lung tumors and colorectal tumor cells.
				Bossolasco, M. et al. (supra)
				Nimmrich, I. et al. Seven genes that are differentially transcribed in colorectal tumor cell lines. Cancer Lett 160, 37-43 (2000).
35	7511576CD1	g13661645	1.3E-77	[Homo sapiens] MS4A6A-polymorph
				Liang, Y. et al. Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4a family members expressed in human and mouse. Genomics 72, 119-127 (2001).
		697394| MS4A6A	4.1E-61	[Homo sapiens][Plasma membrane] Member 6 of the membrane-spanning four-domains, subfamily A group of proteins, has similarity to CD20, HTm4 (CD20L), and high affinity IgE receptor beta chain (FCER1B).
				Ishibashi, K. et al., Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor., Gene 264, 87-93. (2001).
36	7511492CD1	g506861	1.1E-46	[Homo sapiens] BST-2
				Ishikawa, J. et al., Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth, Genomics 26, 527-534 (1995).
		340100|BST2	9.3E-48	[Homo sapiens][Plasma membrane] Bone marrow stromal antigen 2, a cell surface antigen that may play a role in proliferation and cell-cell communication, likely to be involved in humoral defense; elevated levels are associated with myeloma.
				Ohtomo, T. et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 258, 583-91. (1999).
37	7511141CD1	g974282	2.9E-73	[Homo sapiens] secretin receptor
				Chow, B. K. Molecular cloning and functional characterization of a human secretin receptor. Biochem. Biophys. Res. Commun. 212, 204-211 (1995).

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
		337902|SCTR	2.3E-74	[Homo sapiens][Receptor (signalling)][Plasma membrane] Secretin receptor, a class II G protein-coupled receptor that can couple the cAMP and phosphatisylinositol intracellular signaling pathways and is involved in the control of water, bicarbonate and enzyme secretion in pancreas, gall bladder and stomach.
				Shetzline, M. A. et al. A role for receptor kinases in the regulation of class II G protein-coupled receptors. Phosphorylation and desensitization of the secretin receptor. J Biol Chem 273, 6756-62 (1998).
		705026|Sctr	5.9E-46	[Rattus norvegicus][Receptor (signalling)][Plasma membrane] Secretin receptor, a class II G protein-coupled receptor that couples to a stimulatory G protein, activates the cAMP signaling pathway and is involved in the control of water, bicarbonate and enzyme secretion in pancreas, gall bladder and stomach.
				Dong, M., Wang, Y., Hadac, E. M., Pinon, D. I., Holicky, E., and Miller, L. J. Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor. J Biol Chem 274, 19161-7 (1999).
38	7511300CD1	g1685051	0.0	[Homo sapiens] CD97
				Gray, J. X. et al. CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J. Immunol. 157(12):5438-47 (1996).
		762597|CD97	0.0	[Homo sapiens][Receptor (signalling)][Plasma membrane] CD97 antigen, a leukocyte activation antigen that binds CD55 (DAF), may be involved in cell-cell signaling, cell adhesion, immune and inflammatory responses, expressed in thyroid and gastrointestinal tract cancer.
				Gray, J. X. et al. (supra)
				Aust, G. et al. CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 57, 1798-806 (1997).

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO: or PROTEOME ID NO:	Probability Score	Annotation
		584465|Cd97	2.1E-242	[Mus musculus][Adhesin/agglutinin; Receptor (signalling)][Plasma membrane] CD97 antigen, a member of the EGF TM7 family that is a group of class II seven-span transmembrane receptors, receptor for the complement cascade regulator, CD55 (Daf1), plays a role in cell adhesion, may play a role in lymphocyte activation.
				Caminschi, I., Lucas, K. M., O'Keeffe, M. A., Hochrein, H., Laabi, Y., Kontgen, F., Lew, A. M., Shortman, K., and Wright, M. D. Molecular cloning of F4/80-like-receptor, a seven-span membrane protein expressed differentially by dendritic cell and monocyte-macrophage subpopulations. J Immunol 167, 3570-6. (2001).

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	3048626CD1	747	S150 S184 S222 S250 S297 S307 S345 S350 S351 S357 S362 S384 S440 S494 S505 S555 S580 S654 S658 T74 T95 T153 T233 T247 T264 T276 T285 T386 T485 T539 T653	N291 N659 N718	Cytosolic domains: M1-K97, S150-I456, C534-D595, T648-P714 Transmembrane domains: V98-F117, I132-V149, P457-F479, V511-L533, V596-H618, Y628-V647, L715-G737 Non-cytosolic domains: C118-V131, R480-I510, V619-H627, F738-S747	TMHMMER
					Class IA and IB cytochrome C signature PR00604: H374-S381	BLIMPS_PRINTS
					Cytochrome c family heme-binding site signature: C375-S380	MOTIFS
2	2684425CD1	799	S137 S174 S182 S191 S254 S322 S328 S405 S410 S424 S435 S458 S476 S523 S545 S552 S587 S602 S629 S713 S718 S722 S726 S782 T55 T73 T85 T190 T306 T444 T495 T509 T621 T752 T767 Y779	N39 N53 N58 N69 N80 N135 N304 N557 N761	signal_cleavage: M1-A24	SPSCAN
					Signal Peptide: M1-G22	HMMER
					Signal Peptide: M1-A24	HMMER

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					Cytosolic domain: M1-N360 Transmembrane domain: I361-W383 Non-cytosolic domain: R384-I799	TMHMMER
3	7505960CD1	663	S22 S31 S102 S119 S218 S304 S430 S526 S572 T135 T447 Y13	N29 N69 N155 N197 N298 N393 N405 N416 N631	signal_cleavage: M1-G52	SPSCAN
					Cytosolic domains: M1-V35, R251-R251, R331-M355, E473-D549, S610-K663 Transmembrane domains: I36-Y58, S228-L250, L252-Y274, T308-L330, F356-Y378, Y450-L472, L550-S572, L587-F609 Non-cytosolic domains: G59-Q227, Y275-E307, L379-R449, G573-H586	TMHMMER
					Leucine zipper pattern: L245-L266	MOTIFS
4	7507021CD1	150	S21 S73 T16 T26 T85 T87 Y96		signal_cleavage: M1-D19	SPSCAN
					Signal Peptide: M1-D19	HMMER
					Signal Peptide: M1-P22	HMMER
					Signal Peptide: M1-E25	HMMER
					Signal Peptide: M1-S23	HMMER
					Signal Peptide: M1-T20	HMMER
					Vitamin K-dependent carboxylation/gamma-carb: L55-Y96	HMMER_PFAM
					Cytosolic domain: R133-L150 Transmembrane domain: L110-L132 Non-cytosolic domain: M1-S109	TMHMMER
					Vitamin K-dependent carboxylation domain: V30-A111	PROFILESCAN

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					Coagulation factor GLA domain signature PR00001: D54-C67, L68-F81, E82-Y96	BLIMPS_PRINTS
					PROLINERICH GLA PROTEIN 2 PD059428: M1-D54	BLAST_PRODOM
					PROLINERICH GLA PROTEIN 2 PD059430: I95-E146	BLAST_PRODOM
					GLA DOMAIN DM00454 |P25155|2-80: L9-W91 |P19221|5-91: Q28-Y94 |P18292|5-91: Q28-Y94 |S49075|2-80: L7-W91	BLAST_DOMO
					Vitamin K-dependent carboxylation domain: D54-W91	MOTIFS
5	7509099CD1	504	S16 S35 S200 S225 S234 S305 S334 S336 S382 S402 S437 S460 S481 T152 T226 T329 Y94 Y320	N128 N168 N184 N198 N232	signal_cleavage: M1-A20	SPSCAN
					Signal Peptide: M1-S16	HMMER
					Signal Peptide: M1-E19	HMMER
					Signal Peptide: M1-A20	HMMER
					Signal Peptide: M1-K22	HMMER
					Signal Peptide: M1-C23	HMMER
					Signal Peptide: M1-S17	HMMER
					TIR domain: A322-H472	HMMER_PFAM
					Cytosolic domain: K295-G504 Transmembrane domain: H272-F294 Non-cytosolic domain: M1-K271	TMHMMER

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					RECEPTOR INTERLEUKIN-1 P PD02870: L116-F150, E169-V185, N268-K292	BLIMPS_PRODOM
					RECEPTOR PROTEIN PRECURSOR SIGNAL INTERLEUKIN1 TRANSMEMBRANE GLYCOPROTEIN I IMMUNOGLOBULIN FOLD PD002366: G317-V475	BLAST_PRODOM
					RECEPTOR INTERLEUKIN1 I PRECURSOR TRANSMEMBRANE SIGNAL TYPE IL1R1 P80 IMMUNOGLOBULIN PD011274: V216-G317	BLAST_PRODOM
					RECEPTOR TYPE I INTERLEUKIN1 PRECURSOR IL1R1 P80 IMMUNOGLOBULIN FOLD TRANSMEMBRANE PD015419: N168-Y213	BLAST_PRODOM
					RECEPTOR PRECURSOR SIGNAL INTERLEUKIN1 IMMUNOGLOBULIN FOLD GLYCOPROTEIN TRANSMEMBRANE TYPE PROTEIN PD006063: L4-V97	BLAST_PRODOM
					INTERLEUKIN; ACCESSORY; INTRLEUKIN; ST2L; DM02304 |P14778|323-562: A258-E498 |P13504|326-565: A258-K494 |JQ1526|326-555: A258-S488	BLAST_DOMO
					IG-LIKE C2-TYPE DOMAIN DM01362|P14778|11-227: I11-I163, D98-I163	BLAST_DOMO
6	7509361CD1	247	S42 S157 S208 S221 S237 S244 T5 T90	N54 N145 N151	signal_cleavage: M1-G21	SPSCAN
					Signal Peptide: M1-G21	HMMER
					Signal Peptide: M1-P24	HMMER

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					Signal Peptide: M1-G29	HMMER
					TNF-receptor internal cysteine rich dom: C84-C125, C127-C166, C44-C81, C168-C195	HMMER_INCY
					TNFR/NGFR cysteine-rich region: C84-C125, C44-C81, C127-C166, C168-C195	HMMER_PFAM
					Tumor necrosis factor receptor / nerve: C84-C125, C44-C81, C127-C166, C168-C195	HMMER_SMRT
					Cytosolic domain: H33-A247 Transmembrane domain: L10-P32 Non-cytosolic domain: M1-L9	TMHMMER
					TNFR/NGFR family cysteine-rich region proteins BL00652: L9-L15, C58-L68, C117-C127	BLIMPS_BLOCKS
					TUMOR NECROSIS FACTOR RECEPTOR PRECURSOR P60 TNFR1 P55 TRANSMEMBRANE GLYCOPROTEIN PD013401: C168-S208, P214-R236	BLAST_PRODOM
					TUMOR NECROSIS FACTOR RECEPTOR TYPE 1 DM04395 |P19438|120-454: D120-S208 |P50555|120-460: D120-S208, N201-A247	BLAST_DOMO
					TNFR/NGFR FAMILY CYSTEINE-RICH REGION DM00218 |P19438|39-118: K39-V119 |P50555|39-118: K39-V119	BLAST_DOMO
					Cytochrome c family heme-binding site signature: C59-K64	MOTIFS
					EGF-like domain signature 2: C166-C179	MOTIFS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					TNFR/NGFR family cysteine-rich region signature: C44-C81, C84-C125, C125-C166, C127-C166	MOTIFS
7	7506815CD1	363	S127 S171 T270	N7 N30 N36	7 transmembrane receptor (rhodopsin family): V52-Y306	HMMER_PFAM
					Cytosolic domains: M1-H86, S158-R246, M309-G363Transmembrane domains: A87-T109, S135-I157, V247-Y266, A286-F308Non-cytosolic domains: V110-W134, S267-G285	TMHMMER
					G-protein coupled receptors proteins BL00237: N36-P75, F143-Y154, L242-A268, S298-R314	BLIMPS_BLOCKS
					G-protein coupled receptors family 2 proteins BL00649: R129-M150	BLIMPS_BLOCKS
					Gastrin receptor signature PR00527: S20-N36, L37-S53, P75-R89, M102-P116, R117-S135, I157-D174, A201-R217, R323-P342	BLIMPS_PRINTS
					Neuropeptide Y receptor PR01012: R50-A65, L293-N302, L304-C317	BLIMPS_PRINTS
					Rhodopsin-like GPCR superfamily PR00237: R50-I72, H86-V107, S135-S158, V247-W271, I288-R314	BLIMPS_PRINTS
					G-protein coupled receptors signature: G48-T94	PROFILESCAN
					Visual pigments (opsins) retinal binding site: G276-P341	PROFILESCAN
					RECEPTOR GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN LIPOPROTEIN PALMITATE GASTRIN/CHOLECYSTOKININ TYPE B PD005216: T109-G208	BLAST_PRODOM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					GASTRIN/CHOLECYSTOKININ TYPE B RECEPTOR CCKB CCKBR G-PROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN PD009141: C307-G363	BLAST_PRODOM
					GASTRIN/CHOLECYSTOKININ TYPE B RECEPTOR CCKB CCKBR G-PROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN PD007211: M1-I64	BLAST_PRODOM
					G-PROTEIN COUPLED RECEPTORS DM00013 |P30552|48-412: G51-A322 |P32238|35-386: G51-T320 |S17783|95-396: V52-Q182, P236-R314 |P30975|95-396: V52-Q182, P236-R314	BLAST_DOMO
					G-protein coupled receptors signature: V56-I72	MOTIFS
8	7506814CD1	392	S82 S211 S255 T299	N7 N30 N36	7 transmembrane receptor (rhodopsin family): G71-Y335	HMMER_PFAM
					Cytosolic domains: L81-A91, R152-A171, S242-R275, M338-G392 Transmembrane domains: I58-G80, F92-P114, A129-E151, A172-V194, S219-I241, V276-Y295, A315-F337 Non-cytosolic domains: M1-R57, N115-K128, V195-W218, S296-G314	TMHMMER
					G-protein coupled receptors proteins BL00237: F120-P159, F227-Y238, G271-A297, S327-R343	BLIMPS_BLOCKS
					G-protein coupled receptors signature: S131-T178	PROFILESCAN
					Visual pigments (opsins) retinal binding site: G305-P370	PROFILESCAN

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					Rhodopsin-like GPCR superfamily signature PR00237: I56-G80, T89-F110, M134-I156, H170-V191, S219-S242, V276-W300, I317-R343	BLIMPS_PRINTS
					Gastrin receptor signature PR00527: S20-N36, L37-E53, F110-I125, P159-R173, M186-P200, R201-S219, I241-D258, R352-P371	BLIMPS_PRINTS
					Neuropeptide Y receptor signature PR01012: L81-L93, T111-G123, M134-A149, L322-N331, L333-C346	BLIMPS_PRINTS
					GASTRIN/CHOLECYSTOKININ TYPE B RECEPTOR CCKB CCKBR GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN PD007211: M1-R83	BLAST_PRODOM
					RECEPTOR GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN LIPOPROTEIN PALMITATE GASTRIN/CHOLECYSTOKININ TYPE B PD005216: T193-G271	BLAST_PRODOM
					GASTRIN/CHOLECYSTOKININ TYPE B RECEPTOR CCKB CCKBR GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN PD009141: C336-G392	BLAST_PRODOM
					RECEPTOR COUPLED GPROTEIN TRANSMEMBRANE GLYCOPROTEIN PHOSPHORYLATION LIPOPROTEIN PALMITATE PROTEIN FAMILY PD000009: R83-P188	BLAST_PRODOM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					G-PROTEIN COUPLED RECEPTORS DM00013|P30552|48-412: G48-G271, A272-A351, R8-R45	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS DM00013|P32238|35-386: T49-R262, L247-T349	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS DM00013|P25929|34-335: L52-Q344	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS DM00013|P25931|84-384: L60-E348	BLAST_DOMO
					G-protein coupled receptors signature: V140-I156	MOTIFS
9	7506852CD1	125	S117 S122		signal_cleavage: M1-G59	SPSCAN
					7 transmembrane receptor (rhodopsin family): G26-R114	HMMER_PFAM
					Cytosolic domains: A33-T44, V103-S125 Transmembrane domains: A10-W32, F45-I67, C80-A102 Non-cytosolic domains: M1-Q9, L68-T79	TMHMMER
					G-protein coupled receptors proteins BL00237: P73-P112	BLIMPS_BLOCKS
					G-protein coupled receptors signature: A84-S125	PROFILESCAN
					Rhodopsin-like GPCR superfamily signature PR00237: A11-K35, T44-L65, V87-V109	BLIMPS_PRINTS
					Adenosine receptor signature PR00424: A10-I19, T79-T91	BLIMPS_PRINTS
					Adenosine A1 receptor signature PR00552: I5-I15, V34-C46, L68-C80	BLIMPS_PRINTS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					RECEPTOR A1 GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN ADENOSINE LIPOPROTEIN PALMITATE AS PD007911: M1-A39	BLAST_PRODOM
					G-PROTEIN COUPLED RECEPTORS DM00013|I48096|3-304: S4-R114	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS DM00013|P28190|3-303: P3-R114	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS DM00013|P49892|3-304: S4-R114	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS DM00013|S55231|3-304: S4-R114	BLAST_DOMO
					G-protein coupled receptors signature: S93-V109	MOTIFS
10	7503782CD1	728	S9 S200 S243 S248 S419 S437 S472 S536 S573 S666 T60 T72 T175 T220 T261 T342 T528 Y426	N148 N386 N582	Cytosolic domains: M1-F115, R222-S298, Q375-N386, D469-W501, S569-Q728 Transmembrane domains: L116-L138, Y199-L221, Y299-T321, Q352-V374, L387-Q409, S446-V468, M502-I524, T546-V568 Non-cytosolic domains: R139-V198, K322-L351, T410-L445, K525-S545	TMHMMER
					Leucine zipper pattern: L207-L228, L347-L368, L445-L466	MOTIFS
11	7504647CD1	61	S47		signal_cleavage: M1-A23	SPSCAN
					Signal Peptide: M1-G19	HMMER
					Signal Peptide: M1-T21	HMMER
					Signal Peptide: M1-A23	HMMER
					Signal Peptide: M1-Q25	HMMER

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					PRECURSOR SIGNAL ADHALIN ALPHASARCOGLYCAN GLYCOPROTEIN EPSILONSARCOGLYCAN ADHALIN35 A DYSTROPHINASSOCIATED PD009878: M1-H51	BLAST_PRODOM
12	7500424CD1	152			Signal Peptide: M1-G22	HMMER
					Signal Peptide: M1-G25	HMMER
					Signal Peptide: M1-G27	HMMER
13	7500449CD1	283	S8 S67 S139 S165 S176 T111 T146	N93 N104 N135	Domain present in hormone receptors: E94-L166	HMMER_SMART
					Hormone receptor domain: T95-K162	HMMER_PFAM
					Cytosolic domain: R203-S283 Transmembrane domain: G180-F202 Non-cytosolic domain: M1-T179	TMHMMER
					G-protein coupled receptors proteins BL00237: W78-A117, F181-Y192	BLIMPS_BLOCKS
					G-protein coupled receptors family 2 signatures: Y74-G144	PROFILESCAN
					Secretin-like GPCR superfamily signature PR00249: T179-R203, Y211-F235	BLIMPS_PRINTS
					Vasoactive intestinal peptide receptor signature PR00491: P122-G133, N135-P150, P152-K162	BLIMPS_PRINTS
					RECEPTOR TRANSMEMBRANE GPROTEIN COUPLED GLYCOPROTEIN PRECURSOR SIGNAL TYPE POLYPEPTIDE ALTERNATIVE PD000752: C98-S244	BLAST_PRODOM
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378|P32241|25-434: L68-S247	BLAST_DOMO

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378|Q02643|16-422: S62-S244	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378|P41586|13-446: Q81-Q132, V136-C243	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378|A53471|12-420: S66-G257	BLAST_DOMO
					G-protein coupled receptors family 2 signature 1: C98-P122	MOTIFS
14	7503281CD1	246	S42 S122 S202 S222 T39 T83 T125 T226 Y172		signal_cleavage: M1-R44	SPSCAN
					7 transmembrane receptor (rhodopsin family): G29-H246	HMMER_PFAM
					Cytosolic domains: L38-N48, D109-R128, R194-H246 Transmembrane domains: I15-V37, L49-A71, E86-L108, I129-K151, W171-L193 Non-cytosolic domains: M1-A14, N72-C85, G152-A170	TMHMMER
					G-protein coupled receptors signature: A90-V136	PROFILESCAN
					Rhodopsin-like GPCR superfamily signature PR00237: A14-L38, Q47-F68, D92-V114, R128-I149, I173-Y196	BLIMPS_PRINTS
					RECEPTOR COUPLED GPROTEIN TRANSMEMBRANE GLYCOPROTEIN PHOSPHORYLATION LIPOPROTEIN PALMITATE PROTEIN FAMILY PD000009: R41-Y150	BLAST_PRODOM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					ADRENERGIC RECEPTOR ADRENOCEPTOR GPROTEIN COUPLED TRANSMEMBRANE MULTIGENE FAMILY PHOSPHORYLATION GLYCOPROTEIN PD003999: M1-S42	BLAST_PRODOM
					G-PROTEIN COUPLED RECEPTORS DM00013|P18089|6-442: P6-S238	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS DM00013|I49481|27-442: P6-A218, R205-S240	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS DM00013|P08913|27-442: P6-R228	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS DM00013|P18825|45-452: Y7-T217, K200-A245	BLAST_DOMO
					G-protein coupled receptors signature: S98-V114	MOTIFS
15	7503292CD1	319	S5 S252 T148		signal_cleavage: M1-S53	SPSCAN
					7 transmembrane receptor (rhodopsin family): G49-T318	HMMER_PFAM
					Cytosolic domains: L58-R69, E132-R151, T229-W319 Transmembrane domains: F35-V57, H70-Y92, Y112-A131, T152-M174, F206-V228 Non-cytosolic domains: M1-L34, S93-Y111, G175-V205	TMHMMER
					G-protein coupled receptors signature: F113-L158	PROFILESCAN
					Rhodopsin-like GPCR superfamily signature PR00237: L34-L58, L68-V89, H115-V137, R151-V172, I207-V230	BLIMPS_PRINTS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					NEUROTENSIN RECEPTOR TYPE NTR2 LEVOCABASTINE SENSITIVE GPROTEIN COUPLED TRANSMEMBRANE LIPOPROTEIN PD027448: M1-G66	BLAST_PRODOM
					NEUROTENSIN RECEPTOR TYPE 2 NTR2 LOWAFFINITY LEVOCABASTINE SENSITIVE NTRL GPROTEIN COUPLED TRANSMEMBRANE LIPOPROTEIN PALMITATE PD016080: I173-G261	BLAST_PRODOM
					G-PROTEIN COUPLED RECEPTORS DM00013|P30989|57-380: D26-Q239	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS DM00013|P20905|156-522: L34-L225	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS DM00013|P31391|41-326: D26-L219	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS DM00013|P35371|41-345: Y39-S242	BLAST_DOMO
					G-protein coupled receptors signature: A121-V137	MOTIFS
16	7503311CD1	284	T31 T79 T116	N62 N77 N230	Signal Peptide: M1-T25	HMMER
					Domain present in hormone receptors: S57-F127	HMMER_SMART
					7 transmembrane receptor (Secretin family): L134-S284	HMMER_PFAM
					Hormone receptor domain: G58-K123	HMMER_PFAM
					Cytosolic domain: R163-C226 Transmembrane domains: M140-F162, V227-G249 Non-cytosolic domains: M1-V139, G250-S284	TMHMMER
					G-protein coupled receptors family 2 proteins BL00649: C61-L88, G144-S189, C216-L241	BLIMPS_BLOCKS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					G-protein coupled receptors family 2 signatures: W39-G107	PROFILESCAN
					Secretin-like GPCR superfamily signature PR00249: V139-R163, Y171-P195, T218-L241, F256-P281	BLIMPS_PRINTS
					RECEPTOR TRANSMEMBRANE GPROTEIN COUPLED GLYCOPROTEIN PRECURSOR SIGNAL TYPE POLYPEPTIDE ALTERNATIVE PD000752: C61-G265	BLAST_PRODOM
					GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR PRECURSOR GIPR GLUCOSE DEPENDENT INSULINOTROPIC G PROTEIN PD022939: Q21-L59	BLAST_PRODOM
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378|P48546|21-438: Q21-A266	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378|P47871|18-444: L35-A266	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378|P43220|21-448: E34-G265	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378|P25107|23-499: L20-G265	BLAST_DOMO
					G-protein coupled receptors family 2 signature 1: C61-P85	MOTIFS
17	7510384CD1	400	T128 T347	N50	signal_cleavage: M1-G22	SPSCAN
					Signal Peptide: M5-G22	HMMER
					Signal Peptide: M48-G71	HMMER
					Domain present in hormone receptors: T51-E121	HMMER_SMART
					Hormone receptor domain: T52-E117	HMMER_PFAM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					Cytosolic domain: M1-K130 Transmembrane domain: I131-A153 Non-cytosolic domain: L154-D400	TMHMMER
					G-protein coupled receptors family 2 proteins BL00649: C55-F82, G136-L181	BLIMPS_BLOCKS
					G-protein coupled receptors family 2 signatures: L34-G100	PROFILESCAN
					Secretin-like GPCR superfamily signature PR00249: I131-R155, Y163-F187	BLIMPS_PRINTS
					Vasoactive intestinal peptide receptor signature PR00491: P79-G90, A91-P106	BLIMPS_PRINTS
					RECEPTOR TRANSMEMBRANE GPROTEIN COUPLED GLYCOPROTEIN PRECURSOR SIGNAL TYPE POLYPEPTIDE ALTERNATIVE PD000752: C55-V200	BLAST_PRODOM
					GROWTH HORMONERELEASING HORMONE RECEPTOR PRECURSOR GHRH GRF GRFR GPROTEIN COUPLED PD016970: M1-G54	BLAST_PRODOM
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378|Q02643|16-422: P16-M201	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378|P32241|25-434: M24-V200	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378|P41587|13-421: M24-C195	BLAST_DOMO
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378|JC2532|20-434: C28-C195	BLAST_DOMO
					G-protein coupled receptors family 2 signature 1: C55-P79	MOTIFS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
18	7509976CD1	893	S82 S182 S183 S188 S274 S283 S436 S479 S598 S671 S778 S831 T169 T248 T252 T259 T421 T614 T664 T703 T759	N59 N548 N637 N738 N746	signal_cleavage: M1-G19	SPSCAN
					Signal Peptide: M1-A17	HMMER
					Signal Peptide: M1-G19	HMMER
					Signal Peptide: M1-R21	HMMER
					Signal Peptide: M1-P22	HMMER
					Signal Peptide: M1-A25	HMMER
					Domain found in Plexins, Semaphorins and Int: T490-V540, N637-P684, K785-S838	HMMER_SMRT
					Plexin repeat: T490-V540, K785-S838, N637-P684	HMMER_PFAM
					Sema domain: L33-Y357, A415-D471	HMMER_PFAM
					Tyrosinase CuA-binding region proteins BL00497: P461-K481	BLIMPS_BLOCKS
					PLEXIN PROTEIN PRECURSOR SIGNAL KIAA0407 K04B12.1 TRANSMEMBRANE SEX RECEPTOR GLYCOPROTEIN PD010132: S496-H819	BLAST_PRODOM
					PLEXIN PRECURSOR SIGNAL TRANSMEMBRANE PROTEIN SEX RECEPTOR GLYCOPROTEIN PD003973: R352-H474	BLAST_PRODOM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					SEMAPHORIN PROTEIN PRECURSOR RECEPTOR KINASE SIGNAL TYROSINE TYROSINEPROTEIN FAMILY HEPATOCYTE PD001844: T34-W284, I96-V454	BLAST_PRODOM
					do KINASE; TYROSINE; ATP; GROWTH; DM01368|P51805|796-899: C796-R893	BLAST_DOMO
					do KINASE; TYROSINE; HEPATOCYTE; ATP; DM03653|P08581|14-526: D30-A498	BLAST_DOMO
					do KINASE; TYROSINE; HEPATOCYTE; ATP; DM03653|Q04912|17-533: V45-C497	BLAST_DOMO
					do KINASE; TYROSINE; HEPATOCYTE; ATP; DM03653|A48196|13-528: H35-L365	BLAST_DOMO
					ATP/GTP-binding site motif A (P-loop): G168-S175	MOTIFS
19	7510454CD1	203	S53 S198 T45 Y128	N117	Signal Peptide: M1-A15	HMMER
					Signal Peptide: M1-M19	HMMER
					Cytosolic domain: K27-D56 Transmembrane domains: F4-L26, I57-I75 Non-cytosolic domains: M1-S3, C76-P203	TMHMMER
					Leucine zipper pattern: L127-L148	MOTIFS
20	8017335CD1	429	S80 S258 S287 S296 S343 S357 S366 S413 T157	N181 N208 N285	Cytosolic domains: L73-S83, L144-K163, C224-V247, R323-N429 Transmembrane domains: S50-L72, L84-L106, F121-N143, I164-M186, V201-I223, V248-I270, Y300-F322 Non-cytosolic domains: M1-L49, S107-H120, L187-T200, S271-E299	TMHMMER

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					PUTATIVE SEVEN PASS TRANSMEMBRANE PROTEIN TRANSMEMBRANE PD138976: M1-L361	BLAST_PRODOM
21	7510197CD1	101	S40		signal_cleavage: M1-F16	SPSCAN
					Signal Peptide: M1-F16	HMMER
					Signal Peptide: M1-D18	HMMER
					Cytosolic domain: T68-L101 Transmembrane domain: A45-L67 Non-cytosolic domain: M1-C44	TMHMMER
					Leucine zipper pattern: L39-L60, L46-L67, L53-L74	MOTIFS
					Prenyl group binding site (CAAX box): C99-L101	MOTIFS
22	7510055CD1	237	S97 S156 T55 T104 T141 T165 T179	N153 N180	signal_cleavage: M1-P20	SPSCAN
					Signal Peptide: M1-P20	HMMER
					Signal Peptide: M1-E28	HMMER
					Signal Peptide: M1-A25	HMMER
					Signal Peptide: M1-C26	HMMER
					TNF-receptor internal cysteine rich domain: C62-C103, C146-C186, C105-C143, C26-C59	HMMER_INCY
					Tumor necrosis factor receptor / nerve: C105-C143, C62-C103, C146-C186, C26-C59	HMMER_SMART
					TNFR/NGFR cysteine-rich region: C26-C59, C62-C103, C105-C143, C146-C186	HMMER_PFAM
					TNFR/NGFR family cysteine-rich region proteins BL00652: C37-L47, G95-C105	BLIMPS_BLOCKS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					CD40L RECEPTOR PRECURSOR BCELL SURFACE ANTIGEN CD40 BP50 CDW40 GLYCOPROTEIN PD154353: P61-T104	BLAST_PRODOM
					CD40L RECEPTOR PRECURSOR BCELL SURFACE ANTIGEN CD40 BP50 CDW40 GLYCOPROTEIN TRANSMEMBRANE REPEAT SIGNAL PD059682: M1-C59	BLAST_PRODOM
					RECEPTOR ACTIVATOR OF NFKAPPAB RANK PD173848: C8-C103	BLAST_PRODOM
					RECEPTOR FACTOR TUMOR NECROSIS HOMOLOG II PROTEIN PRECURSOR REPEAT SIGNAL PD149629: C105-T165	BLAST_PRODOM
					TNFR/NGFR FAMILY CYSTEINE-RICH REGION DM00218|P25942|99-178: C99-T179	BLAST_DOMO
					TNFR/NGFR FAMILY CYSTEINE-RICH REGION DM00218|P25942|22-97: P22-E98	BLAST_DOMO
					TNFR/NGFR FAMILY CYSTEINE-RICH REGION DM00218|P27512|99-178: T99-T179	BLAST_DOMO
					TNFR/NGFR FAMILY CYSTEINE-RICH REGION DM00218|P27512|22-97: C26-E98	BLAST_DOMO
					EGF-like domain signature 2: C103-C116	MOTIFS
					TNFR/NGFR family cysteine-rich region signature: C26-C59	MOTIFS
23	7501754CD1	460	S134 S207 S276 S318 S349 T156 T157 T286	N130 N205 N284 N355	signal_cleavage: M1-G56	SPSCAN

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					Cytosolic domains: R68-G87, K237-K240, P414-H460Transmembrane domains: L45-I67, G88-Y110, W214-A236, W241-L263, G391-L413Non-cytosolic domains: M1-L44, G111-R213, E264-E390	TMHMMER
					TWEETY F42E11.2 PROTEIN PD043235: L19-S426	BLAST_PRODOM
24	7510517CD1	218	S45 S160 S187 S202 S205 Y55	N7 N177	signal_cleavage: M27-A78	SPSCAN
					7 transmembrane receptor (rhodopsin family): G34-L218	HMMER_PFAM
					Cytosolic domains: C43-T53, E116-L135 Transmembrane domains: P20-L42, F54-T76, T96-V115, A136-L158 Non-cytosolic domains: M1-S19, I77-S95, G159-L218	TMHMMER
					G-protein coupled receptors proteins BL00237: W85-A124"	BLIMPS_BLOCKS
					G-protein coupled receptors signature: F97-Y144	PROFILESCAN
					Prostaglandin receptor signature PR00428: T22-V33, G68-Y80, A136-L149	BLIMPS_PRINTS
					Prostanoid EP4 receptor signature PR00586: S2-T22, C43-G60, M81-F102, N122-T139, F171-Y191	BLIMPS_PRINTS
					RECEPTOR PROSTAGLANDIN E2 EP4 SUBTYPE PROSTANOID PGE G-PROTEIN COUPLED TRANSMEMBRANE PD014814: M1-E51	BLAST_PRODOM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					PROSTAGLANDIN; SUBTYPE; EP3; PROSTACYCLIN DM00355|P35408|11-344: S11-V200 DM00355|P43119|7-307: P20-R212 DM00355|P43253|36-335: P20-C211 DM00355|S52078|36-335: P20-C211	BLAST_DOMO
					G-protein coupled receptors signature: S105-I121	MOTIFS
25	7511014CD1	297	S94 S144 T148 Y201	N4 N19	Signal Peptide: M3-C22, M3-T24	HMMER
					7 transmembrane receptor (rhodopsin family): S43-Y281	HMMER_PFAM
					Cytosolic domains: M1-L28, V89-C108, H174-L202, L272-E297 Transmembrane domains: S29-L51, F66-A88, S109-I131, H151-G173, L203-I225, I249-I271 Non-cytosolic domains: M52-S65, E132-K150, T226-V248	TMHMMER
					G-protein coupled receptors proteins BL00237: F101-P140, S242-Y268	BLIMPS_BLOCKS
					G-protein coupled receptors signature: F111-F162	PROFILESCAN
					Prostaglandin receptor signature PR00428: G80-Y92, S206-C219	BLIMPS_PRINTS
					Thromboxane receptor signature PR00429: G72-G85, F111-G126, H174-N189, E197-G214	BLIMPS_PRINTS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					Prostaglandin F receptor signature PR00855: S2-Q23, E25-V39, K53-L68, I171-T184, Y188-F205, L228-H244	BLIMPS_PRINTS
					PROSTAGLANDIN F2-ALPHA RECEPTOR PROSTANOID FP PGF PGF2 ALPHA G-PROTEIN COUPLED PD012201: M1-F66 PD012850: H174-Y201	BLAST_PRODOM
					PROSTAGLANDIN; SUBTYPE; EP3; PROSTACYCLIN DM00355|P43118|20-319: T20-W293 DM00355|S51281|20-319: T20-W293 DM00355|P37289|20-319: T20-L266 DM00355|P34995|26-365: I35-R238, R238-L266	BLAST_DOMO
					G-protein coupled receptors signature: C121-V137	MOTIFS
26	7506687CD1	917	S199 S260 S509 S545 S555 S625 S646 S793 S834 S870 T173 T185 T203 T283 T411 T661 T720 T783 T856 Y142 Y341	N31 N334 N543	Signal Peptide: M1-T19	HMMER
					Plexin repeat: S481-L534, R636-P682	HMMER_PFAM
					domain found in Plexins, Semaphorins and Integrins: S481-L534, D628-P678	HMMER_SMART
					RECEPTOR KIAA0407 SEMAPHORIN PD184600: M1-H465 PD145279: K663-L882	BLAST_PRODOM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					PLEXIN PROTEIN PRECURSOR SIGNAL KIAA0407 K04B12.1 TRANSMEMBRANE SEX RECEPTOR GLYCOPROTEIN PD010132: P541-T708	BLAST_PRODOM
					RGD cell attachment sequence: R872-D874	MOTIFS
27	7510621CD1	224	S120 S216 S219 T138	N116 N136 N158	signal_cleavage: M7-G74	SPSCAN
					Signal Peptide: M1-A25, M1-G32, M1-A35, M7-A25, M7-G27, M7-A30, M7-V31	HMMER
					Tetraspanin family: K11-I217	HMMER_PFAM
					Cytosolic domains: M1-F12, C73-N188 Transmembrane domains: L13-A35, G50-C72, V189-C211 Non-cytosolic domains: Q36-P49, C212-M224	TMHMMER
					Transmembrane 4 family proteins BL00421: K8-V26, V56-R94, M125-N136, V151-C156, N188-I217	BLIMPS_BLOCKS
					Transmembrane 4 family signature: T48-E100	PROFILESCAN
					Transmembrane four family signature PR00259: F12-A35, G50-C76, V191-I217	BLIMPS_PRINTS
					TRANSMEMBRANE GLYCOPROTEIN SIGNAL ANCHOR PROTEIN ANTIGEN MEMBRANE PHOTORECEPTOR VISION CD9 CELL PD000920: K11-S145, Y80-C163, C163-I217	BLAST_PRODOM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					TRANSMEMBRANE 4 FAMILY DM00947|P08962|1-232: A2-G220 DM00947|S43511|2-233: A2-G220 DM00947|P41732|2-238: C9-I217 DM00947|P27591|3-214: G6-I217	BLAST_DOMO
					Transmembrane 4 family signature: G61-M83	MOTIFS
28	7505533CD1	114	S9 S28 T26		Signal Peptide: M1-S20	HMMER
					Cornichon protein: E2-L110	HMMER_PFAM
					Cytosolic domains: M1-V4, P76-L114 Transmembrane domains: V5-L27, I53-L75 Non-cytosolic domain: S28-L52	TMHMMER
					C5A-anaphylatoxin receptor signature PR00426: L11-F23	BLIMPS_PRINTS
					PROTEIN TRANSMEMBRANE CORNICHON DEVELOPMENTAL CORNICHON-LIKE T09E8.3 ER-DERIVED VESICLES ERV14 ENDOPLASMIC PD008226: F6-R84	BLAST_PRODOM
					CORNICHON DM04292|P53173|1-137: M1-Q87 DM04292|P38312|1-141: V5-T8	BLAST_DOMO
29	7511220CD1	181	S5 S143 T172 Y32		signal_cleavage: M1-A21	SPSCAN
					Signal Peptide: M1-A21, M1-L22, M1-R24, M1-D28	HMMER
					Cytosolic domains: M1-C4, I55-R60, T172-K181 Transmembrane domains: S5-L22, Y32-T54, Y61-Y83, H149-F171 Non-cytosolic domains: E23-G31, L84-L148	TMHMMER

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
30	7510967CD1	1753	S167 S219 S363 S381 S430 S471 S562 S614 S722 S883 S886 S1034 S1164 S1291 S1311 S1350 S1377 S1389 S1411 S1448 S1453 S1479 S1503 S1508 S1565 S1589 S1605 S1634 S1643 S1644 S1719 T233 T432 T434 T590 T621 T791 T862 T904 T939 T950 T998 T1001 T1012 T1148 T1218 T1254 T1336 T1358 T1459 T1715 Y409 Y1442	N71 N165 N231 N303 N315 N766 N971 N1309 N1329 N1578 N1669	Ankyrin repeat: C37-L69, G103-L135, D236-R268, Y170-A202, D335-K367, S269-Q301, D70-M102, Y137-K169, N203-K235, D302-K334, K368-R400	HMMER_PFAM
					ankyrin repeats: C37-L66, G103-V132, Y170-Q199, D236-I265, D335-A364, S269-I298, Y137-C166, D70-H99, D302-I331, N203-L232, K368-Y399	HMMER_SMART

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					Cytosolic domains: F519-N524, R682-H687 Transmembrane domains: F496-A518, L525-G547, P659-F681, L688-L707 Non-cytosolic domains: M1-L495, G548-L658, N708-L1753	TMHMMER
					Ankyrin repeat signature PR01415: G171-H183, N348-A360	BLIMPS_PRINTS
					Ank repeat proteins. PF00023: L42-L57, G369-R378	BLIMPS_PFAM
					Domain present in ZO-1 and Unc5-like netrin receptor PF00791:L42-N96, L354-P392, L983-D1025	BLIMPS_PFAM
					REPEAT PROTEIN ANK NUCLEAR ANKYR. PD00078: D366-R378	BLIMPS_PRODOM
					F36H1.2 PROTEIN PD148722: D267-K304 K361-P1082 L1189-R1252	BLAST_PRODOM
					Cell attachment sequence: R1436-D1438	MOTIFS
					ATP/GTP-binding site motif A (P-loop): A467-S474	MOTIFS
31	7511298CD1	786	S50 S185 S243 S283 S307 S329 S371 S384 S394 S418 S423 S451 S453 S602 T57 T61 T105 T113 T159 T205 T670	N33 N38 N108 N322 N357 N364 N404 N471 N774	signal_cleavage: M1-T20	SPSCAN
					Signal Peptide: M1-T20	HMMER
					7 transmembrane receptor (Secretin family): D495-V744	HMMER_PFAM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					EGF-like domain: C120-C158, C164-G197, C68-G102, C26-P58	HMMER_PFAM
					Latrophilin/CL-1-like GPS domain: Q442-V493	HMMER_PFAM
					Epidermal growth factor-like domain: E119-T159, E163-E208, E67-Q115, G25-D63	HMMER_SMART
					Calcium-binding EGF-like domain: D116-T159, D160-E208, D64-Q115	HMMER_SMART
					G-protein-coupled receptor proteolytic site: Q442-V493	HMMER_SMART
					Cytosolic domains: Q527-T532, F590-L601, W667-K685, N741-I786 Transmembrane domains: V504-I526, I533-I552, A567-Y589, S602-I624, L644-V666, A686-L708, L718-L740 Non-cytosolic domains: M1-R503, E553-V566, Y625-F643, F709-V717	TMHMMER
					G-protein coupled receptors family 2 (secretin-like) IPB000832: G505-A550, C563-L588, G610-Y634, W645-S674, L689-I710, C727-V755	BLIMPS_BLOCKS
					Calcium-binding EGF-like domain IPB001881: C42-S52, C133-C144	BLIMPS_BLOCKS
					Laminin-type EGF-like (LE) domain IPB002049: A41-F51, T132-F148	BLIMPS_BLOCKS
					EMR1 hormone receptor signature PR01128: K450-G468, V523-C540, S621-C635, D679-L700	BLIMPS_PRINTS
					CD97 protein signature PR01278: C26-C42, G96-Q115, D204-H222, H222-D239, Q280-P297, K298-E317, R331-E343, M358-K373, V388-T406, H480-D495, E553-H571, R594-I609, K668-L683	BLIMPS_PRINTS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					CD97 LEUCOCYTE ANTIGEN PRECURSOR G-PROTEIN-COUPLED RECEPTOR TRANSMEMBRANE GLYCOPROTEIN EGF-LIKE PD040384: W192-Q389 PD028353: M1-C114 PD005792: A752-I786	BLAST_PRODOM
					RECEPTOR TRANSMEMBRANE G-PROTEIN-COUPLED GLYCOPROTEIN PRECURSOR SIGNAL TYPE POLYPEPTIDE ALTERNATIVE PD000752: Q477-W751	BLAST_PRODOM
					HORMONE; EMR1; LEUCOCYTE; ANTIGEN; DM05221|I37225|347-738: R391-E783 DM05221|P48960|347-738: R391-E783 DM05221|A57172|465-886: E408-T768	BLAST_DOMO
					LEUCOCYTE; ANTIGEN; CD97; DM08257|P48960|171-254: W215-G299	BLAST_DOMO
					Aspartic acid and asparagine hydroxylation site: C82-C93, C133-C144, C177-C188	MOTIFS
					Calcium-binding EGF-like domain pattern signature: D64-C91, D116-C142, D160-C186	MOTIFS
					G-protein coupled receptors family 2 signature 2: Q729-V744	MOTIFS
32	7510937CD1	1328	S75 S110 S161 S188 S206 S212	N172 N435 N772 N904 N1059 N1234	Cytosolic domain: M1-S6 Transmembrane domain: A7-M29 Non-cytosolic domain: K30-E1328	TMHMMER
			S213 S290 S297 S322 S323 S397	N1300	Tropomyosin IPB000533: L462-E498, K612-Q655, H511-E565	BLIMPS_BLOCKS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
			S625 S632 S694 S794 S812 S906		PROTEIN KINECTIN CG1 KIAA0004 A COILEDCOIL PD017436: M1-K283	BLAST_PRODOM
			S926 S957 S975 S1002 S1017 S1061 S1081		PROTEIN KINECTIN ES/130 RIBOSOME RECEPTOR CG1 KIAA0004 A COILEDCOIL PD013824: Q264-E400	BLAST_PRODOM
			S1142 S1156 S1215 S1290		ES/130 RIBOSOME RECEPTOR PD074881: E1040-E1235	BLAST_PRODOM
			T32 T50 T52 T200 T268 T273 T275		PROTEIN KINECTIN CG1 KIAA0004 A COILEDCOIL PD151414: T401-G467	BLAST_PRODOM
			T364 T463 T466 T508 T631 T746 T760 T830 T859		RIBOSOME; 160K; 180K; DM05457 |S32763|1-529: M1-S531 |A56734|660-1039: P165-E510	BLAST_DOMO
			T878 T893 T1145 T1154 T1276 Y503 Y1194 Y1216		RIBOSOME; 160K; 180K; DM05456 |A56734|1041-1479: Q901-E1235 |S32763|1001-1356: S1002-L1327 |S32763|1001-1356: W1012-E1328	BLAST_DOMO
					Leucine zipper pattern: L935-L956, L942-L963	MOTIFS
33	7511852CD1	355	S77 S129 S174	N171 N193 N274	signal_cleavage: M1-A22	SPSCAN
			S221 S254 S283		Signal Peptide: M1-A20, M1-A22, M1-P24	HMMER
			S305 S309 S318 S326 S337 T39		TNFR/NGFR cysteine-rich region: C40-C75, C78-C118, C120-C161, C164-C200	HMMER_PFAM
			T73 T119 T298		Tumor necrosis factor receptor / nerve growth factor receptor: C120-C161, C78-C118, C40-C75, C164-C200	HMMER_SMART
					TNF-receptor internal cysteine rich domain: C120-C161, C40-C75, C78-C118, C164-C200	HMMER_INCY
					EGF-like domain IPB000561: C118-C126	BLIMPS_BLOCKS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					TNFR/NGFR family cysteine-rich region IPB001368: C53-A63, C110-C120	BLIMPS_BLOCKS
					RECEPTOR TUMOR NECROSIS FACTOR P80 PRECURSOR TNFR2 P75 TRANSMEMBRANE GLYCOPROTEIN PD024155: V149-P166, I190-S355, Q183-T330	BLAST_PRODOM
					RECEPTOR FACTOR TUMOR NECROSIS HOMOLOG II PROTEIN PRECURSOR REPEAT SIGNAL PD149629: C120-H182	BLAST_PRODOM
					RECEPTOR P80 TNFALPHA TUMOR NECROSIS FACTOR PRECURSOR TNFR2 P75 TRANSMEMBRANE PD059688: M1-Q51	BLAST_PRODOM
					TUMOR NECROSIS FACTOR RECEPTOR PRECURSOR BINDING PROTEIN TBPII P80 TNFR2 PD153238: L23-Q51	BLAST_PRODOM
					TUMOR NECROSIS FACTOR RECEPTOR TYPE 2 DM06946 |P20333|195-460: V199-S355 |P25119|197-473: S195-V262, D263-S355	BLAST_DOMO
					TNFR/NGFR FAMILY CYSTEINE-RICH REGION DM00218 |P20333|113-193: E113-A194 |P20333|35-111: E35-R112	BLAST_DOMO
					TNFR/NGFR family cysteine-rich region signature: C40-C75, C78-C118	MOTIFS
34	7511077CD1	295	S120 T286	N34 N243	TMS membrane protein/tumour differentially expressed protein (TDE): S15-L295	HMMER_PFAM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					Cytosolic domains: C28-R39, S119-N130, H183-W201, P257-L295 Transmembrane domains: L5-S27, L40-L57, A96-V118, G131-I150, F160-A182, Y202-F224, F239-L256 Non-cytosolic domains: M1-C4, S58-R95, P151-W159, M225-V238	TMHMMER
					PROTEIN PLACENTAL DIFF33 DEVELOPMENTALLY REGULATED R11H6.2 PD011773: D87-P266 PD018175: C13-E73	BLAST_PRODOM
35	7511576CD1	203	S22 S36 S91 S188 T60 T65 T132 T148 Y197	N8 N20	Cytosolic domains: M1-K66, T158-S203 Transmembrane domains: L67-I89, A135-L157 Non-cytosolic domain: L90-K134	TMHMMER
36	7511492CD1	156	S146 T4 T45 T94	N65 N92	signal_cleavage: M1-G38	SPSCAN
					Cytosolic domain: M1-K21 Transmembrane domain: L22-F44 Non-cytosolic domain: T45-A156	TMHMMER
					BONE MARROW STROMAL ANTIGEN 2 BST2 TRANSMEMBRANE GLYCOPROTEIN SIGNALANCHOR PD095137: M1-G116.	BLAST_PRODOM
37	7511141CD1	170	S130 T97	N72 N100 N106	signal_cleavage: M1-A27	SPSCAN
				N128	Signal Peptide: M1-A22, M1-S24, M1-A27, M1-A19	HMMER
					Hormone receptor domain: V63-N128	HMMER_PFAM
					Domain present in hormone receptors: P62-N132	HMMER_SMART
					G-protein coupled receptors family 2 (secretin-like) IPB000832: C66-L93	BLIMPS_BLOCKS
					Vasoactive intestinal peptide receptor 1 signature PR01154: L31-E52, W76-F92	BLIMPS_PRINTS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					G-protein coupled receptors family 2 signatures: C45-G111	PROFILESCAN
					Secretin receptor signature PR00490: R2-L14, L18-V34, V37-E52, E52-V63, P90-F104, C123-E136	BLIMPS_PRINTS
					G-PROTEIN COUPLED RECEPTORS FAMILY 2 DM00378 |JC2532|20-434: C20-L139 |P47872|20-434: C20-L139 |S47631|30-491: L12-M95 R105-S130 |P41586|13-446: E40-M95 G101-S130	BLAST_DOMO
					G-protein coupled receptors family 2 signature 1: C66-P90	MOTIFS
38	7511300CD1	801	S50 S234 S292	N33 N38 N108	signal_cleavage: M1-T20	SPSCAN
			S332 S356 S378	N203 N371 N406	Signal Peptide: M1-T20	HMMER
			S420 S433 S443 S467 S472 S500	N413 N453 N520	7 transmembrane receptor (Secretin family): D544-A793	HMMER_PFAM
			S502 S651 T57 T61 T105 T113		EGF-like domain: C120-C158, C213-G246, C164-P199, C68-G102, C26-P58	HMMER_PFAM
			T205 T254 T719		Latrophilin/CL-1-like GPS domain: Q491-V542	HMMER_PFAM
					Epidermal growth factor-like domain.: E119-T159, E163-E208, G25-D63, E67-Q115, E212-E257	HMMER_SMART
					Calcium-binding EGF-like domain: D116-T159, D160-E208, D209-E257, D64-Q115	HMMER_SMART
					G-protein-coupled receptor proteolytic site: Q491-V542	HMMER_SMART

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					Cytosolic domains: Q576-T581, Q646-S651, K717-R736, C787-I801 Transmembrane domains: V553-I575, I582-I601, F623-F645, T652-Y674, W694-W716, A737-I759, S764-H786 Non-cytosolic domains: M1-R552, E602-C622, S675-L693, F760-R763	TMHMMER
					Calcium-binding EGF-like domain IPB001881: C142-P152, C133-C144	BLIMPS_BLOCKS
					Laminin-type EGF-like (LE) domain IPB002049: A41-F51	BLIMPS_BLOCKS
					G-protein coupled receptors family IPB000832: G554-A599, C612-L637, G659-S683, W694-S723, L738-I759, C776-I801	BLIMPS_BLOCKS
					Type II EGF-like signature PR00010: D116-C127, G138-F148	BLIMPS_PRINTS
					EMR1 hormone receptor signature PR01128: K499-G517, V572-C589, S670-C684, D728-L749	BLIMPS_PRINTS
					CD97 protein signature PR01278: C26-C42, G96-Q115, D253-H271, H271-D288, Q329-P346, K347-E366, R380-E392, M407-K422, V437-T455, H529-D544, E602-H620, R643-I658, K717-L732	BLIMPS_PRINTS
					CD97 LEUCOCYTE ANTIGEN PRECURSOR GPROTEIN COUPLED RECEPTOR TRANSMEMBRANE GLYCOPROTEIN EGF-LIKE; PD028353: M1-C114 PD040384: W192-V210 W241-Q438	BLAST_PRODOM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					RECEPTOR TRANSMEMBRANE GPROTEIN COUPLED GLYCOPROTEIN PRECURSOR SIGNAL TYPE POLYPEPTIDE ALTERNATIVE PD000752: Q526-K792	BLAST_PRODOM
					HORMONE; EMR1; LEUCOCYTE; ANTIGEN; DM05221 |I37225|347-738: R440-K792 |A57172|465-886: E457-N790 |P48960|347-738: R440-K792	BLAST_DOMO
					LEUCOCYTE; ANTIGEN; CD97; DM08257 |P48960|171-254: W264-G348	BLAST_DOMO
					Calcium-binding EGF-like domain pattern signature: D64-C91, D116-C142, D160-C186, D209-C235	MOTIFS

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
39/3048626CB1/ 2714	1-631, 10-543, 15-646, 80-703, 157-686, 190-754, 205-683, 205-714, 205-741, 218-917, 224-720, 236-885, 256-871, 310-981, 335-894, 335-1009, 351-998, 372-915, 374-1057, 375-948, 378-883, 378-1017, 382-1063, 384-1049, 385-1037, 396-1028, 404-1011, 431-1040, 438-1035, 460-1045, 462-898, 492-1178, 502-1222, 519-1154, 527-714, 533-1174, 553-1057, 558-1195, 566-1041, 566-1190, 575-895, 586-869, 586-1187, 586-1253, 605-1039, 605-1305, 616-1324, 623-1248, 625-1251, 638-1215, 641-1230, 649-1061, 650-1170, 662-1329, 665-1253, 668-1220, 682-1265, 685-845, 687-1258, 695-1360, 703-1354, 704-1230, 709-1240, 724-1314, 726-1402, 735-1335, 747-1435, 751-1329, 777-1430, 781-1263, 787-1233, 789-1532, 794-1549, 804-1351, 812-1353, 824-1138, 824-1375, 824-1386, 824-1399, 824-1402, 858-1314, 861-1378, 911-1556, 916-1547, 930-1551, 935-1427, 935-1643, 936-1617, 946-1628, 968-1639, 974-1481, 977-1549, 1001-1671, 1017-1671, 1031-1640, 1037-1588, 1038-1217, 1038-1361, 1043-1558, 1044-1651, 1087-1669, 1095-1463, 1096-1671, 1102-1671, 1109-1408, 1109-1523, 1151-1671, 1576-2268, 2045-2308, 2178-2714
40/2684425CB1/ 2858	1-298, 19-268, 29-320, 37-883, 55-575, 55-704, 94-356, 99-613, 110-755, 237-1049, 445-1099, 509-1105, 533-785, 533-954, 541-785, 541-813, 541-1174, 544-1223, 546-809, 664-955, 666-1270, 668-1274, 719-1337, 723-1303, 783-1358, 797-1357, 802-1274, 813-1417, 820-1134, 832-1439, 854-1362, 881-1235, 916-1412, 920-1100, 984-1630, 1013-1675, 1015-1272, 1047-1664, 1087-1706, 1106-1704, 1119-1621, 1129-1722, 1215-1749, 1235-1533, 1235-1815, 1304-1886, 1329-1921, 1347-1587, 1360-1621, 1362-1638, 1362-1740, 1369-1872, 1443-1934, 1443-1984, 1445-2045, 1569-2199, 1596-1761, 1599-1980, 1627-1898, 1632-1861, 1639-2223, 1649-2167, 1675-1938, 1675-2151, 1681-1950, 1746-1901, 1753-2427, 1770-2010, 1787-2397, 1904-2180, 1904-2581, 1951-2331, 2181-2777, 2224-2782, 2275-2521, 2310-2790, 2317-2817, 2317-2832, 2413-2819, 2610-2858, 2650-2858, 2714-2855
41/7505960CB1/ 2445	1-315, 1-340, 1-457, 1-479, 1-487, 1-640, 1-646, 1-2239, 2-597, 3-330, 3-626, 5-518, 5-551, 5-620, 8-260, 8-493, 8-521, 8-637, 10-536, 11-571, 12-281, 14-111, 17-274, 18-285, 19-194, 19-259, 19-620, 19-630, 19-636, 20-273, 22-305, 22-584, 24-288, 24-479, 25-288, 25-397, 77-325, 91-364, 91-578, 104-561, 106-868, 131-433, 141-676, 161-784, 171-487, 171-489, 188-330, 194-708, 197-784, 210-411, 210-853, 219-485, 266-879, 269-625, 271-901, 282-814, 294-561, 294-899, 295-805, 298-531, 300-581, 312-861, 335-920, 335-927, 343-962, 387-1114, 418-1146, 450-1185, 450-1289, 454-1009, 457-703, 461-1147, 464-1051, 478-827, 479-611, 482-1072, 532-1163, 534-1057, 538-1216, 545-1070, 583-1165, 585-1107, 602-1241, 630-1190, 645-1202, 656-1237, 657-1243, 658-1054, 663-859, 673-1270, 691-1289, 691-1302, 695-1223, 720-1301, 770-1062, 776-1242, 787-1028, 808-991, 843-976, 865-1275, 902-1017, 903-1276, 922-1190, 932-1073, 955-1253, 961-1222, 964-1246, 966-1214, 971-1208, 985-1245, 1013-1286, 1028-1313, 1040-1313, 1058-1313, 1067-1297, 1247-1515,

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
	1247-1592, 1247-1643, 1247-1646, 1247-1803, 1247-1836, 1254-1876, 1310-1603, 1310-1780, 1310-1785, 1310-1880, 1310-1949, 1312-1586, 1312-1808, 1313-1534, 1313-1877, 1324-1642, 1345-1848, 1356-1717, 1357-1749, 1359-1618, 1369-1637, 1369-1808, 1369-1917, 1371-1884, 1373-2020, 1375-1649, 1379-1588, 1379-1918, 1382-1586, 1385-1946, 1390-1619, 1398-1935, 1400-1777, 1405-1671, 1405-1943, 1408-1775, 1410-1902, 1413-1902, 1428-2133, 1431-2018, 1435-1622, 1442-1758, 1448-2178, 1456-1719, 1456-1764, 1467-1738, 1467-1758, 1474-1967, 1474-2071, 1477-1891, 1479-1603, 1483-1753, 1487-2007, 1492-1762, 1497-2191, 1498-1923, 1507-1769, 1507-1888, 1510-1776, 1511-1758, 1516-1792, 1521-2143, 1526-1853, 1536-1808, 1540-2085, 1542-2053, 1544-2231, 1548-2011, 1548-2083, 1551-1951, 1551-2218, 1552-1991, 1552-2124, 1554-1822, 1554-2378, 1570-1859, 1580-1780, 1580-2360, 1604-1928, 1607-2098, 1608-2229, 1610-1824, 1620-1885, 1626-1895, 1632-1996, 1634-1890, 1634-1898, 1636-2284, 1637-1904, 1637-1915, 1638-2231, 1655-2372, 1658-2207, 1673-2202, 1673-2241, 1677-2269, 1686-2273, 1690-1931, 1691-1934, 1693-2015, 1697-2355, 1701-2147, 1703-2063,
	1705-1922, 1706-2141, 1713-2321, 1714-2359, 1715-2146, 1731-1963, 1743-2032, 1744-2102, 1755-1960, 1759-2271, 1760-2163, 1761-2012, 1765-2039, 1765-2040, 1767-2176, 1776-2251, 1782-2421, 1787-2046, 1787-2278, 1788-2187, 1791-2244, 1794-1985, 1796-2375, 1799-2060, 1799-2101, 1815-2388, 1818-2419, 1820-2359, 1821-2417, 1823-2443, 1827-2061, 1828-2383, 1830-2416, 1831-2358, 1835-2422, 1844-2101, 1849-2062, 1849-2434, 1853-2157, 1862-2357, 1862-2442, 1862-2444, 1873-2283, 1877-2158, 1878-2419, 1886-2033, 1888-2438, 1898-2187, 1903-2444, 1911-2221, 1916-2418, 1927-2101, 1929-2324, 1931-2324, 1933-2101, 1936-2445, 1937-2417, 1941-2101, 1941-2182, 1944-2239, 1959-2161, 1961-2222, 1966-2233, 1981-2399, 1983-2101, 1989-2222, 1989-2425, 1991-2101, 1996-2212, 2002-2101, 2008-2101, 2017-2101, 2021-2077, 2021-2087, 2023-2135, 2028-2101, 2029-2101, 2030-2101, 2031-2101, 2033-2101, 2040-2101, 2043-2322, 2046-2101, 2046-2125, 2118-2147
42/7507021CB1/ 1248	1-137, 1-223, 1-250, 1-357, 1-390, 1-424, 1-433, 1-532, 1-545, 1-573, 1-1248, 3-584, 4-584, 5-224, 5-585, 11-244, 11-299, 11-530, 11-538, 11-554, 11-579, 24-585, 28-585, 56-537, 93-585, 115-328, 115-565, 115-715, 115-767, 116-258, 117-258, 137-359, 137-585, 144-585, 152-566, 203-501, 210-456, 251-513, 292-448, 577-1108, 585-730, 585-816, 585-854, 590-1226, 593-1248, 627-1156, 628-841, 629-1248, 640-1248, 647-868, 648-767, 657-1082, 661-767, 677-1132, 678-912, 678-1197, 699-908, 702-836, 715-1119, 726-1246, 741-767, 743-1248, 746-1228, 748-1247, 755-1248, 762-1248, 804-944, 818-1248, 829-1248, 830-1248, 838-1248, 839-1248, 845-1069, 853-1248, 862-928, 892-1228, 894-1248, 906-1248, 918-1248, 926-1248, 928-1248, 962-1248, 973-1248, 979-1248, 1023-1238, 1025-1248, 1048-1248, 1104-1248

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
43/7509099CB1/ 1989	1-243, 1-1842, 10-761, 10-767, 37-242, 92-365, 374-712, 385-1112, 409-1028, 409-1130, 425-945, 453-1317, 466-1051, 585-1182, 588-1290, 691-1682, 698-1682, 734-1681, 751-1368, 757-1018, 770-1438, 788-1682, 821-1681, 825-1352, 837-1682, 838-1682, 840-1682, 841-1682, 842-1681, 843-1681, 847-1438, 856-1682, 863-1682, 877-1681, 878-1110, 890-1681, 890-1682, 899-1681, 905-1681, 906-1681, 906-1682, 918-1438, 985-1681, 991-1677, 993-1384, 1041-1438, 1055-1752, 1134-1729, 1172-1736, 1317-1910, 1383-1686, 1412-1675, 1429-1633, 1475-1989, 1681-1924, 1686-1855, 1733-1989, 1833-1866
44/7509361CB1/ 1863	1-242, 1-268, 1-361, 1-1863, 3-207, 4-242, 4-261, 5-105, 5-241, 6-258, 7-193, 7-263, 7-284, 7-303, 7-445, 8-294, 8-433, 9-256, 12-237, 15-270, 25-232, 28-736, 28-815, 28-843, 28-863, 29-755, 39-275, 39-282, 39-321, 39-323, 40-280, 40-730, 46-309, 46-321, 46-434, 47-475, 48-694, 50-536, 50-607, 50-632, 53-662, 54-286, 54-357, 54-363, 54-367, 54-639, 55-302, 57-272, 57-329, 57-684, 59-171, 60-305, 61-324, 61-340, 61-364, 62-300, 64-363, 69-317, 69-347, 70-540, 72-445, 74-359, 74-745, 76-712, 79-210, 79-372, 79-382, 80-276, 82-198, 82-303, 83-207, 83-301, 84-651, 90-294, 90-372, 92-281, 96-626, 97-391, 99-400, 102-406, 103-645, 110-702, 111-294, 113-253, 123-703, 129-420, 136-445, 146-347, 153-630, 183-816, 200-261, 206-396, 207-581, 239-734, 239-780, 239-876, 239-877, 239-952, 257-445, 271-679, 280-869, 294-877, 311-532, 354-590, 446-465, 446-800, 446-825, 446-877, 467-722, 467-746, 527-833, 554-679, 566-803, 573-784, 573-786, 585-816, 612-841, 612-856, 658-1441, 692-860, 875-1040, 875-1085, 875-1118, 875-1191, 875-1306, 875-1523,
	875-1569, 875-1577, 880-1034, 881-1149, 884-1441, 897-1441, 899-1154, 900-1173, 918-1152, 920-1159, 935-1167, 942-1148, 952-1159, 952-1219, 957-1117, 961-1557, 962-1205, 968-1270, 973-1596, 974-1243, 994-1258, 997-1089, 1000-1259, 1011-1315, 1028-1403, 1040-1275, 1058-1299, 1078-1337, 1085-1351, 1112-1309, 1117-1335, 1123-1388, 1154-1815, 1155-1846, 1160-1848, 1175-1441, 1180-1778, 1187-1853, 1203-1457, 1209-1482, 1213-1514, 1219-1510, 1223-1496, 1238-1501, 1240-1502, 1240-1507, 1253-1478, 1264-1824, 1271-1848, 1276-1772, 1281-1855, 1291-1565, 1297-1537, 1302-1594, 1302-1776, 1304-1777, 1304-1851, 1314-1539, 1314-1658, 1315-1539, 1315-1557, 1316-1466, 1319-1612, 1323-1562, 1323-1797, 1324-1579, 1327-1863, 1328-1790, 1337-1577, 1337-1585, 1337-1594, 1339-1718, 1340-1579, 1342-1602, 1347-1514, 1347-1584, 1351-1789, 1354-1790, 1357-1658, 1365-1847, 1366-1837, 1367-1718, 1369-1862, 1377-1526, 1377-1851, 1379-1609, 1379-1806, 1386-1633, 1386-1847, 1386-1855, 1387-1859, 1387-1863, 1389-1655, 1389-1700, 1391-1674, 1394-1657, 1398-1777, 1400-1654, 1402-1854, 1406-1850, 1413-1853, 1418-1682, 1418-1850, 1419-1663, 1421-1669,

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
	1422-1654, 1422-1674, 1424-1851, 1425-1857, 1427-1849, 1432-1825, 1433-1848, 1435-1685, 1436-1850, 1438-1848, 1440-1848, 1443-1848, 1447-1602, 1452-1689, 1457-1848, 1457-1851, 1460-1715, 1469-1715, 1472-1650, 1474-1839, 1482-1851, 1483-1862, 1487-1863, 1491-1848, 1492-1863, 1495-1850, 1502-1789, 1513-1848, 1513-1853, 1514-1851, 1520-1863, 1522-1776, 1522-1809, 1522-1848, 1523-1848, 1526-1846, 1526-1848, 1531-1848, 1537-1848, 1537-1850, 1544-1803, 1550-1863, 1554-1785, 1559-1851, 1562-1846, 1562-1848, 1562-1849, 1564-1800, 1565-1848, 1567-1848, 1572-1852, 1575-1778, 1577-1848, 1584-1843, 1589-1799, 1593-1851, 1602-1848, 1604-1848, 1605-1846, 1605-1848, 1605-1855, 1609-1797, 1620-1863, 1625-1855, 1627-1731, 1631-1846, 1633-1861, 1662-1848, 1662-1850, 1662-1858, 1673-1848, 1678-1848, 1678-1850, 1683-1848, 1687-1848, 1688-1848, 1689-1818, 1689-1851, 1689-1863, 1692-1826, 1692-1848, 1693-1863, 1696-1848, 1696-1861, 1708-1838, 1709-1814, 1711-1853, 1712-1851, 1720-1855, 1723-1840, 1752-1858, 1753-1862, 1753-1863, 1757-1860, 1757-1863, 1765-1863, 1768-1850, 1777-1849, 1784-1851, 1785-1863, 1786-1851, 1794-1848
45/7506815CB1/ 1734	1-1734, 123-827, 309-1275, 443-1275, 464-1274, 466-1274, 540-1275, 547-1274, 613-1274, 866-1096, 866-1180, 866-1348, 866-1363, 866-1395, 866-1431, 866-1484, 866-1543, 866-1650, 866-1658, 904-1221, 940-1731, 971-1541, 973-1367, 974-1371, 975-1222, 975-1331, 975-1440, 975-1595, 988-1284, 988-1563, 998-1607, 1020-1427, 1020-1517, 1051-1566, 1071-1427, 1099-1734, 1103-1362, 1109-1604, 1115-1432, 1152-1408, 1159-1694, 1180-1365, 1206-1635, 1228-1734, 1263-1675, 1264-1560, 1293-1691, 1322-1510, 1331-1734, 1352-1620, 1428-1575, 1466-1709, 1507-1702
46/7506814CB1/ 1786	1-785, 1-825, 1-883, 1-901, 1-902, 1-1786, 87-758, 87-804, 87-813, 87-824, 87-904, 87-980, 88-900, 242-820, 363-1327, 740-1328, 918-1148, 918-1232, 918-1400, 918-1415, 918-1447, 918-1483, 918-1536, 918-1595, 918-1702, 918-1710, 956-1273, 992-1783, 1023-1593, 1025-1419, 1026-1423, 1027-1274, 1027-1383, 1027-1492, 1027-1647, 1040-1336, 1040-1615, 1050-1659, 1072-1479, 1072-1569, 1103-1618, 1123-1479, 1151-1786, 1155-1414, 1161-1656, 1167-1484, 1204-1460, 1211-1746, 1232-1417, 1258-1687, 1280-1786, 1315-1727, 1316-1612, 1345-1743, 1374-1562, 1383-1786, 1404-1672, 1480-1627, 1518-1761, 1559-1754
47/7506852CB1/ 2193	1-2193, 56-668, 56-787, 56-793, 532-1066
48/7503782CB1/ 3696	1-3673, 532-1000, 716-895, 1524-2351, 1525-1791, 1863-2448, 1863-2471, 1888-2305, 1903-2671, 1904-2671, 1939-2201, 1979-2671, 2023-2671, 2187-2671, 2211-2453, 2211-2471, 2321-2671, 2321-2735, 2321-2792, 2366-2627, 2371-2786, 2379-2623, 2420-2503, 2421-2696, 2501-2830, 2575-2752, 2735-3211, 2784-3282, 2848-3200, 2899-3384, 2966-3536, 3033-3535, 3037-3671, 3038-3650, 3040-3289, 3064-3673, 3067-3521, 3095-3194, 3104-3682, 3129-3535, 3132-3696, 3140-3668, 3147-3662, 3149-3673, 3185-3420, 3185-3642, 3187-3659, 3191-3535, 3205-3391, 3205-3673, 3281-3535, 3595-3647

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
49/7504647CB1/ 1283	1-132, 1-169, 1-297, 1-439, 1-442, 4-814, 4-1260, 10-166, 12-168, 169-419, 169-552, 169-630, 169-702, 180-777, 235-919, 235-1034, 271-791, 277-497, 277-967, 278-501, 286-520, 313-846, 324-882, 332-844, 339-1004, 342-1151, 346-838, 350-806, 354-625, 357-1121, 362-855, 384-949, 412-1250, 418-1250, 424-1087, 431-893, 434-1175, 457-1132, 465-1159, 466-1101, 469-954, 471-872, 472-599, 472-1000, 480-1011, 487-844, 492-933, 502-763, 502-1075, 521-1170, 537-1214, 555-1151, 562-1222, 563-1050, 570-1218, 595-1110, 596-849, 596-1259, 597-1255, 602-883, 603-1175, 612-1222, 614-1067, 622-1065, 626-1218, 628-1207, 652-1143, 653-1182, 685-1222, 690-1222, 694-1153, 698-1222, 701-1222, 704-1010, 705-1148, 707-1222, 713-971, 718-1208, 718-1222, 723-1214, 725-978, 736-1218, 737-1222, 751-1197, 791-1226, 795-1283, 808-1057, 809-833, 810-1226, 811-1275, 836-1222, 841-1222, 875-1275, 891-1133, 910-1250, 910-1254, 951-1257, 999-1221, 1003-1258, 1099-1224
50/7500424CB1/ 1142	1-245, 1-248, 1-325, 1-377, 1-441, 1-463, 1-1142, 7-61, 18-437, 59-134, 59-283, 59-753, 59-761, 59-879, 59-944, 59-955, 60-732, 100-392, 126-1040, 164-1040, 199-1040, 241-1040, 290-563, 388-1040, 401-1040, 425-1040, 467-678, 467-699, 467-714, 467-882, 467-956, 467-968, 467-1040, 467-1058, 467-1083, 467-1119, 467-1123, 468-718, 468-1116, 469-1086, 469-1116, 469-1122, 471-721, 471-1065, 474-1040, 480-658, 484-707, 484-922, 490-750, 490-761, 491-1092, 493-796, 494-760, 495-710, 495-1065, 496-943, 496-1034, 499-694, 500-851, 503-851, 513-1125, 514-720, 514-1072, 515-1118, 516-1002, 528-792, 528-805, 528-1113, 530-745, 530-967, 531-976, 531-1080, 531-1136, 535-1113, 535-1118, 536-820, 539-818, 540-768, 541-784, 543-849, 544-877, 549-867, 552-1116, 556-1142, 559-851, 559-1114, 561-851, 566-1114, 567-853, 575-1142, 579-832, 579-891, 579-1142, 580-851, 585-1123, 586-1114, 587-885, 596-1119, 598-834, 601-1078, 606-851, 608-1117, 609-1040, 611-1129, 614-949, 615-833, 615-865, 615-1142, 622-1121, 623-861, 624-1123,
	625-1123, 626-898, 635-979, 636-1115, 636-1142, 644-851, 646-1112, 648-940, 650-1138, 652-1142, 654-1142, 656-1132, 657-1133, 658-851, 662-1131, 664-1142, 668-1142, 679-1142, 680-1142, 686-1132, 690-989, 690-1131, 691-1114, 697-1138, 697-1142, 700-932, 704-1121, 704-1134, 705-1139, 709-1142, 710-1131, 711-1133, 712-1084, 714-1131, 715-1130, 715-1132, 716-1129, 716-1135, 717-1129, 718-1127, 719-1042, 720-1129, 721-1123, 721-1129, 721-1142, 722-1133, 722-1136, 723-1121, 724-1121, 724-1133, 725-984, 726-1132, 727-1132, 729-1129, 729-1132, 730-1128, 733-946, 734-851, 736-1130, 739-983, 739-1042, 739-1121, 740-1000, 741-1120, 742-1129, 744-1114, 745-1135, 750-851, 753-1002, 755-1142, 756-1113, 756-1114, 756-1132, 756-1142, 762-1129, 764-1142, 766-1128, 769-1123, 770-1142, 773-1134, 777-1025, 780-1137, 782-1141, 783-1022, 784-1128, 787-1142, 800-1130, 801-1130, 802-1075, 804-1042, 804-1133, 806-1130, 808-1114, 808-1132, 808-1133, 815-1132, 823-1111, 823-1123, 836-1086, 837-1042, 842-1042, 847-1132, 849-1042, 851-1132, 859-1042, 862-1142, 863-1124, 865-1042, 870-1048, 870-1130, 870-1132, 873-1132, 874-1042, 884-1130, 886-1119,
	886-1142, 887-1132, 893-1142, 895-1142, 902-1129, 904-1129, 904-1142, 905-1123, 905-1130, 910-1142, 912-1132, 913-1132, 915-1075, 915-1129, 918-1132, 920-1137, 925-1132, 932-1132, 933-1137, 934-1132, 936-1142, 938-1142, 939-1129, 972-1132, 984-1142, 988-1130, 989-1129, 994-1136, 995-1125, 1004-1142, 1005-1132, 1006-1132, 1022-1142, 1030-1132, 1040-1142, 1068-1142

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
51/7500449CB1/ 1477	1-261, 7-270, 44-271, 47-1477, 52-163, 52-183, 52-199, 52-271, 60-183, 109-217, 273-761, 447-514, 513-1237, 515-757, 515-923, 515-928, 515-970, 515-1000, 515-1033, 515-1074, 515-1173, 515-1210, 515-1211, 515-1212, 515-1332, 515-1344, 515-1350, 517-1236, 519-1107, 809-1364, 899-1448, 1030-1319, 1177-1417, 1211-1400, 1269-1477, 1282-1477
52/7503281CB1/ 1097	1-665, 1-687, 1-696, 1-719, 1-730, 1-731, 1-738, 1-739, 1-775, 1-817, 1-838, 1-1097, 139-523, 293-1059, 298-1059, 311-1059, 334-1059, 419-1059, 432-1059
53/7503292CB1/ 1501	1-1493, 173-754, 173-769, 173-786, 173-812, 173-822, 173-1016, 175-840, 333-1159, 356-674, 405-1140, 484-1101, 548-715, 661-849, 686-1221, 800-1344, 806-1384, 848-1498, 849-1154, 849-1287, 849-1337, 849-1341, 849-1348, 849-1416, 849-1475, 936-1497, 940-1428, 955-1465, 965-1498, 967-1234, 968-1245, 975-1498, 978-1498, 982-1497, 987-1498, 994-1497, 996-1387, 998-1490, 999-1495, 1019-1501, 1025-1501, 1035-1491, 1037-1418, 1042-1497, 1045-1501, 1052-1495, 1057-1374, 1059-1413, 1062-1245, 1069-1496, 1075-1498, 1091-1501, 1115-1424, 1141-1388, 1144-1462, 1146-1497, 1147-1501, 1157-1424, 1172-1416, 1173-1390, 1179-1487, 1190-1496, 1215-1459, 1231-1380, 1242-1494, 1300-1501, 1310-1424
54/7503311CB1/ 1613	1-1613, 240-338, 240-555, 240-570, 240-632, 240-690, 240-715, 240-739, 240-899, 255-1038, 465-729, 584-1466, 628-723, 902-1132, 913-1441, 968-1499, 1050-1152, 1092-1584
55/7510384CB1/ 1523	1-1523, 68-557, 181-329, 224-318, 237-449, 243-418, 527-1059, 532-1059, 1062-1185
56/7509976CB1/ 6826	1-6826, 693-1218, 709-1289, 866-1146, 866-1217, 1001-1539, 1258-1887, 1857-2171, 1960-2223, 2291-2502, 2419-3005, 2419-3012, 2864-3322, 5428-5856, 5452-5888, 5452-5949, 5454-5984, 5471-5969, 5477-5746, 5494-5753, 5515-6064, 5518-5766, 5528-6062, 5540-6086, 5551-5692, 5553-5800, 5559-6119, 5566-6097, 5570-5821, 5578-5842, 5581-5975, 5589-5848, 5594-6130, 5612-5819, 5612-5881, 5614-6218, 5621-5863, 5645-6069, 5655-6226, 5657-5952, 5720-6221, 5742-6119, 5749-5980, 5780-5954, 5788-6179, 5795-6072, 5826-6004, 5834-6071, 5868-6219, 5871-6150, 5884-5985, 5913-6207, 5935-6232, 5944-6491, 5945-6222, 5952-6542, 5970-6209, 6009-6216, 6013-6272, 6033-6242, 6034-6229, 6054-6573, 6064-6333, 6094-6322, 6101-6408, 6101-6750, 6105-6361, 6147-6424, 6165-6431, 6171-6439, 6183-6406, 6194-6816, 6198-6550, 6200-6759, 6201-6796, 6207-6818, 6210-6467, 6210-6498, 6210-6503, 6212-6822, 6213-6516, 6219-6458, 6248-6501, 6254-6684, 6267-6500, 6267-6795, 6272-6611, 6278-6826, 6317-6570, 6317-6801, 6319-6815, 6326-6532, 6333-6546, 6333-6594, 6341-6778, 6352-6826, 6356-6816, 6362-6820, 6372-6821, 6378-6825, 6387-6816, 6394-6817, 6394-6820, 6397-6645,
	6398-6661, 6399-6816, 6401-6542, 6406-6816, 6407-6816, 6409-6815, 6411-6824, 6423-6826, 6431-6703, 6432-6821, 6434-6655, 6435-6821, 6446-6815, 6451-6815, 6456-6746, 6458-6824, 6459-6803, 6460-6739, 6461-6741, 6491-6816, 6505-6821, 6521-6823, 6539-6816, 6558-6826, 6595-6819, 6601-6815, 6614-6818, 6627-6816, 6631-6826, 6638-6821, 6643-6816, 6668-6816, 6669-6808, 6669-6809, 6721-6819, 6724-6826

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
57/7510454CB1/ 2481	1-270, 1-423, 1-432, 1-447, 1-520, 1-532, 1-535, 1-552, 1-565, 1-568, 1-571, 1-602, 1-605, 1-611, 1-623, 1-631, 1-634, 1-663, 1-2481, 309-1087, 334-1085, 393-1006, 402-1085, 406-1085, 423-1085, 431-1085, 454-1212, 455-1085, 455-1179, 456-1085, 459-1085, 475-1075, 475-1085, 479-1085, 482-733, 482-1085, 497-1073, 530-1465, 531-1347, 531-1409, 558-1343, 558-1437, 558-1505, 562-1417, 720-1661, 748-1661, 752-1661, 825-1661, 825-1663, 827-1661, 827-1663, 829-1661, 886-1663, 895-1136, 895-1195, 895-1302, 895-1391, 895-1475, 895-1477, 895-1485, 895-1513, 895-1523, 898-1595, 905-1544, 964-1165, 965-1523, 976-1661, 988-1563, 1077-1609, 1102-1682, 1150-1706, 1160-1800, 1210-1865, 1277-1856, 1334-1917, 1347-1941, 1351-2015, 1384-1934, 1386-1952, 1390-1978, 1393-1960, 1423-2010, 1463-2048, 1464-2112, 1477-2096, 1482-1992, 1491-2031, 1504-2170, 1517-1912, 1522-2023, 1537-2162, 1547-2481, 1549-1723, 1549-1977, 1549-2251, 1550-2010, 1562-2104, 1614-2282, 1616-2114, 1624-2191, 1626-2218, 1626-2219, 1633-1900, 1637-2170, 1658-1962, 1667-2299, 1670-2043, 1811-2064, 2214-2324, 2222-2313
58/8017335CB1/ 2512	1-2498, 34-594, 62-374, 544-862, 544-932, 544-1013, 544-1021, 544-1063, 544-1073, 544-1082, 544-1092, 544-1114, 544-1120, 544-1123, 544-1131, 560-1147, 856-1581, 856-1589, 907-1529, 909-1500, 1065-1926, 1084-1925, 1092-1926, 1099-1926, 1106-1924, 1106-1926, 1114-1925, 1114-1926, 1135-1924, 1180-1892, 1182-1924, 1208-1549, 1230-1926, 1239-1926, 1304-1925, 1495-1841, 1737-2008, 1747-2330, 1763-2324, 1814-2134, 1823-2345, 1904-2427, 1941-2218, 1966-2461, 1968-2512, 1996-2397, 2039-2512, 2061-2504, 2203-2512, 2206-2484
59/7510197CB1/ 754	1-270, 1-343, 1-552, 1-754
60/7510055CB1/ 1660	1-1660, 113-420, 430-480, 472-685, 544-751, 545-826, 585-1147, 585-1259, 676-817, 676-848, 681-931, 690-883, 720-984, 732-951, 763-1204, 775-1071, 792-1207, 793-1045, 794-1163, 806-1015, 806-1026, 858-1368, 886-1147, 886-1160, 923-1143, 923-1355, 923-1358, 923-1405, 976-1398, 976-1405, 983-1210, 983-1239, 990-1246, 991-1219, 1031-1204, 1039-1207, 1048-1422, 1070-1315, 1092-1295, 1115-1356, 1167-1405, 1228-1315, 1298-1377, 1369-1453, 1400-1489, 1404-1453, 1406-1453, 1410-1453, 1424-1453, 1449-1475, 1449-1479, 1449-1481

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
61/7501754CB1/ 2118	1-241, 1-271, 1-340, 1-486, 1-625, 2-645, 4-291, 6-667, 13-527, 14-625, 19-678, 19-685, 21-261, 21-1822, 28-272, 33-612, 35-287, 35-656, 45-741, 74-306, 80-309, 146-597, 193-451, 193-705, 233-512, 248-457, 249-833, 260-829, 280-951, 302-583, 318-528, 363-932, 369-813, 385-898, 390-977, 413-978, 415-595, 423-632, 423-940, 428-668, 428-693, 429-912, 463-937, 476-1151, 493-953, 498-621, 524-1192, 543-1113, 548-1116, 548-1151, 552-1125, 578-1229, 591-1187, 598-1248, 603-886, 606-1146, 649-1239, 651-900, 664-914, 664-1023, 666-1177, 668-1027, 671-1163, 690-1171, 693-958, 704-1223, 707-1140, 707-1239, 714-1362, 715-1132, 726-1142, 729-1316, 737-1184, 738-1266, 750-1035, 754-1176, 763-1039, 764-1389, 771-1298, 780-1023, 793-1046, 799-1313, 804-1281, 814-1029, 814-1116, 814-1347, 815-895, 815-927, 819-1240, 819-1425, 821-1099, 836-1143, 840-1444, 847-1365, 861-1084, 865-993, 885-1348, 891-1287, 891-1316, 897-1170, 897-1325, 906-1389, 914-1161, 914-1167, 914-1177, 926-1372, 928-1207, 937-1195, 940-1179, 942-1190, 942-1195, 942-1226, 942-1243, 942-1344, 945-1286, 950-1209, 950-1217, 950-1520, 953-1428, 953-1629, 969-1230, 972-1073, 972-1228,
	972-1407, 976-1418, 982-1290, 983-1609, 984-1537, 993-1250, 997-1238, 998-1515, 1024-1300, 1024-1506, 1026-1331, 1055-1579, 1070-1323, 1071-1356, 1073-1277, 1080-1569, 1082-1325, 1084-1755, 1091-1545, 1110-1664, 1131-1349, 1133-1617, 1151-1410, 1151-1416, 1167-1811, 1174-1747, 1179-1779, 1184-1698, 1188-1825, 1213-1761, 1217-1482, 1220-1543, 1265-1707, 1280-1546, 1324-1807, 1340-1464, 1347-1632, 1347-1746, 1347-1780, 1347-1792, 1347-1808, 1347-1824, 1350-1551, 1351-1830, 1354-1469, 1355-1611, 1355-1782, 1355-1814, 1356-1824, 1357-1602, 1358-1814, 1362-1814, 1365-1601, 1368-1814, 1369-1814, 1369-1844, 1377-1796, 1380-1833, 1382-1812, 1384-1881, 1385-1812, 1389-1823, 1391-1616, 1391-1812, 1392-1873, 1393-1592, 1393-1679, 1394-1831, 1399-1809, 1400-1636, 1401-1631, 1404-1650, 1404-1882, 1412-1812, 1414-1825, 1419-1540, 1419-1715, 1430-1620, 1430-1811, 1434-1666, 1434-1670, 1444-1874, 1451-1814, 1454-2118, 1456-1725, 1457-1798, 1459-1725, 1459-1791, 1463-1813, 1467-1814, 1468-1743, 1484-1814, 1485-1811, 1499-1811, 1502-1826, 1507-1816, 1509-1735, 1509-1756, 1511-1811, 1512-1903, 1523-1815, 1526-1810, 1548-1810, 1555-1877,
	1560-1854, 1569-1778, 1569-1789, 1569-1797, 1569-1827, 1572-1811, 1572-1814, 1575-1814, 1576-1803, 1578-1810, 1580-1814, 1581-1843, 1588-1793, 1592-1803, 1593-1831, 1594-1826, 1606-1811, 1634-1812, 1639-1814, 1652-1814, 1657-1814, 1660-1817, 1696-1810, 1697-1800, 1697-1827, 1718-1830, 1718-1904

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
62/7510517CB1/ 2800	1-224, 1-286, 1-416, 1-437, 1-454, 1-465, 1-524, 1-587, 1-603, 1-616, 1-697, 4-287, 4-2800, 16-831, 22-466, 22-606, 22-640, 22-793, 22-818, 22-821, 22-831, 25-831, 32-803, 35-778, 59-546, 60-619, 61-205, 62-516, 62-569, 73-499, 82-638, 86-577, 134-453, 149-705, 208-683, 219-653, 220-647, 228-520, 259-486, 263-484, 360-668, 427-578, 454-885, 847-1295, 879-1327, 891-1152, 900-1114, 900-1150, 900-1224, 900-1473, 900-1532, 900-1775, 977-1269, 1006-1241, 1006-1511, 1008-1322, 1008-1345, 1095-1677, 1151-2034, 1223-1470, 1223-1653, 1227-1887, 1235-1430, 1287-1530, 1297-1582, 1308-1607, 1436-1677, 1439-1702, 1441-2064, 1467-1793, 1469-1989, 1475-1988, 1485-1744, 1492-1758, 1497-2397, 1498-1989, 1509-1748, 1542-1772, 1554-1787, 1579-1850, 1589-1827, 1596-1808, 1596-2112, 1600-1988, 1602-2177, 1665-1934, 1679-2129, 1679-2196, 1682-1977, 1713-1958, 1714-1932, 1721-1974, 1728-1950, 1730-2150, 1733-2256, 1734-2397, 1735-2237, 1741-2394, 1762-2010, 1785-2608, 1799-2286, 1799-2517, 1800-2209, 1800-2220, 1800-2321, 1800-2364,
	1800-2394, 1805-2293, 1824-2394, 1826-2607, 1833-2394, 1843-2102, 1843-2344, 1868-2395, 1871-2608, 1877-2604, 1881-2149, 1899-2133, 1899-2145, 1918-2394, 1934-2205, 1947-2604, 1952-2229, 1963-2092, 1969-2273, 1971-2534, 1976-2538, 1991-2493, 1992-2608, 1995-2537, 2003-2537, 2011-2575, 2033-2239, 2038-2291, 2038-2329, 2040-2296, 2040-2553, 2050-2456, 2050-2566, 2052-2245, 2067-2570, 2075-2637, 2081-2791, 2083-2536, 2091-2214, 2116-2309, 2166-2382, 2174-2758, 2177-2793, 2187-2462, 2210-2784, 2215-2760, 2233-2720, 2253-2523, 2272-2752, 2291-2754, 2300-2751, 2301-2789, 2311-2791, 2322-2575, 2322-2600, 2322-2731, 2322-2793, 2324-2606, 2325-2800, 2336-2452, 2350-2798, 2353-2800, 2362-2791, 2374-2794, 2445-2794, 2455-2800, 2480-2789, 2550-2800, 2702-2800
63/7511014CB1/ 1750	1-477, 9-1750, 10-295, 611-1452, 890-1719
64/7506687CB1/ 7106	1-487, 88-7106, 246-807, 446-710, 578-852, 662-1293, 688-1178, 694-1282, 797-1490, 925-1439, 931-1292, 950-1288, 1131-1378, 1131-1426, 1395-1422, 1921-2491, 2447-2687, 2475-2787, 2508-3180, 2613-3272, 2701-3232, 2712-3395, 2742-3405, 2764-3021, 2789-3203, 2814-3396, 2828-3402, 2861-3457, 2873-3235, 2873-3237, 2899-3296, 2924-3464, 3124-3265, 3141-3395, 3251-3801, 3358-4003, 3361-3957, 3491-4067, 3508-4096, 3530-4167, 3555-4093, 3588-4004, 3612-4174, 3678-3977, 3706-3977, 3735-4136, 3771-4055, 3775-4476, 3782-4000, 3804-4067, 3810-4563, 3846-4297, 3847-4297, 3848-4545, 3853-4195, 3853-4238, 3859-4331, 3861-4490, 3900-4056, 3913-4617, 3917-4433, 3919-4307, 3946-4297, 3967-4793, 3992-4328, 4004-4518, 4086-4355, 4124-4714, 4165-4765, 4169-4404, 4169-4413, 4171-4417, 4175-4829, 4251-4856, 4269-4831, 4319-4666, 4322-4729, 4352-4956, 4355-4950, 4372-4869, 4383-4957, 4392-5302, 4479-5089, 4499-4750, 4525-4709, 4528-4811, 4533-5128, 4543-4686, 4557-5004, 4562-4763, 4576-4812, 4597-5169, 4599-4885, 4645-4864, 4646-5190, 4653-5233, 4720-4933, 4735-5016, 4765-4921, 4779-5160, 4780-5137, 4785-5089, 4785-5132, 4785-5144, 4787-5227,

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
	4792-5158, 4798-5153, 4800-5070, 4810-5634, 4816-5062, 4816-5066, 4829-5044, 4850-5348, 4850-5553, 4851-5150, 4855-5561, 4861-5104, 4861-5466, 4869-5460, 4869-5507, 4873-5166, 4878-5561, 4897-5540, 4920-5248, 4937-5253, 4959-5180, 4960-5521, 4965-5217, 4969-5130, 4971-5214, 4979-5166, 4996-5203, 4996-5274, 5014-5666, 5033-5296, 5033-5546, 5038-5271, 5043-5309, 5050-5184, 5070-5723, 5076-5594, 5089-5510, 5094-5291, 5095-5653, 5096-5707, 5101-5498, 5110-5292, 5110-5311, 5116-5773, 5127-5328, 5127-5344, 5141-5412, 5143-5838, 5148-5743, 5148-5753, 5151-5462, 5152-5434, 5156-5333, 5156-5385, 5157-5718, 5159-5747, 5161-5510, 5193-5838, 5194-5736, 5221-6083, 5232-5710, 5260-5697, 5263-5571, 5316-5562, 5336-5874, 5341-5969, 5342-5608, 5342-5989, 5345-5906, 5350-5594, 5377-5989, 5380-5628, 5380-5647, 5382-5495, 5390-5632, 5390-5637, 5390-5830, 5423-5652, 5425-5602, 5425-5698, 5429-5695, 5444-6079, 5450-5546, 5450-5740, 5460-5691, 5463-5820, 5473-5830, 5515-5763, 5521-5770, 5526-5918, 5526-6214, 5535-5773, 5551-5847, 5562-6071, 5566-6041, 5572-5838, 5575-5831, 5585-5816, 5600-6032, 5601-5856, 5605-5833, 5615-5801, 5634-5882,
	5634-5964, 5642-6345, 5651-6071, 5655-6151, 5658-5950, 5673-5964, 5685-5968, 5712-6184, 5715-6362, 5716-5964, 5725-6042, 5738-5808, 5744-6089, 5751-6014, 5761-6116, 5762-5923, 5765-5886, 5765-5922, 5767-6109, 5776-6061, 5776-6464, 5776-6648, 5784-6151, 5785-6041, 5795-6082, 5812-5990, 5812-6035, 5820-6094, 5842-6129, 5859-6100, 5860-6134, 5869-6147, 5877-6167, 5877-6183, 5878-6144, 5888-6109, 5907-6145, 5908-6637, 5916-6548, 5917-6183, 5926-6184, 5926-6508, 5928-6119, 5929-6209, 5943-6221, 5945-6371, 5945-6533, 5961-6220, 5971-6210, 5971-6301, 5971-6450, 5978-6271, 5984-6192, 5987-6628, 5991-6149, 6011-6245, 6012-6256, 6012-6337, 6027-6656, 6029-6281, 6038-6613, 6048-6479, 6053-6378, 6064-6295, 6068-6340, 6072-6348, 6081-6536, 6081-6656, 6106-6372, 6107-6336, 6107-6393, 6108-6382, 6113-6298, 6116-6464, 6119-6406, 6128-6246, 6128-6345, 6134-6545, 6135-6758, 6137-6800, 6171-6388, 6171-6779, 6176-6497, 6186-6453, 6190-6827, 6192-6624, 6193-6387, 6193-6436, 6193-6439, 6193-6713, 6197-6430, 6202-6468, 6209-6480, 6220-6426, 6224-6485, 6225-6455, 6225-7023, 6228-6457, 6228-6459, 6228-6479, 6228-6497, 6234-6429, 6235-6500,
	6235-6780, 6241-6455, 6248-6526, 6250-6762, 6257-6540, 6268-6547, 6277-7011, 6287-6665, 6288-6488, 6288-6772, 6290-7023, 6292-6531, 6293-6946, 6296-6561, 6298-6538, 6300-6429, 6300-6551, 6310-6566, 6317-6551, 6317-6558, 6318-6968, 6318-6979, 6325-6544, 6326-6868, 6327-6583, 6327-6587, 6332-6635, 6337-6570, 6337-6622, 6338-6679, 6340-6913, 6348-6575, 6351-6520, 6361-6639, 6366-6607, 6366-6611, 6366-6679, 6366-6929, 6366-6939, 6369-6877, 6369-6943, 6370-6981, 6375-7001, 6376-6966, 6377-6617, 6379-6581, 6387-6600, 6390-6701, 6394-6956, 6397-6946, 6397-6983, 6400-6905, 6402-6637, 6404-6675, 6405-6649, 6405-6918, 6405-7016, 6406-6675, 6407-7013, 6413-6653, 6413-6656, 6414-6948, 6416-6997, 6425-7014, 6431-6586, 6436-6767, 6437-6685, 6437-6987, 6443-6727, 6445-7019, 6453-6876, 6459-6991, 6468-6770, 6475-6755, 6482-7010, 6487-6742, 6488-6784, 6488-7020, 6488-7029, 6489-6999, 6493-6750, 6493-6895, 6498-6792, 6499-6732, 6500-6779, 6500-6784, 6503-7029, 6506-6676, 6512-7029, 6515-6956, 6516-6768, 6516-6798, 6516-7027, 6526-7027, 6527-6697, 6535-6768, 6535-6839, 6539-6787, 6539-6788, 6542-6802, 6543-6768, 6553-6784, 6553-7002,

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
	6557-7027, 6558-6985, 6560-7027, 6566-6994, 6570-7027, 6574-7027, 6576-6819, 6576-6838, 6578-7021, 6585-6802, 6585-6849, 6587-7027, 6590-7029, 6590-7033, 6593-7029, 6594-7027, 6595-6845, 6595-7032, 6600-7029, 6602-6861, 6602-7029, 6603-6868, 6603-6915, 6605-6986, 6606-7028, 6607-7021, 6607-7027, 6613-6890, 6614-7027, 6615-7027, 6619-7029, 6623-6845, 6623-6906, 6623-7027, 6624-7027, 6627-7029, 6629-6836, 6634-7026, 6635-6919, 6635-7021, 6644-7021, 6647-6765, 6648-6922, 6650-7028, 6654-7027, 6656-6896, 6656-7028, 6658-7028, 6659-6894, 6659-7021, 6659-7023, 6659-7028, 6678-6948, 6683-6907, 6687-6952, 6688-6850, 6689-6944, 6689-6953, 6690-6951, 6690-6952, 6690-7027, 6691-7027, 6692-6922, 6696-7023, 6700-7027, 6714-6967, 6714-7026, 6721-7000, 6724-7020, 6725-7029, 6728-7027, 6730-6989, 6730-6990, 6730-7009, 6733-7028, 6735-6940, 6737-6940, 6737-7026, 6737-7029, 6743-7028, 6760-7027, 6764-7027, 6766-7027, 6767-7027, 6774-7029, 6775-7024, 6782-7029, 6784-7027, 6786-7029, 6790-7027, 6801-7029, 6827-7027, 6831-7029, 6832-7028, 6833-7027, 6860-7029, 6882-7106, 6918-7027, 6928-7028, 6947-7008
65/7510621CB1/ 1187	1-182, 1-212, 1-248, 1-301, 1-334, 1-339, 1-497, 1-590, 1-591, 1-613, 1-628, 1-1114, 2-251, 4-233, 4-252, 8-263, 29-561, 43-204, 59-278, 91-573, 107-652, 169-475, 190-323, 191-414, 191-435, 210-360, 213-567, 239-446, 239-478, 266-470, 272-564, 291-475, 309-417, 317-584, 318-564, 318-594, 334-446, 336-607, 336-630, 336-650, 337-548, 337-551, 337-567, 343-585, 362-586, 362-631, 377-527, 377-528, 377-549, 377-588, 377-595, 377-605, 377-607, 377-617, 377-618, 377-631, 377-636, 377-637, 377-652, 378-652, 379-649, 379-652, 380-649, 381-590, 381-621, 381-624, 381-652, 382-609, 383-652, 386-1058, 392-652, 399-634, 402-649, 402-652, 403-652, 408-652, 409-652, 410-608, 410-652, 411-620, 411-624, 417-566, 417-652, 418-652, 422-632, 422-652, 424-652, 428-641, 429-652, 433-652, 443-644, 444-588, 444-645, 446-652, 447-647, 449-652, 468-652, 490-1114, 494-640, 511-638, 516-581, 524-648, 526-652, 538-649, 564-1114, 613-646, 648-759, 648-781, 648-797, 648-838, 648-842, 648-848, 648-855, 648-858, 648-861, 648-862, 648-864, 648-867, 648-869,
	648-870, 648-872, 648-874, 648-875, 648-876, 648-879, 648-881, 648-882, 648-883, 648-884, 648-885, 648-886, 648-887, 648-888, 648-892, 648-895, 648-897, 648-899, 648-902, 648-903, 648-906, 648-907, 648-908, 648-913, 648-918, 648-920, 648-927, 648-928, 648-935, 648-940, 648-942, 648-944, 648-950, 648-954, 648-956, 648-959, 648-962, 648-965, 648-971, 648-989, 648-1052, 648-1096, 648-1114, 649-918, 650-837, 650-863, 650-889, 650-921, 650-927, 650-946, 650-1027, 651-897, 651-1114, 652-1043, 654-870, 654-988, 655-884, 655-1114, 656-891, 658-787, 662-901, 662-916, 665-942, 665-970, 666-1114, 668-917, 668-937, 668-964, 668-1110, 669-953, 669-960, 670-875, 670-919, 670-923, 671-909, 672-924, 672-934, 672-1114, 673-855, 673-959, 673-960, 674-1114, 675-961, 676-904, 676-937, 676-945, 676-1114, 677-938, 677-958, 678-838, 678-884, 678-895, 678-918, 678-1004, 678-1114, 679-891, 679-934, 680-851, 682-935, 683-845, 683-958, 683-994, 685-990, 685-1114, 687-925, 687-958, 687-967, 687-1077, 687-1114, 688-1114, 689-852, 689-909, 689-910,

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
	689-934, 689-940, 689-942, 689-956, 689-968, 690-897, 694-1114, 695-1016, 695-1030, 695-1114, 696-893, 696-904, 696-911, 696-968, 696-970, 696-1114, 697-931, 697-943, 697-947, 697-948, 697-957, 697-1114, 698-923, 698-1114, 699-851, 699-974, 699-1005, 700-1114, 701-974, 706-928, 706-1114, 708-967, 708-981, 708-992, 709-972, 709-978, 709-983, 709-1114, 710-920, 710-946, 710-976, 710-987, 710-997, 711-978, 711-1070, 711-1114, 714-1114, 715-1114, 716-810, 716-832, 716-924, 716-927, 716-952, 716-971, 716-989, 716-995, 716-996, 716-1002, 716-1009, 716-1012, 717-979, 718-852, 718-949, 719-1015, 719-1023, 719-1089, 722-1114, 724-1008, 724-1114, 725-1114, 726-928, 726-934, 726-998, 726-1006, 726-1022, 726-1114, 727-878, 727-922, 727-944, 727-957, 727-967, 727-982, 727-989, 731-851, 731-1038, 731-1114, 732-1114, 734-858, 734-936, 734-961, 734-991, 734-1008, 734-1030, 734-1114, 735-881, 735-973, 738-851, 738-963, 738-992, 738-1114, 739-1107, 739-1114, 740-1114, 741-1114, 742-953, 742-1014, 742-1114, 743-972, 743-1114, 744-1029, 744-1114, 745-1025, 745-1026, 745-1043, 746-1043, 746-1114, 747-1017, 748-997, 748-1114, 749-1114, 750-974, 751-851,
	751-964, 751-1114, 752-995, 753-1016, 753-1114, 754-1114, 755-980, 755-997, 755-998, 755-1019, 755-1114, 756-998, 756-1030, 757-1059, 757-1113, 757-1114, 758-889, 759-1114, 761-974, 761-1011, 761-1018, 761-1026, 761-1114, 762-1039, 763-1063, 763-1114, 764-1114, 765-959, 765-982, 765-1114, 766-851, 767-1000, 767-1004, 767-1049, 767-1114, 768-1010, 768-1018, 768-1066, 768-1114, 770-1114, 771-1028, 771-1056, 771-1114, 772-851, 772-891, 773-956, 773-996, 773-997, 773-1114, 774-864, 774-981, 774-1112, 775-1114, 776-1114, 777-1114, 778-1114, 779-897, 779-1114, 781-1104, 782-1060, 782-1066, 782-1114, 783-918, 783-1114, 785-1114, 786-1036, 786-1114, 787-1039, 789-1029, 790-1016, 790-1114, 791-1056, 792-922, 792-1034, 792-1038, 792-1039, 792-1046, 792-1114, 793-1021, 793-1062, 799-1114, 800-964, 800-1027, 800-1029, 800-1114, 801-1033, 803-1028, 804-1114, 807-1114, 810-1114, 811-930, 811-1007, 811-1022, 811-1048, 811-1069, 811-1114, 812-1000, 812-1031, 812-1087, 812-1089, 812-1114, 813-1093, 813-1114, 814-1064,
	814-1067, 814-1114, 816-1114, 818-1114, 819-1114, 820-1083, 820-1100, 820-1114, 822-1114, 823-1114, 827-1025, 827-1114, 828-1045, 829-1055, 829-1080, 829-1097, 829-1114, 830-926, 830-1063, 830-1068, 830-1084, 831-1024, 833-1074, 833-1097, 834-1040, 834-1090, 836-1114, 837-1067, 837-1114, 840-1076, 840-1077, 843-1068, 843-1073, 843-1096, 844-1085, 844-1114, 845-1114, 846-1114, 849-1080, 851-1114, 852-1114, 853-1114, 858-1114, 861-1114, 862-1114, 864-1094, 864-1111, 864-1114, 865-1109, 865-1114, 866-988, 866-1040, 866-1114, 870-1089, 871-1114, 872-1114, 874-1114, 876-1114, 877-1048, 877-1088, 877-1108, 877-1114, 879-978, 879-1052, 879-1071, 879-1105, 880-1114, 881-1114, 882-1031, 882-1070, 882-1099, 882-1114, 883-1114, 885-1114, 886-1087, 886-1114, 887-1114, 889-1114, 890-1098, 890-1114, 893-1114, 894-1014, 895-1114, 899-1114, 901-1114, 902-1114, 905-1114, 907-1114, 909-1076, 909-1114, 913-1114, 915-1114, 916-1187, 917-1114, 919-1114, 920-1114, 921-1114, 924-1114, 925-1103, 925-1114, 926-1114, 928-1114, 930-1100, 930-1114, 933-1114, 934-1114, 935-1114, 936-1114, 937-1114, 939-1114, 941-1114, 942-1114, 944-1114, 949-1100,

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
	949-1114, 950-1114, 951-1114, 953-1114, 954-1114, 958-1114, 961-1114, 962-1114, 967-1114, 969-1083, 969-1114, 978-1114, 979-1114, 981-1114, 982-1112, 982-1114, 985-1114, 986-1114, 988-1114, 993-1114, 995-1114, 996-1114, 998-1114, 1004-1114, 1006-1114, 1011-1114, 1020-1096, 1020-1114, 1021-1114, 1027-1114, 1029-1114, 1032-1114, 1034-1114, 1035-1114, 1037-1114, 1042-1083, 1045-1114, 1047-1083, 1048-1083, 1049-1083, 1051-1083, 1052-1083, 1110-1175, 1110-1177, 1110-1181, 1110-1184, 1110-1187, 1112-1175, 1113-1187, 1123-1177, 1140-1163, 1140-1168, 1140-1181, 1141-1160, 1141-1162, 1141-1163, 1141-1164, 1141-1165, 1141-1168, 1141-1169, 1141-1170, 1141-1171, 1141-1172, 1141-1173, 1141-1174, 1141-1175, 1141-1176, 1141-1178, 1141-1180, 1141-1181, 1141-1182, 1141-1183, 1141-1184, 1141-1185, 1141-1186, 1141-1187, 1144-1174, 1144-1175
66/7505533CB1/ 570	1-237, 1-261, 1-283, 12-154, 12-195, 12-249, 12-250, 12-259, 12-268, 12-271, 12-275, 12-276, 12-283, 12-570, 13-278, 14-245, 14-266, 16-236, 21-233, 25-252, 26-248, 26-272, 29-100, 29-261, 37-207, 59-157, 177-563, 223-563, 295-563, 308-442, 467-562
67/7511220CB1 685	1-280, 1-685, 2-554, 170-685
68/7510967CB1/ 5723	1-136, 1-168, 1-203, 1-241, 1-258, 1-359, 1-471, 1-501, 1-612, 1-626, 1-763, 1-5723, 41-631, 201-417, 282-531, 282-536, 282-658, 333-723, 407-581, 505-1142, 505-1143, 505-1181, 505-1192, 505-1197, 505-1238, 505-1254, 505-1255, 505-1263, 505-1296, 505-1297, 505-1302, 505-1319, 563-826, 563-835, 563-1008, 588-1313, 627-1049, 692-819, 759-1077, 791-1440, 811-1615, 867-1615, 869-1615, 876-1615, 879-1615, 889-1615, 898-1615, 902-1615, 929-1615, 944-1615, 945-1391, 1051-1334, 1051-1621, 1199-1727, 1199-1738, 1205-1716, 1221-1504, 1243-1709, 1376-1901, 1381-1641, 1492-1851, 1590-2092, 1628-2218, 1737-2086, 1737-2100, 1737-2155, 1805-2269, 1974-2822, 2011-2683, 2014-2656, 2027-2626, 2027-2633, 2027-2657, 2129-2855, 2138-2390, 2138-2677, 2145-2855, 2203-2905, 2220-2771, 2220-2844, 2243-2845, 2251-2989, 2252-2848, 2257-2888, 2310-2846, 2432-2741, 2484-3162, 2552-3106, 2613-3135, 2620-3166, 2713-3225, 2834-3274, 2857-3496, 2918-3543, 2946-3296, 2948-3447, 3013-3559, 3178-3510, 3233-3807, 3242-3428, 3439-4105, 3445-3839, 3828-4236, 3828-4238, 3832-4076, 3863-4088, 3913-4491, 3923-4387, 3928-4462, 3936-4217, 3975-4479, 3991-4560, 4035-4269,
	4045-4234, 4056-4555, 4100-4715, 4113-4296, 4115-4386, 4131-4791, 4149-4727, 4151-4378, 4197-4451, 4223-4874, 4248-4647, 4257-4505, 4269-4856, 4290-4958, 4310-4789, 4354-4616, 4365-4446, 4406-4586, 4434-4731, 4434-4785, 4464-4824, 4492-4764, 4527-4838, 4561-5159, 4573-4816, 4624-4869, 4629-4889, 4646-5059, 4651-5159, 4697-5326, 4727-5267, 4732-5415, 4736-5334, 4748-5029, 4750-5036, 4752-5177, 4758-5009, 4758-5078, 4778-5131, 4786-5323, 4793-5051, 4814-5267, 4815-5116, 4818-5227, 4823-5127, 4828-4941, 4835-5365, 4836-5164, 4862-5164, 4868-5075, 4875-5199, 4881-5080, 4881-5455, 4891-5428, 4934-5215, 4950-5231, 5050-5418, 5072-5491, 5072-5504, 5130-5514, 5167-5476, 5178-5530, 5201-5267, 5201-5582, 5203-5452, 5203-5485, 5205-5510, 5236-5518, 5237-5510, 5241-5501, 5245-5531, 5256-5526, 5264-5570, 5306-5573

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
69/7511298CB1/ 3044	1-157, 1-202, 1-237, 1-262, 1-275, 1-386, 1-513, 1-528, 1-550, 1-553, 1-3043, 2-241, 2-248, 2-303, 6-273, 6-455, 9-466, 11-259, 11-552, 11-670, 13-313, 13-417, 16-239, 16-250, 18-257, 18-269, 19-629, 25-243, 27-407, 28-553, 33-310, 63-392, 63-445, 107-221, 107-394, 107-456, 145-495, 215-346, 547-1098, 547-1193, 556-1203, 587-1135, 603-989, 625-1000, 637-1105, 645-1299, 645-1364, 655-989, 655-1174, 672-1268, 699-1156, 700-1292, 711-1380, 760-985, 773-969, 777-1283, 794-1269, 796-1451, 798-1065, 805-1264, 829-1475, 830-1297, 840-1631, 859-1550, 862-1493, 869-1022, 869-1034, 869-1353, 871-1122, 873-1275, 892-1141, 937-1237, 937-1248, 937-1538, 937-1568, 937-1720, 937-1770, 937-1812, 937-1817, 939-1683, 941-1186, 941-1189, 945-1192, 947-1194, 947-1355, 950-1195, 950-1454, 951-1220, 972-1817, 993-1647, 1001-1281, 1006-1597, 1008-1692, 1009-1241, 1009-1881, 1025-1700, 1028-1262, 1031-1283, 1031-1319, 1031-1428, 1043-1644, 1053-1653, 1055-1554, 1064-1333, 1072-1937, 1073-1535, 1075-1749, 1076-1560, 1080-1506, 1084-1344, 1106-1548, 1108-1706, 1123-1731, 1127-1977, 1128-1864, 1131-1644, 1137-1540, 1139-1443, 1139-1619, 1139-1652, 1139-1727,
	1139-1790, 1141-1402, 1143-1349, 1146-1375, 1168-1701, 1178-2001, 1180-1814, 1181-1750, 1201-1452, 1205-1467, 1207-2001, 1222-1488, 1222-1501, 1222-1749, 1224-1850, 1227-1367, 1227-1457, 1250-1853, 1253-1531, 1253-1854, 1281-1485, 1282-1486, 1288-1792, 1290-2001, 1295-1978, 1297-1607, 1319-1824, 1334-1713, 1338-1508, 1338-1850, 1349-1853, 1350-2030, 1359-1853, 1367-1603, 1371-1652, 1387-1750, 1416-2094, 1423-1619, 1426-1707, 1428-1682, 1428-1686, 1435-1920, 1444-1707, 1451-1539, 1476-1726, 1480-2142, 1498-2119, 1527-1869, 1535-2358, 1536-1815, 1539-2272, 1552-1761, 1552-1784, 1552-2111, 1552-2112, 1554-2272, 1555-1821, 1555-1823, 1560-2165, 1563-2002, 1567-2238, 1574-2093, 1578-2072, 1581-2136, 1582-2321, 1588-1853, 1596-2099, 1597-2099, 1598-1846, 1600-1876, 1600-2196, 1603-1987, 1605-1882, 1610-2097, 1620-2138, 1620-2194, 1632-2150, 1638-2241, 1643-1912, 1643-1918, 1643-2254, 1654-1877, 1656-1909, 1657-1866, 1664-1958, 1664-2254, 1674-1953, 1686-2555, 1687-1937, 1687-1948, 1695-2375, 1715-1947, 1718-1974, 1719-1952, 1721-1904, 1726-1968, 1727-2036, 1730-1955, 1730-1965, 1730-2265, 1751-2111, 1752-2642, 1763-2025,
	1770-1971, 1782-2322, 1782-2323, 1788-2182, 1790-2372, 1793-2214, 1795-2078, 1804-2358, 1811-2410, 1811-2412, 1812-2264, 1816-2089, 1816-2442, 1816-2513, 1817-2067, 1817-2070, 1817-2089, 1817-2304, 1824-2064, 1837-2083, 1838-2394, 1839-2126, 1839-2247, 1840-2256, 1850-2033, 1852-1936, 1852-2115, 1852-2155, 1852-2294, 1852-2370, 1852-2382, 1854-2348, 1855-2094, 1858-2104, 1858-2443, 1868-2421, 1870-2132, 1871-2119, 1872-2242, 1874-2172, 1891-2486, 1893-2465, 1899-2133, 1899-2458, 1901-2187, 1928-2473, 1954-2465, 1954-2585, 1957-2074, 1961-2591, 1964-2615, 1981-2231, 1984-2250, 2011-2246, 2011-2298, 2011-2600, 2019-2265, 2021-2541, 2023-2158, 2028-2683, 2030-2307, 2033-2310, 2037-2585, 2043-2334, 2048-2248, 2048-2344, 2048-2636, 2054-2305, 2058-2312, 2058-2319, 2061-2310, 2061-2394, 2068-2752, 2072-2645, 2072-2657, 2079-2349, 2089-2236, 2091-2341, 2095-2362, 2095-2700, 2102-2375, 2102-2700, 2103-2343, 2110-2374, 2111-2702, 2113-2358, 2114-2404, 2115-2294, 2116-2388, 2127-2301, 2127-2386, 2127-2406, 2127-2545, 2132-2559, 2133-2685, 2137-2435, 2143-2413, 2156-2570, 2159-2700, 2159-3000, 2160-2630, 2165-2700, 2171-2700,

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
	2180-2700, 2181-2343, 2188-2453, 2189-2452, 2189-2462, 2189-2792, 2203-2651, 2203-2691, 2209-2809, 2210-2700, 2214-2489, 2215-2506, 2215-2803, 2217-2837, 2227-2943, 2230-2700, 2231-2497, 2231-2500, 2232-2709, 2236-2361, 2241-2505, 2243-2521, 2250-2517, 2251-2700, 2261-2594, 2268-2513, 2268-2516, 2273-2506, 2273-2559, 2273-2650, 2277-2826, 2282-2623, 2282-3027, 2283-2526, 2283-2615, 2283-3027, 2284-2700, 2289-3027, 2290-2508, 2293-2666, 2293-2910, 2303-2701, 2303-3027, 2304-2880, 2306-3025, 2306-3027, 2311-2989, 2311-3027, 2318-3028, 2321-3025, 2330-2908, 2353-2557, 2357-2862, 2362-2911, 2363-2609, 2363-3027, 2366-2799, 2369-2569, 2369-2928, 2373-2570, 2373-2913, 2373-2926, 2374-2548, 2374-2881, 2375-2771, 2376-2568, 2376-2613, 2376-2619, 2376-2632, 2378-2868, 2378-2928, 2380-2700, 2381-2639, 2383-2667, 2386-2729, 2387-2966, 2389-2864, 2391-2662, 2391-2912, 2391-2935, 2393-2678, 2394-2927, 2396-2863, 2396-2881, 2396-2999, 2398-3028, 2400-2926, 2405-2702, 2405-3029, 2406-3002, 2410-2949, 2411-2921, 2415-2631, 2423-2606, 2428-2685, 2430-2649, 2432-2585, 2432-2715, 2435-2915, 2435-3029, 2439-3030, 2439-3044, 2441-2695,
	2441-2821, 2447-2994, 2448-2697, 2448-2830, 2448-2927, 2451-3044, 2455-2721, 2455-2880, 2458-2808, 2462-3044, 2472-2774, 2472-2948, 2476-3006, 2478-2996, 2484-2992, 2485-2772, 2485-3031, 2496-2775, 2504-2996, 2520-2779, 2521-2923, 2521-2993, 2522-3040, 2533-2745, 2537-2681, 2543-3006, 2544-2880, 2551-2994, 2552-2776, 2552-2781, 2552-2830, 2553-3036, 2556-2994, 2557-2823, 2558-2637, 2561-2822, 2564-2955, 2565-2796, 2573-2839, 2584-2834, 2584-2873, 2584-2991, 2587-3044, 2590-2991, 2590-3035, 2591-2871, 2591-2916, 2592-2854, 2592-2861, 2593-2846, 2593-2859, 2593-3031, 2594-3037, 2596-3030, 2597-2865, 2601-2846, 2609-3033, 2610-2884, 2613-3040, 2616-3034, 2621-3033, 2633-2993, 2633-3031, 2633-3033, 2633-3034, 2634-3043, 2638-2852, 2638-2875, 2639-3040, 2648-2872, 2649-2854, 2653-2873, 2653-2909, 2653-2933, 2653-3031, 2659-3031, 2661-3023, 2661-3029, 2663-2900, 2663-3032, 2665-3039, 2666-3031, 2667-3035, 2669-3031, 2670-2891, 2673-2909, 2673-2962, 2673-3025, 2673-3036, 2677-3043, 2677-3044, 2678-3032, 2678-3035, 2681-2995, 2682-3033, 2689-2923, 2693-2982, 2701-2923, 2701-2993, 2709-3031, 2716-2776, 2725-2994, 2726-3044,
	2727-3044, 2728-3023, 2729-3035, 2737-2994, 2739-2996, 2740-3043, 2740-3044, 2741-2985, 2742-3043, 2747-2999, 2758-3041, 2760-3029, 2760-3031, 2765-3044, 2772-2981, 2776-2993, 2786-3030, 2788-3030, 2790-3029, 2794-3040, 2802-3028, 2803-3034, 2812-3044, 2814-3034, 2817-3029, 2817-3030, 2820-3031, 2821-2970, 2821-3030, 2825-3036, 2826-3033, 2827-3040, 2847-3038, 2879-3044, 2880-3037, 2893-3044, 2918-3044, 2955-3044

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
70/7510937CB1/ 4455	1-191, 1-4449, 33-482, 35-298, 36-487, 37-917, 38-326, 40-338, 41-297, 41-322, 41-491, 41-494, 41-497, 42-828, 46-315, 49-119, 49-321, 49-322, 49-326, 49-327, 49-332, 49-486, 49-487, 52-323, 53-325, 54-246, 54-307, 59-178, 60-327, 64-327, 65-327, 68-325, 72-487, 74-323, 75-166, 75-300, 75-307, 75-487, 76-325, 77-329, 77-371, 77-604, 78-328, 81-317, 84-145, 88-322, 88-803, 91-444, 92-333, 100-327, 105-487, 108-490, 108-537, 109-487, 110-487, 119-370, 120-487, 124-320, 124-488, 125-487, 125-652, 125-811, 130-475, 140-488, 141-475, 145-487, 154-507, 156-487, 169-320, 173-355, 173-382, 173-419, 173-491, 198-486, 199-322, 199-479, 212-487, 219-480, 225-491, 242-497, 252-710, 319-606, 330-604, 346-794, 351-578, 351-601, 351-619, 364-714, 374-670, 378-1113, 392-1192, 401-1135, 409-644, 416-703, 441-1161, 465-1050, 486-779, 499-895, 504-808, 507-774, 513-790, 522-901, 583-1225, 598-880, 618-925, 620-1199, 648-893, 653-1252, 674-1146, 696-951, 707-1214, 708-1199, 733-1286, 772-1241, 776-1241, 852-1191, 871-1245, 884-1199, 894-1346,
	898-1216, 903-1241, 935-1211, 1001-1200, 1006-1232, 1006-1272, 1032-1600, 1063-1844, 1065-1500, 1073-1835, 1084-1218, 1089-1447, 1104-1382, 1137-1976, 1151-1245, 1153-1766, 1167-1425, 1184-1817, 1200-1730, 1220-1530, 1228-1406, 1231-1991, 1256-1830, 1259-1730, 1284-1554, 1293-2080, 1300-1570, 1354-1591, 1361-1595, 1394-1550, 1398-1634, 1403-2014, 1403-2033, 1422-1942, 1429-2190, 1472-1953, 1494-1827, 1496-1765, 1505-1779, 1568-1985, 1585-2219, 1611-1883, 1615-1874, 1615-1895, 1675-1892, 1692-1942, 1704-2227, 1709-1954, 1711-2568, 1711-2654, 1711-2679, 1712-2074, 1718-2363, 1718-2562, 1728-2281, 1732-2319, 1745-1864, 1756-2331, 1780-1997, 1805-2337, 1811-2582, 1815-2122, 1830-2387, 1840-2076, 1840-2100, 1844-2690, 1851-2567, 1867-2681, 1875-2452, 1877-2166, 1883-2125, 1887-2201, 1892-2160, 1921-2528, 1942-2212, 1981-2215, 1981-2597, 1985-2273, 2001-2223, 2019-2286, 2032-2255, 2035-2626, 2045-2269, 2054-2503, 2070-2168, 2093-2346, 2101-2338, 2102-2682, 2106-2374, 2147-2329, 2158-2410, 2164-2424, 2188-2435, 2198-2419, 2198-2477, 2210-2520, 2211-2457, 2216-2839, 2233-2478, 2243-2494, 2268-2498, 2268-2547, 2288-2439,
	2300-2454, 2311-2580, 2317-2556, 2342-2721, 2348-2616, 2354-2647, 2359-2588, 2359-2594, 2363-2753, 2391-2635, 2479-3076, 2480-3047, 2480-3100, 2481-2871, 2510-2805, 2531-3133, 2542-2798, 2545-2801, 2554-2833, 2563-2833, 2563-2876, 2565-2826, 2571-2762, 2571-2876, 2585-2824, 2585-2839, 2589-2799, 2593-2817, 2595-3266, 2599-2899, 2604-2863, 2648-2914, 2648-2915, 2674-3076, 2694-2948, 2722-2970, 2734-3002, 2742-3320, 2754-3015, 2755-2991, 2765-3023, 2794-3059, 2794-3064, 2801-3010, 2803-3057, 2803-3091, 2809-3112, 2815-3109, 2819-3231, 2830-3069, 2843-3440, 2867-3110, 2875-3032, 2884-3144, 2893-3132, 2893-3167, 2893-3169, 2893-3236, 2904-3171, 2904-3206, 2905-3178, 2916-3222, 2934-3358, 2957-3222, 2961-3365, 2964-3207, 2964-3220, 2964-3559, 2964-3755, 2973-3240, 2978-3491, 2982-3244, 2982-3537, 2991-3226, 2998-3637, 3011-3316, 3011-3358, 3013-3291, 3014-3141, 3015-3373, 3046-3547, 3063-3314, 3074-3208, 3074-3333, 3074-3591, 3088-3297, 3093-3668, 3116-3373, 3131-3538, 3133-3541, 3161-3477, 3166-3419, 3172-3755, 3179-3402, 3181-3460, 3192-3432, 3237-3369, 3237-3490, 3237-3510, 3242-3503, 3242-3733, 3243-3512, 3246-3511,

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
	3246-3550, 3248-3710, 3251-3527, 3255-3492, 3256-3433, 3258-3350, 3258-3532, 3260-3514, 3268-3687, 3270-3559, 3278-3498, 3294-3540, 3316-3607, 3318-3566, 3320-3484, 3320-3555, 3320-3584, 3322-3430, 3322-3571, 3338-3639, 3340-3613, 3341-3641, 3344-3602, 3354-3650, 3372-3635, 3378-3755, 3378-3966, 3382-3675, 3383-3606, 3392-3755, 3396-3642, 3411-3664, 3415-3602, 3417-3764, 3421-3732, 3426-3671, 3427-3683, 3428-3722, 3434-3684, 3456-3755, 3494-3746, 3498-3749, 3504-3776, 3508-3673, 3513-3746, 3559-3755, 3591-3863, 3598-4390, 3599-3755, 3602-4391, 3606-3865, 3607-3860, 3611-4387, 3614-3734, 3617-3911, 3617-3972, 3631-3894, 3632-3814, 3641-4141, 3641-4186, 3641-4216, 3643-3843, 3643-3933, 3654-4391, 3660-4091, 3674-3931, 3702-3973, 3714-3978, 3716-4250, 3718-4269, 3721-4195, 3777-3977, 3789-4391, 3805-4096, 3812-4390, 3819-3934, 3826-4306, 3833-4287, 3833-4388, 3834-3886, 3834-3935, 3834-3956, 3834-4042, 3834-4055, 3837-4241, 3840-4390, 3841-4288, 3849-4152, 3851-4162, 3851-4178, 3859-4165, 3859-4277, 3859-4328, 3861-4100, 3863-4305, 3863-4395, 3865-4304, 3868-4140, 3869-4261, 3875-4364, 3875-4388, 3878-4080, 3879-4305,
	3882-4375, 3886-4157, 3889-4291, 3896-4291, 3903-4288, 3904-4278, 3905-4175, 3912-4015, 3914-4423, 3927-4204, 3931-4185, 3931-4188, 3933-4227, 3940-4171, 3940-4212, 3944-4194, 3944-4288, 3945-4288, 3955-4424, 3959-4239, 3961-4233, 3962-4249, 3975-4391, 3977-4245, 3977-4306, 3992-4227, 3993-4266, 3995-4436, 3997-4271, 4004-4134, 4012-4435, 4025-4455, 4027-4313, 4027-4320, 4032-4435, 4037-4308, 4038-4276, 4042-4443, 4043-4299, 4045-4434, 4049-4291, 4061-4339, 4073-4288, 4094-4333, 4095-4340, 4099-4310, 4109-4272, 4114-4410, 4121-4377, 4136-4288, 4138-4385, 4139-4424, 4141-4402, 4141-4418, 4153-4435, 4174-4357, 4183-4448, 4185-4435, 4186-4435, 4202-4432, 4207-4417, 4214-4435, 4220-4388, 4228-4435, 4261-4372
71/7511852CB1/ 1949	1-252, 1-502, 1-505, 1-548, 1-551, 1-555, 1-570, 1-578, 1-581, 1-594, 1-621, 1-622, 1-626, 1-633, 1-636, 1-640, 1-641, 1-656, 1-657, 1-658, 1-678, 1-680, 1-689, 1-705, 1-711, 1-714, 1-731, 1-735, 1-738, 1-746, 1-751, 1-752, 1-753, 1-755, 1-785, 1-786, 1-790, 1-814, 2-409, 2-509, 2-643, 2-679, 2-738, 2-745, 2-762, 2-1949, 4-640, 21-250, 82-250, 126-767, 154-250, 161-249, 161-251, 215-492, 217-490, 217-500, 320-554, 320-694, 320-757, 331-583, 368-1085, 388-650, 800-1037, 800-1410, 809-1083, 818-1300, 869-1418, 888-1037, 910-1158, 937-1207, 993-1084, 1010-1683, 1037-1321, 1099-1374, 1099-1560, 1107-1313, 1110-1386, 1119-1420, 1179-1469, 1191-1449, 1258-1495, 1299-1565, 1319-1530, 1319-1680, 1339-1472, 1361-1613, 1361-1619, 1361-1624, 1366-1619, 1409-1644, 1432-1860, 1444-1667, 1459-1685, 1491-1693, 1515-1766, 1521-1756, 1524-1805, 1526-1782, 1577-1845, 1591-1693
72/7511077CB1/ 1322	1-280, 1-341, 127-588, 330-685, 377-1066, 383-953, 392-941, 398-858, 411-1128, 475-1137, 490-943, 499-947, 516-1187, 533-1024, 538-980, 538-1075, 565-1066, 575-1296, 613-1025, 625-1042, 654-1088, 663-1248, 847-1322, 854-1319, 854-1322, 899-1322, 1011-1282, 1062-1292

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
73/7511576CB1/ 1381	1-244, 1-339, 5-292, 6-1364, 15-230, 15-265, 15-281, 16-298, 42-286, 46-249, 46-310, 47-191, 47-297, 50-339, 52-331, 52-339, 54-303, 54-309, 54-315, 59-307, 61-339, 62-339, 62-340, 63-339, 65-295, 65-339, 71-339, 72-339, 75-217, 84-333, 84-381, 86-307, 86-333, 90-212, 90-219, 90-334, 90-339, 91-339, 93-328, 95-174, 95-244, 95-306, 95-312, 95-323, 95-327, 95-339, 96-319, 96-320, 96-330, 97-339, 99-327, 99-339, 100-332, 103-339, 104-339, 115-339, 116-320, 117-324, 148-339, 194-339, 339-499, 340-538, 340-540, 340-557, 340-569, 340-583, 340-607, 340-799, 340-814, 340-921, 340-930, 340-948, 343-948, 346-605, 346-621, 348-588, 348-596, 348-614, 348-941, 348-948, 349-546, 353-583, 353-879, 357-948, 359-551, 360-575, 361-943, 367-948, 369-909, 371-667, 374-609, 383-795, 387-662, 387-784, 397-933, 398-905, 403-653, 406-903, 418-687, 418-948, 419-668, 420-679, 421-841, 431-670, 437-670, 445-684, 447-691, 451-947, 453-942, 460-745, 461-948, 468-658, 469-741, 476-948, 483-948, 484-948, 485-948, 486-947, 489-947, 489-951, 492-947, 492-948,
	493-947, 494-947, 496-947, 497-948, 498-927, 498-948, 499-923, 504-947, 506-943, 507-948, 508-942, 509-950, 512-948, 514-943, 515-947, 515-948, 516-798, 517-941, 518-952, 526-942, 531-733, 531-948, 532-947, 534-947, 536-948, 539-948, 539-951, 540-951, 541-947, 541-948, 542-947, 543-917, 543-947, 544-948, 545-945, 546-941, 547-947, 547-948, 548-910, 550-941, 553-941, 558-948, 563-875, 568-857, 574-828, 579-830, 579-893, 579-923, 581-800, 590-947, 592-941, 595-771, 595-948, 607-948, 611-872, 611-899, 611-947, 615-946, 617-948, 618-947, 622-939, 622-948, 623-947, 627-769, 627-907, 629-948, 630-946, 637-941, 670-948, 682-911, 695-948, 700-947, 708-947, 713-943, 759-948, 798-947, 807-947, 811-948, 821-953, 822-948, 839-947, 843-948, 867-951, 878-948, 885-948, 922-1381, 1058-1084, 1112-1138
74/7511492CB1/ 1027	1-162, 1-265, 1-269, 1-270, 1-275, 1-289, 1-314, 1-316, 1-1027, 10-238, 10-263, 10-291, 11-254, 11-304, 14-184, 14-214, 14-337, 16-249, 16-281, 19-247, 19-287, 19-300, 20-249, 20-261, 20-271, 20-282, 25-229, 25-250, 25-269, 25-341, 27-254, 27-263, 27-270, 27-278, 27-285, 27-287, 27-310, 27-321, 27-349, 28-328, 30-229, 30-269, 31-323, 32-298, 33-199, 33-325, 34-313, 35-295, 35-301, 36-263, 36-299, 37-246, 37-264, 37-275, 37-319, 39-267, 40-273, 40-294, 40-296, 40-322, 40-325, 40-328, 42-242, 45-212, 45-325, 45-346, 46-226, 46-240, 46-285, 46-294, 46-297, 46-298, 46-302, 46-309, 46-312, 46-316, 46-319, 46-333, 46-334, 47-197, 47-282, 47-292, 47-295, 47-300, 47-320, 47-322, 47-329, 47-333, 47-334, 47-335, 47-338, 47-342, 47-349, 48-248, 48-322, 48-323, 48-324, 48-325, 48-328, 48-343, 48-346, 48-349, 49-279, 49-293, 49-322, 51-248, 51-301, 51-349, 52-190, 52-202, 52-294, 52-306, 52-310, 52-317, 52-319, 52-320, 52-325, 52-326, 52-332, 52-339, 52-349, 53-178, 53-205, 53-271, 53-274, 53-282, 53-283, 53-286, 53-293, 53-294, 53-300, 53-302, 53-304,

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
	53-306, 53-310, 53-311, 53-317, 53-318, 53-323, 53-328, 53-335, 53-349, 54-139, 54-257, 54-264, 54-265, 54-271, 54-280, 54-307, 54-310, 54-316, 54-323, 54-349, 55-250, 55-270, 55-288, 55-295, 55-305, 55-318, 55-346, 55-348, 55-349, 56-349, 57-197, 57-211, 57-250, 57-258, 57-292, 57-295, 57-298, 57-304, 57-306, 57-308, 57-310, 57-318, 57-320, 57-324, 57-325, 57-326, 57-328, 57-330, 57-337, 57-341, 57-349, 58-250, 58-253, 58-275, 58-282, 58-286, 58-295, 58-296, 58-306, 58-309, 58-313, 58-322, 58-329, 58-336, 58-346, 58-349, 59-298, 59-304, 59-315, 59-316, 59-326, 59-349, 60-183, 60-226, 60-253, 60-264, 60-277, 60-282, 60-292, 60-293, 60-294, 60-296, 60-297, 60-298, 60-301, 60-302, 60-307, 60-308, 60-309, 60-311, 60-316, 60-317, 60-327, 60-334, 60-335, 60-338, 60-339, 60-342, 60-349, 61-223, 61-251, 61-295, 61-300, 61-304, 61-319, 61-337, 61-342, 61-347, 61-349, 62-266, 62-304, 62-306, 62-314, 62-318, 62-321, 62-331, 62-346, 62-349, 63-314, 64-215, 64-264, 64-343, 64-349, 66-285, 66-315, 66-329, 66-338, 66-343, 67-321, 67-345, 69-315, 69-329,
	69-338, 70-296, 70-329, 70-343, 70-349, 72-201, 72-294, 72-336, 74-296, 86-311, 86-341, 89-166, 89-317, 89-326, 89-333, 89-337, 89-348, 90-309, 94-271, 102-294, 102-349, 102-392, 105-295, 108-337, 108-349, 108-356, 109-289, 112-349, 118-327, 132-349, 141-304, 142-251, 166-338, 183-310, 343-460, 343-481, 343-483, 343-490, 343-503, 343-525, 343-545, 343-546, 343-549, 343-554, 343-555, 343-565, 343-569, 343-575, 343-577, 343-580, 343-585, 343-586, 343-598, 343-599, 343-601, 343-608, 343-610, 343-611, 343-642, 343-647, 343-712, 343-718, 344-588, 344-633, 348-585, 348-603, 348-615, 351-610, 353-584, 353-635, 358-618, 369-607, 371-654, 371-688, 372-559, 377-633, 377-636, 377-643, 380-659, 381-636, 381-648, 382-655, 383-614, 385-625, 394-496, 406-604, 406-654, 409-642, 409-711, 412-717, 414-670, 416-717, 421-691, 443-557, 446-562, 458-696, 460-680, 460-683, 460-693, 460-694, 460-717, 461-653, 462-716, 463-717, 469-626, 469-637, 486-675, 489-717, 506-672, 510-717, 512-644, 530-679, 535-637, 578-717, 593-677
75/7511141CB1/ 3040	1-228, 1-518, 1-538, 5-710, 250-824, 250-826, 292-1101, 343-914, 359-903, 450-1096, 528-1167, 561-1252, 673-1397, 773-1481, 776-1427, 828-1553, 829-1557, 837-1461, 846-1436, 851-1469, 853-1707, 919-1605, 930-1670, 958-1752, 959-1514, 970-1544, 986-1588, 1116-1494, 1270-1832, 1389-2037, 1402-2184, 1554-2212, 1602-2231, 1676-2200, 1780-2403, 1799-2294, 2053-2619, 2053-2621, 2270-2736, 2271-3040, 2376-2807
76/7511300CB1/ 3158	1-157, 1-202, 1-237, 1-262, 1-275, 1-386, 1-513, 1-528, 1-550, 1-555, 1-619, 1-3088, 2-241, 2-248, 2-303, 6-273, 6-455, 6-627, 6-666, 9-466, 13-313, 13-417, 16-239, 16-250, 18-257, 18-269, 25-243, 27-407, 28-556, 33-310, 63-392, 63-445, 107-382, 107-445, 107-456, 139-629, 145-609, 174-677, 188-823, 215-346, 217-672, 336-594, 356-1261, 378-886, 393-885, 411-710, 466-697, 466-931, 545-1467, 547-615, 547-646, 554-1077, 560-646, 560-752, 560-808, 582-953, 587-646, 690-1245, 690-1416, 694-793, 697-793, 703-1350, 707-793, 732-793, 734-1282, 750-1136, 772-1147, 784-1252, 792-1511, 792-1630, 802-1136, 802-1321, 819-1415, 846-1116, 846-1303, 847-1439, 858-1527, 907-1132, 924-1430, 935-1640, 941-1416, 943-1598, 945-1212, 952-1411, 976-1622, 977-1444, 987-1778, 1006-1697, 1016-1169, 1016-1181, 1016-1500, 1018-1269, 1020-1422, 1039-1288, 1084-1384, 1084-1395, 1084-1685, 1084-1715, 1084-1867, 1084-1917, 1084-1959, 1084-1964, 1086-1830, 1088-1333, 1088-1336, 1092-1339, 1094-1341, 1094-1502, 1097-1342, 1097-1601, 1098-1367, 1106-1839,

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
	1119-1964, 1140-1794, 1148-1428, 1153-1744, 1156-1388, 1156-2028, 1172-1847, 1175-1409, 1178-1430, 1178-1466, 1178-1575, 1190-1791, 1194-1425, 1200-1800, 1202-1701, 1211-1480, 1219-2084, 1220-1682, 1222-1896, 1223-1707, 1227-1653, 1231-1491, 1253-1695, 1255-1853, 1270-1878, 1274-2124, 1275-2011, 1278-1791, 1284-1841, 1286-1590, 1286-1766, 1286-1799, 1286-1874, 1286-1937, 1288-1549, 1290-1496, 1293-1522, 1315-1848, 1325-2148, 1327-1961, 1328-1897, 1348-1599, 1352-1614, 1354-2148, 1369-1635, 1369-1648, 1369-1896, 1371-2031, 1374-1514, 1374-1604, 1397-2059, 1400-1678, 1400-2001, 1428-1632, 1429-1633, 1435-1939, 1437-2148, 1442-2125, 1444-1754, 1452-2177, 1466-1971, 1481-1860, 1485-1655, 1485-2175, 1496-2111, 1506-2000, 1514-1750, 1518-1799, 1534-1897, 1563-2241, 1570-1766, 1573-1854, 1575-1829, 1575-1833, 1582-2067, 1591-1854, 1598-1686, 1623-1873, 1627-2289, 1645-2266, 1674-2016, 1683-1962, 1686-2419, 1699-1908, 1699-1931, 1699-2258, 1699-2259, 1701-2419, 1702-1968, 1702-1970, 1707-2312, 1710-2149, 1714-2385, 1721-2240, 1725-2219, 1728-2283, 1729-2445, 1735-2080, 1738-2403, 1743-2246, 1744-2246, 1745-1993, 1747-2023,
	1747-2343, 1750-2134, 1752-2029, 1757-2244, 1767-2285, 1767-2341, 1779-2297, 1785-2388, 1790-2059, 1790-2065, 1790-2401, 1801-2024, 1803-2056, 1804-2013, 1811-2105, 1811-2401, 1821-2100, 1834-2084, 1834-2095, 1862-2094, 1865-2121, 1866-2099, 1868-2051, 1873-2115, 1874-2183, 1877-2102, 1877-2112, 1877-2412, 1898-2258, 1910-2172, 1917-2118, 1935-2329, 1940-2361, 1942-2225, 1959-2411, 1963-2236, 1964-2214, 1964-2217, 1964-2236, 1964-2447, 1971-2211, 1984-2230, 1986-2273, 1986-2394, 1997-2180, 1999-2083, 1999-2262, 1999-2302, 1999-2441, 2002-2241, 2005-2251, 2017-2279, 2018-2266, 2019-2389, 2021-2319, 2046-2280, 2048-2334, 2128-2378, 2131-2397, 2158-2393, 2158-2445, 2166-2412, 2170-2305, 2177-2447, 2180-2447, 2195-2395, 2201-2447, 2205-2447, 2208-2447, 2236-2383, 2262-2441, 2274-2447, 2328-2447, 2425-2711, 2446-2593, 2446-2613, 2446-2615, 2446-2658, 2446-2664, 2446-2677, 2446-2684, 2446-2707, 2446-2712, 2446-2723, 2446-2774, 2446-2909, 2446-2926, 2446-2971, 2446-2972, 2446-2973, 2446-2980, 2446-3011, 2446-3034, 2446-3044, 2446-3072, 2446-3073, 2446-3088, 2450-2747, 2450-3074, 2451-3047, 2455-2994, 2456-2966, 2460-2676,
	2468-2651, 2473-2730, 2475-2696, 2477-2630, 2477-2760, 2480-2960, 2480-3074, 2484-3075, 2484-3089, 2486-2740, 2486-2866, 2492-3039, 2493-2742, 2493-2875, 2493-2972, 2496-3089, 2500-2766, 2500-2925, 2503-2853, 2507-3091, 2517-2819, 2517-2993, 2521-3051, 2523-3041, 2529-3037, 2530-2817, 2530-3076, 2541-2820, 2547-2884, 2549-3041, 2565-2824, 2566-2968, 2566-3038, 2567-3085, 2578-2790, 2582-2726, 2588-3051, 2589-2925, 2596-3039, 2597-2821, 2597-2826, 2597-2875, 2598-3081, 2601-3039, 2602-2868, 2603-2682, 2606-2867, 2609-3000, 2610-2841, 2629-2879, 2629-2918, 2629-3036, 2632-3110, 2635-3036, 2635-3080, 2636-2916, 2636-2961, 2637-2899, 2637-2906, 2638-2891, 2638-2904, 2638-3076, 2639-3082, 2641-3075, 2642-2910, 2646-2891, 2654-3078, 2655-2929, 2658-3085, 2661-3079, 2666-3078, 2676-3076, 2676-3079, 2678-3038, 2678-3078, 2679-3088, 2683-2897, 2683-2920, 2684-3085, 2693-2917, 2694-2899, 2698-2918, 2698-2954, 2698-2978, 2698-3076, 2704-3076, 2706-3068, 2706-3074, 2708-2945, 2708-3077, 2710-3084, 2711-3076, 2712-3080, 2714-3076, 2715-2936, 2718-2954, 2718-3007, 2718-3070, 2718-3081, 2722-3093, 2723-3077, 2723-3080, 2726-3040,

Table 4

Polynucleotide SEQ ID NO:/ Incyte ID/ Sequence Length	Sequence Fragments
	2727-3078, 2734-2968, 2738-3027, 2746-2968, 2746-3038, 2754-3076, 2761-2946, 2770-3039, 2771-3093, 2772-3092, 2773-3068, 2774-3080, 2782-3039, 2784-3041, 2785-3088, 2785-3089, 2786-3030, 2787-3088, 2792-3044, 2803-3086, 2805-3074, 2805-3076, 2810-3090, 2817-3026, 2821-3038, 2831-3075, 2833-3075, 2835-3074, 2839-3085, 2847-3073, 2848-3079, 2857-3097, 2859-3079, 2862-3074, 2862-3075, 2865-3076, 2866-3015, 2866-3075, 2870-3081, 2871-3078, 2872-3085, 2892-3083, 2924-3158, 2925-3095, 2938-3090, 2963-3143, 3000-3137

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID:	Representative Library
39	3048626CB1	FIBRUNT02
40	2684425CB1	PONSAZT01
41	7505960CB1	PROSTUT20
42	7507021CB1	THYRNOT02
43	7509099CB1	MIXDTUE01
44	7509361CB1	LIVRTUE01
45	7506815CB1	BRAINOT11
46	7506814CB1	BRAINOT11
47	7506852CB1	BRAINOT20
48	7503782CB1	TMLR2DT01
49	7504647CB1	COLNNOT23
50	7500424CB1	THYRNOT03
51	7500449CB1	BRSTNOT16
53	7503292CB1	BRAINOT18
54	7503311CB1	CONNNOT01
55	7510384CB1	PITUDIR01
56	7509976CB1	FIBRTXS07
57	7510454CB1	BRAINOT18
58	8017335CB1	LATRTUT02
59	7510197CB1	PANCNOT17
60	7510055CB1	SINTBST01
61	7501754CB1	BRAITUT03
62	7510517CB1	BRSTNOT01
63	7511014CB1	BRAIFET01
64	7506687CB1	CORPNOT02
65	7510621CB1	FIBRUNT02
66	7505533CB1	MIXDTME02
67	7511220CB1	BRAITUT12
68	7510967CB1	MLP000032
69	7511298CB1	EOSINOT01
70	7510937CB1	UTRSTMR01
71	7511852CB1	SCOMDIT01
72	7511077CB1	COLNTUT03
73	7511576CB1	UCMCL5T01
74	7511492CB1	PROSTUS23
75	7511141CB1	PANCNOT15
76	7511300CB1	BRAVUNT02

Table 6

Library	Vector	Library Description
BRAIFET01	pINCY	Library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus, who was stillborn with a hypoplastic left heart at 23 weeks' gestation.
BRAINOT11	pINCY	Library was constructed using RNA isolated from brain tissue removed from the right temporal lobe of a 5-year-old Caucasian male during a hemispherectomy. Pathology indicated extensive polymicrogyria and mild to moderate gliosis (predominantly subpial and subcortical), consistent with chronic seizure disorder. Family history included a cervical neoplasm.
BRAINOT18	pINCY	Library was constructed using RNA isolated from left temporal lobe brain tissue removed from a 34-year-old Caucasian male during cerebral meninges lesion excision. Pathology for the associated tumor tissue indicated metastatic malignant melanoma. Neoplastic cells strongly expressed HMB-45. Patient history included malignant melanoma of skin of the trunk. Family history included liver cancer, acute myocardial infarction, atherosclerotic coronary artery disease, and cerebrovascular disease.
BRAINOT20	pINCY	Library was constructed using RNA isolated from diseased brain tissue removed from the left temporal lobe of a 27-year-old Caucasian male during a brain lobectomy. Pathology for the left temporal lobe, including the mesial temporal structures, indicated focal, marked pyramidal cell loss and gliosis in hippocampal sector CA1, consistent with mesial temporal sclerosis. The left frontal lobe showed a focal deep white matter lesion, characterized by marked gliosis, calcifications, and hemosiderin-laden macrophages, consistent with a remote perinatal injury. This frontal lobe tissue also showed mild to moderate generalized gliosis, predominantly subpial and subcortical, consistent with chronic seizure disorder. GFAP was positive for astrocytes. Family history included brain cancer.
BRAITUT03	PSPORT1	Library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 17-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a grade 4 fibrillary giant and small-cell astrocytoma. Family history included benign hypertension and cerebrovascular disease.
BRAITUT12	pINCY	Library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 40-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated grade 4 gemistocytic astrocytoma.
BRAVUNT02	PSPORT1	Library was constructed using pooled RNA isolated from separate populations of unstimulated astrocytes.
BRSTNOT01	PBLUESCRIPT	Library was constructed using RNA isolated from the breast tissue of a 56-year-old Caucasian female who died in a motor vehicle accident.
BRSTNOT16	pINCY	Library was constructed using RNA isolated from diseased breast tissue removed from a 59-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated an invasive lobular carcinoma with extension into ducts. Patient history included liver cirrhosis, esophageal ulcer, hyperlipidemia, and neuropathy.

Table 6

Library	Vector	Library Description
COLNNOT23	pINCY	Library was constructed using RNA isolated from diseased colon tissue removed from a 16-year-old Caucasian male during a total colectomy with abdominal/perineal resection. Pathology indicated gastritis and pancolonitis consistent with the acute phase of ulcerative colitis. Inflammation was more severe in the transverse colon, with inflammation confined to the mucosa. There was only mild involvement of the ascending and sigmoid colon, and no significant involvement of the cecum, rectum, or terminal ileum. Family history included irritable bowel syndrome.
COLNTUT03	pINCY	Library was constructed using RNA isolated from colon tumor tissue obtained from the sigmoid colon of a 62-year-old Caucasian male during a sigmoidectomy and permanent colostomy. Pathology indicated invasive grade 2 adenocarcinoma. One lymph node contained metastasis with extranodal extension. Patient history included hyperlipidemia, cataract disorder, and dermatitis. Family history included benign hypertension, atherosclerotic coronary artery disease, hyperlipidemia, breast cancer, and prostate cancer.
CONNNOT01	pINCY	Library was constructed using RNA isolated from mesentery fat tissue obtained from a 71-year-old Caucasian male during a partial colectomy and permanent colostomy. Family history included atherosclerotic coronary artery disease, myocardial infarction, and extrinsic asthma.
CORPNOT02	pINCY	Library was constructed using RNA isolated from diseased corpus callosum tissue removed from the brain of a 74-year-old Caucasian male who died from Alzheimer's disease.
EOSINOT01	pINCY	Library was constructed using RNA isolated from microscopically normal eosinophils from 31 non-allergic donors. Donors abstained from prescription and over- the-counter drug use for at least one week prior to donating 200 ml of peripheral venous blood.
FIBRTXS07	pINCY	This subtracted library was constructed using 1.3 million clones from a dermal fibroblast library and was subjected to two rounds of subtraction hybridization with 2.8 million clones from an untreated dermal fibroblast tissue library. The starting library for subtraction was constructed using RNA isolated from treated dermal fibroblast tissue removed from the breast of a 31-year-old Caucasian female. The cells were treated with 9CIS retinoic acid. The hybridization probe for subtraction was derived from a similarly constructed library from RNA isolated from untreated dermal fibroblast tissue from the same donor. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR (1991) 19:1954 and Bonaldo, et al., Genome Research (1996) 6:791.
FIBRUNT02	pINCY	Library was constructed using RNA isolated from an untreated MG-63 cell line derived from an osteosarcoma removed from a 14-year-old Caucasian male.

Table 6

Library	Vector	Library Description
LATRTUT02	pINCY	Library was constructed using RNA isolated from a myxoma removed from the left atrium of a 43-year-old Caucasian male during annuloplasty. Pathology indicated atrial myxoma. Patient history included pulmonary insufficiency, acute myocardial infarction, atherosclerotic coronary artery disease, hyperlipidemia, and tobacco use. Family history included benign hypertension, acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
LIVRTUE01	PCDNA2.1	This 5' biased random primed library was constructed using RNA isolated from liver tumor tissue removed from a 72-year-old Caucasian male during partial hepatectomy. Pathology indicated metastatic grade 2 (of 4) neuroendocrine carcinoma forming a mass. The patient presented with metastatic liver cancer. Patient history included benign hypertension, type I diabetes, prostatic hyperplasia, prostate cancer, alcohol abuse in remission, and tobacco abuse in remission. Previous surgeries included destruction of a pancreatic lesion, closed prostatic biopsy, transurethral prostatectomy, removal of bilateral testes and total splenectomy. Patient medications included Eulexin, Hytrin, Proscar, Ecotrin, and insulin. Family history included atherosclerotic coronary artery disease and acute myocardial infarction in the mother; atherosclerotic coronary artery disease and type II diabetes in the father.
MIXDTME02	PBK-CMV	This 5' biased random primed library was constructed using pooled cDNA from five donors. cDNA was generated using mRNA isolated from heart tissue removed from a Caucasian male fetus who died after 20 weeks gestation from Patau's syndrome (donor A); adrenal gland removed from a 43-year-old Caucasian male (donor B) during nephroureterectomy, regional lymph node excision and unilateral adrenalectomy; kidney cortex removed from a 65-year-old male (donor C) during nephroureterectomy; lung tissue removed from a 14-month-old Caucasian female who died from drowning (donor D); and kidney tissue removed from an 8-year-old Caucasian female who died from a motor vehicle accident (donor E). For donor B, pathology for the associated tumor indicated grade 2 (of 4) renal cell carcinoma in the left kidney with invasion into the renal pelvis. Patient presented with hematuria and anemia. Patient history included benign hypertension and obesity. Previous surgeries included adenotonsillectomy and indirect inguinal hernia repair. The patient was not taking any medications. Family
		history included benign hypertension and atherosclerotic coronary artery disease in the father. For donor C pathology for the associated tumor shows grade 3 (of 4) renal cell carcinoma, clear cell type, within the mid-portion of the kidney. For donor D, serologies were negative. For donor E, medications included respiradol.

Table 6

Library	Vector	Library Description
MIXDTUE01	PBK-CMV	This 5' biased random primed library was constructed using pooled cDNA from seven donors. cDNA was generated using mRNA isolated from placental tissue removed from a Caucasian fetus (A), who died after 16 weeks' gestation from fetal demise and hydrocephalus; from placental tissue removed from a Caucasian male fetus (B), who died after 18 weeks' gestation from fetal demise; from an untreated LNCaP cell line, derived from prostate carcinoma with metastasis to the left supraclavicular lymph nodes, removed from a 50-year-old Caucasian male (C); from endometrial tissue removed from a 32-year-old female (D); from diseased right ovary tissue removed from a 45-year-old Caucasian female (E); from diseased right ovary tissue removed from a 47-year-old Caucasian female (donor F) and from right fallopian tube tumor tissue removed from an 85-year-old Caucasian female (donor G). For donor A, patient history included umbilical cord wrapped around the head (3 times) and the shoulders (1 time). Serology was positive for anti-CMV. Family history included multiple pregnancies and live births, and an
		abortion in the mother. For donor B, serologies were negative. For donor D, pathology indicated the endometrium was in secretory phase. For donor E, pathology indicated stromal hyperthecosis of the right and left ovaries. For donor F, pathology indicated endometriosis. For donor G, pathology indicated poorly differentiated mixed endometrioid (80%) and serous (20%) adenocarcinoma of the right fallopian tube. Patient history included medullary carcinoma of the thyroid.
MLP000032	PCR2-TOPOTA	Library was constructed using pooled cDNA from different donors. cDNA was generated using mRNA isolated from the following: aorta, cerebellum, lymph nodes, muscle, tonsil (lymphoid hyperplasia), bladder tumor (invasive grade 3 transitional cell carcinoma.), breast (proliferative fibrocystic changes without atypia characterized by epithelial ductal hyperplasia, testicle tumor (embryonal carcinoma), spleen, ovary, parathyroid, ileum, breast skin, sigmoid colon, penis tumor (fungating invasive grade 4 squamous cell carcinoma), fetal lung,, breast, fetal small intestine, fetal liver, fetal pancreas, fetal lung, fetal skin, fetal penis, fetal bone, fetal ribs, frontal brain tumor (grade 4 gemistocytic astrocytoma), ovary (stromal hyperthecosis), bladder, bladder tumor (invasive grade 3 transitional cell carcinoma), stomach, lymph node tumor (metastatic basaloid squamous cell carcinoma), tonsil (reactive lymphoid hyperplasia), periosteum from the tibia, fetal brain, fetal spleen, uterus tumor, endometrial (grade 3 adenosquamous carcinoma), seminal vesicle, liver, aorta, adrenal gland, lymph node

Table 6

Library	Vector	Library Description
		(metastatic grade 3 squamous cell carcinoma), glossal muscle, esophagus, esophagus tumor (invasive grade 3 adenocarcinoma), ileum, pancreas, soft tissue tumor from the skull (grade 3 ependymoma), transverse colon, (benign familial polyposis), rectum tumor (grade 3 colonic adenocarcinoma), rib tumor, (metastatic grade 3 osteosarcoma), lung, heart, placenta, thymus, stomach, spleen (splenomegaly with congestion), uterus, cervix (mild chronic cervicitis with focal squamous metaplasia), spleen tumor (malignant lymphoma, diffuse large cell type, B-cell phenotype with abundant reactive T-cells and marked granulomatous response), umbilical cord blood mononuclear cells, upper lobe lung tumor, (grade 3 squamous cell carcinoma), endometrium (secretory phase), liver, liver tumor (metastatic grade 2 neuroendocrine carcinoma), colon, umbilical cord blood, Th1 cells, nonactivated, umbilical cord blood, Th2 cells, nonactivated, coronary artery endothelial cells (untreated), coronary artery smooth muscle cells, (untreated), coronary artery smooth muscle cells (treated with TNF & IL-1
		10ng/ml each for 20 hours), bladder (mild chronic cystitis), epiglottis, breast skin, small intestine, fetal prostate stroma fibroblasts, prostate epithelial cells (PrEC cells), fetal adrenal glands, fetal liver, kidney transformed embryonal cell line (293-EBNA) (untreated), kidney transformed embryonal cell line (293-EBNA) (treated with 5Aza-2deoxycytidine for 72 hours), mammary epithelial cells, (HMEC cells), peripheral blood monocytes (treated with IL-10 at time 0, 10ng/ml, LPS was added at 1 hour at 5ng/ml. Incubation 24 hours), peripheral blood monocytes (treated with anti-IL-10 at time 0, 10ng/ml, LPS was added at 1 hour at 5ng/ml. Incubation 24 hours), spinal cord, base of medulla (Huntington's chorea), thigh and arm muscle (ALS), breast skin fibroblast (untreated), breast skin fibroblast (treated with 9CIS Retinoic Acid 1μM for 20 hours), breast skin fibroblast (treated with TNF-alpha & IL-1 beta, 10ng/ml each for 20 hours), fetal liver mast cells, hematopoietic (Mast cells prepared from human fetal liver hematopoietic progenitor cells (CD34+ stem cells) cultured in the presence of
		hIL-6 and hSCF for 18 days), epithelial layer of colon, bronchial epithelial cells (treated for 20hours with 20% smoke conditioned media), lymph node, pooled peripheral blood mononuclear cells (untreated), pooled brain segments: striatum, globus pallidus and posterior putamen (Alzheimer's Disease), pituitary gland, umbilical cord blood, CD34+ derived dendritic cells (treated with SCF, GM-CSF & TNF alpha, 13 days), umbilical cord blood, CD34+ derived dendritic cells (treated with SCF, GM-CSF & TNF alpha, 13 days followed by PMA/Ionomycin for 5 hours), small intestine, rectum, bone marrow neuroblastoma cell line (SH-SY5Y cells, treated with 6-Hydroxydopamine 100 uM for 8 hours), bone marrow, neuroblastoma cell line (SH-SY5Y cells, untreated), brain segments from one donor: amygdala, entorhinal cortex, globus pallidus, substantia innominata, striatum, dorsal caudate nucleus, dorsal putamen, ventral nucleus accumbens, archaecortex (hippocampus anterior and posterior), thalamus, nucleus raphe magnus, periaqueductal gray, midbrain, substantia nigra, and dentate nucleus,

Table 6

Library	Vector	Library Description
		pineal gland (Alzheimer's Disease), preadipocytes (untreated), preadipocytes (treated with a peroxisome proliferator-activated receptor gamma agonist, 1microM, 4 hours), pooled prostate (adenofibromatous hyperplasia), pooled kidney, pooled adipocytes (untreated), pooled adipocytes (treated with human insulin), pooled mesentaric and abdomenal fat, pooled adrenal glands, pooled thyroid (normal and adenomatous hyperplasia), pooled spleen (normal and with changes consistent with idiopathic thrombocytopenic purpura), pooled right and left breast, pooled lung, pooled nasal polyps, pooled fat, pooled synovium (normal and rhumatoid arthritis), pooled brain (meningioma, gemistocytic astrocytoma. and Alzheimer's disease), pooled fetal colon, pooled colon: ascending, descending (chronic ulcerative colitis), and rectal tumor (adenocarcinoma), pooled esophagus, normal and tumor (invasive grade 3 adenocarcinoma), pooled breast skin fibroblast (one treated w/9CIS Retinoic Acid and the other with TNF-alpha & IL-1 beta), pooled gallbladder (acute necrotizing
		cholecystitis with cholelithiasis (clinically hydrops), acute hemorrhagic cholecystitis with cholelithiasis, chronic cholecystitis and cholelithiasis), pooled fetal heart, (Patau's and fetal demise), pooled neurogenic tumor cell line, SK-N-MC, (neuroepitelioma, metastasis to supra-orbital area, untreated) and neuron, NT-2 cell line, (treated with mouse leptin at 1 μg/ml and 9cis retinoic acid at 3.3 μM for 6 days), pooled ovary (normal and polycystic ovarian disease), pooled prostate, (adenofibromatous hyperplasia), pooled seminal vesicle, pooled small intestine, pooled fetal small intestine, pooled stomach and fetal stomach, prostate epithelial cells, pooled testis (normal and embryonal carcinoma), pooled uterus, pooled uterus tumor (grade 3 adenosquamous carcinoma and leiomyoma), pooled uterus, endometrium, and myometrium, (normal and adenomatous hyperplasia with squamous metaplasia and focal atypia), pooled brain: (temporal lobe meningioma, cerebellum and hippocampus (Alzheimer's Disease), pooled skin, fetal lung, adrenal tumor (adrenal cortical carcinoma), prostate tumor (adenocarcinoma), fetal heart,
		fetal small intestine, ovary tumor (mucinous cystadenoma), ovary, ovary tumor (transitional cell carcinoma), disease prostate (adenofibromatous hyperplasia), fetal colon, uterus tumor (leiomyoma), temporal brain, submandibular gland, colon tumor (adenocarcinoma), ascending and transverse colon, ovary tumor (endometrioid carcinoma), lung tumor (squamous cell carcinoma), fetal brain, fetal lung, ureter tumor (transitional cell carcinoma), untreated HNT cells, para-aortic soft tissue, testis, seminal vesicle, diseased ovary (endometriosis), temporal lobe, myometrium, diseased gallbladder (cholecystitis, cholelithiasis), placenta, breast tumor (ductal adenocarcinoma), breast, lung tumor (liposarcoma), endometrium, abdominal fat, cervical spine dorsal root ganglion, thoracic spine dorsal root ganglion, diseased thyroid (adenomatous hyperplasia), liver, kidney, fetal liver, NT-2 cells (treated with mouse leptin and 9cis RA), K562 cells (treated with 9cis RA), cerebellum, corpus callosum, hypothalamus, fetal brain astrocytes (treated with TNFa and IL-1b), inferior parietal cortex, posterior hippocampus, pons,

Table 6

Library	Vector	Library Description
		thalamus, C3A cells (untreated), C3A cells (treated with 3-methylcholanthrene), testis, colon epithelial layer, pooled prostate, pooled liver, substantia nigra, thigh muscle, rib bone, fallopian tube tumor (endometrioid and serous adenocarcinoma), diseased lung (idiopathic pulmonary disease), cingulate anterior allocortex and neocortex, cingulate posterior allocortex, auditory neocortex, frontal neocortex, orbital inferior neocortex, parietal superior neocortex, visual primary neocortex, dentate nucleus, posterior cingulate, cerebellum, vermis, inferior temporal cortex, medulla, posterior parietal cortex, colon polyp, pooled breast, anterior and posterior hippocampus, mesenteric and abdominal fat, pooled esophagus, pooled fetal kidney, pooled fetal liver, ileum, small intestine, pooled gallbladder, frontal and superior temporal cortex, pooled ovary, pooled endometrium, pooled prostate, pooled kidney, fetal femur, sacrum tumor (giant cell tumor), pooled kidney and kidney tumor (renal cell carcinoma clear-cell type), pooled liver and liver tumor (neuroendocrine carcinoma), pooled fetal liver,
		pooled lung, fetal pancreas, pancreas, parotid gland, parotid tumor (sebaceous lymphadenoma), retroperitoneal and suprglottic soft tissue, spleen, fetal spleen, spleen tumor (malignant lymphoma), diseased spleen (idiopathic thrombocytopenic purpura), parathyroid, thyroid, thymus, tonsil ureter tumor (transitional cell carcinoma), pooled adrenal gland and adrenal tumor (pheochromocytoma), pooled lymph node tumor (Hodgkin's disease and metastatic adenocarcinoma), pooled neck and calf muscles, and pooled bladder.
PANCNOT15	pINCY	Library was constructed using RNA isolated from diseased pancreatic tissue removed from a 15-year-old Caucasian male during a exploratory laparotomy with distal pancreatectomy and total splenectomy. Pathology indicated islet cell hyperplasia. Family history included prostate cancer and cardiovacular disease.
PANCNOT17	pINCY	Library was constructed using RNA isolated from pancreatic tissue removed from a 65-year-old female. Pathology for the associated tumor tissue indicated well-differentiated, metastatic, neuroendocrine carcinoma (nuclear grade 1).
PITUDIR01	PCDNA2.1	This random primed library was constructed using RNA isolated from pituitary gland tissue removed from a 70-year-old female who died from metastatic adenocarcinoma.
PONSAZT01	pINCY	Library was constructed using RNA isolated from diseased pons tissue removed from the brain of a 74-year-old Caucasian male who died from Alzheimer's disease.

Table 6

Library	Vector	Library Description
PROSTUS23	pINCY	This subtracted prostate tumor library was constructed using 10 million clones from a pooled prostate tumor library that was subjected to 2 rounds of subtractive hybridization with 10 million clones from a pooled prostate tissue library. The starting library for subtraction was constructed by pooling equal numbers of clones from 4 prostate tumor libraries using mRNA isolated from prostate tumor removed from Caucasian males at ages 58 (A), 61 (B), 66 (C), and 68 (D) during prostatectomy with lymph node excision. Pathology indicated adenocarcinoma in all donors. History included elevated PSA, induration and tobacco abuse in donor A; elevated PSA, induration, prostate hyperplasia, renal failure, osteoarthritis, renal artery stenosis, benign HTN, thrombocytopenia, hyperlipidemia, tobacco/alcohol abuse and hepatitis C (carrier) in donor B; elevated PSA, induration, and tobacco abuse in donor C; and elevated PSA, induration, hypercholesterolemia, and kidney calculus in donor D. The hybridization probe for subtraction was constructed by pooling equal numbers of cDNA clones from 3 prostate
		tissue libraries derived from prostate tissue, prostate epithelial cells, and fibroblasts from prostate stroma from 3 different donors. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR 19 (1991):1954 and Bonaldo, et al. Genome Research 6 (1996):791.
PROSTUT20	pINCY	The library was constructed using RNA isolated from prostate umor tissue removed from a 58-year-old Caucasian male during radical prostatectomy, regional lymph node excision, and prostate needle biopsy. Pathology indicated adenocarcinoma (Gleason grade 3+2) of the prostate, which formed a predominant mass involving primarily the right side and focally involved the left side, peripherally and anteriorly. The patient presented with elevated prostate specific antigen (PSA)and induration. Family history included breast cancer .
SCOMDIT01	pINCY	Library was constructed using RNA isolated from diseased spinal cord tissue removed from the base of the medulla of a 57-year-old Caucasian male who died from a cerebrovascular accident. Patient history included Huntington's disease and emphysema.
SINTBST01	pINCY	Library was constructed using RNA isolated from ileum tissue obtained from an 18-year-old Caucasian female during bowel anastomosis. Pathology indicated Crohn's disease of the ileum, involving 15 cm of the small bowel. Family history included cerebrovascular disease and atherosclerotic coronary artery disease.
THYRNOT02	PSPORT1	Library was constructed using RNA isolated from the diseased thyroid tissue of a 16-year-old Caucasian female with Graves' disease (hyperthyroidism).
THYRNOT03	pINCY	Library was constructed using RNA isolated from thyroid tissue removed from the left thyroid of a 28-year-old Caucasian female during a complete thyroidectomy. Pathology indicated a small nodule of adenomatous hyperplasia present in the left thyroid. Pathology for the associated tumor tissue indicated dominant follicular adenoma, forming a well-encapsulated mass in the left thyroid.

Table 6

Library	Vector	Library Description
TMLR2DT01	PBLUESCRIPT	Library was constructed using RNA isolated from non-adherent peripheral blood mononuclear cells. The blood was obtained from unrelated male and female donors. Cells from each donor were purified on Ficoll Hypaque, then co-cultured for 24 hours in medium containing normal human serum at a cell density of 2million cells/ml.
UCMCL5T01	PBLUESCRIPT	Library was constructed using RNA isolated from mononuclear cells obtained from the umbilical cord blood of 12 individuals. The cells were cultured for 12 days with IL-5 before RNA was obtained from the pooled lysates.
UTRSTMR01	pINCY	Library was constructed using RNA isolated from uterine myometrial tissue removed from a 41-year-old Caucasian female during a vaginal hysterectomy. The endometrium was secretory and contained fragments of endometrial polyps. Pathology for associated tumor tissue indicated uterine leiomyoma. Patient history included ventral hernia and a benign ovarian neoplasm.

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value = 1.0E-8 or less; Full Length sequences: Probability value = 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises as least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value = 1.06E-6; Assembled ESTs: fasta Identity = 95% or greater and Match length = 200 bases or greater; fastx E value = 1.0E-8 or less; Full Length sequences: fastx score = 100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value = 1.0E-3 or less

Table 7

Program	Description	Reference	Parameter Threshold
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM, INCY, SMART and TIGRFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM, INCY, SMART or TIGRFAM hits: Probability value = 1.0E-3 or less; Signal peptide hits: Score = 0 or greater
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score ≥ GCG specified "HIGH" value for that particular Prosite motif. Generally, score = 1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score = 120 or greater; Match length = 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score = 3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	

Table 7

Program	Description	Reference	Parameter Threshold
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. On Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence (AAAI) Press, Menlo Park, CA, and MIT Press, Cambridge, MA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

Table 8

SEQ ID NO:	PID	EST ID	SNP ID	EST SNP	CB1 SNP	EST Allele	Allele 1	Allele 2	Amino Acid	Caucasian Allele 1 frequency	African Allele 1 frequency	Asian Allele 1 frequency	Hispanic Allele 1 frequency
39	3048626	3504115H1	SNP00142220	215	249	T	T	C	S68	n/a	n/a	n/a	n/a
39	3048626	3517533H1	SNP00038815	179	382	T	C	T	S113	n/a	n/a	n/a	n/a
39	3048626	7409370H1	SNP00142220	376	252	T	T	C	P69	n/a	n/a	n/a	n/a
40	2684425	2120782H1	SNP00096166	164	709	T	T	C	I165	n/a	n/a	n/a	n/a
40	2684425	2291826H1	SNP00027861	175	2682	T	C	T	noncoding	n/a	n/a	n/a	n/a
40	2684425	4379356H1	SNP00096166	169	708	T	T	C	I165	n/a	n/a	n/a	n/a
40	2684425	4380813H1	SNP00096166	165	706	T	T	C	N164	n/a	n/a	n/a	n/a
40	2684425	4574989H1	SNP00073769	107	2351	T	C	T	C713	n/d	n/d	n/d	n/d
40	2684425	5814109H1	SNP00105399	56	2524	G	G	A	E770	n/a	n/a	n/a	n/a
40	2684425	5817776H1	SNP00105399	57	2525	G	G	A	E771	n/a	n/a	n/a	n/a
40	2684425	5821814H1	SNP00105399	55	2523	G	G	A	G770	n/a	n/a	n/a	n/a
40	2684425	6196749H1	SNP00073769	105	2354	C	C	T	H714	n/d	n/d	n/d	n/d
40	2684425	6725305H1	SNP00105399	330	2527	G	G	A	Q771	n/a	n/a	n/a	n/a
41	7505960	2699329H1	SNP00113522	36	1589	A	A	C	K528	n/d	n/d	n/d	n/d
41	7505960	2743044H1	SNP00060643	34	820	T	C	T	Y271	n/a	n/a	n/a	n/a
41	7505960	4443424H1	SNP00113522	8	1587	A	A	C	D527	n/d	n/d	n/d	n/d
41	7505960	4860526H1	SNP00113522	79	1588	A	A	C	A527	n/d	n/d	n/d	n/d
41	7505960	6298990H1	SNP00122314	88	387	G	G	A	G127	n/d	n/d	n/d	n/d
41	7505960	6455382H1	SNP00122314	391	390	G	G	A	G128	n/d	n/d	n/d	n/d
42	7507021	6041339H1	SNP00058963	323	903	C	T	C	noncoding	n/d	n/d	n/a	n/d
43	7509099	7196339H1	SNP00116698	483	1254	A	A	C	R391	0.97	0.96	n/d	0.99
44	7509361	1307093H1	SNP00076254	169	753	C	C	G	T167	n/a	n/a	n/a	n/a
44	7509361	1314858H1	SNP00148375	150	1207	G	G	A	noncoding	n/a	n/a	n/a	n/a
44	7509361	1442760H1	SNP00011095	243	288	G	G	A	P12	n/a	n/a	n/a	n/a
44	7509361	1554337H1	SNP00011095	144	289	A	G	A	M13	n/a	n/a	n/a	n/a
44	7509361	1560591H1	SNP00148375	94	1205	G	G	A	noncoding	n/a	n/a	n/a	n/a
44	7509361	1620178H1	SNP00148375	90	1206	G	G	A	noncoding	n/a	n/a	n/a	n/a
44	7509361	2697396H1	SNP00011095	279	287	G	G	A	R12	n/a	n/a	n/a	n/a

Table 8

SEQ ID NO:	PID	EST ID	SNP ID	EST SNP	CB1 SNP	EST Allele	Allele 1	Allele 2	Amino Acid	Caucasian Allele 1 frequency	African Allele 1 frequency	Asian Allele 1 frequency	Hispanic Allele 1 frequency
44	7509361	2841966H1	SNP00100840	34	500	G	G	C	G83	n/d	n/d	n/a	n/d
44	7509361	2842095H1	SNP00100840	35	501	G	G	C	E83	n/d	n/d	n/a	n/d
44	7509361	2848215H1	SNP00011095	184	286	G	G	A	A12	n/a	n/a	n/a	n/a
44	7509361	3112588H1	SNP00011095	239	285	G	G	A	L11	n/a	n/a	n/a	n/a
44	7509361	3498684H1	SNP00148375	29	1200	G	G	A	noncoding	n/a	n/a	n/a	n/a
44	7509361	3551794H1	SNP00076254	116	752	C	C	G	T167	n/a	n/a	n/a	n/a
44	7509361	5120295H1	SNP00076254	115	741	G	C	G	K163	n/a	n/a	n/a	n/a
44	7509361	7432084H1	SNP00148375	235	1198	G	G	A	noncoding	n/a	n/a	n/a	n/a
47	7506852	1401073H1	SNP00036002	67	1691	T	C	T	noncoding	n/a	n/a	n/a	n/a
47	7506852	3724338H1	SNP00036002	254	1687	C	C	T	noncoding	n/a	n/a	n/a	n/a
47	7506852	3854972H1	SNP00036002	17	1689	C	C	T	noncoding	n/a	n/a	n/a	n/a
47	7506852	4205312H1	SNP00036002	192	1677	C	C	T	noncoding	n/a	n/a	n/a	n/a
48	7503782	6366326H1	SNP00096612	255	2675	C	C	A	H627	0.45	0.28	0.50	0.38
48	7503782	6587229H1	SNP00058173	320	3251	A	A	G	noncoding	0.62	n/a	n/a	n/a
48	7503782	7036138H1	SNP00096612	125	2677	A	C	A	Q628	0.45	0.28	0.50	0.38
49	7504647	5051517H1	SNP00065898	155	1110	A	A	G	noncoding	n/a	n/a	n/a	n/a
49	7504647	5051533H1	SNP00065898	155	1111	A	A	G	noncoding	n/a	n/a	n/a	n/a
50	7500424	1335968H1	SNP00001367	118	696	G	G	A	noncoding	n/a	n/a	n/a	n/a
50	7500424	1335968H1	SNP00149783	49	627	A	A	G	noncoding	n/a	n/a	n/a	n/a
50	7500424	1445563H1	SNP00121362	107	574	G	G	C	noncoding	n/a	n/a	n/a	n/a
50	7500424	3407118H1	SNP00001367	154	694	G	G	A	noncoding	n/a	n/a	n/a	n/a
50	7500424	3407118H1	SNP00149783	85	625	A	A	G	noncoding	n/a	n/a	n/a	n/a
50	7500424	3484021H1	SNP00148356	184	193	C	C	T	P33	n/a	n/a	n/a	n/a
50	7500424	3614711H1	SNP00148356	112	112	C	C	T	P6	n/a	n/a	n/a	n/a
50	7500424	3646188H1	SNP00001367	137	693	G	G	A	noncoding	n/a	n/a	n/a	n/a
50	7500424	3714764H1	SNP00149783	131	624	A	A	G	noncoding	n/a	n/a	n/a	n/a
50	7500424	4201810H1	SNP00121362	24	573	G	G	C	noncoding	n/a	n/a	n/a	n/a
50	7500424	4457406H1	SNP00148356	18	117	C	C	T	Q8	n/a	n/a	n/a	n/a

Table 8

SEQ ID NO:	PID	EST ID	SNP ID	EST SNP	CB1 SNP	EST Allele	Allele 1	Allele 2	Amino Acid	Caucasian Allele 1 frequency	African Allele 1 frequency	Asian Allele 1 frequency	Hispanic Allele 1 frequency
50	7500424	4822857H1	SNP00121362	34	572	G	G	C	noncoding	n/a	n/a	n/a	n/a
50	7500424	4992535H1	SNP00148356	129	109	C	C	T	S5	n/a	n/a	n/a	n/a
50	7500424	5810876H1	SNP00121362	204	571	G	G	C	noncoding	n/a	n/a	n/a	n/a
51	7500449	2376438H1	SNP00037402	81	185	T	T	C	R39	n/a	n/a	n/a	n/a
51	7500449	6880929J1	SNP00142781	103	930	C	C	A	noncoding	n/a	n/a	n/a	n/a
53	7503292	7076246H1	SNP00111578	128	1217	G	A	G	noncoding	0.03	n/a	n/a	n/a
54	7503311	7455178H2	SNP00126507	378	1463	C	C	A	noncoding	n/a	n/a	n/a	n/a
54	7503311	8007727H1	SNP00137525	212	1326	G	G	A	noncoding	n/a	n/a	n/a	n/a
55	7510384	6908872J1	SNP00062894	404	528	C	T	C	P165	n/d	n/a	n/a	n/a
55	7510384	6912987J1	SNP00062894	374	520	T	T	C	N162	n/d	n/a	n/a	n/a
58	8017335	1351856H1	SNP00120957	54	1790	C	C	T	noncoding	n/a	n/a	n/a	n/a
58	8017335	4776360H1	SNP00031314	199	2140	C	A	C	noncoding	0.87	0.87	0.88	0.84
58	8017335	6839382H1	SNP00031314	379	2141	A	A	C	noncoding	0.87	0.87	0.88	0.84
60	7510055	1432995H1	SNP00015901	1	1031	G	G	A	noncoding	n/a	n/a	n/a	n/a
60	7510055	1432995H1	SNP00015902	56	1086	C	C	G	noncoding	0.91	n/a	n/a	n/a
60	7510055	1452055H1	SNP00000585	7	77	C	C	T	noncoding	0.83	0.97	0.58	0.81
60	7510055	1536017H1	SNP00000585	20	76	C	C	T	noncoding	0.83	0.97	0.58	0.81
60	7510055	2610356H1	SNP00000585	59	75	C	C	T	noncoding	0.83	0.97	0.58	0.81
60	7510055	2970103H2	SNP00015901	154	1032	G	G	A	noncoding	n/a	n/a	n/a	n/a
60	7510055	2970103H2	SNP00015902	209	1087	C	C	G	noncoding	0.91	n/a	n/a	n/a
60	7510055	3520995H1	SNP00000585	18	74	C	C	T	noncoding	0.83	0.97	0.58	0.81
60	7510055	3679678H1	SNP00000585	44	73	T	C	T	noncoding	0.83	0.97	0.58	0.81
60	7510055	4689661H1	SNP00000585	38	71	C	C	T	noncoding	0.83	0.97	0.58	0.81
61	7501754	1287052H1	SNP00020471	223	1622	C	C	T	noncoding	n/a	n/a	n/a	n/a
61	7501754	1366741H1	SNP00020470	16	957	C	C	T	L292	n/a	n/a	n/a	n/a
61	7501754	1366741H1	SNP00144758	230	1171	T	T	C	L364	n/a	n/a	n/a	n/a
61	7501754	1412435H1	SNP00020469	240	267	C	C	T	I62	n/a	n/a	n/a	n/a
61	7501754	1416519H1	SNP00020471	188	1621	C	C	T	noncoding	n/a	n/a	n/a	n/a

Table 8

SEQ ID NO:	PID	EST ID	SNP ID	EST SNP	CB1 SNP	EST Allele	Allele 1	Allele 2	Amino Acid	Caucasian Allele 1 frequency	African Allele 1 frequency	Asian Allele 1 frequency	Hispanic Allele 1 frequency
61	7501754	1477407H1	SNP00115549	182	609	A	A	G	R176	n/a	n/a	n/a	n/a
61	7501754	1592982H1	SNP00144757	103	916	G	G	A	D279	n/a	n/a	n/a	n/a
61	7501754	1593474H1	SNP00060616	79	396	T	T	G	I105	n/a	n/a	n/a	n/a
61	7501754	2110613H1	SNP00002430	142	1269	A	A	G	L396	0.55	0.30	0.67	0.69
61	7501754	2286353H1	SNP00002429	69	732	C	C	T	Y217	n/a	n/a	n/a	n/a
61	7501754	3268502H1	SNP00020469	199	233	C	C	T	A51	n/a	n/a	n/a	n/a
61	7501754	3603324H1	SNP00020470	16	956	C	C	T	P292	n/a	n/a	n/a	n/a
61	7501754	3603324H1	SNP00144758	230	1170	T	T	C	H363	n/a	n/a	n/a	n/a
61	7501754	3665554H1	SNP00002430	31	1266	G	A	G	L395	0.55	0.30	0.67	0.69
61	7501754	3782483H1	SNP00002429	129	731	T	C	T	F217	n/a	n/a	n/a	n/a
61	7501754	3782483H1	SNP00115549	6	608	A	A	G	Q176	n/a	n/a	n/a	n/a
61	7501754	3825869H1	SNP00020469	249	251	C	C	T	P57	n/a	n/a	n/a	n/a
61	7501754	4061686H1	SNP00144757	220	913	G	G	A	A278	n/a	n/a	n/a	n/a
61	7501754	4205282H1	SNP00119977	113	1541	A	A	C	noncoding	n/a	n/a	n/a	n/a
61	7501754	4259242H1	SNP00020470	15	955	C	C	T	L292	n/a	n/a	n/a	n/a
61	7501754	4259242H1	SNP00144758	229	1169	T	T	C	L363	n/a	n/a	n/a	n/a
61	7501754	4753963H1	SNP00020470	4	952	C	C	T	R291	n/a	n/a	n/a	n/a
61	7501754	4753963H1	SNP00144758	217	1165	T	T	C	Y362	n/a	n/a	n/a	n/a
61	7501754	5269726H1	SNP00144758	167	1163	T	T	C	F361	n/a	n/a	n/a	n/a
61	7501754	5662745H1	SNP00144757	129	915	G	G	A	P278	n/a	n/a	n/a	n/a
61	7501754	5832111H1	SNP00020471	101	1607	C	C	T	noncoding	n/a	n/a	n/a	n/a
61	7501754	5847218H1	SNP00144757	93	914	G	G	A	R278	n/a	n/a	n/a	n/a
61	7501754	5847579H1	SNP00020470	164	940	C	C	T	Q287	n/a	n/a	n/a	n/a
61	7501754	5847579H1	SNP00144757	123	898	G	G	A	D273	n/a	n/a	n/a	n/a
61	7501754	6882567J1	SNP00119977	271	1543	C	A	C	noncoding	n/a	n/a	n/a	n/a
61	7501754	6997953H1	SNP00020469	121	265	C	C	T	L62	n/a	n/a	n/a	n/a
61	7501754	6997953H1	SNP00060616	250	394	T	T	G	F105	n/a	n/a	n/a	n/a
62	7510517	1252418F6	SNP00053146	95	2574	C	C	T	noncoding	n/a	n/a	n/a	n/a

Table 8

SEQ ID NO:	PID	EST ID	SNP ID	EST SNP	CB1 SNP	EST Allele	Allele 1	Allele 2	Amino Acid	Caucasian Allele 1 frequency	African Allele 1 frequency	Asian Allele 1 frequency	Hispanic Allele 1 frequency
62	7510517	1252418T6	SNP00053146	135	2575	C	C	T	noncoding	n/a	n/a	n/a	n/a
62	7510517	1253746H1	SNP00016073	86	2252	A	A	G	noncoding	n/a	n/a	n/a	n/a
62	7510517	1560944H1	SNP00016072	183	1896	G	A	G	noncoding	0.12	n/a	n/a	n/a
62	7510517	2137250T6	SNP00053146	110	2600	C	C	T	noncoding	n/a	n/a	n/a	n/a
62	7510517	2771793T6	SNP00053146	155	2581	C	C	T	noncoding	n/a	n/a	n/a	n/a
62	7510517	3009863T7	SNP00053146	147	2594	C	C	T	noncoding	n/a	n/a	n/a	n/a
62	7510517	3472133T6	SNP00053146	131	2579	T	C	T	noncoding	n/a	n/a	n/a	n/a
62	7510517	415685T6	SNP00053146	138	2616	C	C	T	noncoding	n/a	n/a	n/a	n/a
62	7510517	461386T6	SNP00053146	105	2605	C	C	T	noncoding	n/a	n/a	n/a	n/a
62	7510517	6521830H1	SNP00053145	453	432	C	C	T	T53	0.91	n/a	n/a	n/a
62	7510517	950639T6	SNP00053146	160	2593	C	C	T	noncoding	n/a	n/a	n/a	n/a
63	7511014	1439526F7	SNP00144232	42	1598	C	C	T	noncoding	n/a	n/a	n/a	n/a
63	7511014	1439526F7	SNP00144233	87	1643	A	G	A	noncoding	n/a	n/a	n/a	n/a
63	7511014	1446257F6	SNP00144233	389	1646	G	G	A	noncoding	n/a	n/a	n/a	n/a
63	7511014	7612633H1	SNP00144232	444	1600	C	C	T	noncoding	n/a	n/a	n/a	n/a
64	7506687	1415884H1	SNP00041797	78	5120	T	T	C	noncoding	n/d	n/a	n/a	n/a
64	7506687	1477444H1	SNP00076239	52	4874	T	T	C	noncoding	n/d	n/d	n/d	n/d
64	7506687	1485053H1	SNP00076240	117	5540	C	C	T	noncoding	n/d	n/d	n/d	n/d
64	7506687	1965096R6	SNP00041797	87	5119	T	T	C	noncoding	n/d	n/a	n/a	n/a
64	7506687	3679061H1	SNP00011057	18	6519	C	C	T	noncoding	n/d	n/a	n/a	n/a
65	7510621	076193H1	SNP00039731	93	502	T	T	C	V38	n/d	n/a	n/a	n/a
65	7510621	076193H1	SNP00069420	159	568	T	T	G	V60	n/d	n/d	n/d	n/d
65	7510621	076193H1	SNP00135470	154	563	C	C	T	I58	n/a	n/a	n/a	n/a
65	7510621	1002877H1	SNP00069735	152	807	T	T	G	W140	n/a	n/a	n/a	n/a
65	7510621	1281484H1	SNP00074872	32	932	T	T	G	I181	n/a	n/a	n/a	n/a
65	7510621	1636307H1	SNP00132688	94	734	C	C	T	N115	n/a	n/a	n/a	n/a
65	7510621	1731529F6	SNP00124792	79	79	C	C	T	noncoding	n/a	n/a	n/a	n/a
65	7510621	3216409T6	SNP00069735	269	823	T	T	G	F145	n/a	n/a	n/a	n/a

Table 8

SEQ ID NO:	PID	EST ID	SNP ID	EST SNP	CB1 SNP	EST Allele	Allele 1	Allele 2	Amino Acid	Caucasian Allele 1 frequency	African Allele 1 frequency	Asian Allele 1 frequency	Hispanic Allele 1 frequency
65	7510621	3216409T6	SNP00074872	144	948	T	T	G	stop187	n/a	n/a	n/a	n/a
65	7510621	3905994H1	SNP00039731	153	504	T	T	C	L39	n/d	n/a	n/a	n/a
65	7510621	3905994H1	SNP00069420	219	570	T	T	G	C61	n/d	n/d	n/d	n/d
65	7510621	3905994H1	SNP00135470	214	565	C	C	T	A59	n/a	n/a	n/a	n/a
65	7510621	5020934T1	SNP00074872	113	966	T	T	G	S193	n/a	n/a	n/a	n/a
65	7510621	6804058J1	SNP00069735	356	790	G	T	G	G134	n/a	n/a	n/a	n/a
65	7510621	6804058J1	SNP00074872	481	915	G	T	G	G176	n/a	n/a	n/a	n/a
65	7510621	7618082H1	SNP00132688	410	735	C	C	T	H116	n/a	n/a	n/a	n/a
66	7505533	5210141H1	SNP00152657	57	307	T	T	C	D92	n/a	n/a	n/a	n/a
66	7505533	5210141H1	SNP00152658	94	344	A	A	G	T105	n/a	n/a	n/a	n/a
66	7505533	5210141H1	SNP00152659	218	468	T	T	C	noncoding	n/a	n/a	n/a	n/a
66	7505533	5210183H1	SNP00152657	56	304	T	T	C	A91	n/a	n/a	n/a	n/a
66	7505533	5210183H1	SNP00152658	93	340	A	A	G	stop103	n/a	n/a	n/a	n/a
67	7511220	6863270H1	SNP00062114	182	437	A	A	C	D131	0.23	0.10	0.33	0.16
67	7511220	6863270H1	SNP00065517	55	310	A	C	A	I89	n/a	n/a	n/a	n/a
68	7510967	1269923F6	SNP00068898	197	5398	A	A	G	E1750	n/a	n/a	n/a	n/a
68	7510967	1269923F6	SNP00116132	65	5265	T	T	C	I1706	n/d	n/d	n/d	n/d
68	7510967	1269923F6	SNP00116133	310	5511	C	C	T	noncoding	n/a	n/a	n/a	n/a
68	7510967	2215706F6	SNP00004638	161	4918	G	G	T	Q1590	n/a	n/a	n/a	n/a
68	7510967	2215706F6	SNP00025482	195	4952	G	G	C	D1602	n/d	n/d	n/d	n/d
68	7510967	4252319F6	SNP00134721	171	452	A	A	G	M102	n/a	n/a	n/a	n/a
68	7510967	5089321H1	SNP00134719	13	7	C	C	G	noncoding	n/a	n/a	n/a	n/a
68	7510967	6977458H1	SNP00134720	282	275	A	A	G	M43	n/a	n/a	n/a	n/a
69	7511298	1359892H1	SNP00114894	62	1791	T	T	C	F574	n/a	n/a	n/a	n/a
69	7511298	1389872F6	SNP00136492	371	2647	C	C	A	noncoding	n/a	n/a	n/a	n/a
69	7511298	1391007F6	SNP00114895	532	2085	A	A	G	K672	n/d	n/d	n/d	n/d
69	7511298	1391007F6	SNP00148080	277	1828	G	G	A	L586	n/a	n/a	n/a	n/a
69	7511298	1429445F6	SNP00016801	294	1546	C	C	T	D492	n/a	n/a	n/a	n/a

Table 8

SEQ ID NO:	PID	EST ID	SNP ID	EST SNP	CB1 SNP	EST Allele	Allele 1	Allele 2	Amino Acid	Caucasian Allele 1 frequency	African Allele 1 frequency	Asian Allele 1 frequency	Hispanic Allele 1 frequency
69	7511298	1429445F6	SNP00151717	252	1504	C	C	T	C478	n/a	n/a	n/a	n/a
69	7511298	1501745F6	SNP00058189	420	2271	C	C	T	S734	n/a	n/a	n/a	n/a
69	7511298	1519651F6	SNP00123884	164	676	A	A	G	Q202	n/d	n/a	n/a	n/a
69	7511298	1877054H1	SNP00058189	23	2272	C	C	T	Y734	n/a	n/a	n/a	n/a
69	7511298	1878525H1	SNP00016803	213	2588	T	C	T	noncoding	n/a	n/a	n/a	n/a
69	7511298	2044874F6	SNP00062888	285	596	G	C	G	V176	n/d	n/a	n/a	n/a
69	7511298	2082962T6	SNP00136492	332	2654	C	C	A	noncoding	n/a	n/a	n/a	n/a
69	7511298	2437515F6	SNP00016802	456	2185	C	C	T	V705	n/a	n/a	n/a	n/a
69	7511298	2803211H1	SNP00126602	25	2370	C	T	C	T767	n/a	n/a	n/a	n/a
69	7511298	5615830F6	SNP00016801	407	1540	T	C	T	H490	n/a	n/a	n/a	n/a
69	7511298	5615830F6	SNP00151717	365	1498	C	C	T	C476	n/a	n/a	n/a	n/a
69	7511298	7226075H1	SNP00123884	182	675	A	A	G	Q202	n/d	n/a	n/a	n/a
69	7511298	7607396J1	SNP00062884	266	690	C	C	A	S207	n/d	n/a	n/a	n/a
70	7510937	1213711H1	SNP00001099	182	4086	G	G	A	A1312	n/a	n/a	n/a	n/a
70	7510937	1233991H1	SNP00046056	49	2149	G	G	C	E667	n/a	n/a	n/a	n/a
70	7510937	1294381H1	SNP00016843	76	4277	G	G	A	noncoding	n/d	n/a	n/a	n/a
70	7510937	1702543F6	SNP00108395	156	3932	T	T	C	L1261	n/a	n/a	n/a	n/a
70	7510937	183926H1	SNP00046055	148	1856	T	T	C	M569	n/a	n/a	n/a	n/a
70	7510937	1867984H1	SNP00108393	161	2808	A	A	G	K886	n/d	n/d	n/d	n/d
70	7510937	2056164T6	SNP00016843	279	4281	G	G	A	noncoding	n/d	n/a	n/a	n/a
70	7510937	2070471H1	SNP00046057	28	2631	G	G	A	K827	n/a	n/a	n/a	n/a
70	7510937	2705113T6	SNP00016843	274	4279	G	G	A	noncoding	n/d	n/a	n/a	n/a
70	7510937	2786224T6	SNP00001099	276	4087	G	G	A	V1313	n/a	n/a	n/a	n/a
70	7510937	2903742T6	SNP00016843	180	4374	G	G	A	noncoding	n/d	n/a	n/a	n/a
70	7510937	3773791H1	SNP00046054	183	1287	G	A	G	R379	0.86	0.93	n/d	0.95
70	7510937	3790871H1	SNP00016841	4	3240	G	G	C	K1030	n/a	n/a	n/a	n/a
70	7510937	6597222H1	SNP00108394	384	3239	A	A	C	N1030	n/a	n/a	n/a	n/a
70	7510937	7459195H1	SNP00046054	99	1282	A	A	G	N378	0.86	0.93	n/d	0.95

Table 8

SEQ ID NO:	PID	EST ID	SNP ID	EST SNP	CB1 SNP	EST Allele	Allele 1	Allele 2	Amino Acid	Caucasian Allele 1 frequency	African Allele 1 frequency	Asian Allele 1 frequency	Hispanic Allele 1 frequency
71	7511852	1674771H1	SNP00124011	23	1466	C	C	T	noncoding	n/a	n/a	n/a	n/a
71	7511852	2330339H1	SNP00004236	163	1261	A	A	G	noncoding	0.64	0.82	0.57	n/a
71	7511852	2330339H1	SNP00004237	190	1288	C	T	C	noncoding	0.31	0.19	0.09	0.26
71	7511852	3555370H1	SNP00024881	213	1393	C	C	T	noncoding	n/a	n/a	n/a	n/a
72	7511077	1223450H1	SNP00124213	14	30	G	G	A	noncoding	n/a	n/a	n/a	n/a
72	7511077	1315226H1	SNP00124215	130	1229	G	G	A	noncoding	0.98	n/a	n/a	n/a
72	7511077	1434590H1	SNP00124214	208	399	C	C	T	R122	n/d	n/a	n/a	n/a
72	7511077	1581204H1	SNP00017009	17	524	T	C	T	G163	n/d	n/a	n/a	n/a
72	7511077	1705518H1	SNP00017008	155	485	T	T	C	I150	n/a	n/a	n/a	n/a
72	7511077	1843956R6	SNP00017008	328	486	C	T	C	P151	n/a	n/a	n/a	n/a
72	7511077	1843956R6	SNP00124214	242	400	C	C	T	P122	n/d	n/a	n/a	n/a
72	7511077	4586519H1	SNP00124216	223	1251	C	C	T	noncoding	n/a	n/a	n/a	n/a
72	7511077	6481807H1	SNP00001218	40	1248	G	G	C	noncoding	n/a	n/a	n/a	n/a
72	7511077	7639431J2	SNP00017008	354	457	C	T	C	A141	n/a	n/a	n/a	n/a
72	7511077	7639431J2	SNP00017009	393	496	C	C	T	S154	n/d	n/a	n/a	n/a
72	7511077	7639431J2	SNP00124214	269	371	C	C	T	T112	n/d	n/a	n/a	n/a
73	7511576	034843H1	SNP00098584	220	335	T	T	C	I48	n/a	n/a	n/a	n/a
73	7511576	1493422H1	SNP00034873	58	384	G	A	G	L64	n/a	n/a	n/a	n/a
73	7511576	1520967H1	SNP00033391	154	442	C	C	T	L84	n/a	n/a	n/a	n/a
73	7511576	1724713F6	SNP00033392	303	1128	A	A	C	noncoding	n/a	n/a	n/a	n/a
73	7511576	1724713T6	SNP00033392	160	1134	A	A	C	noncoding	n/a	n/a	n/a	n/a
73	7511576	8588603T1	SNP00154298	467	395	G	A	G	W68	n/a	n/a	n/a	n/a
73	7511576	8588603T1	SNP00154299	363	500	G	A	G	R103	n/a	n/a	n/a	n/a
74	7511492	008076H1	SNP00001520	204	306	T	T	C	F81	n/a	n/a	n/a	n/a
74	7511492	1216191H1	SNP00050705	215	565	G	G	A	noncoding	n/a	n/a	n/a	n/a
74	7511492	1693356H1	SNP00064907	56	648	C	C	A	noncoding	n/a	n/a	n/a	n/a
74	7511492	1907176H1	SNP00001521	222	703	C	C	G	noncoding	n/a	n/a	n/a	n/a
75	7511141	1435538T6	SNP00003434	193	2614	T	T	C	noncoding	n/a	n/a	n/a	n/a

Table 8

SEQ ID NO:	PID	EST ID	SNP ID	EST SNP	CB1 SNP	EST Allele	Allele 1	Allele 2	Amino Acid	Caucasian Allele 1 frequency	African Allele 1 frequency	Asian Allele 1 frequency	Hispanic Allele 1 frequency
75	7511141	1435538T6	SNP00065777	28	2777	A	A	G	noncoding	n/a	n/a	n/a	n/a
75	7511141	1513489T6	SNP00003434	145	2602	C	T	C	noncoding	n/a	n/a	n/a	n/a
75	7511141	1631170F6	SNP00003434	381	2601	T	T	C	noncoding	n/a	n/a	n/a	n/a
75	7511141	1631170F6	SNP00065776	212	2432	C	C	T	noncoding	n/a	n/a	n/a	n/a
75	7511141	1631170T6	SNP00003434	165	2629	T	T	C	noncoding	n/a	n/a	n/a	n/a
75	7511141	1631170T6	SNP00065776	335	2459	C	C	T	noncoding	n/a	n/a	n/a	n/a
75	7511141	1632763T6	SNP00003434	193	2605	T	T	C	noncoding	n/a	n/a	n/a	n/a
75	7511141	1632763T6	SNP00065776	363	2435	C	C	T	noncoding	n/a	n/a	n/a	n/a
75	7511141	1632763T6	SNP00065777	28	2769	A	A	G	noncoding	n/a	n/a	n/a	n/a
75	7511141	2091984H2	SNP00065777	206	2767	A	A	G	noncoding	n/a	n/a	n/a	n/a
75	7511141	2216503T6	SNP00003434	139	2654	C	T	C	noncoding	n/a	n/a	n/a	n/a
75	7511141	2640569T6	SNP00003434	177	2631	C	T	C	noncoding	n/a	n/a	n/a	n/a
75	7511141	2640569T6	SNP00065776	347	2461	C	C	T	noncoding	n/a	n/a	n/a	n/a
75	7511141	2640569T6	SNP00065777	12	2794	A	A	G	noncoding	n/a	n/a	n/a	n/a
75	7511141	2676369F6	SNP00065777	381	2766	A	A	G	noncoding	n/a	n/a	n/a	n/a
75	7511141	2676369T6	SNP00003434	121	2685	C	T	C	noncoding	n/a	n/a	n/a	n/a
75	7511141	2676369T6	SNP00065776	291	2515	C	C	T	noncoding	n/a	n/a	n/a	n/a
75	7511141	3835977T6	SNP00065776	377	2431	C	C	T	noncoding	n/a	n/a	n/a	n/a
76	7511300	1359892H1	SNP00114894	62	1938	T	T	C	F623	n/a	n/a	n/a	n/a
76	7511300	1389872F6	SNP00136492	371	2692	C	C	A	noncoding	n/a	n/a	n/a	n/a
76	7511300	1391007F6	SNP00114895	532	2232	A	A	G	K721	n/d	n/d	n/d	n/d
76	7511300	1391007F6	SNP00148080	277	1975	G	G	A	L635	n/a	n/a	n/a	n/a
76	7511300	1429445F6	SNP00016801	294	1693	C	C	T	D541	n/a	n/a	n/a	n/a
76	7511300	1429445F6	SNP00151717	252	1651	C	C	T	C527	n/a	n/a	n/a	n/a
76	7511300	1501745F6	SNP00058189	420	2418	C	C	T	S783	n/a	n/a	n/a	n/a
76	7511300	1519651F6	SNP00123884	164	823	A	A	G	Q251	n/d	n/a	n/a	n/a
76	7511300	1878525H1	SNP00016803	213	2633	T	C	T	noncoding	n/a	n/a	n/a	n/a
76	7511300	2044874F6	SNP00062888	285	743	G	C	G	V225	n/d	n/a	n/a	n/a

Table 8

SEQ ID NO:	PID	EST ID	SNP ID	EST SNP	CB1 SNP	EST Allele	Allele 1	Allele 2	Amino Acid	Caucasian Allele 1 frequency	African Allele 1 frequency	Asian Allele 1 frequency	Hispanic Allele 1 frequency
76	7511300	2082962T6	SNP00136492	332	2699	C	C	A	noncoding	n/a	n/a	n/a	n/a
76	7511300	2242331H1	SNP00058189	214	2419	C	C	T	Y783	n/a	n/a	n/a	n/a
76	7511300	2437515F6	SNP00016802	456	2332	C	C	T	V754	n/a	n/a	n/a	n/a
76	7511300	5615830F6	SNP00016801	407	1687	T	C	T	H539	n/a	n/a	n/a	n/a
76	7511300	5615830F6	SNP00151717	365	1645	C	C	T	C525	n/a	n/a	n/a	n/a
76	7511300	7226075H1	SNP00123884	182	822	A	A	G	Q251	n/d	n/a	n/a	n/a

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:

a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38,

b) a polypeptide comprising a naturally occurring amino acid sequence at least 94% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:16,

c) a polypeptide consisting essentially of a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:2-3, SEQ ID NO:5, SEQ ID NO:7-8, SEQ ID NO:27, SEQ ID NO:31, SEQ ID NO:33, and SEQ ID NO:38,

d) a polypeptide comprising a naturally occurring amino acid sequence at least 98% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:32,

e) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:10-15, SEQ ID NO:17, SEQ ID NO:19-22, SEQ ID NO:24, SEQ ID NO:28, and SEQ ID NO:36-37,

f) a polypeptide comprising a naturally occurring amino acid sequence at least 92% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:23, and SEQ ID NO:25,

g) a polypeptide comprising a naturally occurring amino acid sequence at least 97% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:26 and SEQ ID NO:29,

h) a polypeptide comprising a naturally occurring amino acid sequence at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:30 and SEQ ID NO:35,

i) a polypeptide comprising a naturally occurring amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:34,

j) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, and

k) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-38.

2. An isolated polypeptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38.

3. An isolated polynucleotide encoding a polypeptide of claim 1.

4. An isolated polynucleotide encoding a polypeptide of claim 2.

5. An isolated polynucleotide of claim 4 comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76.

6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

7. A cell transformed with a recombinant polynucleotide of claim 6.

8. A transgenic organism comprising a recombinant polynucleotide of claim 6.

9. A method of producing a polypeptide of claim 1, the method comprising:

a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

b) recovering the polypeptide so expressed.

10. A method of claim 9, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-38.

11. An isolated antibody which specifically binds to a polypeptide of claim 1.

12. An isolated polynucleotide selected from the group consisting of:

a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:39-76,

b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 92% identical to the polynucleotide sequence of SEQ ID NO:39,

c) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 99% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:40, SEQ ID NO:53, SEQ ID NO:64, and SEQ ID NO:66,

d) a polynucleotide consisting essentially of a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:46, SEQ ID NO:51-52, SEQ ID NO:54, and SEQ ID NO:68-69,

e) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:42, SEQ ID NO:48, SEQ ID NO:55-63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:72, and SEQ ID NO:74-75,

f) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 91% identical to the polynucleotide sequence of SEQ ID NO:47,

g) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 98% identical to the polynucleotide sequence of SEQ ID NO:49,

h) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 96% identical to the polynucleotide sequence of SEQ ID NO:50,

i) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 97% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:44-45, SEQ ID NO:70, and SEQ ID NO:76,

j) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 95% identical to the polynucleotide sequence of SEQ ID NO:71,

k) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 94% identical to the polynucleotide sequence of SEQ ID NO:73,

l) a polynucleotide complementary to a polynucleotide of a),

m) a polynucleotide complementary to a polynucleotide of b),

n) a polynucleotide complementary to a polynucleotide of c),

o) a polynucleotide complementary to a polynucleotide of d),

p) a polynucleotide complementary to a polynucleotide of e),

q) a polynucleotide complementary to a polynucleotide of f),

r) a polynucleotide complementary to a polynucleotide of g),

s) a polynucleotide complementary to a polynucleotide of h),

t) a polynucleotide complementary to a polynucleotide of i),

u) a polynucleotide complementary to a polynucleotide of j),

v) a polynucleotide complementary to a polynucleotide of k), and

w) an RNA equivalent of a)-v).

13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 12.

14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and

b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.

16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and

b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

18. A composition of claim 17, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-38.

19. A method for treating a disease or condition associated with decreased expression of functional REMAP, comprising administering to a patient in need of such treatment the composition of claim 17.

20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting agonist activity in the sample.

21. A composition comprising an agonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.

22. A method for treating a disease or condition associated with decreased expression of functional REMAP, comprising administering to a patient in need of such treatment a composition of claim 21.

23. A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting antagonist activity in the sample.

24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.

25. A method for treating a disease or condition associated with overexpression of functional REMAP, comprising administering to a patient in need of such treatment a composition of claim 24.

26. A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising:

a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and

b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising:

a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,

b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and

c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

28. A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,

b) detecting altered expression of the target polynucleotide, and

c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

29. A method of assessing toxicity of a test compound, the method comprising:

a) treating a biological sample containing nucleic acids with the test compound,

b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof,

c) quantifying the amount of hybridization complex, and

d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

30. A method for a diagnostic test for a condition or disease associated with the expression of REMAP in a biological sample, the method comprising:

a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and

b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

31. The antibody of claim 11, wherein the antibody is:

a) a chimeric antibody,

b) a single chain antibody,

c) a Fab fragment,

d) a $F(ab')_2$ fragment, or

e) a humanized antibody.

32. A composition comprising an antibody of claim 11 and an acceptable excipient.

33. A method of diagnosing a condition or disease associated with the expression of REMAP in a subject, comprising administering to said subject an effective amount of the composition of claim 32.

34. A composition of claim 32, further comprising a label.

35. A method of diagnosing a condition or disease associated with the expression of REMAP in a subject, comprising administering to said subject an effective amount of the composition of claim 34.

36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:

a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, or an immunogenic fragment thereof, under conditions to elicit an antibody response,

b) isolating antibodies from the animal, and

c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38.

37. A polyclonal antibody produced by a method of claim 36.

38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

39. A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:

a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-38, or an immunogenic fragment thereof, under conditions to elicit an antibody response,

b) isolating antibody producing cells from the animal,

c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,

d) culturing the hybridoma cells, and

e) isolating from the culture monoclonal antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38.

40. A monoclonal antibody produced by a method of claim 39.

41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.

42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.

43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant immunoglobulin library.

44. A method of detecting a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38 in a sample, the method comprising:

a) incubating the antibody of claim 11 with the sample under conditions to allow specific binding of the antibody and the polypeptide, and

b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38 in the sample.

45. A method of purifying a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38 from a sample, the method comprising:

a) incubating the antibody of claim 11 with the sample under conditions to allow specific binding of the antibody and the polypeptide, and

b) separating the antibody from the sample and obtaining the purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-38.

46. A microarray wherein at least one element of the microarray is a polynucleotide of claim 13.

47. A method of generating an expression profile of a sample which contains polynucleotides, the method comprising:

a) labeling the polynucleotides of the sample,

b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and

c) quantifying the expression of the polynucleotides in the sample.

48. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, and wherein said target polynucleotide is a polynucleotide of claim 12.

49. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

50. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.

51. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.

52. An array of claim 48, which is a microarray.

53. An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.

54. An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

55. An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another distinct physical location on the substrate.

56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.

65. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.

66. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.

67. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.

68. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.

69. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.

70. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.

71. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.

72. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.

73. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.

74. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:19.

75. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:20.

76. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:21.

77. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:22.

78. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:23.

79. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:24.

80. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:25.

81. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:26.

82. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:27.

83. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:28.

84. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:29.

85. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:30.

86. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:31.

87. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:32.

88. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:33.

89. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:34.

90. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:35.

91. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:36.

92. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:37.

93. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:38.

94. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:39.

95. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:40.

96. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:41.

97. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:42.

98. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:43.

99. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:44.

100. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:45.

101. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:46.

102. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:47.

103. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:48.

104. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:49.

105. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:50.

106. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:51.

107. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:52.

108. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:53.

109. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:54.

110. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:55.

111. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:56.

112. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:57.

113. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:58.

114. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:59.

115. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:60.

116. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:61.

117. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:62.

118. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:63.

119. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:64.

120. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:65.

121. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:66.

122. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:67.

123. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:68.

124. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:69.

125. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:70.

126. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:71.

127. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:72.

128. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:73.

129. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:74.

130. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:75.

131. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:76.

<110> INCYTE GENOMICS, INC.; CHAWLA, Narinder K.;
YUE, Henry; RICHARDSON, Thomas W.;
MARQUIS, Joseph P.; GORVAD, Ann E.;
BECHA, Shanya D.; KABLE, Amy E.;
SWARNAKAR, Anita; JIN, Pei;
HAWKINS, Phillip R.; CHIEN, David;
RAMKUMAR, Jayalaxmi; LEHR-MASON, Patricia M.;
TRAN, Uyen K.; HAFALIA, April J.A.;
BAUGHN, Mariah R.; LEE, Soo Yeun;
JIAN, Xin; JACKSON, Alan A.;
KHARE, Reena; BULLOCH, Sean A.

<120> RECEPTORS AND MEMBRANE-ASSOCIATED PROTEINS

<130> PF-1381 PCT

<140> To Be Assigned
<141> Herewith

<150> US 60/358,279
<151> 2002-02-20

<150> US 60/364,338
<151> 2002-03-13

<150> US 60/375,657
<151> 2002-04-25

<150> US 60/376,669
<151> 2002-04-29

<150> US 60/379,837
<151> 2002-05-10

<150> US 60/379,853
<151> 2002-05-10

<160> 76
<170> PERL Program

<210> 1
<211> 747
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3048626CD1

<400> 1
Met Ala Ser Lys Val Thr Asp Ala Ile Val Trp Tyr Gln Lys Lys
1 5 10 15
Ile Gly Ala Tyr Asp Gln Gln Ile Trp Glu Lys Ser Val Glu Gln
20 25 30
Arg Glu Ile Lys Gly Leu Arg Asn Lys Pro Lys Lys Thr Ala His
35 40 45
Val Lys Pro Asp Leu Ile Asp Val Asp Leu Val Arg Gly Ser Ala
50 55 60
Phe Ala Lys Ala Lys Pro Glu Ser Pro Trp Thr Ser Leu Thr Arg
65 70 75
Lys Gly Ile Val Arg Val Val Phe Phe Pro Phe Phe Phe Arg Trp
80 85 90
Trp Leu Gln Val Thr Ser Lys Val Ile Phe Phe Trp Leu Leu Val

```
                95                  100                 105
Leu Tyr Leu Leu Gln Val Ala Ala Ile Val Leu Phe Cys Ser Thr
            110                 115                 120
Ser Ser Pro His Ser Ile Pro Leu Thr Glu Val Ile Gly Pro Ile
        125                 130                 135
Trp Leu Met Leu Leu Leu Gly Thr Val His Cys Gln Ile Val Ser
    140                 145                 150
Thr Arg Thr Pro Lys Pro Pro Leu Ser Thr Gly Gly Lys Arg Arg
155                 160                 165
Arg Lys Leu Arg Lys Ala Ala His Leu Glu Val His Arg Glu Gly
            170                 175                 180
Asp Gly Ser Ser Thr Thr Asp Asn Thr Gln Glu Gly Ala Val Gln
        185                 190                 195
Asn His Gly Thr Ser Thr Ser His Ser Val Gly Thr Val Phe Arg
    200                 205                 210
Asp Leu Trp His Ala Ala Phe Phe Leu Ser Gly Ser Lys Lys Ala
215                 220                 225
Lys Asn Ser Ile Asp Lys Ser Thr Glu Thr Asp Asn Gly Tyr Val
            230                 235                 240
Ser Leu Asp Gly Lys Lys Thr Val Lys Ser Gly Glu Asp Gly Ile
        245                 250                 255
Gln Asn His Glu Pro Gln Cys Glu Thr Ile Arg Pro Glu Glu Thr
    260                 265                 270
Ala Trp Asn Thr Gly Thr Leu Arg Asn Gly Pro Ser Lys Asp Thr
275                 280                 285
Gln Arg Thr Ile Thr Asn Val Ser Asp Glu Val Ser Ser Glu Glu
            290                 295                 300
Gly Pro Glu Thr Gly Tyr Ser Leu Arg Arg His Val Asp Arg Thr
        305                 310                 315
Ser Glu Gly Val Leu Arg Asn Arg Lys Ser His His Tyr Lys Lys
    320                 325                 330
His Tyr Pro Asn Glu Asp Ala Pro Lys Ser Gly Thr Ser Cys Ser
335                 340                 345
Ser Arg Cys Ser Ser Ser Arg Gln Asp Ser Glu Ser Ala Arg Pro
            350                 355                 360
Glu Ser Glu Thr Glu Asp Val Leu Trp Glu Asp Leu Leu His Cys
        365                 370                 375
Ala Glu Cys His Ser Ser Cys Thr Ser Glu Thr Asp Val Glu Asn
    380                 385                 390
His Gln Ile Asn Pro Cys Val Lys Lys Glu Tyr Arg Asp Asp Pro
395                 400                 405
Phe His Gln Ser His Leu Pro Trp Leu His Ser Ser His Pro Gly
            410                 415                 420
Leu Glu Lys Ile Ser Ala Ile Val Trp Glu Gly Asn Asp Cys Lys
        425                 430                 435
Lys Ala Asp Met Ser Val Leu Glu Ile Ser Gly Met Ile Met Asn
    440                 445                 450
Arg Val Asn Ser His Ile Pro Gly Ile Gly Tyr Gln Ile Phe Gly
455                 460                 465
Asn Ala Val Ser Leu Ile Leu Gly Leu Thr Pro Phe Val Phe Arg
            470                 475                 480
Leu Ser Gln Ala Thr Asp Leu Glu Gln Leu Thr Ala His Ser Ala
        485                 490                 495
Ser Glu Leu Tyr Val Ile Ala Phe Gly Ser Asn Glu Asp Val Ile
    500                 505                 510
Val Leu Ser Met Val Ile Ile Ser Phe Val Val Arg Val Ser Leu
515                 520                 525
Val Trp Ile Phe Phe Phe Leu Leu Cys Val Ala Glu Arg Thr Tyr
            530                 535                 540
Lys Gln Arg Leu Leu Phe Ala Lys Leu Phe Gly His Leu Thr Ser
        545                 550                 555
Ala Arg Arg Ala Arg Lys Ser Glu Val Pro His Phe Arg Leu Lys
    560                 565                 570
```

```
Lys Val Gln Asn Ile Lys Met Trp Leu Ser Leu Arg Ser Tyr Leu
                575                 580                 585
Lys Arg Arg Gly Pro Gln Arg Ser Val Asp Val Ile Val Ser Ser
                590                 595                 600
Ala Phe Leu Leu Thr Ile Ser Val Val Phe Ile Cys Cys Ala Gln
                605                 610                 615
Val Leu His Val His Glu Ile Phe Leu Asp Cys His Tyr Asn Trp
                620                 625                 630
Glu Leu Val Ile Trp Cys Ile Ser Leu Thr Leu Phe Leu Leu Arg
                635                 640                 645
Phe Val Thr Leu Gly Ser Glu Thr Ser Lys Lys Tyr Ser Asn Thr
                650                 655                 660
Ser Ile Leu Leu Thr Glu Gln Ile Asn Leu Tyr Leu Lys Met Glu
                665                 670                 675
Lys Lys Pro Asn Lys Lys Glu Glu Leu Thr Leu Val Asn Asn Val
                680                 685                 690
Leu Lys Leu Ala Thr Lys Leu Leu Lys Glu Leu Asp Ser Pro Phe
                695                 700                 705
Arg Leu Tyr Gly Leu Thr Met Asn Pro Leu Leu Tyr Asn Ile Thr
                710                 715                 720
Gln Val Val Ile Leu Ser Ala Val Ser Gly Val Ile Ser Asp Leu
                725                 730                 735
Leu Gly Phe Asn Leu Lys Leu Trp Lys Ile Lys Ser
                740                 745
```

<210> 2
<211> 799
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2684425CD1

<400> 2

```
Met Lys Pro Met Leu Lys Asp Phe Ser Asn Leu Leu Leu Val Val
  1                 5                  10                  15
Leu Cys Asp Tyr Val Leu Gly Glu Ala Glu Tyr Leu Leu Leu Arg
                 20                  25                  30
Glu Pro Gly His Val Ala Leu Ser Asn Asp Thr Val Tyr Val Asp
                 35                  40                  45
Phe Gln Tyr Phe Asp Gly Ala Asn Gly Thr Leu Arg Asn Val Ser
                 50                  55                  60
Val Leu Leu Leu Glu Ala Asn Thr Asn Gln Thr Val Thr Thr Lys
                 65                  70                  75
Tyr Leu Leu Thr Asn Gln Ser Gln Gly Thr Leu Lys Phe Glu Cys
                 80                  85                  90
Phe Tyr Phe Lys Glu Ala Gly Asp Tyr Trp Phe Thr Met Thr Pro
                 95                 100                 105
Glu Ala Thr Asp Asn Ser Thr Pro Phe Pro Trp Trp Glu Lys Ser
                110                 115                 120
Ala Phe Leu Lys Val Glu Trp Pro Val Phe His Val Asp Leu Asn
                125                 130                 135
Arg Ser Ala Lys Ala Ala Glu Gly Thr Phe Gln Val Gly Leu Phe
                140                 145                 150
Thr Ser Gln Pro Leu Cys Pro Phe Pro Val Asp Lys Pro Asn Ile
                155                 160                 165
Val Val Asp Val Ile Phe Thr Asn Ser Leu Pro Glu Ala Arg Arg
                170                 175                 180
Asn Ser Arg Gln Pro Leu Glu Ile Arg Thr Ser Lys Arg Thr Glu
                185                 190                 195
Leu Ala Gln Gly Gln Trp Val Glu Phe Gly Cys Ala Pro Leu Gly
                200                 205                 210
```

```
Pro Glu Ala Tyr Val Thr Val Val Leu Lys Leu Leu Gly Arg Asp
                215                 220                 225
Ser Val Ile Thr Ser Thr Gly Pro Ile Asp Leu Ala Gln Lys Phe
                230                 235                 240
Gly Tyr Lys Leu Val Met Val Pro Glu Leu Thr Cys Glu Ser Gly
                245                 250                 255
Val Glu Val Thr Val Leu Pro Pro Pro Cys Thr Phe Val Gln Gly
                260                 265                 270
Val Val Thr Val Phe Lys Glu Ala Pro Arg Tyr Pro Gly Lys Arg
                275                 280                 285
Thr Ile His Leu Ala Glu Asn Ser Leu Pro Leu Gly Glu Arg Arg
                290                 295                 300
Thr Ile Phe Asn Cys Thr Leu Phe Asp Met Gly Lys Asn Lys Tyr
                305                 310                 315
Cys Phe Asp Phe Gly Ile Ser Ser Arg Ser His Phe Ser Ala Lys
                320                 325                 330
Glu Glu Cys Met Leu Ile Gln Arg Asn Thr Ala Phe Gln Pro Ser
                335                 340                 345
Ser Pro Ser Pro Leu Gln Pro Gln Gly Pro Val Lys Ser Asn Asn
                350                 355                 360
Ile Val Thr Val Thr Gly Ile Ser Leu Cys Leu Phe Ile Ile Ile
                365                 370                 375
Ala Thr Val Leu Ile Thr Leu Trp Arg Arg Phe Gly Arg Pro Ala
                380                 385                 390
Lys Cys Ser Thr Pro Ala Arg His Asn Ser Ile His Ser Pro Ser
                395                 400                 405
Phe Arg Lys Asn Ser Asp Glu Glu Asn Ile Cys Glu Leu Ser Glu
                410                 415                 420
Gln Arg Gly Ser Phe Ser Asp Gly Gly Asp Gly Pro Thr Gly Ser
                425                 430                 435
Pro Gly Asp Thr Gly Ile Pro Leu Thr Tyr Arg Arg Ser Gly Pro
                440                 445                 450
Val Pro Pro Glu Asp Asp Ala Ser Gly Ser Glu Ser Phe Gln Ser
                455                 460                 465
Asn Ala Gln Lys Ile Ile Pro Pro Leu Phe Ser Tyr Arg Leu Ala
                470                 475                 480
Gln Gln Gln Leu Lys Glu Met Lys Lys Lys Gly Leu Thr Glu Thr
                485                 490                 495
Thr Lys Val Tyr His Val Ser Gln Ser Pro Leu Thr Asp Thr Ala
                500                 505                 510
Ile Asp Ala Ala Pro Ser Ala Pro Leu Asp Leu Glu Ser Pro Glu
                515                 520                 525
Glu Ala Ala Ala Asn Lys Phe Arg Ile Lys Ser Pro Phe Pro Glu
                530                 535                 540
Gln Pro Ala Val Ser Ala Gly Glu Arg Pro Pro Ser Arg Leu Asp
                545                 550                 555
Leu Asn Val Thr Gln Ala Ser Cys Ala Ile Ser Pro Ser Gln Thr
                560                 565                 570
Leu Ile Arg Lys Ser Gln Ala Arg His Val Gly Ser Arg Gly Gly
                575                 580                 585
Pro Ser Glu Arg Ser His Ala Arg Asn Ala His Phe Arg Arg Thr
                590                 595                 600
Ala Ser Phe His Glu Ala Arg Gln Ala Arg Pro Phe Arg Glu Arg
                605                 610                 615
Ser Met Ser Thr Leu Thr Pro Arg Gln Ala Pro Ala Tyr Ser Ser
                620                 625                 630
Arg Thr Arg Thr Cys Glu Gln Ala Glu Asp Arg Phe Arg Pro Gln
                635                 640                 645
Ser Arg Gly Ala His Leu Phe Pro Glu Lys Leu Glu His Phe Gln
                650                 655                 660
Glu Ala Ser Gly Thr Arg Gly Pro Leu Asn Pro Leu Pro Lys Ser
                665                 670                 675
Tyr Thr Leu Gly Gln Pro Leu Arg Lys Pro Asp Leu Gly Asp His
```

680 685 690
Gln Ala Gly Leu Val Ala Gly Ile Glu Arg Thr Glu Pro His Arg
695 700 705
Ala Arg Arg Gly Pro Ser Pro Ser His Lys Ser Val Ser Arg Lys
710 715 720
Gln Ser Ser Pro Ile Ser Pro Lys Asp Asn Tyr Gln Arg Val Ser
725 730 735
Ser Leu Ser Pro Ser Gln Cys Arg Lys Asp Lys Cys Gln Ser Phe
740 745 750
Pro Thr His Pro Glu Phe Ala Phe Tyr Asp Asn Thr Ser Phe Gly
755 760 765
Leu Thr Glu Ala Glu Gln Arg Met Leu Asp Leu Pro Gly Tyr Phe
770 775 780
Gly Ser Asn Glu Glu Asp Glu Thr Thr Ser Thr Leu Ser Val Glu
785 790 795
Lys Leu Val Ile

<210> 3
<211> 663
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7505960CD1

<400> 3
Met Gly Gly Lys Gln Arg Asp Glu Asp Asp Glu Ala Tyr Gly Lys
1 5 10 15
Pro Val Lys Tyr Asp Pro Ser Phe Arg Gly Pro Ile Lys Asn Arg
20 25 30
Ser Cys Thr Asp Val Ile Cys Cys Val Leu Phe Leu Leu Phe Ile
35 40 45
Leu Gly Tyr Ile Val Val Gly Ile Val Ala Trp Leu Tyr Gly Asp
50 55 60
Pro Arg Gln Val Leu Tyr Pro Arg Asn Ser Thr Gly Ala Tyr Cys
65 70 75
Gly Met Gly Glu Asn Lys Asp Lys Pro Tyr Leu Leu Tyr Phe Asn
80 85 90
Ile Phe Ser Cys Ile Leu Ser Ser Asn Ile Ile Ser Val Ala Glu
95 100 105
Asn Gly Leu Gln Cys Pro Thr Pro Gln Val Cys Val Ser Ser Cys
110 115 120
Pro Glu Asp Pro Trp Thr Val Gly Lys Asn Glu Phe Ser Gln Thr
125 130 135
Val Gly Glu Val Phe Tyr Thr Lys Asn Arg Asn Phe Cys Leu Pro
140 145 150
Gly Val Pro Trp Asn Met Thr Val Ile Thr Ser Leu Gln Gln Glu
155 160 165
Leu Cys Pro Ser Phe Leu Leu Pro Ser Ala Pro Ala Leu Gly Arg
170 175 180
Cys Phe Pro Trp Thr Asn Ile Thr Pro Pro Ala Leu Pro Gly Ile
185 190 195
Thr Asn Asp Thr Thr Ile Gln Gln Gly Ile Ser Gly Leu Ile Asp
200 205 210
Ser Leu Asn Ala Arg Asp Ile Ser Val Lys Ile Phe Glu Asp Phe
215 220 225
Ala Gln Ser Trp Tyr Trp Ile Leu Val Ala Leu Gly Val Ala Leu
230 235 240
Val Leu Ser Leu Leu Phe Ile Leu Leu Leu Arg Leu Val Ala Gly
245 250 255
Pro Leu Val Leu Val Leu Ile Leu Gly Val Leu Gly Val Leu Ala

```
                260                 265                 270
Tyr Gly Ile Tyr Tyr Cys Trp Glu Glu Tyr Arg Val Leu Arg Asp
                275                 280                 285
Lys Gly Ala Ser Ile Ser Gln Leu Gly Phe Thr Thr Asn Leu Ser
                290                 295                 300
Ala Tyr Gln Ser Val Gln Glu Thr Trp Leu Ala Ala Leu Ile Val
                305                 310                 315
Leu Ala Val Leu Glu Ala Ile Leu Leu Leu Val Leu Ile Phe Leu
                320                 325                 330
Arg Gln Arg Ile Arg Ile Ala Ile Ala Leu Leu Lys Glu Ala Ser
                335                 340                 345
Lys Ala Val Gly Gln Met Met Ser Thr Met Phe Tyr Pro Leu Val
                350                 355                 360
Thr Phe Val Leu Leu Leu Ile Cys Ile Ala Tyr Trp Ala Met Thr
                365                 370                 375
Ala Leu Tyr Leu Ala Thr Ser Gly Gln Pro Gln Tyr Val Leu Trp
                380                 385                 390
Ala Ser Asn Ile Ser Ser Pro Gly Cys Glu Lys Val Pro Ile Asn
                395                 400                 405
Thr Ser Cys Asn Pro Thr Ala His Leu Val Asn Ser Ser Cys Pro
                410                 415                 420
Gly Leu Met Cys Val Phe Gln Gly Tyr Ser Ser Lys Gly Leu Ile
                425                 430                 435
Pro Thr Phe Pro Leu Ile Ser Ala Phe Ile Arg Thr Leu Arg Tyr
                440                 445                 450
His Thr Gly Ser Leu Ala Phe Gly Ala Leu Ile Leu Thr Leu Val
                455                 460                 465
Gln Ile Ala Arg Val Ile Leu Glu Tyr Ile Asp His Lys Leu Arg
                470                 475                 480
Gly Val Gln Asn Pro Val Ala Arg Cys Ile Met Cys Cys Phe Lys
                485                 490                 495
Cys Cys Leu Trp Cys Leu Glu Lys Phe Ile Lys Phe Leu Asn Arg
                500                 505                 510
Asn Ala Tyr Ile Met Ile Ala Ile Tyr Gly Lys Asn Phe Cys Val
                515                 520                 525
Ser Ala Lys Asn Ala Phe Met Leu Leu Met Arg Asn Ile Val Arg
                530                 535                 540
Val Val Val Leu Asp Lys Val Thr Asp Leu Leu Leu Phe Phe Gly
                545                 550                 555
Lys Leu Leu Val Val Gly Gly Val Gly Val Leu Ser Phe Phe Phe
                560                 565                 570
Phe Ser Gly Arg Ile Pro Gly Leu Gly Lys Asp Phe Lys Ser Pro
                575                 580                 585
His Leu Asn Tyr Tyr Trp Leu Pro Ile Met Thr Ser Ile Leu Gly
                590                 595                 600
Ala Tyr Val Ile Ala Ser Gly Phe Phe Ser Val Phe Gly Met Cys
                605                 610                 615
Val Asp Thr Leu Phe Leu Cys Phe Leu Glu Asp Leu Glu Arg Asn
                620                 625                 630
Asn Gly Ser Leu Asp Arg Pro Tyr Tyr Met Ser Lys Ser Leu Leu
                635                 640                 645
Lys Ile Leu Gly Lys Lys Asn Glu Ala Pro Pro Asp Asn Lys Lys
                650                 655                 660
Arg Lys Lys
```

<210> 4
<211> 150
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature

<223> Incyte ID No: 7507021CD1

<400> 4
Met Arg Gly His Pro Ser Leu Leu Leu Leu Tyr Met Ala Leu Thr
1 5 10 15
Thr Cys Leu Asp Thr Ser Pro Ser Glu Glu Thr Asp Gln Glu Val
20 25 30
Phe Leu Gly Pro Pro Glu Ala Gln Ser Phe Leu Ser Ser His Thr
35 40 45
Arg Ile Pro Arg Ala Asn His Trp Asp Leu Glu Leu Leu Thr Pro
50 55 60
Gly Asn Leu Glu Arg Glu Cys Leu Glu Glu Arg Cys Ser Trp Glu
65 70 75
Glu Ala Arg Glu Tyr Phe Glu Asp Asn Thr Leu Thr Glu Arg Phe
80 85 90
Trp Glu Ser Tyr Ile Tyr Asn Gly Lys Gly Gly Arg Gly Arg Val
95 100 105
Asp Val Ala Ser Leu Ala Val Gly Leu Thr Gly Gly Ile Leu Leu
110 115 120
Ile Val Leu Ala Gly Leu Gly Ala Phe Trp Tyr Leu Arg Trp Arg
125 130 135
Gln His Arg Gly Gln Gln Pro Cys Pro Gln Glu Pro Pro His Leu
140 145 150

<210> 5
<211> 504
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7509099CD1

<400> 5
Met Lys Val Leu Leu Arg Leu Ile Cys Phe Ile Ala Leu Leu Ile
1 5 10 15
Ser Ser Leu Glu Ala Asp Lys Cys Lys Glu Arg Glu Glu Lys Ile
20 25 30
Ile Leu Val Ser Ser Ala Asn Glu Ile Asp Val Arg Pro Cys Pro
35 40 45
Leu Asn Pro Asn Glu His Lys Gly Thr Ile Thr Trp Tyr Lys Asp
50 55 60
Asp Ser Lys Thr Pro Val Ser Thr Glu Gln Ala Ser Arg Ile His
65 70 75
Gln His Lys Glu Lys Leu Trp Phe Val Pro Ala Lys Val Glu Asp
80 85 90
Ser Gly His Tyr Tyr Cys Val Asp Cys Lys Pro Leu Leu Leu Asp
95 100 105
Asn Ile His Phe Ser Gly Val Lys Asp Arg Leu Ile Val Met Asn
110 115 120
Val Ala Glu Lys His Arg Gly Asn Tyr Thr Cys His Ala Ser Tyr
125 130 135
Thr Tyr Leu Gly Lys Gln Tyr Pro Ile Thr Arg Val Ile Glu Phe
140 145 150
Ile Thr Leu Glu Glu Asn Lys Pro Thr Arg Pro Val Ile Val Ser
155 160 165
Pro Ala Asn Glu Thr Met Glu Val Asp Leu Gly Ser Gln Ile Gln
170 175 180
Leu Ile Cys Asn Val Thr Gly Gln Leu Ser Asp Ile Ala Tyr Trp
185 190 195
Lys Trp Asn Gly Ser Val Ile Asp Glu Asp Asp Pro Val Leu Gly
200 205 210

```
Glu Asp Tyr Tyr Ser Val Glu Asn Pro Ala Asn Lys Arg Arg Ser
                215                 220                 225
Thr Leu Ile Thr Val Leu Asn Ile Ser Glu Ile Glu Ser Arg Phe
                230                 235                 240
Tyr Lys His Pro Phe Thr Cys Phe Ala Lys Asn Thr His Gly Ile
                245                 250                 255
Asp Ala Ala Tyr Ile Gln Leu Ile Tyr Pro Val Thr Asn Phe Gln
                260                 265                 270
Lys His Met Ile Gly Ile Cys Val Thr Leu Thr Val Ile Ile Val
                275                 280                 285
Cys Ser Val Phe Ile Tyr Lys Ile Phe Lys Ile Asp Ile Val Leu
                290                 295                 300
Trp Tyr Arg Asp Ser Cys Tyr Asp Phe Leu Pro Ile Lys Ala Ser
                305                 310                 315
Asp Gly Lys Thr Tyr Asp Ala Tyr Ile Leu Tyr Pro Lys Thr Val
                320                 325                 330
Gly Glu Gly Ser Thr Ser Asp Cys Asp Ile Phe Val Phe Lys Val
                335                 340                 345
Leu Pro Glu Val Leu Glu Lys Gln Cys Gly Tyr Lys Leu Phe Ile
                350                 355                 360
Tyr Gly Arg Asp Asp Tyr Val Gly Glu Asp Ile Val Glu Val Ile
                365                 370                 375
Asn Glu Asn Val Lys Lys Ser Arg Arg Leu Ile Ile Ile Leu Val
                380                 385                 390
Arg Glu Thr Ser Gly Phe Ser Trp Leu Gly Gly Ser Ser Glu Glu
                395                 400                 405
Gln Ile Ala Met Tyr Asn Ala Leu Val Gln Asp Gly Ile Lys Val
                410                 415                 420
Val Leu Leu Glu Leu Glu Lys Ile Gln Asp Tyr Glu Lys Met Pro
                425                 430                 435
Glu Ser Ile Lys Phe Ile Lys Gln Lys His Gly Ala Ile Arg Trp
                440                 445                 450
Ser Gly Asp Phe Thr Gln Gly Pro Gln Ser Ala Lys Thr Arg Phe
                455                 460                 465
Trp Lys Asn Val Arg Tyr His Met Pro Val Gln Arg Arg Ser Pro
                470                 475                 480
Ser Ser Lys His Gln Leu Leu Ser Pro Ala Thr Lys Glu Lys Leu
                485                 490                 495
Gln Arg Glu Ala His Val Pro Leu Gly
                500

<210> 6
<211> 247
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7509361CD1

<400> 6
Met Gly Leu Ser Thr Val Pro Asp Leu Leu Leu Pro Leu Val Leu
  1                 5                  10                  15
Leu Glu Leu Leu Val Gly Ile Tyr Pro Ser Gly Val Ile Gly Leu
                 20                  25                  30
Val Pro His Leu Gly Asp Arg Glu Lys Arg Asp Ser Val Cys Pro
                 35                  40                  45
Gln Gly Lys Tyr Ile His Pro Gln Asn Asn Ser Ile Cys Cys Thr
                 50                  55                  60
Lys Cys His Lys Gly Thr Tyr Leu Tyr Asn Asp Cys Pro Gly Pro
                 65                  70                  75
Gly Gln Asp Thr Asp Cys Arg Glu Cys Glu Ser Gly Ser Phe Thr
                 80                  85                  90
```

```
Ala Ser Glu Asn His Leu Arg His Cys Leu Ser Cys Ser Lys Cys
                 95                  100                 105
Arg Lys Glu Met Gly Gln Val Glu Ile Ser Ser Cys Thr Val Asp
                110                 115                 120
Arg Asp Thr Val Cys Gly Cys Arg Lys Asn Gln Tyr Arg His Tyr
                125                 130                 135
Trp Ser Glu Asn Leu Phe Gln Cys Phe Asn Cys Ser Leu Cys Leu
                140                 145                 150
Asn Gly Thr Val His Leu Ser Cys Gln Glu Lys Gln Asn Thr Val
                155                 160                 165
Cys Thr Cys His Ala Gly Phe Phe Leu Arg Glu Asn Glu Cys Val
                170                 175                 180
Ser Cys Ser Asn Cys Lys Lys Ser Leu Glu Cys Thr Lys Leu Cys
                185                 190                 195
Leu Pro Gln Ile Glu Asn Val Lys Gly Thr Glu Asp Ser Glu Arg
                200                 205                 210
Trp His His Pro Ile Arg Gly Leu Thr Pro Ser Leu Arg Gln Pro
                215                 220                 225
Ser Pro Pro Thr Pro Ser Pro Thr Pro Phe Arg Ser Gly Arg Thr
                230                 235                 240
Ala Pro Thr Ser His Arg Ala
                245
```

<210> 7
<211> 363
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7506815CD1

<400> 7

```
Met Glu Leu Leu Lys Leu Asn Arg Ser Val Gln Gly Thr Gly Pro
  1               5                  10                  15
Gly Pro Gly Ala Ser Leu Cys Arg Pro Gly Ala Pro Leu Leu Asn
                 20                  25                  30
Ser Ser Ser Val Gly Asn Leu Ser Cys Glu Pro Pro Arg Ile Arg
                 35                  40                  45
Gly Ala Gly Thr Arg Gly Val Ser Val Ser Val Ser Thr Leu Ser
                 50                  55                  60
Leu Val Ala Ile Ala Leu Glu Arg Tyr Ser Ala Ile Cys Arg Pro
                 65                  70                  75
Leu Gln Ala Arg Val Trp Gln Thr Arg Ser His Ala Ala Arg Val
                 80                  85                  90
Ile Val Ala Thr Trp Leu Leu Ser Gly Leu Leu Met Val Pro Tyr
                 95                 100                 105
Pro Val Tyr Thr Val Val Gln Pro Val Gly Pro Arg Val Leu Gln
                110                 115                 120
Cys Val His Arg Trp Pro Ser Ala Arg Val Arg Gln Thr Trp Ser
                125                 130                 135
Val Leu Leu Leu Leu Leu Leu Leu Phe Phe Ile Pro Gly Val Val Met
                140                 145                 150
Ala Val Ala Tyr Gly Leu Ile Ser Arg Glu Leu Tyr Leu Gly Leu
                155                 160                 165
Arg Phe Asp Gly Asp Ser Asp Ser Asp Ser Gln Ser Arg Val Arg
                170                 175                 180
Asn Gln Gly Gly Leu Pro Gly Ala Val His Gln Asn Gly Arg Cys
                185                 190                 195
Arg Pro Glu Thr Gly Ala Val Gly Glu Asp Ser Asp Gly Cys Tyr
                200                 205                 210
Val Gln Leu Pro Arg Ser Arg Pro Ala Leu Glu Leu Thr Ala Leu
                215                 220                 225
```

```
Thr Ala Pro Gly Pro Gly Ser Gly Ser Arg Pro Thr Gln Ala Lys
                230                 235                 240
Leu Leu Ala Lys Lys Arg Val Val Arg Met Leu Leu Val Ile Val
                245                 250                 255
Val Leu Phe Phe Leu Cys Trp Leu Pro Val Tyr Ser Ala Asn Thr
                260                 265                 270
Trp Arg Ala Phe Asp Gly Pro Gly Ala His Arg Ala Leu Ser Gly
                275                 280                 285
Ala Pro Ile Ser Phe Ile His Leu Leu Ser Tyr Ala Ser Ala Cys
                290                 295                 300
Val Asn Pro Leu Val Tyr Cys Phe Met His Arg Arg Phe Arg Gln
                305                 310                 315
Ala Cys Leu Glu Thr Cys Ala Arg Cys Cys Pro Arg Pro Pro Arg
                320                 325                 330
Ala Arg Pro Arg Ala Leu Pro Asp Glu Asp Pro Pro Thr Pro Ser
                335                 340                 345
Ile Ala Ser Leu Ser Arg Leu Ser Tyr Thr Thr Ile Ser Thr Leu
                350                 355                 360
Gly Pro Gly
```

<210> 8
<211> 392
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7506814CD1

<400> 8

```
Met Glu Leu Leu Lys Leu Asn Arg Ser Val Gln Gly Thr Gly Pro
  1                 5                  10                  15
Gly Pro Gly Ala Ser Leu Cys Arg Pro Gly Ala Pro Leu Leu Asn
                 20                  25                  30
Ser Ser Ser Val Gly Asn Leu Ser Cys Glu Pro Pro Arg Ile Arg
                 35                  40                  45
Gly Ala Gly Thr Arg Glu Leu Glu Leu Ala Ile Arg Ile Thr Leu
                 50                  55                  60
Tyr Ala Val Ile Phe Leu Met Ser Val Gly Gly Asn Met Leu Ile
                 65                  70                  75
Ile Val Val Leu Gly Leu Ser Arg Arg Leu Arg Thr Val Thr Asn
                 80                  85                  90
Ala Phe Leu Leu Ser Leu Ala Val Ser Asp Leu Leu Leu Ala Val
                 95                 100                 105
Ala Cys Met Pro Phe Thr Leu Leu Pro Asn Leu Met Gly Thr Phe
                110                 115                 120
Ile Phe Gly Thr Ile Ile Cys Lys Ala Val Ser Tyr Leu Met Gly
                125                 130                 135
Val Ser Val Ser Val Ser Thr Leu Ser Leu Val Ala Ile Ala Leu
                140                 145                 150
Glu Arg Tyr Ser Ala Ile Cys Arg Pro Leu Gln Ala Arg Val Trp
                155                 160                 165
Gln Thr Arg Ser His Ala Ala Arg Val Ile Val Ala Thr Trp Leu
                170                 175                 180
Leu Ser Gly Leu Leu Met Val Pro Tyr Pro Val Tyr Thr Val Val
                185                 190                 195
Gln Pro Val Gly Pro Arg Val Leu Gln Cys Val His Arg Trp Pro
                200                 205                 210
Ser Ala Arg Val Arg Gln Thr Trp Ser Val Leu Leu Leu Leu Leu
                215                 220                 225
Leu Phe Phe Ile Pro Gly Val Val Met Ala Val Ala Tyr Gly Leu
                230                 235                 240
```

```
Ile Ser Arg Glu Leu Tyr Leu Gly Leu Arg Phe Asp Gly Asp Ser
                245                 250                 255
Asp Ser Asp Ser Gln Ser Arg Val Arg Asn Gln Gly Gly Leu Pro
                260                 265                 270
Gly Ala Lys Lys Arg Val Val Arg Met Leu Leu Val Ile Val Val
                275                 280                 285
Leu Phe Phe Leu Cys Trp Leu Pro Val Tyr Ser Ala Asn Thr Trp
                290                 295                 300
Arg Ala Phe Asp Gly Pro Gly Ala His Arg Ala Leu Ser Gly Ala
                305                 310                 315
Pro Ile Ser Phe Ile His Leu Leu Ser Tyr Ala Ser Ala Cys Val
                320                 325                 330
Asn Pro Leu Val Tyr Cys Phe Met His Arg Arg Phe Arg Gln Ala
                335                 340                 345
Cys Leu Glu Thr Cys Ala Arg Cys Cys Pro Arg Pro Pro Arg Ala
                350                 355                 360
Arg Pro Arg Ala Leu Pro Asp Glu Asp Pro Pro Thr Pro Ser Ile
                365                 370                 375
Ala Ser Leu Ser Arg Leu Ser Tyr Thr Thr Ile Ser Thr Leu Gly
                380                 385                 390
Pro Gly
```

<210> 9
<211> 125
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7506852CD1

<400> 9

```
Met Pro Pro Ser Ile Ser Ala Phe Gln Ala Ala Tyr Ile Gly Ile
  1                 5                  10                  15
Glu Val Leu Ile Ala Leu Val Ser Val Pro Gly Asn Val Leu Val
                 20                  25                  30
Ile Trp Ala Val Lys Val Asn Gln Ala Leu Arg Asp Ala Thr Phe
                 35                  40                  45
Cys Phe Ile Val Ser Leu Ala Val Ala Asp Val Ala Val Gly Ala
                 50                  55                  60
Leu Val Ile Pro Leu Ala Ile Leu Ile Asn Ile Gly Pro Gln Thr
                 65                  70                  75
Tyr Phe His Thr Cys Leu Met Val Ala Cys Pro Val Leu Ile Leu
                 80                  85                  90
Thr Gln Ser Ser Ile Leu Ala Leu Leu Ala Ile Ala Val Asp Arg
                 95                 100                 105
Tyr Leu Arg Val Lys Ile Pro Leu Arg Arg Ile Ser Gln Cys Met
                110                 115                 120
Ala Ser Thr Lys Ser
                125
```

<210> 10
<211> 728
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7503782CD1

<400> 10

```
Met Leu Leu Pro Arg Ser Val Ser Ser Glu Arg Ala Pro Gly Val
```

```
  1               5                  10                  15
Pro Glu Pro Glu Glu Leu Trp Glu Ala Glu Met Glu Arg Leu Arg
             20                  25                  30
Gly Ser Gly Thr Pro Val Arg Gly Leu Pro Tyr Ala Met Met Asp
         35                  40                  45
Lys Arg Leu Ile Trp Gln Leu Arg Glu Pro Ala Gly Val Gln Thr
     50                  55                  60
Leu Arg Trp Gln Arg Trp Gln Arg Arg Arg Gln Thr Val Glu Arg
 65                  70                  75
Arg Leu Arg Glu Ala Ala Gln Arg Leu Ala Arg Gly Leu Gly Leu
             80                  85                  90
Trp Glu Gly Ala Leu Tyr Glu Ile Gly Gly Leu Phe Gly Thr Gly
         95                 100                 105
Ile Arg Ser Tyr Phe Thr Phe Leu Arg Phe Leu Leu Leu Leu Asn
    110                 115                 120
Leu Leu Ser Leu Leu Leu Thr Ala Ser Phe Val Leu Leu Pro Leu
    125                 130                 135
Val Trp Leu Arg Pro Pro Asp Pro Gly Pro Thr Leu Asn Leu Thr
    140                 145                 150
Leu Gln Cys Pro Gly Ser Arg Gln Ser Pro Pro Gly Val Leu Arg
    155                 160                 165
Phe His Asn Gln Leu Trp His Val Leu Thr Gly Arg Ala Phe Thr
    170                 175                 180
Asn Thr Tyr Leu Phe Tyr Gly Ala Tyr Arg Val Gly Pro Glu Ser
    185                 190                 195
Ser Ser Val Tyr Ser Ile Arg Leu Ala Tyr Leu Leu Ser Pro Leu
    200                 205                 210
Ala Cys Leu Leu Leu Cys Phe Cys Gly Thr Leu Arg Arg Met Val
    215                 220                 225
Lys Gly Leu Pro Gln Lys Thr Leu Leu Gly Gln Gly Tyr Gln Ala
    230                 235                 240
Pro Leu Ser Ala Lys Val Phe Ser Ser Trp Asp Phe Cys Ile Arg
    245                 250                 255
Val Gln Glu Ala Ala Thr Ile Lys Lys His Glu Ile Ser Asn Glu
    260                 265                 270
Phe Lys Val Glu Leu Glu Glu Gly Arg Arg Phe Gln Leu Met Gln
    275                 280                 285
Gln Gln Thr Arg Ala Gln Thr Ala Cys Arg Leu Leu Ser Tyr Leu
    290                 295                 300
Arg Val Asn Val Leu Ile Gly Leu Leu Val Val Gly Ala Ile Ser
    305                 310                 315
Ala Ile Phe Trp Ala Thr Lys Tyr Ser Gln Asp Asn Lys Glu Val
    320                 325                 330
Ser Gly Asn Cys Ile His Leu Ile Leu Ala Arg Thr Ala Gly Glu
    335                 340                 345
Ser Leu Phe Leu Leu Leu Gln Tyr Leu Pro Pro Gly Val Ile Ala
    350                 355                 360
Leu Val Asn Phe Leu Gly Pro Leu Leu Phe Thr Phe Leu Val Gln
    365                 370                 375
Leu Glu Asn Tyr Pro Pro Asn Thr Glu Val Asn Leu Thr Leu Ile
    380                 385                 390
Trp Cys Val Val Leu Lys Leu Ala Ser Leu Gly Met Phe Ser Val
    395                 400                 405
Ser Leu Gly Gln Thr Ile Leu Cys Ile Gly Arg Asp Lys Ser Ser
    410                 415                 420
Cys Glu Ser Tyr Gly Tyr Asn Val Cys Asp Tyr Gln Cys Trp Glu
    425                 430                 435
Asn Ser Val Gly Glu Glu Leu Tyr Lys Leu Ser Ile Phe Asn Phe
    440                 445                 450
Leu Leu Thr Val Ala Phe Ala Phe Leu Val Thr Leu Pro Arg Arg
    455                 460                 465
Leu Leu Val Asp Arg Phe Ser Gly Arg Phe Trp Ala Trp Leu Glu
    470                 475                 480
```

```
Arg Glu Glu Phe Leu Val Pro Lys Asn Val Leu Asp Ile Val Ala
                485                 490                 495
Gly Gln Thr Val Thr Trp Met Gly Leu Phe Tyr Cys Pro Leu Leu
                500                 505                 510
Pro Leu Leu Asn Ser Val Phe Leu Phe Leu Thr Phe Tyr Ile Lys
                515                 520                 525
Lys Tyr Thr Leu Leu Lys Asn Ser Arg Ala Ser Ser Arg Pro Phe
                530                 535                 540
Arg Ala Ser Ser Ser Thr Phe Phe Phe Gln Leu Val Leu Leu Leu
                545                 550                 555
Gly Leu Leu Leu Ala Ala Val Pro Leu Gly Tyr Val Val Ser Ser
                560                 565                 570
Ile His Ser Ser Trp Asp Cys Gly Leu Phe Thr Asn Tyr Ser Ala
                575                 580                 585
Pro Trp Gln Val Val Pro Glu Leu Val Ala Leu Gly Leu Pro Pro
                590                 595                 600
Ile Gly Gln Arg Ala Leu His Tyr Leu Gly Ser His Ala Phe Ser
                605                 610                 615
Phe Pro Leu Leu Ile Met Leu Arg Phe Ser Gly Gln Gln Gly Pro
                620                 625                 630
Trp Glu Gly Thr Pro Gly Gly Gly Gly Pro Ser Phe His Gly Gly
                635                 640                 645
Gly Glu Pro Val His Pro Gln Pro Gly Ala Arg Arg Arg Lys Pro
                650                 655                 660
Arg Glu Ala Gly Ala Ser Glu Lys Gln Glu Pro Pro Gly Pro Thr
                665                 670                 675
Leu Trp Ala Ala Met Gly Ile Ala Gly Ser Leu Gly Lys His Arg
                680                 685                 690
Val Trp Val Ala Ala Ala Ala Glu Leu Leu Val Leu Leu Cys Gln
                695                 700                 705
Arg Gly Gly Asp Glu Gly Leu Cys Glu Glu Gly Glu Glu Gly Pro
                710                 715                 720
Ile Leu Arg Tyr Ser Ser Val Gln
                725
```

<210> 11
<211> 61
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7504647CD1

<400> 11

```
Met Ala Glu Thr Leu Phe Trp Thr Pro Leu Leu Val Val Leu Leu
  1               5                  10                  15
Ala Gly Leu Gly Asp Thr Glu Ala Gln Gln Thr Thr Leu His Pro
                20                  25                  30
Leu Val Gly Arg Val Phe Val His Thr Leu Asp His Glu Thr Phe
                35                  40                  45
Leu Ser Leu Pro Glu His Val Gly His Ser Leu Gln Ser Gly Gln
                50                  55                  60
Leu
```

<210> 12
<211> 152
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature

<223> Incyte ID No: 7500424CD1

<400> 12
Met Thr Pro Gln Ser Leu Leu Gln Thr Thr Leu Phe Leu Leu Ser
1 5 10 15
Leu Leu Phe Leu Val Gln Gly Ala His Gly Arg Gly His Arg Glu
20 25 30
Asp Phe Arg Phe Cys Ser Gln Arg Asn Gln Thr His Arg Ser Ser
35 40 45
Leu His Tyr Lys Pro Thr Pro Asp Leu Arg Ile Ser Ile Glu Asn
50 55 60
Ser Glu Glu Ala Leu Thr Val His Ala Pro Phe Pro Ala Ala His
65 70 75
Pro Ala Ser Arg Ser Phe Pro Asp Pro Arg Gly Leu Tyr His Phe
80 85 90
Cys Leu Tyr Trp Asn Arg His Ala Gly Arg Leu His Leu Leu Tyr
95 100 105
Gly Lys Arg Asp Phe Leu Leu Ser Asp Lys Ala Ser Ser Leu Leu
110 115 120
Cys Phe Gln His Gln Ala Arg Tyr Arg Cys Val Gly Trp Ala Arg
125 130 135
Ser Leu Cys Pro Ser Gly Pro Leu Tyr Glu Leu His Cys Pro Cys
140 145 150
Ser Pro

<210> 13
<211> 283
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7500449CD1

<400> 13
Met Pro Pro Pro Pro Leu Leu Ser Leu Arg Arg Leu Gly Gly Gly
1 5 10 15
Trp Ser Ala Val Thr Arg Leu Val Val Ala Ala Ala Gly Ala Arg
20 25 30
Ser Arg Gly Gly Arg Gly Gly Ser Arg Gly Ala Gly Gly Gly Gly
35 40 45
Arg Gly Gly Val Ala Arg Arg Arg Arg Leu Glu Leu Arg Ala Ala
50 55 60
Arg Ser Leu Leu Gly Ser Ser Leu Gln Glu Glu Cys Asp Tyr Val
65 70 75
Gln Met Ile Glu Val Gln His Lys Gln Cys Leu Glu Glu Ala Gln
80 85 90
Leu Glu Asn Glu Thr Ile Gly Cys Ser Lys Met Trp Asp Asn Leu
95 100 105
Thr Cys Trp Pro Ala Thr Pro Arg Gly Gln Val Val Val Leu Ala
110 115 120
Cys Pro Leu Ile Phe Lys Leu Phe Ser Ser Ile Gln Gly Arg Asn
125 130 135
Val Ser Arg Ser Cys Thr Asp Glu Gly Trp Thr His Leu Glu Pro
140 145 150
Gly Pro Tyr Pro Ile Ala Cys Gly Leu Asp Asp Lys Ala Ala Ser
155 160 165
Leu Asp Glu Gln Gln Thr Met Phe Tyr Gly Ser Val Lys Thr Gly
170 175 180
Tyr Thr Ile Gly Tyr Gly Leu Ser Leu Ala Thr Leu Leu Val Ala
185 190 195
Thr Ala Ile Leu Ser Leu Phe Arg Lys Leu His Cys Thr Arg Asn

```
                200                 205                 210
Tyr Ile His Met His Leu Phe Ile Ser Phe Ile Leu Arg Ala Ala
                215                 220                 225
Ala Val Phe Ile Lys Asp Leu Ala Leu Phe Asp Ser Gly Glu Ser
                230                 235                 240
Asp Gln Cys Ser Glu Gly Ser Gly Tyr Pro Ala His Ser Pro Trp
                245                 250                 255
Cys Gly Pro Ser Pro Gly Ser Ile Leu Arg Ile Met Val Cys Ser
                260                 265                 270
Gly Ala Gly Thr Pro Ser Thr Pro His Cys Gly Gly Ser
                275                 280
```

<210> 14
<211> 246
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7503281CD1

<400> 14

```
Met Asp His Gln Asp Pro Tyr Ser Val Gln Ala Thr Ala Ala Ile
  1               5                  10                  15
Ala Ala Ala Ile Thr Phe Leu Ile Leu Phe Thr Ile Phe Gly Asn
                20                  25                  30
Ala Leu Val Ile Leu Ala Val Leu Thr Ser Arg Ser Leu Arg Ala
                35                  40                  45
Pro Gln Asn Leu Phe Leu Val Ser Leu Ala Ala Ala Asp Ile Leu
                50                  55                  60
Val Ala Thr Leu Ile Ile Pro Phe Ser Leu Ala Asn Glu Leu Leu
                65                  70                  75
Gly Tyr Trp Tyr Phe Arg Arg Thr Trp Cys Glu Val Tyr Leu Ala
                80                  85                  90
Leu Asp Val Leu Phe Cys Thr Ser Ser Ile Val His Leu Cys Ala
                95                 100                 105
Ile Ser Leu Asp Arg Tyr Trp Ala Val Ser Arg Ala Leu Glu Tyr
               110                 115                 120
Asn Ser Lys Arg Thr Pro Arg Arg Ile Lys Cys Ile Ile Leu Thr
               125                 130                 135
Val Trp Leu Ile Ala Ala Val Ile Ser Leu Pro Pro Leu Ile Tyr
               140                 145                 150
Lys Gly Asp Gln Gly Pro Gln Pro Arg Gly Arg Pro Gln Cys Lys
               155                 160                 165
Leu Asn Gln Glu Ala Trp Tyr Ile Leu Ala Ser Ser Ile Gly Ser
               170                 175                 180
Phe Phe Ala Pro Cys Leu Ile Met Ile Leu Val Tyr Leu Arg Ile
               185                 190                 195
Tyr Leu Ile Ala Lys Arg Ser Asn Arg Arg Gly Pro Arg Ala Lys
               200                 205                 210
Gly Gly Pro Gly Gln Ala Thr Ala Trp Ala Pro Ser Ala Arg Ser
               215                 220                 225
Thr Ala Arg Cys Pro Met Ala Ser Ser Ser Ser Ser Ser Gly Ser
               230                 235                 240
Ala Thr Ala Thr Ala His
               245
```

<210> 15
<211> 319
<212> PRT
<213> Homo sapiens

<220>

<221> misc_feature
<223> Incyte ID No: 7503292CD1

<400> 15
Met Glu Thr Ser Ser Pro Arg Pro Pro Arg Pro Ser Ser Asn Pro
1 5 10 15
Gly Leu Ser Leu Asp Ala Arg Leu Gly Val Asp Thr Arg Leu Trp
20 25 30
Ala Lys Val Leu Phe Thr Ala Leu Tyr Ala Leu Ile Trp Ala Leu
35 40 45
Gly Ala Ala Gly Asn Ala Leu Ser Val His Val Val Leu Lys Ala
50 55 60
Arg Ala Gly Arg Ala Gly Arg Leu Arg His His Val Leu Ser Leu
65 70 75
Ala Leu Ala Gly Leu Leu Leu Leu Leu Val Gly Val Pro Val Glu
80 85 90
Leu Tyr Ser Phe Val Trp Phe His Tyr Pro Trp Val Phe Gly Asp
95 100 105
Leu Gly Cys Arg Gly Tyr Tyr Phe Val His Glu Leu Cys Ala Tyr
110 115 120
Ala Thr Val Leu Ser Val Ala Gly Leu Ser Ala Glu Arg Cys Leu
125 130 135
Ala Val Cys Gln Pro Leu Arg Ala Arg Ser Leu Leu Thr Pro Arg
140 145 150
Arg Thr Arg Trp Leu Val Ala Leu Ser Trp Ala Ala Ser Leu Gly
155 160 165
Leu Ala Leu Pro Met Ala Val Ile Met Gly Gln Lys His Glu Leu
170 175 180
Glu Thr Ala Asp Gly Glu Pro Glu Pro Ala Ser Arg Val Cys Thr
185 190 195
Val Leu Val Ser Arg Thr Ala Leu Gln Val Phe Ile Gln Val Asn
200 205 210
Val Leu Val Ser Phe Val Leu Pro Leu Ala Leu Thr Ala Phe Leu
215 220 225
Asn Gly Val Thr Val Ser His Leu Leu Ala Leu Cys Ser Gln Val
230 235 240
Pro Ser Thr Ser Thr Pro Gly Ser Ser Thr Pro Ser Arg Leu Glu
245 250 255
Leu Leu Ser Glu Glu Gly Leu Leu Ser Phe Ile Val Trp Lys Lys
260 265 270
Thr Phe Ile Gln Gly Gly Gln Glu Pro Ser Trp Ser Cys Met Ser
275 280 285
Ser Ala Gly Cys Arg Thr Met Pro Ala Gly Ser Cys Thr Ala Thr
290 295 300
Tyr Leu Met Thr Arg Gly Leu Thr His Cys Thr Ile Ser Thr Thr
305 310 315
Thr Ser Thr Trp

<210> 16
<211> 284
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7503311CD1

<400> 16
Met Thr Thr Ser Pro Ile Leu Gln Leu Leu Leu Arg Leu Ser Leu
1 5 10 15
Cys Gly Leu Leu Leu Gln Arg Ala Glu Thr Gly Ser Lys Gly Gln
20 25 30

```
Thr Ala Gly Glu Leu Tyr Gln Arg Trp Glu Arg Tyr Arg Arg Glu
                35                  40                  45
Cys Gln Glu Thr Leu Ala Ala Ala Glu Pro Pro Ser Gly Leu Ala
                50                  55                  60
Cys Asn Gly Ser Phe Asp Met Tyr Val Cys Trp Asp Tyr Ala Ala
                65                  70                  75
Pro Asn Ala Thr Ala Arg Ala Ser Cys Pro Trp Tyr Leu Pro Trp
                80                  85                  90
His His His Val Ala Ala Gly Phe Val Leu Arg Gln Cys Gly Ser
                95                 100                 105
Asp Gly Gln Trp Gly Leu Trp Arg Asp His Thr Gln Cys Glu Asn
               110                 115                 120
Pro Glu Lys Asn Glu Ala Phe Leu Asp Gln Arg Leu Ile Leu Glu
               125                 130                 135
Arg Leu Gln Val Met Tyr Thr Val Gly Tyr Ser Leu Ser Leu Ala
               140                 145                 150
Thr Leu Leu Leu Ala Leu Leu Ile Leu Ser Leu Phe Arg Arg Leu
               155                 160                 165
His Cys Thr Arg Asn Tyr Ile His Ile Asn Leu Phe Thr Ser Phe
               170                 175                 180
Met Leu Arg Ala Ala Ala Ile Leu Ser Arg Asp Arg Leu Leu Pro
               185                 190                 195
Arg Pro Gly Pro Tyr Leu Gly Asp Gln Ala Leu Ala Leu Trp Asn
               200                 205                 210
Gln Ala Leu Ala Ala Cys Arg Thr Ala Gln Ile Val Thr Gln Tyr
               215                 220                 225
Cys Val Gly Ala Asn Tyr Thr Trp Leu Leu Val Glu Gly Val Tyr
               230                 235                 240
Leu His Ser Leu Leu Val Leu Val Gly Gly Ser Glu Glu Gly His
               245                 250                 255
Phe Arg Tyr Tyr Leu Leu Leu Gly Trp Gly Ala Gly Ser Ala Thr
               260                 265                 270
Lys Ser Arg Pro Phe Gly Gly Leu Tyr Gly Pro Pro Ser Ser
               275                 280
```

<210> 17
<211> 400
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510384CD1

<400> 17

```
Met Asp Arg Arg Met Trp Gly Ala His Val Phe Cys Val Leu Ser
  1               5                  10                  15
Pro Leu Pro Thr Val Leu Gly His Met His Pro Glu Cys Asp Phe
                20                  25                  30
Ile Thr Gln Leu Arg Glu Asp Glu Ser Ala Cys Leu Gln Ala Ala
                35                  40                  45
Glu Glu Met Pro Asn Thr Thr Leu Gly Cys Pro Ala Thr Trp Asp
                50                  55                  60
Gly Leu Leu Cys Trp Pro Thr Ala Gly Ser Gly Glu Trp Val Thr
                65                  70                  75
Leu Pro Cys Pro Asp Phe Phe Ser His Phe Ser Ser Glu Ser Gly
                80                  85                  90
Ala Val Lys Arg Asp Cys Thr Ile Thr Gly Trp Ser Glu Pro Phe
                95                 100                 105
Pro Pro Tyr Pro Val Ala Cys Pro Val Pro Leu Glu Leu Leu Ala
               110                 115                 120
Glu Glu Glu Ser Tyr Phe Ser Thr Val Lys Ile Ile Tyr Thr Val
               125                 130                 135
```

```
Gly His Ser Ile Ser Ile Val Ala Leu Phe Val Ala Ile Thr Ile
                140                 145                 150
Leu Val Ala Leu Arg Arg Leu His Cys Pro Arg Asn Tyr Val His
                155                 160                 165
Thr Gln Leu Phe Thr Thr Phe Ile Leu Lys Ala Gly Ala Val Phe
                170                 175                 180
Leu Lys Asp Ala Ala Leu Phe His Ser Asp Asp Thr Asp His Cys
                185                 190                 195
Ser Phe Ser Thr Val Met Ala Met Gly Glu Gly Ala Gly Gln Val
                200                 205                 210
Gly Glu Arg Gly Gly Ser Met Gln Gly Leu Cys Gly Arg Leu Pro
                215                 220                 225
Phe Arg His His Asp Gln Leu Gln Leu Ala Val Gly Arg Ser Arg
                230                 235                 240
Leu Pro Glu Leu Pro Pro Gly Leu His Leu Pro Gln Leu Lys Glu
                245                 250                 255
Ser Leu Leu Val Ala Gly Ser Arg Trp Leu Gly Ala Ala Arg Ala
                260                 265                 270
Leu His Trp His Val Gly Glu Leu Gln Thr Gly Leu Arg Gly His
                275                 280                 285
Arg Val Leu Gly Pro Gly Arg His Leu Pro Leu Leu Val Asp His
                290                 295                 300
Gln Arg Ala His Cys Pro Leu Gly Arg Gly Glu Leu Trp Ala Phe
                305                 310                 315
Ser Gln Tyr Tyr Pro His Pro Gly Glu Glu Thr Gly Ala Ser Ser
                320                 325                 330
Gly Gln Pro Pro Tyr Pro Val Ser Val Leu Ala Ser Leu Gln Val
                335                 340                 345
Asp Thr Phe Pro Asp Pro Thr Leu Trp Asn Ser Leu His His Leu
                350                 355                 360
Gln Leu Pro Ala Arg Gln Cys Trp Pro Gly His Pro Pro Pro Pro
                365                 370                 375
Gly Ala Gly Thr Gly Phe Leu Pro Gly Leu His Cys Cys His Pro
                380                 385                 390
Leu Leu Leu Pro Gln Pro Arg Gly Glu Asp
                395                 400
```

<210> 18
<211> 893
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7509976CD1

<400> 18

```
Met Pro Ser Val Cys Leu Leu Leu Leu Leu Phe Leu Ala Val Gly
  1                 5                  10                  15
Gly Ala Leu Gly Asn Arg Pro Phe Arg Ala Phe Val Val Thr Asp
             20                  25                  30
Thr Thr Leu Thr His Leu Ala Val His Arg Val Thr Gly Glu Val
             35                  40                  45
Phe Val Gly Ala Val Asn Arg Val Phe Lys Leu Ala Pro Asn Leu
             50                  55                  60
Thr Glu Leu Arg Ala His Val Thr Gly Pro Val Glu Asp Asn Ala
             65                  70                  75
Arg Cys Tyr Pro Pro Pro Ser Met Arg Val Cys Ala His Arg Leu
             80                  85                  90
Ala Pro Val Asp Asn Ile Asn Lys Leu Leu Leu Ile Asp Tyr Ala
             95                 100                 105
Ala Arg Arg Leu Val Ala Cys Gly Ser Ile Trp Gln Gly Ile Cys
            110                 115                 120
```

```
Gln Phe Leu Arg Leu Asp Asp Leu Phe Lys Leu Gly Glu Pro His
                125                 130                 135
His Arg Lys Glu His Tyr Leu Ser Gly Ala Gln Glu Pro Asp Ser
                140                 145                 150
Met Ala Gly Val Ile Val Glu Gln Gly Gln Gly Pro Ser Lys Leu
                155                 160                 165
Phe Val Gly Thr Ala Val Asp Gly Lys Ser Glu Tyr Phe Pro Thr
                170                 175                 180
Leu Ser Ser Arg Lys Leu Ile Ser Asp Glu Asp Ser Ala Asp Met
                185                 190                 195
Phe Ser Leu Val Tyr Gln Asp Glu Phe Val Ser Ser Gln Ile Lys
                200                 205                 210
Ile Pro Ser Asp Thr Leu Ser Leu Tyr Pro Ala Phe Asp Ile Tyr
                215                 220                 225
Tyr Ile Tyr Gly Phe Val Ser Ala Ser Phe Val Tyr Phe Leu Thr
                230                 235                 240
Leu Gln Leu Asp Thr Gln Gln Thr Leu Leu Asp Thr Ala Gly Glu
                245                 250                 255
Lys Phe Phe Thr Ser Lys Ile Val Arg Met Cys Ala Gly Asp Ser
                260                 265                 270
Glu Phe Tyr Ser Tyr Val Glu Phe Pro Ile Gly Cys Ser Trp Arg
                275                 280                 285
Gly Val Glu Tyr Arg Leu Val Gln Ser Ala His Leu Ala Lys Pro
                290                 295                 300
Gly Leu Leu Leu Ala Gln Ala Leu Gly Val Pro Ala Asp Glu Asp
                305                 310                 315
Val Leu Phe Thr Ile Phe Ser Gln Gly Gln Lys Asn Arg Ala Ser
                320                 325                 330
Pro Pro Arg Gln Thr Ile Leu Cys Leu Phe Thr Leu Ser Asn Ile
                335                 340                 345
Asn Ala His Ile Arg Arg Arg Ile Gln Ser Cys Tyr Arg Gly Glu
                350                 355                 360
Gly Thr Leu Ala Leu Pro Trp Leu Leu Asn Lys Glu Leu Pro Cys
                365                 370                 375
Ile Asn Thr Pro Met Gln Ile Asn Gly Asn Phe Cys Gly Leu Val
                380                 385                 390
Leu Asn Gln Pro Leu Gly Gly Leu His Val Ile Glu Gly Leu Pro
                395                 400                 405
Leu Leu Ala Asp Ser Thr Asp Gly Met Ala Ser Val Ala Ala Tyr
                410                 415                 420
Thr Tyr Arg Gln His Ser Val Val Phe Ile Gly Thr Arg Ser Gly
                425                 430                 435
Ser Leu Lys Lys Val Arg Val Asp Gly Phe Gln Asp Ala His Leu
                440                 445                 450
Tyr Glu Thr Val Pro Val Val Asp Gly Ser Pro Ile Leu Arg Asp
                455                 460                 465
Leu Leu Phe Ser Pro Asp His Arg His Ile Tyr Leu Leu Ser Glu
                470                 475                 480
Lys Gln Val Ser Gln Leu Pro Val Glu Thr Cys Glu Gln Tyr Gln
                485                 490                 495
Ser Cys Ala Ala Cys Leu Gly Ser Gly Asp Pro His Cys Gly Trp
                500                 505                 510
Cys Val Leu Arg His Arg Cys Cys Arg Glu Gly Ala Cys Leu Gly
                515                 520                 525
Ala Ser Ala Pro His Gly Phe Ala Glu Glu Leu Ser Lys Cys Val
                530                 535                 540
Gln Val Arg Val Arg Pro Asn Asn Val Ser Val Thr Ser Pro Gly
                545                 550                 555
Val Gln Leu Thr Val Thr Leu His Asn Val Pro Asp Leu Ser Ala
                560                 565                 570
Gly Val Ser Cys Ala Phe Glu Ala Ala Ala Glu Asn Glu Ala Val
                575                 580                 585
Leu Leu Pro Ser Gly Glu Leu Leu Cys Pro Ser Pro Ser Leu Gln
```

590 595 600
Glu Leu Arg Ala Leu Thr Arg Gly His Gly Ala Thr Arg Thr Val
605 610 615
Arg Leu Gln Leu Leu Ser Lys Glu Thr Gly Val Arg Phe Ala Gly
620 625 630
Ala Asp Phe Val Phe Tyr Asn Cys Ser Val Leu Gln Ser Cys Met
635 640 645
Ser Cys Val Gly Ser Pro Tyr Pro Cys His Trp Cys Lys Tyr Arg
650 655 660
His Thr Cys Thr Ser Arg Pro His Glu Cys Ser Phe Gln Glu Gly
665 670 675
Arg Val His Ser Pro Glu Gly Cys Pro Glu Ile Leu Pro Ser Gly
680 685 690
Asp Leu Leu Ile Pro Val Gly Val Met Gln Pro Leu Thr Leu Arg
695 700 705
Ala Lys Asn Leu Pro Gln Pro Gln Ser Gly Gln Lys Asn Tyr Glu
710 715 720
Cys Val Val Arg Val Gln Gly Arg Gln Gln Arg Val Pro Ala Val
725 730 735
Arg Phe Asn Ser Ser Ser Val Gln Cys Gln Asn Ala Ser Tyr Ser
740 745 750
Tyr Glu Gly Asp Glu His Gly Asp Thr Glu Leu Asp Phe Ser Val
755 760 765
Val Trp Asp Gly Asp Phe Pro Ile Asp Lys Pro Pro Ser Phe Arg
770 775 780
Ala Leu Leu Tyr Lys Cys Trp Ala Gln Arg Pro Ser Cys Gly Leu
785 790 795
Cys Leu Lys Ala Asp Pro Arg Phe Asn Cys Gly Trp Cys Ile Ser
800 805 810
Glu His Arg Cys Gln Leu Arg Thr His Cys Pro Ala Pro Lys Thr
815 820 825
Asn Trp Met His Leu Ser Gln Lys Gly Thr Arg Cys Ser His Pro
830 835 840
Arg Ile Thr Gln Ile His Pro Leu Val Gly Pro Lys Glu Gly Gly
845 850 855
Thr Arg Val Thr Ile Val Gly Asp Asn Leu Gly Leu Leu Ser Arg
860 865 870
Glu Val Gly Leu Arg Val Ala Gly Val Arg Cys Asn Ser Ile Pro
875 880 885
Ala Glu Tyr Ile Ser Ala Glu Arg
890

<210> 19
<211> 203
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510454CD1

<400> 19
Met Lys Ser Phe Leu Pro Gly Thr Cys Ile Leu Leu Cys Ser Ala
1 5 10 15
Phe Asn Leu Met Phe Phe Ser Leu Phe Arg Leu Lys Tyr Asn Ile
20 25 30
Cys Ile Ile Leu Arg Ala Cys Asn Thr Met Leu Ser Ser Asn Thr
35 40 45
Ile Met Glu Ile Phe Phe Leu Ser His Ile Asp Ile Gly Ile Trp
50 55 60
Arg Asn Leu Leu Leu Leu Leu Met Pro Ile Tyr Thr Phe Leu Ile
65 70 75
Cys Pro Gln Gln Lys Lys Pro Met Gly Leu Leu Phe Leu His Leu

```
                80                  85                  90
Ser Val Ala Asn Thr Met Thr Leu Leu Arg Lys Val Ile Pro Leu
                95                 100                 105
Ala Val Lys Ser Phe Asn Thr Lys Asn Leu Leu Asn Tyr Thr Gly
               110                 115                 120
Cys Arg Glu Phe Glu Phe Leu Tyr Arg Val Ser Trp Gly Leu Pro
               125                 130                 135
Leu Cys Thr Thr Tyr Leu Leu Ser Met Val Gln Ala Leu Arg Gly
               140                 145                 150
Ser Pro Ser Lys Ser Arg Trp Thr Trp Leu Lys Asp Lys Met Leu
               155                 160                 165
Lys Thr Pro Leu Cys Phe Phe Leu His Ser Gly Ser Ser Thr Val
               170                 175                 180
Ser Ser Thr Ser Ser Leu Cys His Leu Leu Thr Leu Ser Asn Met
               185                 190                 195
Ala Val Ser Pro Arg Ile Ser Pro
               200

<210> 20
<211> 429
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 8017335CD1

<400> 20
Met Arg Val Ser Val Pro Gly Pro Ala Ala Ala Ala Ala Pro Ala
  1                 5                  10                  15
Ala Gly Arg Glu Pro Ser Thr Pro Gly Gly Gly Ser Gly Gly Gly
               20                  25                  30
Gly Ala Val Ala Ala Ala Ser Gly Ala Ala Val Pro Gly Ser Val
               35                  40                  45
Gln Leu Ala Leu Ser Val Leu His Ala Leu Leu Tyr Ala Ala Leu
               50                  55                  60
Phe Ala Phe Ala Tyr Leu Gln Leu Trp Arg Leu Leu Leu Tyr Arg
               65                  70                  75
Glu Arg Arg Leu Ser Tyr Gln Ser Leu Cys Leu Phe Leu Cys Leu
               80                  85                  90
Leu Trp Ala Ala Leu Arg Thr Thr Leu Phe Ser Ala Ala Phe Ser
               95                 100                 105
Leu Ser Gly Ser Leu Pro Leu Leu Arg Pro Pro Ala His Leu His
              110                 115                 120
Phe Phe Pro His Trp Leu Leu Tyr Cys Phe Pro Ser Cys Leu Gln
              125                 130                 135
Phe Ser Thr Leu Cys Leu Leu Asn Leu Tyr Leu Ala Glu Val Ile
              140                 145                 150
Cys Lys Val Arg Cys Ala Thr Glu Leu Asp Arg His Lys Ile Leu
              155                 160                 165
Leu His Leu Gly Phe Ile Met Ala Ser Leu Leu Phe Leu Val Val
              170                 175                 180
Asn Leu Thr Cys Ala Met Leu Val His Gly Asp Val Pro Glu Asn
              185                 190                 195
Gln Leu Lys Trp Thr Val Phe Val Arg Ala Leu Ile Asn Asp Ser
              200                 205                 210
Leu Phe Ile Leu Cys Ala Ile Ser Leu Val Cys Tyr Ile Cys Lys
              215                 220                 225
Ile Thr Lys Met Ser Ser Ala Asn Val Tyr Leu Glu Ser Lys Gly
              230                 235                 240
Met Ser Leu Cys Gln Thr Val Val Val Gly Ser Val Val Ile Leu
              245                 250                 255
Leu Tyr Ser Ser Arg Ala Cys Tyr Asn Leu Val Val Val Thr Ile
```

```
                260                 265                 270
Ser Gln Asp Thr Leu Glu Ser Pro Phe Asn Tyr Gly Trp Asp Asn
                275                 280                 285
Leu Ser Asp Lys Ala His Val Glu Asp Ile Ser Gly Glu Glu Tyr
                290                 295                 300
Ile Val Phe Gly Met Val Leu Phe Leu Trp Glu His Val Pro Ala
                305                 310                 315
Trp Ser Val Val Leu Phe Phe Arg Ala Gln Arg Leu Asn Gln Asn
                320                 325                 330
Leu Ala Pro Ala Gly Met Ile Asn Ser His Ser Tyr Ser Ser Arg
                335                 340                 345
Ala Tyr Phe Phe Asp Asn Pro Arg Arg Tyr Asp Ser Asp Asp Asp
                350                 355                 360
Leu Pro Arg Leu Gly Ser Ser Arg Glu Gly Ser Leu Pro Asn Ser
                365                 370                 375
Gln Ser Leu Gly Trp Tyr Gly Thr Met Thr Gly Cys Gly Ser Ser
                380                 385                 390
Ser Tyr Thr Val Thr Pro His Leu Asn Gly Pro Met Thr Asp Thr
                395                 400                 405
Ala Pro Leu Leu Phe Thr Cys Ser Asn Leu Asp Leu Asn Asn His
                410                 415                 420
His Ser Leu Tyr Val Thr Pro Gln Asn
                425
```

<210> 21
<211> 101
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510197CD1

```
<400> 21
Met Asn Pro Phe Leu Ile Leu Ala Phe Val Gly Ala Ala Gly Glu
  1                 5                  10                  15
Phe His Asp Leu Pro Gln Ala Pro Pro Thr Pro Phe Pro Gly Arg
                 20                  25                  30
His Met Pro Cys His Ser Cys His Leu Ser Ser Phe Asp Cys Ala
                 35                  40                  45
Leu Ile Phe Tyr Phe Leu His Leu Thr Tyr Leu Leu Pro Ile Leu
                 50                  55                  60
Leu Gly Leu Ser Leu Ser Leu Thr Cys Phe Thr Cys Ser Leu Ile
                 65                  70                  75
Ser Leu Pro Pro Leu Ser Phe Ile His Ile Arg Ala Val Leu Glu
                 80                  85                  90
Lys Leu Gly Arg Glu Thr Ser Cys Cys Pro Leu
                 95                 100
```

<210> 22
<211> 237
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510055CD1

```
<400> 22
Met Val Arg Leu Pro Leu Gln Cys Val Leu Trp Gly Cys Leu Leu
  1                 5                  10                  15
Thr Ala Val His Pro Glu Pro Pro Thr Ala Cys Arg Glu Lys Gln
                 20                  25                  30
```

```
Tyr Leu Ile Asn Ser Gln Cys Cys Ser Leu Cys Gln Pro Gly Gln
                35                  40                  45
Lys Leu Val Ser Asp Cys Thr Glu Phe Thr Glu Thr Glu Cys Leu
                50                  55                  60
Pro Cys Gly Glu Ser Glu Phe Leu Asp Thr Trp Asn Arg Glu Thr
                65                  70                  75
His Cys His Gln His Lys Tyr Cys Asp Pro Asn Leu Gly Leu Arg
                80                  85                  90
Val Gln Gln Lys Gly Thr Ser Glu Thr Asp Thr Ile Cys Thr Cys
                95                 100                 105
Glu Glu Gly Trp His Cys Thr Ser Glu Ala Cys Glu Ser Cys Val
               110                 115                 120
Leu His Gly Ser Cys Ser Pro Gly Phe Gly Val Lys Gln Ile Ala
               125                 130                 135
Thr Gly Val Ser Asp Thr Ile Cys Glu Pro Cys Pro Val Gly Phe
               140                 145                 150
Phe Ser Asn Val Ser Ser Ala Phe Glu Lys Cys His Pro Trp Thr
               155                 160                 165
Ser Cys Glu Thr Lys Asp Leu Val Val Gln Gln Ala Gly Thr Asn
               170                 175                 180
Lys Thr Asp Val Val Cys Gly Glu Ser Trp Thr Met Gly Pro Gly
               185                 190                 195
Glu Ser Leu Gly Arg Ser Pro Gly Ser Ala Glu Ser Pro Gly Gly
               200                 205                 210
Asp Pro His His Leu Arg Asp Pro Val Cys His Pro Leu Gly Ala
               215                 220                 225
Gly Leu Tyr Gln Lys Gly Gly Gln Glu Ala Asn Gln
               230                 235
```

<210> 23
<211> 460
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7501754CD1

<400> 23

```
Met Gly Ala Pro Pro Gly Tyr Arg Pro Ser Ala Trp Val His Leu
  1               5                  10                  15
Leu His Gln Leu Pro Arg Ala Asp Phe Gln Leu Arg Pro Val Pro
                20                  25                  30
Ser Val Phe Ala Pro Gln Glu Gln Glu Tyr Gln Gln Ala Leu Leu
                35                  40                  45
Leu Val Ala Ala Leu Ala Gly Leu Gly Leu Gly Leu Ser Leu Ile
                50                  55                  60
Phe Ile Ala Val Tyr Leu Ile Arg Phe Cys Cys Cys Arg Pro Pro
                65                  70                  75
Glu Pro Pro Gly Ser Lys Ile Pro Ser Pro Gly Gly Gly Cys Val
                80                  85                  90
Thr Trp Ser Cys Ile Val Ala Leu Leu Ala Gly Cys Thr Gly Ile
                95                 100                 105
Gly Ile Gly Phe Tyr Gly Asn Ser Glu Thr Ser Asp Gly Val Ser
               110                 115                 120
Gln Leu Ser Ser Ala Leu Leu His Ala Asn His Thr Leu Ser Thr
               125                 130                 135
Ile Asp His Leu Val Leu Glu Thr Val Glu Arg Leu Gly Glu Ala
               140                 145                 150
Val Arg Thr Glu Leu Thr Thr Leu Glu Glu Val Leu Glu Pro Arg
               155                 160                 165
Thr Glu Leu Val Ala Ala Ala Arg Gly Ala Arg Arg Gln Ala Glu
               170                 175                 180
```

```
Ala Ala Ala Gln Gln Leu Gln Gly Leu Ala Phe Trp Gln Gly Val
                185                 190                 195
Pro Leu Ser Pro Leu Gln Val Ala Glu Asn Val Ser Phe Val Glu
                200                 205                 210
Glu Tyr Arg Trp Leu Ala Tyr Val Leu Leu Leu Leu Leu Glu Leu
                215                 220                 225
Leu Val Cys Leu Phe Thr Leu Leu Gly Leu Ala Lys Gln Ser Lys
                230                 235                 240
Trp Leu Val Ile Val Met Thr Val Met Ser Leu Leu Val Leu Val
                245                 250                 255
Leu Ser Trp Gly Ser Met Gly Leu Glu Ala Ala Thr Ala Val Gly
                260                 265                 270
Leu Ser Asp Phe Cys Ser Asn Pro Asp Pro Tyr Val Leu Asn Leu
                275                 280                 285
Thr Gln Glu Glu Thr Gly Leu Ser Ser Asp Ile Leu Ser Tyr Tyr
                290                 295                 300
Leu Leu Cys Asn Arg Ala Val Ser Asn Pro Phe Gln Gln Arg Leu
                305                 310                 315
Thr Leu Ser Gln Arg Ala Leu Ala Asn Ile His Ser Gln Leu Leu
                320                 325                 330
Gly Leu Glu Arg Glu Ala Val Pro Gln Phe Pro Ser Ala Gln Lys
                335                 340                 345
Pro Leu Leu Ser Leu Glu Glu Thr Leu Asn Val Thr Glu Gly Asn
                350                 355                 360
Phe His Gln Leu Val Ala Leu Leu His Cys Arg Ser Leu His Lys
                365                 370                 375
Asp Tyr Gly Ala Ala Leu Arg Gly Leu Cys Glu Asp Ala Leu Glu
                380                 385                 390
Gly Leu Leu Phe Leu Leu Leu Phe Ser Leu Leu Ser Ala Gly Ala
                395                 400                 405
Leu Ala Thr Ala Leu Cys Ser Leu Pro Arg Ala Trp Ala Leu Phe
                410                 415                 420
Pro Pro Arg Asn Pro Ser Ala Leu Cys Ser Gly Ser Arg Leu Ser
                425                 430                 435
Glu Pro Leu Leu Pro Ala Gly Leu Glu Pro Gly Ser Pro Leu Arg
                440                 445                 450
Ser Phe Pro Gly Cys Arg Arg Arg Pro His
                455                 460
```

<210> 24
<211> 218
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510517CD1

<400> 24

```
Met Ser Thr Pro Gly Val Asn Ser Ser Ala Ser Leu Ser Pro Asp
  1               5                  10                  15
Arg Leu Asn Ser Pro Val Thr Ile Pro Ala Val Met Phe Ile Phe
                20                  25                  30
Gly Val Val Gly Asn Leu Val Ala Ile Val Val Leu Cys Lys Ser
                35                  40                  45
Arg Lys Glu Gln Lys Glu Thr Thr Phe Tyr Thr Leu Val Cys Gly
                50                  55                  60
Leu Ala Val Thr Asp Leu Leu Gly Thr Leu Leu Val Ser Pro Val
                65                  70                  75
Thr Ile Ala Thr Tyr Met Lys Gly Gln Trp Pro Gly Gly Gln Pro
                80                  85                  90
Leu Cys Glu Tyr Ser Thr Phe Ile Leu Leu Phe Phe Ser Leu Ser
                95                 100                 105
```

```
Gly Leu Ser Ile Ile Cys Ala Met Ser Val Glu Arg Tyr Leu Ala
                110                 115                 120
Ile Asn His Ala Tyr Phe Tyr Ser His Tyr Val Asp Lys Arg Leu
                125                 130                 135
Ala Gly Leu Thr Leu Phe Ala Val Tyr Ala Ser Asn Val Leu Phe
                140                 145                 150
Cys Ala Leu Pro Asn Met Gly Leu Gly Ser Ser Arg Leu Gln Tyr
                155                 160                 165
Pro Asp Thr Trp Cys Phe Ile Asp Trp Thr Thr Asn Val Thr Ala
                170                 175                 180
His Ala Ala Tyr Ser Tyr Ser Trp Cys Glu Tyr Ser Ser Thr Ser
                185                 190                 195
Tyr Ile Ser Gln Val Trp Ser Glu Lys Ser Val Lys Ile Gln Ile
                200                 205                 210
Cys Arg Pro Ser Glu Leu Leu Leu
                215

<210> 25
<211> 297
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511014CD1

<400> 25
Met Ser Met Asn Asn Ser Lys Gln Leu Val Ser Pro Ala Ala Ala
  1               5                  10                  15
Leu Leu Ser Asn Thr Thr Cys Gln Thr Glu Asn Arg Leu Ser Val
                20                  25                  30
Phe Phe Ser Val Ile Phe Met Thr Val Gly Ile Leu Ser Asn Ser
                35                  40                  45
Leu Ala Ile Ala Ile Leu Met Lys Ala Tyr Gln Arg Phe Arg Gln
                50                  55                  60
Lys Ser Lys Ala Ser Phe Leu Leu Leu Ala Ser Gly Leu Val Ile
                65                  70                  75
Thr Asp Phe Phe Gly His Leu Ile Asn Gly Ala Ile Ala Val Phe
                80                  85                  90
Val Tyr Ala Ser Asp Lys Glu Trp Ile Arg Phe Asp Gln Ser Asn
                95                 100                 105
Val Leu Cys Ser Ile Phe Gly Ile Cys Met Val Phe Ser Gly Leu
                110                 115                 120
Cys Pro Leu Leu Leu Gly Ser Val Met Ala Ile Glu Arg Cys Ile
                125                 130                 135
Gly Val Thr Lys Pro Ile Phe His Ser Thr Lys Ile Thr Ser Lys
                140                 145                 150
His Val Lys Met Met Leu Ser Gly Val Cys Leu Phe Ala Val Phe
                155                 160                 165
Ile Ala Leu Leu Pro Ile Leu Gly His Arg Asp Tyr Lys Ile Gln
                170                 175                 180
Ala Ser Arg Thr Trp Cys Phe Tyr Asn Thr Glu Asp Ile Lys Asp
                185                 190                 195
Trp Glu Asp Arg Phe Tyr Leu Leu Leu Phe Ser Phe Leu Gly Leu
                200                 205                 210
Leu Ala Leu Gly Val Ser Leu Leu Cys Asn Ala Ile Thr Gly Ile
                215                 220                 225
Thr Leu Leu Arg Val Lys Phe Lys Ser Gln Gln His Arg Gln Gly
                230                 235                 240
Arg Ser His His Leu Glu Met Val Ile Gln Leu Leu Ala Ile Met
                245                 250                 255
Cys Val Ser Cys Ile Cys Trp Ser Pro Phe Leu Gly Tyr Arg Ile
                260                 265                 270
```

```
Ile Leu Asn Gly Lys Glu Lys Tyr Lys Val Tyr Glu Glu Gln Ser
                275                 280                 285
Asp Phe Leu His Arg Leu Gln Trp Pro Thr Leu Glu
                290                 295

<210> 26
<211> 917
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7506687CD1

<400> 26
Met Pro Ala Leu Gly Pro Ala Leu Leu Gln Ala Leu Trp Ala Gly
  1               5                  10                  15
Trp Val Leu Thr Leu Gln Pro Leu Pro Pro Thr Ala Phe Thr Pro
                20                  25                  30
Asn Gly Thr Tyr Leu Gln His Leu Ala Arg Asp Pro Thr Ser Gly
                35                  40                  45
Thr Leu Tyr Leu Gly Ala Thr Asn Phe Leu Phe Gln Leu Ser Pro
                50                  55                  60
Gly Leu Gln Leu Glu Ala Thr Val Ser Thr Gly Pro Val Leu Asp
                65                  70                  75
Ser Arg Asp Cys Leu Pro Pro Val Met Pro Asp Glu Cys Pro Gln
                80                  85                  90
Ala Gln Pro Thr Asn Asn Pro Asn Gln Leu Leu Leu Val Ser Pro
                95                 100                 105
Gly Ala Leu Val Val Cys Gly Ser Val His Gln Gly Val Cys Glu
               110                 115                 120
Gln Arg Arg Leu Gly Gln Leu Glu Gln Leu Leu Leu Arg Pro Glu
               125                 130                 135
Arg Pro Gly Asp Thr Gln Tyr Val Ala Ala Asn Asp Pro Ala Val
               140                 145                 150
Ser Thr Val Gly Leu Val Ala Gln Gly Leu Ala Gly Glu Pro Leu
               155                 160                 165
Leu Phe Val Gly Arg Gly Tyr Thr Ser Arg Gly Val Gly Gly Gly
               170                 175                 180
Ile Pro Pro Ile Thr Thr Arg Ala Leu Trp Pro Pro Asp Pro Gln
               185                 190                 195
Ala Ala Phe Ser Tyr Glu Glu Thr Ala Lys Leu Ala Val Gly Arg
               200                 205                 210
Leu Ser Glu Tyr Ser His His Phe Val Ser Ala Phe Ala Arg Gly
               215                 220                 225
Ala Ser Ala Tyr Phe Leu Phe Leu Arg Arg Asp Leu Gln Ala Gln
               230                 235                 240
Ser Arg Ala Phe Arg Ala Tyr Val Ser Arg Val Cys Leu Arg Asp
               245                 250                 255
Gln His Tyr Tyr Ser Tyr Val Glu Leu Pro Leu Ala Cys Glu Gly
               260                 265                 270
Gly Arg Tyr Gly Leu Ile Gln Ala Ala Ala Val Ala Thr Ser Arg
               275                 280                 285
Glu Val Ala His Gly Glu Val Leu Phe Ala Ala Phe Ser Ser Ala
               290                 295                 300
Ala Pro Pro Thr Val Gly Arg Pro Pro Ser Ala Ala Ala Gly Ala
               305                 310                 315
Ser Gly Ala Ser Ala Leu Cys Ala Phe Pro Leu Asp Glu Val Asp
               320                 325                 330
Arg Leu Ala Asn Arg Thr Arg Asp Ala Cys Tyr Thr Arg Glu Gly
               335                 340                 345
Arg Ala Glu Asp Gly Thr Glu Val Ala Tyr Ile Glu Tyr Asp Val
               350                 355                 360
```

```
Asn Ser Asp Cys Ala Gln Leu Pro Val Asp Thr Leu Asp Ala Tyr
                365                 370                 375
Pro Cys Gly Ser Asp His Thr Pro Ser Pro Met Ala Ser Arg Val
                380                 385                 390
Pro Leu Glu Ala Thr Pro Ile Leu Glu Trp Pro Gly Ile Gln Leu
                395                 400                 405
Thr Ala Val Ala Val Thr Met Glu Asp Gly His Thr Ile Ala Phe
                410                 415                 420
Leu Gly Asp Ser Gln Gly Gln Leu His Arg Val Tyr Leu Gly Pro
                425                 430                 435
Gly Ser Asp Gly His Pro Tyr Ser Thr Gln Ser Ile Gln Gln Gly
                440                 445                 450
Ser Ala Val Ser Arg Asp Leu Thr Phe Asp Gly Thr Phe Glu His
                455                 460                 465
Leu Tyr Val Met Thr Gln Ser Thr Leu Leu Lys Val Pro Val Ala
                470                 475                 480
Ser Cys Ala Gln His Leu Asp Cys Ala Ser Cys Leu Ala His Arg
                485                 490                 495
Asp Pro Tyr Cys Gly Trp Cys Val Leu Leu Gly Arg Cys Ser Arg
                500                 505                 510
Arg Ser Glu Cys Ser Arg Gly Gln Gly Pro Glu Gln Trp Leu Trp
                515                 520                 525
Ser Phe Gln Pro Glu Leu Gly Cys Leu Gln Val Ala Ala Met Ser
                530                 535                 540
Pro Ala Asn Ile Ser Arg Glu Glu Thr Arg Glu Val Phe Leu Ser
                545                 550                 555
Val Pro Asp Leu Pro Pro Leu Trp Pro Gly Glu Ser Tyr Ser Cys
                560                 565                 570
His Phe Gly Glu His Gln Ser Pro Ala Leu Leu Thr Gly Ser Gly
                575                 580                 585
Val Met Cys Pro Ser Pro Asp Pro Ser Glu Ala Pro Val Leu Pro
                590                 595                 600
Arg Gly Ala Asp Tyr Val Ser Val Ser Val Glu Leu Arg Phe Gly
                605                 610                 615
Ala Val Val Ile Ala Lys Thr Ser Leu Ser Phe Tyr Asp Cys Val
                620                 625                 630
Ala Val Thr Glu Leu Arg Pro Ser Ala Gln Cys Gln Ala Cys Val
                635                 640                 645
Ser Ser Arg Trp Gly Cys Asn Trp Cys Val Trp Gln His Leu Cys
                650                 655                 660
Thr His Lys Ala Ser Cys Asp Ala Gly Pro Met Val Ala Ser His
                665                 670                 675
Gln Ser Pro Leu Val Ser Pro Asp Pro Pro Ala Arg Gly Gly Pro
                680                 685                 690
Ser Pro Ser Pro Pro Thr Ala Pro Lys Ala Leu Ala Thr Pro Ala
                695                 700                 705
Pro Asp Thr Leu Pro Val Glu Pro Gly Ala Pro Ser Thr Ala Thr
                710                 715                 720
Ala Ser Asp Ile Ser Pro Gly Ala Ser Pro Ser Leu Leu Ser Pro
                725                 730                 735
Trp Gly Pro Trp Ala Gly Ser Gly Ser Ile Ser Ser Pro Gly Ser
                740                 745                 750
Thr Gly Ser Pro Leu His Glu Glu Pro Ser Pro Pro Ser Pro Gln
                755                 760                 765
Asn Gly Pro Gly Thr Ala Val Pro Ala Pro Thr Asp Phe Arg Pro
                770                 775                 780
Ser Ala Thr Pro Glu Asp Leu Leu Ala Ser Pro Leu Ser Pro Ser
                785                 790                 795
Glu Val Ala Ala Val Pro Pro Ala Asp Pro Gly Pro Glu Ala Leu
                800                 805                 810
His Pro Thr Val Pro Leu Asp Leu Pro Pro Ala Thr Val Pro Ala
                815                 820                 825
Thr Thr Phe Pro Gly Ala Met Gly Ser Val Lys Pro Ala Leu Asp
```

```
                830                 835                 840
Trp Leu Thr Arg Glu Gly Gly Glu Leu Pro Glu Ala Asp Glu Trp
                845                 850                 855
Thr Gly Gly Asp Ala Pro Ala Phe Ser Thr Ser Thr Leu Leu Ser
                860                 865                 870
Gly Arg Gly Asp Leu Gly Gly Lys Leu Leu Pro Leu Cys Gly Glu
                875                 880                 885
Arg Ser Gly Leu His Val Asp Ala Gly Pro Cys Gly Ala Gly Asn
                890                 895                 900
Pro Ala Ala Arg Gln Glu Pro Ala Pro Phe Pro Gly Trp Pro Arg
                905                 910                 915
Arg Gln
```

<210> 27
<211> 224
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510621CD1

<400> 27

```
Met Ala Val Glu Gly Gly Met Lys Cys Val Lys Phe Leu Leu Tyr
  1               5                  10                  15
Val Leu Leu Leu Ala Phe Cys Ala Cys Ala Val Gly Leu Ile Ala
                20                  25                  30
Val Gly Val Gly Ala Gln Leu Val Leu Ser Gln Thr Ile Ile Gln
                35                  40                  45
Gly Ala Thr Pro Gly Ser Leu Leu Pro Val Val Ile Ile Ala Val
                50                  55                  60
Gly Val Phe Leu Phe Leu Val Ala Phe Val Gly Cys Cys Gly Ala
                65                  70                  75
Cys Lys Glu Asn Tyr Cys Leu Met Ile Thr Phe Ala Ile Ala Gly
                80                  85                  90
Tyr Val Phe Arg Asp Lys Val Met Ser Glu Phe Asn Asn Asn Phe
                95                 100                 105
Arg Gln Gln Met Glu Asn Tyr Pro Lys Asn Asn His Thr Ala Ser
               110                 115                 120
Ile Leu Asp Arg Met Gln Ala Asp Phe Lys Cys Cys Gly Ala Ala
               125                 130                 135
Asn Tyr Thr Asp Trp Glu Lys Ile Pro Ser Met Ser Lys Asn Arg
               140                 145                 150
Val Pro Asp Ser Cys Cys Ile Asn Val Thr Val Gly Cys Gly Ile
               155                 160                 165
Asn Phe Asn Glu Lys Ala Ile His Lys Glu Gly Cys Val Glu Lys
               170                 175                 180
Ile Gly Gly Trp Leu Arg Lys Asn Val Leu Val Val Ala Ala Ala
               185                 190                 195
Ala Leu Gly Ile Ala Phe Val Glu Val Leu Gly Ile Val Phe Ala
               200                 205                 210
Cys Cys Leu Val Lys Ser Ile Arg Ser Gly Tyr Glu Val Met
               215                 220
```

<210> 28
<211> 114
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7505533CD1

<400> 28
Met Glu Ala Val Val Phe Val Phe Ser Leu Leu Asp Cys Cys Ala
1 5 10 15
Leu Ile Phe Leu Ser Val Tyr Phe Ile Ile Thr Leu Ser Asp Leu
20 25 30
Glu Cys Asp Tyr Ile Asn Ala Arg Ser Cys Cys Ser Lys Leu Asn
35 40 45
Lys Trp Val Ile Pro Glu Leu Ile Gly His Thr Ile Val Thr Val
50 55 60
Leu Leu Leu Met Ser Leu His Trp Phe Ile Phe Leu Leu Asn Leu
65 70 75
Pro Val Ala Thr Trp Asn Ile Tyr Arg Asn Thr Gln Ser Arg Ala
80 85 90
Ala Glu Val Thr His Glu Arg Ser His Asp Gln Ala Trp Phe Pro
95 100 105
Leu Ala Leu Leu Leu His Val Ser Leu
110

<210> 29
<211> 181
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511220CD1

<400> 29
Met Gly Ser Cys Ser Gly Arg Cys Ala Leu Val Val Leu Cys Ala
1 5 10 15
Phe Gln Leu Val Ala Ala Leu Glu Arg Gln Val Phe Asp Phe Leu
20 25 30
Gly Tyr Gln Trp Ala Pro Ile Leu Ala Asn Phe Val His Ile Ile
35 40 45
Ile Val Ile Leu Gly Leu Phe Gly Thr Ile Gln Tyr Arg Leu Arg
50 55 60
Tyr Val Met Val Tyr Thr Leu Trp Ala Ala Val Trp Val Thr Trp
65 70 75
Asn Val Phe Ile Ile Cys Phe Tyr Leu Glu Val Gly Gly Leu Leu
80 85 90
Gln Asp Ser Glu Leu Leu Thr Phe Ser Leu Ser Arg His Arg Ser
95 100 105
Trp Trp Arg Glu Arg Trp Pro Gly Cys Leu His Glu Glu Val Pro
110 115 120
Ala Val Gly Leu Gly Ala Pro His Gly Gln Ala Leu Val Ser Gly
125 130 135
Ala Gly Cys Ala Leu Glu Pro Ser Tyr Val Glu Ala Leu His Ser
140 145 150
Gly Leu Gln Ile Leu Ile Ala Leu Leu Gly Phe Val Cys Gly Cys
155 160 165
Gln Val Val Ser Val Phe Thr Glu Glu Glu Asp Ser Cys Leu Arg
170 175 180
Lys

<210> 30
<211> 1753
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510967CD1

<400> 30

```
Met Ser Val Leu Ile Ser Gln Ser Val Ile Asn Tyr Val Glu Glu
 1               5                  10                  15
Glu Asn Ile Pro Ala Leu Lys Ala Leu Leu Glu Lys Cys Lys Asp
            20                  25                  30
Val Asp Glu Arg Asn Glu Cys Gly Gln Thr Pro Leu Met Ile Ala
        35                  40                  45
Ala Glu Gln Gly Asn Leu Glu Ile Val Lys Glu Leu Ile Lys Asn
    50                  55                  60
Gly Ala Asn Cys Asn Leu Glu Asp Leu Asp Asn Trp Thr Ala Leu
65                  70                  75
Ile Ser Ala Ser Lys Glu Gly His Val His Ile Val Glu Glu Leu
                80                  85                  90
Leu Lys Cys Gly Val Asn Leu Glu His Arg Asp Met Gly Gly Trp
            95                  100                 105
Thr Ala Leu Met Trp Ala Cys Tyr Lys Gly Arg Thr Asp Val Val
        110                 115                 120
Glu Leu Leu Leu Ser His Gly Ala Asn Pro Ser Val Thr Gly Leu
    125                 130                 135
Gln Tyr Ser Val Tyr Pro Ile Ile Trp Ala Ala Gly Arg Gly His
140                 145                 150
Ala Asp Ile Val His Leu Leu Leu Gln Asn Gly Ala Lys Val Asn
155                 160                 165
Cys Ser Asp Lys Tyr Gly Thr Thr Pro Leu Val Trp Ala Ala Arg
                170                 175                 180
Lys Gly His Leu Glu Cys Val Lys His Leu Leu Ala Met Gly Ala
            185                 190                 195
Asp Val Asp Gln Glu Gly Ala Asn Ser Met Thr Ala Leu Ile Val
        200                 205                 210
Ala Val Lys Gly Gly Tyr Thr Gln Ser Val Lys Glu Ile Leu Lys
    215                 220                 225
Arg Asn Pro Asn Val Asn Leu Thr Asp Lys Asp Gly Asn Thr Ala
230                 235                 240
Leu Met Ile Ala Ser Lys Glu Gly His Thr Glu Ile Val Gln Asp
                245                 250                 255
Leu Leu Asp Ala Gly Thr Tyr Val Asn Ile Pro Asp Arg Ser Gly
            260                 265                 270
Asp Thr Val Leu Ile Gly Ala Val Arg Gly Gly His Val Glu Ile
        275                 280                 285
Val Arg Ala Leu Leu Gln Lys Tyr Ala Asp Ile Asp Ile Arg Gly
    290                 295                 300
Gln Asp Asn Lys Thr Ala Leu Tyr Trp Ala Val Glu Lys Gly Asn
305                 310                 315
Ala Thr Met Val Arg Asp Ile Leu Gln Cys Asn Pro Asp Thr Glu
                320                 325                 330
Ile Cys Thr Lys Asp Gly Glu Thr Pro Leu Ile Lys Ala Thr Lys
            335                 340                 345
Met Arg Asn Ile Glu Val Val Glu Leu Leu Leu Asp Lys Gly Ala
        350                 355                 360
Lys Val Ser Ala Val Asp Lys Lys Gly Asp Thr Pro Leu His Ile
    365                 370                 375
Ala Ile Arg Gly Arg Ser Arg Lys Leu Ala Glu Leu Leu Leu Arg
380                 385                 390
Asn Pro Lys Asp Gly Arg Leu Leu Tyr Arg Pro Asn Lys Ala Gly
                395                 400                 405
Glu Thr Pro Tyr Asn Ile Asp Cys Ser His Gln Lys Ser Ile Leu
            410                 415                 420
Thr Gln Ile Phe Gly Ala Arg His Leu Ser Pro Thr Glu Thr Asp
        425                 430                 435
Gly Asp Met Leu Gly Tyr Asp Leu Tyr Ser Ser Ala Leu Ala Asp
    440                 445                 450
Ile Leu Ser Glu Pro Thr Met Gln Pro Pro Ile Cys Val Gly Leu
455                 460                 465
```

```
Tyr Ala Gln Trp Gly Ser Gly Lys Ser Phe Leu Leu Lys Lys Leu
                470                 475                 480
Glu Asp Glu Met Lys Thr Phe Ala Gly Gln Gln Ile Glu Pro Leu
                485                 490                 495
Phe Gln Phe Ser Trp Leu Ile Val Phe Leu Thr Leu Leu Leu Cys
                500                 505                 510
Gly Gly Leu Gly Leu Leu Phe Ala Phe Thr Val His Pro Asn Leu
                515                 520                 525
Gly Ile Ala Val Ser Leu Ser Phe Leu Ala Leu Leu Tyr Ile Phe
                530                 535                 540
Phe Ile Val Ile Tyr Phe Gly Gly Arg Arg Glu Gly Glu Ser Trp
                545                 550                 555
Asn Trp Ala Trp Val Leu Ser Thr Arg Leu Ala Arg His Ile Gly
                560                 565                 570
Tyr Leu Glu Leu Leu Leu Lys Leu Met Phe Val Asn Pro Pro Glu
                575                 580                 585
Leu Pro Glu Gln Thr Thr Lys Ala Leu Pro Val Arg Phe Leu Phe
                590                 595                 600
Thr Asp Tyr Asn Arg Leu Ser Ser Val Gly Gly Glu Thr Ser Leu
                605                 610                 615
Ala Glu Met Ile Ala Thr Leu Ser Asp Ala Cys Glu Arg Glu Phe
                620                 625                 630
Gly Phe Leu Ala Thr Arg Leu Phe Arg Val Phe Lys Thr Glu Asp
                635                 640                 645
Thr Gln Gly Lys Lys Lys Trp Lys Lys Thr Cys Cys Leu Pro Ser
                650                 655                 660
Phe Val Ile Phe Leu Phe Ile Ile Gly Cys Ile Ile Ser Gly Ile
                665                 670                 675
Thr Leu Leu Ala Ile Phe Arg Val Asp Pro Lys His Leu Thr Val
                680                 685                 690
Asn Ala Val Leu Ile Ser Ile Ala Ser Val Val Gly Leu Ala Phe
                695                 700                 705
Val Leu Asn Cys Arg Thr Trp Trp Gln Val Leu Asp Ser Leu Leu
                710                 715                 720
Asn Ser Gln Arg Lys Arg Leu His Asn Ala Ala Ser Lys Leu His
                725                 730                 735
Lys Leu Lys Ser Glu Gly Phe Met Lys Val Leu Lys Cys Glu Val
                740                 745                 750
Glu Leu Met Ala Arg Met Ala Lys Thr Ile Asp Ser Phe Thr Gln
                755                 760                 765
Asn Gln Thr Arg Leu Val Val Ile Ile Asp Gly Leu Asp Ala Cys
                770                 775                 780
Glu Gln Asp Lys Val Leu Gln Met Leu Asp Thr Val Arg Val Leu
                785                 790                 795
Phe Ser Lys Gly Pro Phe Ile Ala Ile Phe Ala Ser Asp Pro His
                800                 805                 810
Ile Ile Ile Lys Ala Ile Asn Gln Asn Leu Asn Ser Val Leu Arg
                815                 820                 825
Asp Ser Asn Ile Asn Gly His Asp Tyr Met Arg Asn Ile Val His
                830                 835                 840
Leu Pro Val Phe Leu Asn Ser Arg Gly Leu Ser Asn Ala Arg Lys
                845                 850                 855
Phe Leu Val Thr Ser Ala Thr Asn Gly Asp Val Pro Cys Ser Asp
                860                 865                 870
Thr Thr Gly Ile Gln Glu Asp Ala Asp Arg Arg Val Ser Gln Asn
                875                 880                 885
Ser Leu Gly Glu Met Thr Lys Leu Gly Ser Lys Thr Ala Leu Asn
                890                 895                 900
Arg Arg Asp Thr Tyr Arg Arg Arg Gln Met Gln Arg Thr Ile Thr
                905                 910                 915
Arg Gln Met Ser Phe Asp Leu Thr Lys Leu Leu Val Thr Glu Asp
                920                 925                 930
Trp Phe Ser Asp Ile Ser Pro Gln Thr Met Arg Arg Leu Leu Asn
```

935 940 945
Ile Val Ser Val Thr Gly Arg Leu Leu Arg Ala Asn Gln Ile Ser
950 955 960
Phe Asn Trp Asp Arg Leu Ala Ser Trp Ile Asn Leu Thr Glu Gln
965 970 975
Trp Pro Tyr Arg Thr Ser Trp Leu Ile Leu Tyr Leu Glu Glu Thr
980 985 990
Glu Gly Ile Pro Asp Gln Met Thr Leu Lys Thr Ile Tyr Glu Arg
995 1000 1005
Ile Ser Lys Asn Ile Pro Thr Thr Lys Asp Val Glu Pro Leu Leu
1010 1015 1020
Glu Ile Asp Gly Asp Ile Arg Asn Phe Glu Val Phe Leu Ser Ser
1025 1030 1035
Arg Thr Pro Val Leu Val Ala Arg Asp Val Lys Val Phe Leu Pro
1040 1045 1050
Cys Thr Val Asn Leu Asp Pro Lys Leu Arg Glu Ile Ile Ala Asp
1055 1060 1065
Val Arg Ala Ala Arg Glu Gln Ile Ser Ile Gly Gly Leu Ala Tyr
1070 1075 1080
Pro Pro Leu Pro Leu His Glu Gly Pro Pro Arg Ala Pro Ser Gly
1085 1090 1095
Tyr Ser Gln Pro Pro Ser Val Cys Ser Ser Thr Ser Phe Asn Gly
1100 1105 1110
Pro Phe Ala Gly Gly Val Val Ser Pro Gln Pro His Ser Ser Tyr
1115 1120 1125
Tyr Ser Gly Met Thr Gly Pro Gln His Pro Phe Tyr Asn Arg Pro
1130 1135 1140
Phe Phe Ala Pro Tyr Leu Tyr Thr Pro Arg Tyr Tyr Pro Gly Gly
1145 1150 1155
Ser Gln His Leu Ile Ser Arg Pro Ser Val Lys Thr Ser Leu Pro
1160 1165 1170
Arg Asp Gln Asn Asn Gly Leu Gly Ser Gly Pro Ala Pro Gly Pro
1175 1180 1185
Val Val Leu Leu Asn Ser Leu Asn Val Asp Ala Val Cys Glu Lys
1190 1195 1200
Leu Lys Gln Ile Glu Gly Leu Asp Gln Ser Met Leu Pro Gln Tyr
1205 1210 1215
Cys Thr Thr Ile Lys Lys Ala Asn Ile Asn Gly Arg Val Leu Ala
1220 1225 1230
Gln Cys Asn Ile Asp Glu Leu Lys Lys Glu Met Asn Met Asn Phe
1235 1240 1245
Gly Asp Trp His Leu Phe Arg Ser Thr Val Leu Glu Met Arg Asn
1250 1255 1260
Ala Glu Ser His Val Val Pro Glu Asp Pro Arg Phe Leu Ser Glu
1265 1270 1275
Ser Ser Ser Gly Pro Ala Pro His Gly Glu Pro Ala Arg Arg Ala
1280 1285 1290
Ser His Asn Glu Leu Pro His Thr Glu Leu Ser Ser Gln Thr Pro
1295 1300 1305
Tyr Thr Leu Asn Phe Ser Phe Glu Glu Leu Asn Thr Leu Gly Leu
1310 1315 1320
Asp Glu Gly Ala Pro Arg His Ser Asn Leu Ser Trp Gln Ser Gln
1325 1330 1335
Thr Arg Arg Thr Pro Ser Leu Ser Ser Leu Asn Ser Gln Asp Ser
1340 1345 1350
Ser Ile Glu Ile Ser Lys Leu Thr Asp Lys Val Gln Ala Glu Tyr
1355 1360 1365
Arg Asp Ala Tyr Arg Glu Tyr Ile Ala Gln Met Ser Gln Leu Glu
1370 1375 1380
Gly Gly Pro Gly Ser Thr Thr Ile Ser Gly Arg Ser Ser Pro His
1385 1390 1395
Ser Thr Tyr Tyr Met Gly Gln Ser Ser Ser Gly Gly Ser Ile His
1400 1405 1410

```
Ser Asn Leu Glu Gln Glu Lys Gly Lys Asp Ser Glu Pro Lys Pro
                1415                1420                1425
Asp Asp Gly Arg Lys Ser Phe Leu Met Lys Arg Gly Asp Val Ile
                1430                1435                1440
Asp Tyr Ser Ser Ser Gly Val Ser Thr Asn Asp Ala Ser Pro Leu
                1445                1450                1455
Asp Pro Ile Thr Glu Glu Asp Glu Lys Ser Asp Gln Ser Gly Ser
                1460                1465                1470
Lys Leu Leu Pro Gly Lys Lys Ser Ser Glu Arg Ser Ser Leu Phe
                1475                1480                1485
Gln Thr Asp Leu Lys Leu Lys Gly Ser Gly Leu Arg Tyr Gln Lys
                1490                1495                1500
Leu Pro Ser Asp Glu Asp Glu Ser Gly Thr Glu Glu Ser Asp Asn
                1505                1510                1515
Thr Pro Leu Leu Lys Asp Asp Lys Asp Arg Lys Ala Glu Gly Lys
                1520                1525                1530
Val Glu Arg Val Pro Lys Ser Pro Glu His Ser Ala Glu Pro Ile
                1535                1540                1545
Arg Thr Phe Ile Lys Ala Lys Glu Tyr Leu Ser Asp Ala Leu Leu
                1550                1555                1560
Asp Lys Lys Asp Ser Ser Asp Ser Gly Val Arg Ser Ser Glu Ser
                1565                1570                1575
Ser Pro Asn His Ser Leu His Asn Glu Val Ala Asp Asp Ser Gln
                1580                1585                1590
Leu Glu Lys Ala Asn Leu Ile Glu Leu Glu Asp Asp Ser His Ser
                1595                1600                1605
Gly Lys Arg Gly Ile Pro His Ser Leu Ser Gly Leu Gln Asp Pro
                1610                1615                1620
Ile Ile Ala Arg Met Ser Ile Cys Ser Glu Asp Lys Lys Ser Pro
                1625                1630                1635
Ser Glu Cys Ser Leu Ile Ala Ser Ser Pro Glu Glu Asn Trp Pro
                1640                1645                1650
Ala Cys Gln Lys Ala Tyr Asn Leu Asn Arg Thr Pro Ser Thr Val
                1655                1660                1665
Thr Leu Asn Asn Asn Ser Ala Pro Ala Asn Arg Ala Asn Gln Asn
                1670                1675                1680
Phe Asp Glu Met Glu Gly Ile Arg Glu Thr Ser Gln Val Ile Leu
                1685                1690                1695
Arg Pro Ser Ser Ser Pro Asn Pro Thr Thr Ile Gln Asn Glu Asn
                1700                1705                1710
Leu Lys Ser Met Thr His Lys Arg Ser Gln Arg Ser Ser Tyr Thr
                1715                1720                1725
Arg Leu Ser Lys Asp Pro Pro Glu Leu His Ala Ala Ala Ser Ser
                1730                1735                1740
Glu Ser Thr Gly Phe Gly Glu Glu Arg Glu Ser Ile Leu
                1745                1750
```

<210> 31
<211> 786
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511298CD1

<400> 31

```
Met Gly Gly Arg Val Phe Leu Ala Phe Cys Val Trp Leu Thr Leu
  1               5                  10                  15
Pro Gly Ala Glu Thr Gln Asp Ser Arg Gly Cys Ala Arg Trp Cys
                20                  25                  30
Pro Gln Asn Ser Ser Cys Val Asn Ala Thr Ala Cys Arg Cys Asn
                35                  40                  45
```

```
Pro Gly Phe Ser Ser Phe Ser Glu Ile Ile Thr Thr Pro Thr Glu
                50                  55                  60
Thr Cys Asp Asp Ile Asn Glu Cys Ala Thr Pro Ser Lys Val Ser
                65                  70                  75
Cys Gly Lys Phe Ser Asp Cys Trp Asn Thr Glu Gly Ser Tyr Asp
                80                  85                  90
Cys Val Cys Ser Pro Gly Tyr Glu Pro Val Ser Gly Ala Lys Thr
                95                 100                 105
Phe Lys Asn Glu Ser Glu Asn Thr Cys Gln Asp Val Asp Glu Cys
               110                 115                 120
Gln Gln Asn Pro Arg Leu Cys Lys Ser Tyr Gly Thr Cys Val Asn
               125                 130                 135
Thr Leu Gly Ser Tyr Thr Cys Gln Cys Leu Pro Gly Phe Lys Phe
               140                 145                 150
Ile Pro Glu Asp Pro Lys Val Cys Thr Asp Val Asp Glu Cys Ser
               155                 160                 165
Ser Gly Gln His Gln Cys Asp Ser Ser Thr Val Cys Phe Asn Thr
               170                 175                 180
Val Gly Ser Tyr Ser Cys Arg Cys Arg Pro Gly Trp Lys Pro Arg
               185                 190                 195
His Gly Ile Pro Asn Asn Gln Lys Asp Thr Val Cys Glu Asp Met
               200                 205                 210
Thr Phe Ser Thr Trp Thr Pro Pro Pro Gly Val His Ser Gln Thr
               215                 220                 225
Leu Ser Arg Phe Phe Asp Lys Val Gln Asp Leu Gly Arg Asp Ser
               230                 235                 240
Lys Thr Ser Ser Ala Glu Val Thr Ile Gln Asn Val Ile Lys Leu
               245                 250                 255
Val Asp Glu Leu Met Glu Ala Pro Gly Asp Val Glu Ala Leu Ala
               260                 265                 270
Pro Pro Val Arg His Leu Ile Ala Thr Gln Leu Leu Ser Asn Leu
               275                 280                 285
Glu Asp Ile Met Arg Ile Leu Ala Lys Ser Leu Pro Lys Gly Pro
               290                 295                 300
Phe Thr Tyr Ile Ser Pro Ser Asn Thr Glu Leu Thr Leu Met Ile
               305                 310                 315
Gln Glu Arg Gly Asp Lys Asn Val Thr Met Gly Gln Ser Ser Ala
               320                 325                 330
Arg Met Lys Leu Asn Trp Ala Val Ala Ala Gly Ala Glu Asp Pro
               335                 340                 345
Gly Pro Ala Val Ala Gly Ile Leu Ser Ile Gln Asn Met Thr Thr
               350                 355                 360
Leu Leu Ala Asn Ala Ser Leu Asn Leu His Ser Lys Lys Gln Ala
               365                 370                 375
Glu Leu Glu Glu Ile Tyr Glu Ser Ser Ile Arg Gly Val Gln Leu
               380                 385                 390
Arg Arg Leu Ser Ala Val Asn Ser Ile Phe Leu Ser His Asn Asn
               395                 400                 405
Thr Lys Glu Leu Asn Ser Pro Ile Leu Phe Ala Phe Ser His Leu
               410                 415                 420
Glu Ser Ser Asp Gly Glu Ala Gly Arg Asp Pro Pro Ala Lys Asp
               425                 430                 435
Val Met Pro Gly Pro Arg Gln Glu Leu Leu Cys Ala Phe Trp Lys
               440                 445                 450
Ser Asp Ser Asp Arg Gly Gly His Trp Ala Thr Glu Gly Cys Gln
               455                 460                 465
Val Leu Gly Ser Lys Asn Gly Ser Thr Thr Cys Gln Cys Ser His
               470                 475                 480
Leu Ser Ser Phe Ala Ile Leu Met Ala His Tyr Asp Val Glu Asp
               485                 490                 495
Trp Lys Leu Thr Leu Ile Thr Arg Val Gly Leu Ala Leu Ser Leu
               500                 505                 510
Phe Cys Leu Leu Leu Cys Ile Leu Thr Phe Leu Leu Val Arg Pro
```

```
                515                 520                 525
Ile Gln Gly Ser Arg Thr Thr Ile His Leu His Leu Cys Ile Cys
                530                 535                 540
Leu Phe Val Gly Ser Thr Ile Phe Leu Ala Gly Ile Glu Asn Glu
                545                 550                 555
Gly Gly Gln Val Gly Leu Arg Cys Arg Leu Val Ala Gly Leu Leu
                560                 565                 570
His Tyr Cys Phe Leu Ala Ala Phe Cys Trp Met Ser Leu Glu Gly
                575                 580                 585
Leu Glu Leu Tyr Phe Leu Val Val Arg Val Phe Gln Gly Gln Gly
                590                 595                 600
Leu Ser Thr Arg Trp Leu Cys Leu Ile Gly Tyr Gly Val Pro Leu
                605                 610                 615
Leu Ile Val Gly Val Ser Ala Ala Ile Tyr Ser Lys Gly Tyr Gly
                620                 625                 630
Arg Pro Arg Tyr Cys Trp Leu Asp Phe Glu Gln Gly Phe Leu Trp
                635                 640                 645
Ser Phe Leu Gly Pro Val Thr Phe Ile Ile Leu Cys Asn Ala Val
                650                 655                 660
Ile Phe Val Thr Thr Val Trp Lys Leu Thr Gln Lys Phe Ser Glu
                665                 670                 675
Ile Asn Pro Asp Met Lys Lys Leu Lys Lys Ala Arg Ala Leu Thr
                680                 685                 690
Ile Thr Ala Ile Ala Gln Leu Phe Leu Leu Gly Cys Thr Trp Val
                695                 700                 705
Phe Gly Leu Phe Ile Phe Asp Asp Arg Ser Leu Val Leu Thr Tyr
                710                 715                 720
Val Phe Thr Ile Leu Asn Cys Leu Gln Gly Ala Phe Leu Tyr Leu
                725                 730                 735
Leu His Cys Leu Leu Asn Lys Lys Val Arg Glu Glu Tyr Arg Lys
                740                 745                 750
Trp Ala Cys Leu Val Ala Gly Gly Ser Lys Tyr Ser Glu Phe Thr
                755                 760                 765
Ser Thr Thr Ser Gly Thr Gly His Asn Gln Thr Arg Ala Leu Arg
                770                 775                 780
Ala Ser Glu Ser Gly Ile
                785
```

<210> 32
<211> 1328
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510937CD1

<400> 32

```
Met Glu Phe Tyr Glu Ser Ala Tyr Phe Ile Val Leu Ile Pro Ser
  1               5                  10                  15
Ile Val Ile Thr Val Ile Phe Leu Phe Phe Trp Leu Phe Met Lys
                20                  25                  30
Glu Thr Leu Tyr Asp Glu Val Leu Ala Lys Gln Lys Arg Glu Gln
                35                  40                  45
Lys Leu Ile Pro Thr Lys Thr Asp Lys Lys Lys Ala Glu Lys Lys
                50                  55                  60
Lys Asn Lys Lys Lys Glu Ile Gln Asn Gly Asn Leu His Glu Ser
                65                  70                  75
Asp Ser Glu Ser Val Pro Arg Asp Phe Lys Leu Ser Asp Ala Leu
                80                  85                  90
Ala Val Glu Asp Asp Gln Val Ala Pro Val Pro Leu Asn Val Val
                95                 100                 105
Glu Thr Ser Ser Ser Val Arg Glu Arg Lys Lys Lys Glu Lys Lys
```

```
                110                 115                 120
Gln Lys Pro Val Leu Glu Glu Gln Val Ile Lys Glu Ser Asp Ala
            125                 130                 135
Ser Lys Ile Pro Gly Lys Lys Val Glu Pro Val Pro Val Thr Lys
        140                 145                 150
Gln Pro Thr Pro Pro Ser Glu Ala Ala Ala Ser Lys Lys Lys Pro
    155                 160                 165
Gly Gln Lys Lys Ser Lys Asn Gly Ser Asp Asp Gln Asp Lys Lys
170                 175                 180
Val Glu Thr Leu Met Val Pro Ser Lys Arg Gln Glu Ala Leu Pro
            185                 190                 195
Leu His Gln Glu Thr Lys Gln Glu Ser Gly Ser Gly Lys Lys Lys
        200                 205                 210
Ala Ser Ser Lys Lys Gln Lys Thr Glu Asn Val Phe Val Asp Glu
    215                 220                 225
Pro Leu Ile His Ala Thr Thr Tyr Ile Pro Leu Met Asp Asn Ala
230                 235                 240
Asp Ser Ser Pro Val Val Asp Lys Arg Glu Val Ile Asp Leu Leu
            245                 250                 255
Lys Pro Asp Gln Val Glu Gly Ile Gln Lys Ser Gly Thr Lys Lys
        260                 265                 270
Leu Lys Thr Glu Thr Asp Lys Glu Asn Ala Glu Val Lys Phe Lys
    275                 280                 285
Asp Phe Leu Leu Ser Leu Lys Thr Met Met Phe Ser Glu Asp Glu
290                 295                 300
Ala Leu Cys Val Val Asp Leu Leu Lys Glu Lys Ser Gly Val Ile
            305                 310                 315
Gln Asp Ala Leu Lys Lys Ser Ser Lys Gly Glu Leu Thr Thr Leu
        320                 325                 330
Ile His Gln Leu Gln Glu Lys Asp Lys Leu Leu Ala Ala Val Lys
    335                 340                 345
Glu Asp Ala Ala Ala Thr Lys Asp Arg Cys Lys Gln Leu Thr Gln
350                 355                 360
Glu Met Met Thr Glu Lys Glu Arg Ser Asn Val Val Ile Thr Arg
            365                 370                 375
Met Lys Asp Arg Ile Gly Thr Leu Glu Lys Glu His Asn Val Phe
        380                 385                 390
Gln Asn Lys Ile His Val Ser Tyr Gln Glu Thr Gln Gln Met Gln
    395                 400                 405
Met Lys Phe Gln Gln Val Arg Glu Gln Met Glu Ala Glu Ile Ala
410                 415                 420
His Leu Lys Gln Glu Asn Gly Ile Leu Arg Asp Ala Val Ser Asn
            425                 430                 435
Thr Thr Asn Gln Leu Glu Ser Lys Gln Ser Ala Glu Leu Asn Lys
        440                 445                 450
Leu Arg Gln Asp Tyr Ala Arg Leu Val Asn Glu Leu Thr Glu Lys
    455                 460                 465
Thr Gly Lys Leu Gln Gln Glu Glu Val Gln Lys Lys Asn Ala Glu
470                 475                 480
Gln Ala Ala Thr Gln Leu Lys Val Gln Leu Gln Glu Ala Glu Arg
            485                 490                 495
Arg Trp Glu Glu Val Gln Ser Tyr Ile Arg Lys Arg Thr Ala Glu
        500                 505                 510
His Glu Ala Ala Gln Gln Asp Leu Gln Ser Lys Phe Val Ala Lys
    515                 520                 525
Glu Asn Glu Val Gln Ser Leu His Ser Lys Leu Thr Asp Thr Leu
530                 535                 540
Val Ser Lys Gln Gln Leu Glu Gln Arg Leu Met Gln Leu Met Glu
            545                 550                 555
Ser Glu Gln Lys Arg Val Asn Lys Glu Glu Ser Leu Gln Met Gln
        560                 565                 570
Val Gln Asp Ile Leu Glu Gln Asn Glu Ala Leu Lys Ala Gln Ile
    575                 580                 585
```

```
Gln Gln Phe His Ser Gln Ile Ala Ala Gln Thr Ser Ala Ser Val
                590                 595                 600
Leu Ala Glu Glu Leu His Lys Val Ile Ala Glu Lys Asp Lys Gln
                605                 610                 615
Ile Lys Gln Thr Glu Asp Ser Leu Ala Ser Glu Arg Asp Arg Leu
                620                 625                 630
Thr Ser Lys Glu Glu Glu Leu Lys Asp Ile Gln Asn Met Asn Phe
                635                 640                 645
Leu Leu Lys Ala Glu Val Gln Lys Leu Gln Ala Leu Ala Asn Glu
                650                 655                 660
Gln Ala Ala Ala Ala His Glu Leu Glu Lys Met Gln Gln Ser Val
                665                 670                 675
Tyr Val Lys Asp Asp Lys Ile Arg Leu Leu Glu Glu Gln Leu Gln
                680                 685                 690
His Glu Ile Ser Asn Lys Met Glu Glu Phe Lys Ile Leu Asn Asp
                695                 700                 705
Gln Asn Lys Ala Leu Lys Ser Glu Val Gln Lys Leu Gln Thr Leu
                710                 715                 720
Val Ser Glu Gln Pro Asn Lys Asp Val Val Glu Gln Met Glu Lys
                725                 730                 735
Cys Ile Gln Glu Lys Asp Glu Lys Leu Lys Thr Val Glu Glu Leu
                740                 745                 750
Leu Glu Thr Gly Leu Ile Gln Val Ala Thr Lys Glu Glu Glu Leu
                755                 760                 765
Asn Ala Ile Arg Thr Glu Asn Ser Ser Leu Thr Lys Glu Val Gln
                770                 775                 780
Asp Leu Lys Ala Lys Gln Asn Asp Gln Val Ser Phe Ala Ser Leu
                785                 790                 795
Val Glu Glu Leu Lys Lys Val Ile His Glu Lys Asp Gly Lys Ile
                800                 805                 810
Lys Ser Val Glu Glu Leu Leu Glu Ala Glu Leu Leu Lys Val Ala
                815                 820                 825
Asn Lys Glu Lys Thr Val Gln Asp Leu Lys Gln Glu Ile Lys Ala
                830                 835                 840
Leu Lys Glu Glu Ile Gly Asn Val Gln Leu Glu Lys Ala Gln Gln
                845                 850                 855
Leu Ser Ile Thr Ser Lys Val Gln Glu Leu Gln Asn Leu Leu Lys
                860                 865                 870
Gly Lys Glu Glu Gln Met Asn Thr Met Lys Ala Val Leu Glu Glu
                875                 880                 885
Lys Glu Lys Asp Leu Ala Asn Thr Gly Lys Trp Leu Gln Asp Leu
                890                 895                 900
Gln Glu Glu Asn Glu Ser Leu Lys Ala His Val Gln Glu Val Ala
                905                 910                 915
Gln His Asn Leu Lys Glu Ala Ser Ser Ala Ser Gln Phe Glu Glu
                920                 925                 930
Leu Glu Ile Val Leu Lys Glu Lys Glu Asn Glu Leu Lys Arg Leu
                935                 940                 945
Glu Ala Met Leu Lys Glu Arg Glu Ser Asp Leu Ser Ser Lys Thr
                950                 955                 960
Gln Leu Leu Gln Asp Val Gln Asp Glu Asn Lys Leu Phe Lys Ser
                965                 970                 975
Gln Ile Glu Gln Leu Lys Gln Gln Asn Tyr Gln Gln Ala Ser Ser
                980                 985                 990
Phe Pro Pro His Glu Glu Leu Leu Lys Val Ile Ser Glu Arg Glu
                995                1000                1005
Lys Glu Ile Ser Gly Leu Trp Asn Glu Leu Asp Ser Leu Lys Asp
               1010                1015                1020
Ala Val Glu His Gln Arg Lys Lys Asn Asn Glu Arg Gln Gln Gln
               1025                1030                1035
Val Glu Ala Val Glu Leu Glu Ala Lys Glu Val Leu Lys Lys Leu
               1040                1045                1050
Phe Pro Lys Val Ser Val Pro Ser Asn Leu Ser Tyr Gly Glu Trp
```

```
                1055                1060                1065
Leu His Gly Phe Glu Lys Lys Ala Lys Glu Cys Met Ala Gly Thr
                1070                1075                1080
Ser Gly Ser Glu Glu Val Lys Val Leu Glu His Lys Leu Lys Glu
                1085                1090                1095
Ala Asp Glu Met His Thr Leu Leu Gln Leu Glu Cys Glu Lys Tyr
                1100                1105                1110
Lys Ser Val Leu Ala Glu Thr Glu Gly Ile Leu Gln Lys Leu Gln
                1115                1120                1125
Arg Ser Val Glu Gln Glu Glu Asn Lys Trp Lys Val Lys Val Asp
                1130                1135                1140
Glu Ser His Lys Thr Ile Lys Gln Met Gln Ser Ser Phe Thr Ser
                1145                1150                1155
Ser Glu Gln Glu Leu Glu Arg Leu Arg Ser Glu Asn Lys Asp Ile
                1160                1165                1170
Glu Asn Leu Arg Arg Glu Arg Glu His Leu Glu Met Glu Leu Glu
                1175                1180                1185
Lys Ala Glu Met Glu Arg Ser Thr Tyr Val Thr Glu Val Arg Glu
                1190                1195                1200
Leu Lys Asp Leu Leu Thr Glu Leu Gln Lys Lys Leu Asp Asp Ser
                1205                1210                1215
Tyr Ser Glu Ala Val Arg Gln Asn Glu Glu Leu Asn Leu Leu Lys
                1220                1225                1230
Ala Gln Leu Asn Glu Thr Leu Thr Lys Leu Arg Thr Glu Gln Asn
                1235                1240                1245
Glu Arg Gln Lys Val Ala Gly Asp Leu His Lys Ala Gln Gln Ser
                1250                1255                1260
Leu Glu Leu Ile Gln Ser Lys Ile Val Lys Ala Ala Gly Asp Thr
                1265                1270                1275
Thr Val Ile Glu Asn Ser Asp Val Ser Pro Glu Thr Glu Ser Ser
                1280                1285                1290
Glu Lys Glu Thr Met Ser Val Ser Leu Asn Gln Thr Val Thr Gln
                1295                1300                1305
Leu Gln Gln Leu Leu Gln Ala Val Asn Gln Gln Leu Thr Lys Glu
                1310                1315                1320
Lys Glu His Tyr Gln Val Leu Glu
                1325

<210> 33
<211> 355
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511852CD1

<400> 33
Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu
  1                 5                  10                  15
Leu Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr
                 20                  25                  30
Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr
                 35                  40                  45
Tyr Asp Gln Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly
                 50                  55                  60
Gln His Ala Lys Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys
                 65                  70                  75
Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val
                 80                  85                  90
Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser Asp Gln Val
                 95                 100                 105
Glu Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys Thr Cys
```

```
                110                 115                 120
Arg Pro Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys Arg
                125                 130                 135
Leu Cys Ala Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala
                140                 145                 150
Arg Pro Gly Thr Glu Thr Ser Asp Val Val Cys Lys Pro Cys Ala
                155                 160                 165
Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr Asp Ile Cys Arg
                170                 175                 180
Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly Asn Ala Ser
                185                 190                 195
Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser Met Ala
                200                 205                 210
Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser Gln
                215                 220                 225
His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser
                230                 235                 240
Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu Gly Ser Thr
                245                 250                 255
Gly Asp Phe Ala Leu Pro Val Asp Ser Ser Pro Gly Gly His Gly
                260                 265                 270
Thr Gln Val Asn Val Thr Cys Ile Val Asn Val Cys Ser Ser Ser
                275                 280                 285
Asp His Ser Ser Gln Cys Ser Ser Gln Ala Ser Ser Thr Met Gly
                290                 295                 300
Asp Thr Asp Ser Ser Pro Ser Glu Ser Pro Lys Asp Glu Gln Val
                305                 310                 315
Pro Phe Ser Lys Glu Glu Cys Ala Phe Arg Ser Gln Leu Glu Thr
                320                 325                 330
Pro Glu Thr Leu Leu Gly Ser Thr Glu Glu Lys Pro Leu Pro Leu
                335                 340                 345
Gly Val Pro Asp Ala Gly Met Lys Pro Ser
                350                 355
```

<210> 34
<211> 295
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511077CD1

<400> 34

```
Met Gly Ala Cys Leu Gly Ala Cys Ser Leu Leu Ser Cys Ala Ser
  1                 5                  10                  15
Cys Leu Cys Gly Ser Ala Pro Cys Ile Leu Cys Ser Cys Cys Pro
                 20                  25                  30
Ala Ser Arg Asn Ser Thr Val Ser Arg Leu Ile Phe Thr Phe Phe
                 35                  40                  45
Leu Phe Leu Gly Val Leu Val Ser Ile Ile Met Leu Ser Pro Gly
                 50                  55                  60
Val Glu Ser Gln Leu Tyr Lys Leu Pro Trp Val Cys Glu Glu Gly
                 65                  70                  75
Ala Gly Ile Pro Thr Val Leu Gln Gly His Ile Asp Cys Gly Ser
                 80                  85                  90
Leu Leu Gly Tyr Arg Ala Val Tyr Arg Met Cys Phe Ala Thr Ala
                 95                 100                 105
Ala Phe Phe Phe Phe Phe Thr Leu Leu Met Leu Cys Val Ser Ser
                110                 115                 120
Ser Arg Asp Pro Arg Ala Ala Ile Gln Asn Gly Phe Trp Phe Phe
                125                 130                 135
Lys Phe Leu Ile Leu Val Gly Leu Thr Val Gly Ala Phe Tyr Ile
```

```
                140                 145                 150
Pro Asp Gly Ser Phe Thr Asn Ile Trp Phe Tyr Phe Gly Val Val
                155                 160                 165
Gly Ser Phe Leu Phe Ile Leu Ile Gln Leu Val Leu Leu Ile Asp
                170                 175                 180
Phe Ala His Ser Trp Asn Gln Arg Trp Leu Gly Lys Ala Glu Glu
                185                 190                 195
Cys Asp Ser Arg Ala Trp Tyr Ala Gly Leu Phe Phe Phe Thr Leu
                200                 205                 210
Leu Phe Tyr Leu Leu Ser Ile Ala Ala Val Ala Leu Met Phe Met
                215                 220                 225
Tyr Tyr Thr Glu Pro Ser Gly Cys His Glu Gly Lys Val Phe Ile
                230                 235                 240
Ser Leu Asn Leu Thr Phe Cys Val Cys Val Ser Ile Ala Ala Val
                245                 250                 255
Leu Pro Lys Val Gln Ser Ala Leu Leu Arg Pro Pro Ala Gly Glu
                260                 265                 270
Gln Pro Asp Ala Asp Arg Gly Val Pro Thr Tyr Ala Arg Arg His
                275                 280                 285
Thr Ala Ala Ala Ala Ala Gly Gly Ser Leu
                290                 295
```

<210> 35
<211> 203.
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511576CD1

<400> 35

```
Met Thr Ser Gln Pro Val Pro Asn Glu Thr Ile Ile Val Leu Pro
  1                 5                  10                  15
Ser Asn Val Ile Asn Phe Ser Gln Ala Glu Lys Pro Glu Pro Thr
                 20                  25                  30
Asn Gln Gly Gln Asp Ser Leu Lys Lys His Leu His Ala Glu Ile
                 35                  40                  45
Lys Val Ile Gly Phe Ile Ile Ser Gly Ser Leu Ser Ile Ala Thr
                 50                  55                  60
Glu Lys Arg Leu Thr Lys Leu Leu Val His Ser Ser Leu Val Gly
                 65                  70                  75
Ser Ile Leu Ser Ala Leu Ser Ala Leu Val Gly Phe Ile Ile Leu
                 80                  85                  90
Ser Val Lys Gln Ala Thr Leu Asn Pro Ala Ser Leu Gln Cys Glu
                 95                 100                 105
Leu Asp Lys Asn Asn Ile Pro Thr Arg Ser Tyr Val Ser Tyr Phe
                110                 115                 120
Tyr His Asp Ser Leu Tyr Thr Thr Asp Cys Tyr Thr Ala Lys Ala
                125                 130                 135
Ser Leu Ala Gly Thr Leu Ser Leu Met Leu Ile Cys Thr Leu Leu
                140                 145                 150
Glu Phe Cys Leu Ala Val Leu Thr Ala Val Leu Arg Trp Lys Gln
                155                 160                 165
Ala Tyr Ser Asp Phe Pro Gly Ser Val Leu Phe Leu Pro His Ser
                170                 175                 180
Tyr Ile Gly Asn Ser Gly Met Ser Ser Lys Met Thr His Asp Cys
                185                 190                 195
Gly Tyr Glu Glu Leu Leu Thr Ser
                200
```

<210> 36
<211> 156

<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511492CD1

<400> 36
Met Ala Ser Thr Ser Tyr Asp Tyr Cys Arg Val Pro Met Glu Asp
1 5 10 15
Gly Asp Lys Arg Cys Lys Leu Leu Leu Gly Ile Gly Ile Leu Val
20 25 30
Leu Leu Ile Ile Val Ile Leu Gly Val Pro Leu Ile Ile Phe Thr
35 40 45
Ile Lys Ala Asn Ser Glu Ala Cys Arg Asp Gly Leu Arg Ala Val
50 55 60
Met Glu Cys Arg Asn Val Thr His Leu Leu Gln Gln Glu Leu Thr
65 70 75
Glu Ala Gln Lys Gly Phe Gln Asp Val Glu Ala Gln Ala Ala Thr
80 85 90
Cys Asn His Thr Val Lys Arg Lys Pro Gly Leu Lys Arg Glu Asn
95 100 105
Arg Gly Gln Glu Val Leu Pro Gln Leu Pro Gly Leu Gln Leu Arg
110 115 120
Cys Gly Ala Pro Ala Ala Asp Cys Ala Ala Gly Pro Gln Arg Ser
125 130 135
Ala Ala Val Arg Ser Gln Glu Ala Gly Thr Ser Trp Lys Val Arg
140 145 150
Pro Ala Arg Leu Phe Ala
155

<210> 37
<211> 170
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511141CD1

<400> 37
Met Arg Pro His Leu Ser Pro Pro Leu Gln Gln Leu Leu Leu Pro
1 5 10 15
Val Leu Leu Ala Cys Ala Ala His Ser Thr Gly Ala Leu Pro Arg
20 25 30
Leu Cys Asp Val Leu Gln Val Leu Trp Glu Glu Gln Asp Gln Cys
35 40 45
Leu Gln Glu Leu Ser Arg Glu Gln Thr Gly Asp Leu Gly Thr Glu
50 55 60
Gln Pro Val Pro Gly Cys Glu Gly Met Trp Asp Asn Ile Ser Cys
65 70 75
Trp Pro Ser Ser Val Pro Gly Arg Met Val Glu Val Glu Cys Pro
80 85 90
Arg Phe Leu Arg Met Leu Thr Ser Arg Asn Gly Ser Leu Phe Arg
95 100 105
Asn Cys Thr Gln Asp Gly Trp Ser Glu Thr Phe Pro Arg Pro Asn
110 115 120
Leu Ala Cys Gly Val Asn Val Asn Asp Ser Ser Asn Glu Lys Arg
125 130 135
Glu Ala Pro Leu His Ser Gln Leu His Pro His Ala Pro Val Arg
140 145 150
Val Leu His Pro Ser Cys Pro Val Gln Leu His Gln Gly Arg Arg
155 160 165

Ala Leu Leu Leu Arg
170

<210> 38
<211> 801
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511300CD1

<400> 38
Met Gly Gly Arg Val Phe Leu Ala Phe Cys Val Trp Leu Thr Leu
1 5 10 15
Pro Gly Ala Glu Thr Gln Asp Ser Arg Gly Cys Ala Arg Trp Cys
20 25 30
Pro Gln Asn Ser Ser Cys Val Asn Ala Thr Ala Cys Arg Cys Asn
35 40 45
Pro Gly Phe Ser Ser Phe Ser Glu Ile Ile Thr Thr Pro Thr Glu
50 55 60
Thr Cys Asp Asp Ile Asn Glu Cys Ala Thr Pro Ser Lys Val Ser
65 70 75
Cys Gly Lys Phe Ser Asp Cys Trp Asn Thr Glu Gly Ser Tyr Asp
80 85 90
Cys Val Cys Ser Pro Gly Tyr Glu Pro Val Ser Gly Ala Lys Thr
95 100 105
Phe Lys Asn Glu Ser Glu Asn Thr Cys Gln Asp Val Asp Glu Cys
110 115 120
Gln Gln Asn Pro Arg Leu Cys Lys Ser Tyr Gly Thr Cys Val Asn
125 130 135
Thr Leu Gly Ser Tyr Thr Cys Gln Cys Leu Pro Gly Phe Lys Phe
140 145 150
Ile Pro Glu Asp Pro Lys Val Cys Thr Asp Val Asn Glu Cys Thr
155 160 165
Ser Gly Gln Asn Pro Cys His Ser Ser Thr His Cys Leu Asn Asn
170 175 180
Val Gly Ser Tyr Gln Cys Arg Cys Arg Pro Gly Trp Gln Pro Ile
185 190 195
Pro Gly Ser Pro Asn Gly Pro Asn Asn Thr Val Cys Glu Asp Val
200 205 210
Asp Glu Cys Ser Ser Gly Gln His Gln Cys Asp Ser Ser Thr Val
215 220 225
Cys Phe Asn Thr Val Gly Ser Tyr Ser Cys Arg Cys Arg Pro Gly
230 235 240
Trp Lys Pro Arg His Gly Ile Pro Asn Asn Gln Lys Asp Thr Val
245 250 255
Cys Glu Asp Met Thr Phe Ser Thr Trp Thr Pro Pro Pro Gly Val
260 265 270
His Ser Gln Thr Leu Ser Arg Phe Phe Asp Lys Val Gln Asp Leu
275 280 285
Gly Arg Asp Ser Lys Thr Ser Ser Ala Glu Val Thr Ile Gln Asn
290 295 300
Val Ile Lys Leu Val Asp Glu Leu Met Glu Ala Pro Gly Asp Val
305 310 315
Glu Ala Leu Ala Pro Pro Val Arg His Leu Ile Ala Thr Gln Leu
320 325 330
Leu Ser Asn Leu Glu Asp Ile Met Arg Ile Leu Ala Lys Ser Leu
335 340 345
Pro Lys Gly Pro Phe Thr Tyr Ile Ser Pro Ser Asn Thr Glu Leu
350 355 360
Thr Leu Met Ile Gln Glu Arg Gly Asp Lys Asn Val Thr Met Gly
365 370 375

```
Gln Ser Ser Ala Arg Met Lys Leu Asn Trp Ala Val Ala Ala Gly
                380                 385                 390
Ala Glu Asp Pro Gly Pro Ala Val Ala Gly Ile Leu Ser Ile Gln
                395                 400                 405
Asn Met Thr Thr Leu Leu Ala Asn Ala Ser Leu Asn Leu His Ser
                410                 415                 420
Lys Lys Gln Ala Glu Leu Glu Glu Ile Tyr Glu Ser Ser Ile Arg
                425                 430                 435
Gly Val Gln Leu Arg Arg Leu Ser Ala Val Asn Ser Ile Phe Leu
                440                 445                 450
Ser His Asn Asn Thr Lys Glu Leu Asn Ser Pro Ile Leu Phe Ala
                455                 460                 465
Phe Ser His Leu Glu Ser Ser Asp Gly Glu Ala Gly Arg Asp Pro
                470                 475                 480
Pro Ala Lys Asp Val Met Pro Gly Pro Arg Gln Glu Leu Leu Cys
                485                 490                 495
Ala Phe Trp Lys Ser Asp Ser Asp Arg Gly Gly His Trp Ala Thr
                500                 505                 510
Glu Gly Cys Gln Val Leu Gly Ser Lys Asn Gly Ser Thr Thr Cys
                515                 520                 525
Gln Cys Ser His Leu Ser Ser Phe Ala Ile Leu Met Ala His Tyr
                530                 535                 540
Asp Val Glu Asp Trp Lys Leu Thr Leu Ile Thr Arg Val Gly Leu
                545                 550                 555
Ala Leu Ser Leu Phe Cys Leu Leu Leu Cys Ile Leu Thr Phe Leu
                560                 565                 570
Leu Val Arg Pro Ile Gln Gly Ser Arg Thr Thr Ile His Leu His
                575                 580                 585
Leu Cys Ile Cys Leu Phe Val Gly Ser Thr Ile Phe Leu Ala Gly
                590                 595                 600
Ile Glu Asn Glu Gly Gly Gln Val Gly Leu Arg Cys Arg Leu Val
                605                 610                 615
Ala Gly Leu Leu His Tyr Cys Phe Leu Ala Ala Phe Cys Trp Met
                620                 625                 630
Ser Leu Glu Gly Leu Glu Leu Tyr Phe Leu Val Val Arg Val Phe
                635                 640                 645
Gln Gly Gln Gly Leu Ser Thr Arg Trp Leu Cys Leu Ile Gly Tyr
                650                 655                 660
Gly Val Pro Leu Leu Ile Val Gly Val Ser Ala Ala Ile Tyr Ser
                665                 670                 675
Lys Gly Tyr Gly Arg Pro Arg Tyr Cys Trp Leu Asp Phe Glu Gln
                680                 685                 690
Gly Phe Leu Trp Ser Phe Leu Gly Pro Val Thr Phe Ile Ile Leu
                695                 700                 705
Cys Asn Ala Val Ile Phe Val Thr Thr Val Trp Lys Leu Thr Gln
                710                 715                 720
Lys Phe Ser Glu Ile Asn Pro Asp Met Lys Lys Leu Lys Lys Ala
                725                 730                 735
Arg Ala Leu Thr Ile Thr Ala Ile Ala Gln Leu Phe Leu Leu Gly
                740                 745                 750
Cys Thr Trp Val Phe Gly Leu Phe Ile Phe Asp Asp Arg Ser Leu
                755                 760                 765
Val Leu Thr Tyr Val Phe Thr Ile Leu Asn Cys Leu Gln Gly Ala
                770                 775                 780
Phe Leu Tyr Leu Leu His Cys Leu Leu Asn Lys Lys Ala Leu Arg
                785                 790                 795
Ala Ser Glu Ser Gly Ile
                800
```

<210> 39
<211> 2714
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3048626CB1

<400> 39
cgctcctacg cctaaaatga ccaatgtgtg atttcagtgg aataaatggc gtccaaagtc 60
acagatgcta tagtctggta tcaaaagaag attggagcat atgatcaaca aatatgggaa 120
aaatctgttg aacagagaga aatcaagggg ctaaggaata aaccaaagaa aacagcacat 180
gtgaaaccag acctcataga tgttgatctt gtaagagggt ctgcatttgc aaaggcaaag 240
cctgaaagtc cttggacttc tctgaccaga aagggaattg ttcgagttgt atttttcccc 300
ttttttcttcc ggtggtggtt acaagtaaca tcaaaggtca tcttttttctg gcttcttgtc 360
ctttatcttc ttcaagttgc tgcaatagta ttattctgct ccacttctag cccacacagc 420
atacctctga cagaggtgat tgggccgata tggctgatgc tgctcctggg aactgtgcat 480
tgccagattg tttccacaag aacacccaaa cctcctctaa gtacaggggg taaaagaaga 540
aggaaattaa gaaaagcagc ccatttggaa gtacataggg aaggagatgg ttctagtacc 600
acagataaca cacaagaggg agcagttcag aaccacggta caagcacctc tcacagcgtt 660
ggcactgtct tcagagatct ctggcatgct gctttctttt tatcaggatc aaagaaagca 720
aagaattcaa ttgataaatc aactgaaact gacaatggct atgtatccct tgatgggaag 780
aagactgtta aaagcggtga agatggaata caaaaccatg aacctcagtg tgaaactatt 840
cgaccagaag agacagcctg gaacacagga acactgagga atggtcctag caaagatacc 900
caaaggacaa taacaaatgt ctctgatgaa gtctccagtg aggaaggtcc tgaaacagga 960
tactcattac gtcgtcatgt ggacaggact tctgaaggtg ttcttcggaa tagaaagtca 1020
caccattata agaaacatta ccctaatgag gacgccccta aatcgggtac tagttgcagc 1080
tctcgctgtt caagttccag acaggattct gagagtgcaa ggccagaatc tgaaacagaa 1140
gatgtgttat gggaagactt gttacattgt gcagaatgcc attcatcttg taccagtgag 1200
acagatgtgg aaaatcatca gattaatcca tgtgtgaaaa aagaatatag agatgaccct 1260
tttcatcaga gtcatttgcc ctggctccat agttcccacc caggattaga aaaaataagt 1320
gctatagtat gggaaggtaa tgattgtaag aaagcagaca tgtctgtact tgaaatcagt 1380
ggaatgataa tgaacagagt gaacagccat ataccaggaa taggatacca gatttttgga 1440
aatgcagtct ctctcatact gggtttaact ccatttgttt tccgactttc tcaagctaca 1500
gacttggaac aactcacagc acattctgct tcagaacttt atgtgattgc atttggttct 1560
aatgaagatg tcatagttct ttctatggtt ataataagtt ttgtggttcg cgtgtctctt 1620
gtgtggattt tctttttttt gctctgtgta gcagaaagaa cttataaaca gcgattactt 1680
tttgcaaaac tctttggaca tttaacatct gcaaggaggg ctcgaaaatc tgaggttcct 1740
catttccggt tgaagaaagt acagaatata aaaatgtggc tatctctccg ttcctatctt 1800
aagcgtcgag gtcctcagcg atcagttgat gtaatagttt catctgcttt cttattgact 1860
atctcagttg tatttatctg ttgtgcccag gtgcttcatg tacacgagat cttccttgat 1920
tgtcactaca attgggaatt ggtaatctgg tgcatctcgt taacactttt tctcctaaga 1980
tttgttaccc ttggatcaga aacaagtaaa aaatatagta atacctcaat attacttact 2040
gaacagataa acctctactt gaaaatggag aaaaaaccta acaaaaagga ggaactgaca 2100
ctagtgaata atgttttaaa actggctact aaactgctaa aggagttgga cagtcctttt 2160
agattatatg ggcttacaat gaatccgctg ctttataaca tcacccaggt tgttatcctg 2220
tcagctgttt ctggtgttat cagtgacttg cttggattta atttaaagct atggaagatt 2280
aagtcatgac aattcaaaga aaagaagatg tagcctcttt tccagaataa gagtactgac 2340
taagctgcct gaaagcttgt cactgattcc ttgcttcaag agtctcagct aaggagttga 2400
agtggttaca tcagactggc ctgtggaaat cctaagatta atttaccggg tcacctttt 2460
ttacaattaa tttagtcctt aaaatttaa ttttaaagct ttgaggtcct aaggtggtgg 2520
aaaggttgtt gaaccgggaa tcggattgct tgggaccctg gaaatgggcc agaaataatg 2580
ggcgaagtac caaatgttga aattagaggc catggctagg accggtttct ccaccaagcc 2640
ggaaacttgg catactttgg ggaaaatccg tgaacttgga aagtggcatg gagctgggca 2700
tgaccctaga agat 2714

<210> 40
<211> 2858
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2684425CB1

<400> 40
gaacgccgcg gggtcagggc gtgcagtctg ggacgcggga tgcttggcgc tctacctcgc 60

cgcccctgag ccttcccgtc cgcctcgcca cgcgcccgga cggcctgggg ttgctgcccg 120
tcagtctcga aaggtgtttt tggggaaaaa aatcacaatc tggacgtgag aaaggacatg 180
aggagactaa agacctggga ttttgtcaat cagaatgaaa ccaatgttga aagacttttc 240
aaatctattg ttggtggtac tctgtgacta tgttcttgga gaagctgaat atcttctctt 300
gagagagcca ggccatgtag cactaagcaa cgacacagtg tatgtggatt tccagtattt 360
tgatggtgct aatgggacac tgaggaatgt atctgtcctg ctgttggagg ccaacaccaa 420
tcagactgta actaccaagt acctcctgac caaccagtcc cagggaacac taaagtttga 480
gtgcttctat ttcaaggagg ctggtgacta ctggttcaca atgactccag aagcaacaga 540
caacagcact ccattcccct ggtgggagaa aagtgccttt ctgaaggtgg aatggcctgt 600
ctttcacgtt gacttgaata ggagtgccaa ggcagcagaa ggcaccttcc aagtgggcct 660
atttaccagt caaccactgt gcccgtttcc tgtggacaag cccaacattg tagtggatgt 720
catcttcacc aacagtcttc ctgaggcaag aagaaattca agacagccgc tggaaataag 780
aaccagcaaa aggacagaac ttgctcaagg tcagtgggtt gagtttggct gtgcaccctt 840
ggggccagaa gcctatgtca ccgtggtgct gaagctgctt gggcgagact cagtcattac 900
ctccacagga cccattgacc tggcccagaa atttggatac aaactggtga tggtgccaga 960
actcacatgt gagtccgggg tagaggtgac agtgctgcct ccaccatgca ccttcgtcca 1020
aggagtggtc actgtcttca aggaggcccc cagataccct gggaagagga ccattcactt 1080
ggctgaaaac agcctgcccc tgggagagag gaggacaatt tttaactgta ctttgtttga 1140
catggggaag aataagtact gctttgactt tggcatttca agcagaagcc atttttctgc 1200
aaaggaggag tgcatgctaa ttcagagaaa tacagctttc cagccatcca gcccatctcc 1260
tcttcagccc cagggtccag tgaagtccaa caacatcgtg actgtcactg gtatatcctt 1320
gtgcttgttc atcatcattg ccactgtgct catcacgctg tggaggaggt tcggccggcc 1380
agccaagtgc agcacacctg ctcgacacaa ctccatccac tcccccagct tccggaagaa 1440
ctcggacgag gagaatatct gcgagctgag cgagcagcgc gggagcttct cggatggggg 1500
agacgggccc acggggagtc caggggacac aggcatccct ctgacctaca ggcggagcgg 1560
gccggtacct cccgaggatg atgcctctgg cagcgagagc ttccagtcca acgcccagaa 1620
gataatccca cctctgttca gctaccgcct tgcccagcag cagttaaagg agatgaaaaa 1680
gaaaggtctg acggaaacta ccaaagtgta tcacgtgtct cagagtcccc tgacagacac 1740
tgccattgat gcggcccccа gcgctccctt agatttggaa agcccggaag aagctgcagc 1800
aaacaagttc cggatcaaat ccccatttcc ggagcagccc gcggtcagtg ccggggaaag 1860
gcctccctcc aggctggatc taaatgtgac tcaggccagt tgtgccataa gccccagcca 1920
gactctgatc cgcaagtcac aggcaaggca cgtgggcagc agaggggccc cgtccgaaag 1980
gagccatgcc aggaacgccc atttcaggag gacagcgagt ttccatgaag ccaggcaggc 2040
ccggccgttc cgagagagga gcatgtccac tctgactcca cggcaggccc ctgcctacag 2100
ctctaggacg cggacctgcg agcaggcaga ggacagattt aggcctcaga gtcgaggtgc 2160
ccacctgttt cctgaaaaac tggagcattt ccaagaggca agtggaaccc gtggtccatt 2220
aaaccctctc cctaaatcct acactttggg gcagcccttg aggaaaccag accttgggga 2280
tcaccaggca ggattagtgg ccggaattga gagaacagag ccccacagag ctcgtcgggg 2340
accgtccccc agtcacaaga gtgtctcaag gaagcagtct tctcccatat cccccaaaga 2400
taactaccag agggtcagtt ctctgagccc ttctcagtgt agaaaagaca agtgtcaaag 2460
cttccccact caccctgagt ttgccttcta tgacaatacg tcgtttggcc tcactgaggc 2520
tgagcagagg atgctggacc tcccaggata ttttgggtca aatgaagagg atgaaaccac 2580
aagtacactt agcgtggaga agctggtgat ctagactgag aatcagcctg agctttacac 2640
agctggggtc tgctactcgc gttttgtaga cttttgtgta actatttgta ccgtaggaca 2700
gaatgtgagg aggaagtaac acacagagga ggatgtgtgt gtatgcatgt gtttgaattc 2760
acaaggaaga aattatttat cttgagcttt ttcctttgtt attcaatttc tattgattta 2820
ttagtaataa caatgataat aaaatgtaaa tgagcaaa 2858

<210> 41
<211> 2445
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7505960CB1

<400> 41
ctgagccatg gggggaaagc agcgggacga ggatgacgag gcctacggga agccagtcaa 60
atacgacccc tcctttcgag gccccatcaa gaacagaagc tgcacagatg tcatctgctg 120
cgtcctcttc ctgctcttca ttctaggtta catcgtggtg gggattgtgg cctggttgta 180
tggagacccc cggcaagtcc tctaccccag gaactctact ggggcctact gtggcatggg 240
ggagaacaaa gataagccgt atctcctgta cttcaacatc ttcagctgca tcctgtccag 300

caacatcatc tcagttgctg agaacggcct acagtgcccc acaccccagg tgtgtgtgtc 360
ctcctgcccg gaggacccat ggactgtggg aaaaaacgag ttctcacaga ctgttgggga 420
agtcttctat acaaaaaaca ggaacttttg tctgccaggg gtaccctgga atatgacggt 480
gatcacaagc ctgcaacagg aactctgccc cagtttcctc ctcccctctg ctccagctct 540
gggacgctgc tttccatgga ccaacattac tccaccggcg ctcccaggga tcaccaatga 600
caccaccata cagcagggga tcagcggtct tattgacagc ctcaatgccc gagacatcag 660
tgttaagatc tttgaagatt ttgcccagtc ctggtattgg attcttgttg ccctgggggt 720
ggctctggtc ttgagcctac tgtttatctt gcttctgcgc ctggtggctg ggcccctggt 780
gctggtgctg atcctgggag tgctgggcgt gctggcatac ggcatctact actgctggga 840
ggagtaccga gtgctgcggg acaagggcgc ctccatctcc cagctgggtt tcaccaccaa 900
cctcagtgcc taccagagcg tgcaggagac ctggctggcc gccctgatcg tgttggcggt 960
gcttgaagcc atcctgctgc tggtgctcat cttcctgcgg cagcggattc gtattgccat 1020
cgccctcctg aaggaggcca gcaaggctgt gggacagatg atgtctacca tgttctaccc 1080
actggtcacc tttgtcctcc tcctcatctg cattgcctac tgggccatga ctgctctgta 1140
cctggctaca tcggggcaac cccagtatgt gctctgggca tccaacatca gctcccccgg 1200
ctgtgagaaa gtgccaataa atacatcatg caaccccacg gcccaccttg tgaactcctc 1260
gtgcccaggg ctgatgtgcg tcttccaggg ctactcatcc aaaggcctaa tccctacctt 1320
ccccttaatc tctgccttca tccgcacact ccgttaccac actgggtcat tggcatttgg 1380
agccctcatc ctgacccttg tgcagatagc ccgggtcatc ttggagtata ttgaccacaa 1440
gctcagagga gtgcagaacc ctgtagcccg ctgcatcatg tgctgtttca agtgctgcct 1500
ctggtgtctg gaaaaattta tcaagttcct aaaccgcaat gcatacatca tgatcgccat 1560
ctacgggaag aatttctgtg tctcagccaa aaatgcgttc atgctactca tgcgaaacat 1620
tgtcagggtg gtcgtcctgg acaaagtcac agacctgctg ctgttctttg ggaagctgct 1680
ggtggtcgga ggcgtggggg tcctgtcctt ctttttttc tccggtcgca tcccgggct 1740
gggtaaagac tttaagagcc cccacctcaa ctattactgg ctgcccatca tgacctccat 1800
cctgggggcc tatgtcatcg ccagcggctt cttcagcgtt ttcggcatgt gtgtggacac 1860
gctcttcctc tgcttcctgg aagacctgga gcggaacaac ggctccctgg accggcccta 1920
ctacatgtcc aagagccttc taaagattct gggcaagaag aacgaggcgc ccccggacaa 1980
caagaagagg aagaagtgac agctccggcc ctgatccagg actgcacccc acccccaccg 2040
tccagccatc caacctcact tcgccttaca ggtctccatt ttgtggtaaa aaaaggtttt 2100
aggccaggcg ccgtggctca cgcctgtaat ccaacacttt gagaggctga ggcgggcgga 2160
tcacctgagt caggagttcg agaccagcct ggccaacatg gtgaaacctc cgtctctatt 2220
aaaaatacaa aaattagccg agagtggtgg catgcacctg tcatcccagc tactcgggag 2280
gctgaggcag gagaatcgct tgaacccggg aggcagaggt tgcagtgagc cgagatcgcg 2340
ccactgcact ccaacctggg tgacagactc tgtctccaaa acaaaacaaa caaacaaaaa 2400
gattttatta aagatatttt gttaactcag taaaaaaaaa aaaag 2445

<210> 42
<211> 1248
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7507021CB1

<400> 42
gcctggttac cgggagtggg gcgcccctcc tccttatccc ctcccctctt ccctgtcccc 60
tttcacagct ggctgtagct ggccaaggag ttctcgatta aagaggaagg ggcagtgctc 120
acatttctgg gcaggtgtct ggaaaatatg aggggccacc cctctctgct gctgctatat 180
atggcattaa ccacctgcct ggatacttca cccagtgagg agacagacca agaagtcttc 240
ctgggtcccc cagaggccca gagcttcctg agtagccata cccggattcc aagagccaac 300
cactgggacc tggagctgct cacaccaggg aacctggaac gggagtgtct ggaagagagg 360
tgttcctggg aagaggccag ggagtatttt gaggacaaca ctctcacgga gcgcttttgg 420
gagagctaca tctacaatgg caaaggaggg cgtggacgag tggatgtggc cagcctggct 480
gtggggctga caggtggcat cctgctcatt gtcctggccg gcctgggagc cttttggtat 540
ctgcgctggc gacagcaccg aggccagcag ccctgtcccc aagagcctcc ccacctatga 600
gcaggcgctg gcagcctctg gggtacacga cgcacctcca ccccctaca ccagcctcag 660
gaggcctcac tgaagagctg ctttcgagac ccggctctcc gaaccgtgcc cctgattcat 720
accggattcc ggaagccgct aggcctcata gacgccgaag ctggacttgg agtggggaat 780
ggtgggagta ggggtcatcc ggcccgaggc ctgccctggc acacgcgttt ccgccgcgta 840
tggatataca catgttttcg gcaacgtgtt cccgtgtcct ggcccctcac gggcccccac 900
actctcctga ccgtgagggc actggtcagt tccgcccccg tggtaggcag acgcgcgggg 960

aaattcggac ccaggagccc agccccggct gtgccatctt gtgtatgggc agatatgacc 1020
tgacagcccc ctccagtgcc acagggtacg cacacgcaga gccccgcctg tgcacacgcg 1080
tgtcttcgtg cactccccgt gcggtacagg ggcacttcgt aacccaggga aagggcgggg 1140
ggcatatttg caagcgcgct cggtgcgggc aggctcgcat tgcacccagg gagctggagt 1200
tgagctgttc ccctaaataa aaacccttcg gaaaggagac caaaaaaa 1248

<210> 43
<211> 1989
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7509099CB1

<400> 43
gtagacgcac cctctgaaga tggtgactcc ctcctgagaa gctggacccc ttggtaaaag 60
acaaggcctt ctccaagaag aatatgaaag tgttactcag acttatttgt ttcatagctc 120
tactgatttc ttctctggag gctgataaat gcaaggaacg tgaagaaaaa ataattttag 180
tgtcatctgc aaatgaaatt gatgttcgtc cctgtcctct taacccaaat gaacacaaag 240
gcactataac ttggtataaa gatgacagca agacacctgt atctacagaa caagcctcca 300
ggattcatca acacaaagag aaactttggt ttgttcctgc taaggtggag gattcaggac 360
attactattg cgtggattgc aaacctctac ttcttgacaa tatacacttt agtggagtca 420
aagataggct catcgtgatg aatgtggctg aaaagcatag agggaactat acttgtcatg 480
catcctacac atacttgggc aagcaatatc ctattacccg ggtaatagaa tttattactc 540
tagaggaaaa caaacccaca aggcctgtga ttgtgagccc agctaatgag acaatggaag 600
tagacttggg atcccagata caattgatct gtaatgtcac cggccagttg agtgacattg 660
cttactggaa gtggaatggg tcagtaattg atgaagatga cccagtgcta ggggaagact 720
attacagtgt ggaaaatcct gcaaacaaaa gaaggagtac cctcatcaca gtgcttaata 780
tatcggaaat tgaaagtaga ttttataaac atccatttac ctgttttgcc aagaatacac 840
atggtataga tgcagcatat atccagttaa tatatccagt cactaatttc cagaagcaca 900
tgattggtat atgtgtcacg ttgacagtca taattgtgtg ttctgttttc atctataaaa 960
tcttcaagat tgacattgtg ctttggtaca gggattcctg ctatgatttt ctcccaataa 1020
aagcttcaga tggaaagacc tatgacgcat atatactgta tccaaagact gttggggaag 1080
ggtctacctc tgactgtgat atttttgtgt ttaaagtctt gcctgaggtc ttggaaaaac 1140
agtgtggata taagctgttc atttatggaa gggatgacta cgttggggaa gacattgttg 1200
aggtcattaa tgaaaacgta aagaaaagca gaagactgat tatcatttta gtcagagaaa 1260
catcaggctt cagctggctg ggtggttcat ctgaagagca aatagccatg tataatgctc 1320
ttgttcagga tggaattaaa gttgtcctgc ttgagctgga gaaaatccaa gactatgaga 1380
aaatgccaga atcgattaaa ttcattaagc agaaacatgg ggctatccgc tggtcagggg 1440
actttacaca gggaccacag tctgcaaaga caaggttctg gaagaatgtc aggtaccaca 1500
tgccagtcca gcgacggtca ccttcatcta aacaccagtt actgtcacca gccactaagg 1560
agaaactgca aagagaggct cacgtgcctc tcgggtagca tggagaagtt gccaagagtt 1620
ctttaggtgc ctcctgtctt atggcgttgc aggccaggtt atgcctcatg ctgacttgca 1680
gagttcatgg aatgtaacta tatcatcctt tatccctgag gtcacctgga atcagattat 1740
taagggaata agccatgacg tcaatagcag cccagggcac ttcagagtag agggcttggg 1800
aagatctttt aaaaaggcag taggcccggt gtggtggctc acgcctataa tcccagcact 1860
ttgggaggct gaagtgggtg gatcaccaga ggtcaggagt tcgagaccag cccagccaac 1920
atggcaaaac cccatctcta ctaaaaatac aaaaatgagc taggcatggt ggcacacgcc 1980
tgtaatccc 1989

<210> 44
<211> 1863
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7509361CB1

<400> 44
tcccaccttc tctcccctcc tctctgcttt aattttctca gaattctctg gactgaggct 60
ccagttctgg cctttggggt tcaagatcac tgggaccagg ccgtgatctc tatgcccgag 120

tctcaaccct caactgtcac cccaaggcac ttgggacgtc ctggacagac cgagtcccgg 180
gaagccccag cactgccgct gccacactgc cctgagccca aatgggggag tgagaggcca 240
tagctgtctg gcatgggcct ctccaccgtg cctgacctgc tgctgccact ggtgctcctg 300
gagctgttgg tgggaatata cccctcaggg gttattggac tggtccctca cctaggggac 360
agggagaaga gagatagtgt gtgtccccaa ggaaaatata tccaccctca aaataattcg 420
atttgctgta ccaagtgcca caaaggaacc tacttgtaca atgactgtcc aggcccgggg 480
caggatacgg actgcaggga gtgtgagagc ggctccttca ccgcttcaga aaaccacctc 540
agacactgcc tcagctgctc caaatgccga aaggaaatgg gtcaggtgga gatctcttct 600
tgcacagtgg accgggacac cgtgtgtggc tgcaggaaga accagtaccg gcattattgg 660
agtgaaaacc ttttccagtg cttcaattgc agcctctgcc tcaatgggac cgtgcacctc 720
tcctgccagg agaaacagaa caccgtgtgc acctgccatg caggtttctt tctaagagaa 780
aacgagtgtg tctcctgtag taactgtaag aaaagcctgg agtgcacgaa gttgtgccta 840
ccccagattg agaatgttaa gggcactgag gactcagaga ggtggcacca ccctatcagg 900
gggctgaccc catccttgcg acagccctcg cctccgaccc catccccaac ccccttcaga 960
agtgggagga cagcgcccac aagccacaga gcctagacac tgatgacccc gcgacgctgt 1020
acgccgtggt ggagaacgtg cccccgttgc gctggaagga attcgtgcgg cgcctagggc 1080
tgagcgacca cgagatcgat cggctggagc tgcagaacgg gcgctgcctg cgcgaggcgc 1140
aatacagcat gctggcgacc tggaggcggc gcacgccgcg gcgcgaggcc acgctggagc 1200
tgctgggacg cgtgctccgc gacatggacc tgctgggctg cctggaggac atcgaggagg 1260
cgctttgcgg ccccgccgcc ctcccgcccg cgcccagtct tctcagatga ggctgcgccc 1320
ctgcgggcag ctctaaggac cgtcctgcga gatcgccttc caaccccact tttttctgga 1380
aaggaggggt cctgcagggg caagcaggag ctagcagccg cctacttggt gctaaccccc 1440
cgatgtacat agcttttctc agctgcctgc gcgccgccga cagtcagcgc tgtgcgcgcg 1500
gagagaggtg cgccgtgggc tcaagagcct gagtgggtgg tttgcgagga tgagggacgc 1560
tatgcctcat gcccgttttg ggtgtcctca ccagcaaggc tgctcggggg cccctggttc 1620
gtccctgagc ctttttcaca gtgcataagc agtttttttt gtttttgttt tgttttgttt 1680
tgtttttaaa tcaatcatgt tacactaata gaaacttggc actcctgtgc cctctgcctg 1740
gacaagcaca tagcaagctg aactgtccta aggcaggggc gagcacggaa caatggggcc 1800
ttcagctgga gctgtggact tttgtacata cactaaaatt ctgaagttaa aaaaaaaaaa 1860
aaa 1863

<210> 45
<211> 1734
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7506815CB1

<400> 45
ggggcagggg gcagggagag gagggcggcg ggacgtgagc cggaatcgca gcgtgacgag 60
gtggagcctg cggtgggagc cgccgggtcg agctgagtaa ggcggctggg ctcggtgggg 120
gccatggagc tgctaaagct gaaccggagc gtgcagggaa ccggacccgg gccgggggct 180
tccctgtgcc gcccgggggc ccctctcctc aacagcagca gtgtgggcaa cctcagctgc 240
gagccccctc gcattcgcgg agccgggaca cgaggggtgt ctgtgagtgt gtccacgcta 300
agcctcgtgg ccatcgcact ggagcggtac agcgccatct gccgaccact gcaggcacga 360
gtgtggcaga cgcgctccca cgcggctcgc gtgattgtag ccacgtggct gctgtccgga 420
ctactcatgg tgccctaccc cgtgtacact gtcgtgcaac cagtggggcc tcgtgtgctg 480
cagtgcgtgc atcgctggcc cagtgcgcgg gtccgccaga cctggtccgt actgctgctt 540
ctgctcttgt tcttcatccc gggtgtggtt atggccgtgg cctacgggct tatctctcgc 600
gagctctact tagggcttcg ctttgacggc gacagtgaca gcgacagcca aagcagggtc 660
cgaaaccaag gcgggctgcc aggggctgtt caccagaacg ggcgttgccg gcctgagact 720
ggcgcggttg gcgaagacag cgatggctgc tacgtgcaac ttccacgttc ccggcctgcc 780
ctggagctga cggcgctgac ggctcctggg ccgggatccg gctcccggcc cacccaggcc 840
aagctgctgg ctaagaagcg cgtggtgcga atgttgctgg tgatcgttgt gctttttttt 900
ctgtgttggt tgccagttta tagtgccaac acgtggcgcg cctttgatgg cccgggtgca 960
caccgagcac tctcgggtgc tcctatctcc ttcattcact tgctgagcta cgcctcggcc 1020
tgtgtcaacc ccctggtcta ctgcttcatg caccgtcgct ttcgccaggc ctgcctggaa 1080
acttgcgctc gctgctgccc ccggcctcca cgagctcgcc ccagggctct tcccgatgag 1140
gaccctccca ctccctccat tgcttcgctg tccaggctta gctacaccac catcagcaca 1200
ctgggccctg gctgaggagt agaggggccg tgggggttga ggcagggcaa atgacatgca 1260
ctgacccttc cagacataga aaacacaaac cacaactgac acaggaaacc aacacccaaa 1320

gcatggacta accccaacgc acaggaaaag gtagcttacc tgacacaaga ggaataagaa 1380
tggagcagta catgggaaag gaggcatgcc tctgatatgg gactgagcct ggcccataga 1440
aacatgacac tgaccttgga gagacacagc gtccctagca gtgaactatt tctacacagt 1500
gggaactctg acaagggctg acctgcctct cacacacata gattaatggc actgattgtt 1560
ttagagacta tggagcctgg cacaggactg actctgggat gctcctagtt tgacctcaca 1620
gtgacccttc ccaatcagca ctgaaaatac catcaggcct aatctcatac ctctgaccaa 1680
caggctgttc tgcactgaaa aggttcttca tccctttcca gttaaggacc gtgg 1734

<210> 46
<211> 1786
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7506814CB1

<400> 46
gtgagccgga atcgcagcgt gacgaggtgg agccgcggtg ggagcccgcc gggtcgagct 60
gagtaaggcg gcgggctcgg cgggggccat ggagctgcta aagctgaacc ggagcgtgca 120
gggaaccgga cccgggccgg gggcttccct gtgccgcccg ggggcgcctc tcctcaacag 180
cagcagtgtg ggcaacctca gctgcgagcc ccctcgcatt cgcggagccg ggacacgaga 240
attggagctg gccattagaa tcactcttta cgcagtgatc ttcctgatga gcgttggagg 300
aaatatgctc atcatcgtgg tcctgggact gagccgccgc ctgaggactg tcaccaatgc 360
cttcctcctc tcactggcag tcagcgacct cctgctggct gtggcttgca tgcccttcac 420
cctcctgccc aatctcatgg gcacattcat ctttggcacc atcatctgca aggcggtttc 480
ctacctcatg ggggtgtctg tgagtgtgtc cacgctaagc ctcgtggcca tcgcactgga 540
gcggtacagc gccatctgcc gaccactgca ggcacgagtg tggcagacgc gctcccacgc 600
ggctcgcgtg attgtagcca cgtggctgct gtccggacta ctcatggtgc cctaccccgt 660
gtacactgtc gtgcaaccag tggggcctcg tgtgctgcag tgcgtgcatc gctggcccag 720
tgcgcgggtc cgccagacct ggtccgtact gctgcttctg ctcttgttct tcatcccggg 780
tgtggttatg gccgtggcct acgggcttat ctctcgcgag ctctacttag ggcttcgctt 840
tgacggcgac agtgacagcg acagccaaag cagggtccga aaccaaggcg ggctgccagg 900
ggctaagaag cgcgtggtgc gaatgttgct ggtgatcgtt gtgctttttt ttctgtgttg 960
gttgccagtt tatagtgcca acacgtggcg cgcctttgat ggcccgggtg cacaccgagc 1020
actctcgggt gctcctatct ccttcattca cttgctgagc tacgcctcgg cctgtgtcaa 1080
ccccctggtc tactgcttca tgcaccgtcg ctttcgccag gcctgcctgg aaacttgcgc 1140
tcgctgctgc ccccggcctc cacgagctcg ccccagggct cttcccgatg aggaccctcc 1200
cactccctcc attgcttcgc tgtccaggct tagctacacc accatcagca cactgggccc 1260
tggctgagga gtagaggggc cgtgggggtt gaggcagggc aaatgacatg cactgaccct 1320
tccagacata gaaaacacaa accacaactg acacaggaaa ccaacaccca aagcatggac 1380
taaccccaac gcacaggaaa aggtagctta cctgacacaa gaggaataag aatggagcag 1440
tacatgggaa aggaggcatg cctctgatat gggactgagc ctggcccata gaaacatgac 1500
actgaccttg gagagacaca gcgtccctag cagtgaacta tttctacaca gtgggaactc 1560
tgacaagggc tgacctgcct ctcacacaca tagattaatg gcactgattg ttttagagac 1620
tatggagcct ggcacaggac tgactctggg atgctcctag tttgacctca cagtgaccct 1680
tcccaatcag cactgaaaat accatcaggc ctaatctcat acctctgacc aacaggctgt 1740
tctgcactga aaaggttctt catccctttc cagttaagga ccgtgg 1786

<210> 47
<211> 2193
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7506852CB1

<400> 47
gtccagagcc cagcccagcc ctaccgcgcg cggcccggag ctctgttccc tggaactttg 60
ggcactgcct ctgggacccc tgccggccag caggcaggat ggtgcttgcc tcgtgccccc 120
tggtgcccgt ctgctgatgt gcccagcctg tgcccgccat gccgccctcc atctcagctt 180
tccaggccgc ctacatcggc atcgaggtgc tcatcgccct ggtctctgtg cccgggaacg 240

tgctggtgat ctgggcggtg aaggtgaacc aggcgctgcg ggatgccacc ttctgcttca 300
tcgtgtcgct ggcggtggct gatgtggccg tgggtgccct ggtcatcccc ctcgccatcc 360
tcatcaacat tgggccacag acctacttcc acacctgcct catggttgcc tgtccggtcc 420
tcatcctcac ccagagctcc atcctggccc tgctggcaat tgctgtggac cgctacctcc 480
gggtcaagat ccctctccgg agaataagcc aatgcatggc aagcactaaa tcttagatcc 540
tgaagactca gccctcgagc aaaagacatg cacctcccca ctcaccgggc cctggaagag 600
gagggtgctc ctcttagagg cccctggagg ccaggcgtgc ctcagagggg cctttcgagg 660
cagctgggag gcagatcctc acactctgcc ctcctctccc ccaggtacaa gatggtggtg 720
acccccggga gggcggcggt ggccatagcc ggctgctgga tcctctcctt cgtggtggga 780
ctgaccccta tgtttggctg gaacaatctg agtgcggtgg agcgggcctg ggcagccaac 840
ggcagcatgg gggagcccgt gatcaagtgc gagttcgaga aggtcatcag catggagtac 900
atggtctact tcaacttctt tgtgtgggtg ctgcccccgc ttctcctcat ggtcctcatc 960
tacctggagg tcttctacct aatccgcaag cagctcaaca agaaggtgtc ggcctcctcc 1020
ggcgacccgc agaagtacta tgggaaggag ctgaagatcg ccaagtcgct ggccctcatc 1080
ctcttcctct ttgccctcag ctggctgcct ttgcacatcc tcaactgcat caccctcttc 1140
tgcccgtcct gccacaagcc cagcatcctt acctacattg ccatcttcct cacgcacggc 1200
aactcggcca tgaaccccat tgtctatgcc ttccgcatcc agaagttccg cgtcaccttc 1260
cttaagattt ggaatgacca tttccgctgc cagcctgcac ctcccattga cgaggatctc 1320
ccagaagaga ggcctgatga ctagaccccg ccttccgctc ccaccagccc acatccagtg 1380
gggtctcagt ccagtcctca catgcccgct gtcccagggg tctccctgag cctgccccag 1440
ctgggctgtt ggctgggggc atgggggagg ctctgaagag atacccacag agtgtggtcc 1500
ctccactagg agttaactac cctacacctc tgggccctgc aggaggcctg ggagggcaag 1560
ggtcctacgg agggaccagg tgtctagagg caacagtgtt ctgagccccc acctgcctga 1620
ccatcccatg agcagtccag agcttcaggg ctgggcaggt cctggggagg ctgagactgc 1680
agaggagcca cctgggctgg gagaaggtgc ttgggcttct gcggtgaggc aggggagtct 1740
gcttgtctta gatgttggtg gtgcagcccc aggaccaagc ttaaggagag gagagcatct 1800
gctctgagac ggatggaagg agagaggttg aggatgcact ggcctgttct gtaggagaga 1860
ctggccagag gcagctaagg ggcaggaatc aaggagcctc cgttcccacc tctgaggact 1920
ctggacccca ggccatacca ggtgctaggg tgcctgctct ccttgccctg ggccagccca 1980
ggattgtacg tgggagaggc agaaagggta ggttcagtaa tcatttctga tatttgctgg 2040
agtgctggct ccacgccctg gggagtgagc ttggtgcggt aggtgctggc ctcaaacagc 2100
cacgaggtgg tagctctgag ccctccttct tgccctgagc tttccgggga ggagccttgg 2160
agtgtaatta cctgtcatct gggccaccag ctc 2193

<210> 48
<211> 3696
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7503782CB1

<400> 48
ctgtggcacc tcggcgtgcg gtcgctccgt ccagctttgt cttgtgcgtc tcgttcgtgt 60
cgcctggtct ctcggtgttc cgtgtccctc atcttctcag ctcctggccg gctcctgtct 120
atgcttccgc tcacgcttct ggggttttgg cggtatgctg cccctcggcc agcagtctct 180
gcagtccggt cgcgcatatt gtcctgctgg agtcgggagg cccgcttgtg cgtcacttgt 240
agtccccagg agcagaagac ggtgatggcg tggatgccag aggtgctgcc cacccggtag 300
ctctctccgt ttagagtgag ccatggctgt acaccaggat gatgcaggtg atcaagaagc 360
tcacgcccac agtggagagg taggcccagg cacaggtgga tacggggtgc agcaggtctt 420
ggctttcttt gcctgtgccg gtccagacgt ttctgtgccc tttggatctt tcaccccatt 480
tgacagatgg ggagactgag gccgtggctg tgtgtccctc tgagagttgg agcggggctg 540
ggcccgaatt cgaccgcagc aggattctct ctcatttctg agccccggag gtggcagagc 600
ggcagactcg ggcaagtgaa ccctagggct gcaggagccc aggccccgac gccggcgcag 660
aggggacgga agggcccgcc cccagcccag cgtgcacaga ggccatagcc aaggccttaa 720
ggctcatcca accggggact catatccccc ccaccggcag cccggcgccc cagcctctac 780
ccgtgcccgc cgagatgctg ctgccgcggt cggtgtcatc ggagcgggcc cctggggtgc 840
cggagccgga ggagctgtgg gaggcagaga tggagcggct gcgcggctct gggacgcccg 900
tgcgcgggct gccctatgcc atgatggaca agcgcctcat ctggcagctg cgggagcccg 960
cgggggtgca gaccttgcgc tggcagcggt ggcagcgccg gcggcagacg gtggaaaggc 1020
gcctgcggga ggcagcgcag cggctggccc ggggccttgg gctctgggag ggggcgctct 1080
acgagatcgg gggcctcttc ggcacaggaa ttcggtccta cttcaccttc ctccgcttcc 1140

tgctgctact caacctgctg agcctgctgc tcaccgcaag cttcgtgctg ctgcccctgg 1200
tctggctccg ccccccctgac ccaggcccca ccctgaactt gaccctccag tgccctggta 1260
gccgccagtc cccgcctggc gttttgaggt tccacaatca actttggcat gttttgactg 1320
gcagggcctt caccaacacc tatctcttct acggtgcgta ccgagtgggg ccggagagca 1380
gctccgtgta cagcatccgc ctggcctacc tcctcagccc gctggcctgc ctgctcctct 1440
gcttctgtgg gactctgcgg cggatggtga aggggctgcc gcagaagact ctgctgggtc 1500
agggctatca ggcgcctctc agcgccaagg tcttctcctc atgggacttc tgcatccggg 1560
tgcaggaagc agccaccatc aagaagcatg agatcagcaa cgagttcaag gtggagctgg 1620
aggagggccg tcgcttccag ctgatgcagc agcagacccg ggcccagacg gcctgccgcc 1680
tgctctccta cctgcgggtc aacgtactca tcgggctcct ggtggttggg gccatcagcg 1740
ccatcttctg ggctaccaag tactcacagg acaacaagga ggtgtcaggc aactgcattc 1800
atttaatcct ggccagaact gcgggggagt ccctgtttct gctgctccag tacctgcccc 1860
ctggggtcat cgccctggtc aacttcctgg gtcccctgct gttcacattt ctggtccagc 1920
tggagaacta ccctcccaac acggaggtca acctcactct gatctggtgc gtggtgctga 1980
agctggccag cttggggatg ttctccgtct ccctgggtca gaccatactg tgcattggca 2040
gagacaagag cagctgtgag tcctacggct acaacgtttg tgactatcag tgctgggaga 2100
actccgtggg ggaggagctg tacaagctga gtatcttcaa cttcctcctc accgtggcct 2160
tcgccttcct ggtcaccctg cctcggaggc tgctggtgga ccggttctca ggccggttct 2220
gggcctggct ggaacgggag gagttcctgg tccccaagaa tgtgctggac atcgtggcgg 2280
ggcagacggt cacctggatg ggcctcttct actgcccccc gctgcccctg ctgaatagcg 2340
tcttcctctt cctcaccttc tacatcaaga agtacaccct cctgaagaac tccagggcat 2400
cttcgcggcc cttccgtgcc tccagctcca ccttcttctt ccagctagtg ctcctcctgg 2460
gcctgcttct ggctgcagtg cccctgggct atgtggtcag cagcatccac tcctcctggg 2520
actgcggcct cttcaccaac tactcagcac cctggcaagt ggtcccggag ctggtggccc 2580
ttgggctccc gcccattggc cagcgtgccc tccactacct gggctcccac gccttcagct 2640
tccccctcct catcatgctc aggttctcag ggcagcaggg gccatgggag gggacacctg 2700
gagggggagg tccttccttc catgggggtg gtgagcctgt gcacccccaa ccaggagcca 2760
gacgcagaaa gccaagggaa gcaggggcct ctgaaaagca ggaacctcct gggcccaccc 2820
tctgggctgc catgggggatt gcaggatcac tggggaagca ccgtgtctgg gtggctgcag 2880
ctgctgagct attggtattg ctgtgccaga ggggagggga tgaggggctc tgcgaggaag 2940
gagaggaggg tcccatcctc agatacagca gtgtgcagtg agaagacccc agtaccgcgt 3000
attgtagaga ttgaggtggg gagagaggaa gtcagggaga ggcgcctgtg gccccagggg 3060
caactgacca cgaatccccc tcccacccaa gccttgtcct gacggtgtgc gtctcccaga 3120
cccaggccaa tgccagggcc atccacaggc tccggaagca gctggtgtgg gtgagtgtcc 3180
tcggggctgg tgaggggaca gcagcttcag tggaaaccct tccctatgtg tggccgaggg 3240
cctagaacac gtctgagcgg gtcaggtggg ttcttcccac tggagggcgt ggcctcaggc 3300
tgagagtgaa gacggggaag gggaggaaga gaacagctcg ggctcctgag accaggagcc 3360
agacctggta agtacatgac cttaggggct gggcctttgc ctgtaatccc aacgctttgg 3420
aggcccaggc aggaggatcg gatcacttga agccatgagt taaaaccagc ctgggcaaca 3480
aagcaagacc ctggtctcca ccaaaaataa gtaattaatt ttttaaaagg agaatgtggc 3540
cgggcgtggt gactcacgcc tgtaatccca gcactttcag aggccgaggt gggtggatca 3600
cctgaggtca ggagttcaag accagcctgg ccaaaatagc gaaaccccgt ctctacttaa 3660
aaaaaaaaaa aaaggggcgg gccggccaga atagtg 3696

<210> 49
<211> 1283
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7504647CB1

<400> 49
ggccgggcag ccatggctga gacactcttc tggactcctc tcctcgtggt tctcctggca 60
gggctggggg acaccgaggc ccagcagacc acgctacacc cacttgtggg ccgtgtcttt 120
gtgcacacct tggaccatga gacgtttctg agccttcctg agcatgtcgg tcacagccta 180
caatcgggac agctttgata ccactcggca gaggctggtg ctggagattg gggacccaga 240
aggccccctg ctgccatacc aagccgagtt cctggtgcgc agccacgatg cggaggaggt 300
gctgccctca acacctgcca gccgcttcct ctcagccttg gggggactct gggagcccgg 360
agagcttcag ctgctcaacg tcacctctgc cttggaccgt gggggccgtg tccccttcc 420
cattgagggc cgaaaagaag gggtatacat taaggtgggt tctgcctcac ctttttctac 480
ttgcctgaag atggtggcat cccccgatag ccacgcccgc tgtgcccagg gccagcctcc 540

acttctgtct tgctacgaca ccttggcacc ccacttccgc gttgactggt gcaatgtgac 600
cctggtggat aagtcagtgc cggagcctgc agatgaggtg cccaccccag gtgatgggat 660
cctggagcat gacccgttct tctgcccacc cactgaggcc ccagaccgtg acttcttggt 720
ggatgctctg gtcaccctcc tggtgccccc gctggtggcc ctgcttctca ccttgctgct 780
ggcctatgtc atgtgctgcc ggcgggaggg aaggctgaag agagacctgg ctacctccga 840
catccagatg gtccaccact gcaccatcca cgggaacaca gaggagctgc ggcagatggc 900
ggccagccgc gaggtgcccc ggccactctc caccctgccc atgttcaatg tgcacacagg 960
tgagcggctg cctccccgcg tggacagcgc ccaggtgccc ctcattctgg accagcactg 1020
acagcccagc cagtggttcc aggtccagcc ctgacttcat cctcccttct ctgtccacac 1080
cacgagtggc acatcccacc tgctgattcc agctcctggc cctcctggaa cccaggctct 1140
aaacaagcag ggagaggggg tggggtgggg tgagagtgtg tggagtaagg acattcagaa 1200
taaatatctg ctgctctgct caccaattgc tgctggcagc ctctcccgtc aaaaaaaaaa 1260
aaaaaaaaaa aaaaattgcg gtc 1283

<210> 50
<211> 1142
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7500424CB1

<400> 50
ggaaggggag gagcaggcca cacaggcaca ggccggtgag ggacctgccc agacctggag 60
gtggtgactt ccaagagtga ctccgtcgga ggaaaatgac tccccagtcg ctgctgcaga 120
cgacactgtt cctgctgagt ctgctcttcc tggtccaagg tgcccacggc aggggccaca 180
gggaagactt tcgcttctgc agccagcgga accagacaca caggagcagc ctccactaca 240
aacccacacc agacctgcgc atctccatcg agaactccga agaggccctc acagtccatg 300
ccccttcccc tgcagcccac cctgcttccc gatccttccc tgaccccagg ggcctctacc 360
acttctgcct ctactggaac cgacatgctg ggagattaca tcttctctat ggcaagcgtg 420
acttcttgct gagtgacaaa gcctctagcc tcctctgctt ccagcaccag gctcggtacc 480
gatgcgtggg ctgggctagg tccctctgtc catctgggcc tttgtatgag ctgcattgcc 540
cttgctcacc ctgaccaagc acacgcctca gaggggccct cagcctctcc tgaagccctc 600
ttgtggcaag aactgtggac catgccagtc ccgtctggtt tccatcccac cactccaagg 660
actgagactg acctcctctg gtgacactgg cctagagcct gacactctcc taagaggttc 720
tctccaagcc cccaaatagc tccaggcgcc ctcggccgcc catcatggtt aattctgtcc 780
aacaaacaca cacgggtaga ttgctggcct gttgtaggtg gtagggacac agatgaccga 840
cctggtcact cctcctgcca acattcagtc tggtatgtga ggcgtgcgtg aagcaagaac 900
tcctggagct acagggacag ggagccatca ttcctgcctg ggaatcctgg aagacttcct 960
gcaggagtca gcgttcaatc ttgaccttga agatgggaag gatgttcttt ttacgtacca 1020
attcttttgt cttttgatat taaaaagaag tacatgttca ttgtagagaa tttggaaact 1080
gtagaagaga atcaagaaga aaaataaaaa tcagctgttg taatcaccta gcaaaaaaaa 1140
aa 1142

<210> 51
<211> 1477
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7500449CB1

<400> 51
cgccgcctcc gtcggagcct gcgggagggt ggtggtggtg gtggtggtgg ccctcgcccg 60
cctcactcat gcctcctcct cctctgctct cgctcaggcg cctcggtggc ggttggtcgg 120
cggttacgcg gctggtggtc gcggcggccg gggctcgctc tcggggaggc cggggcggat 180
ctcgcggcgc aggcggcggc ggccgaggtg gggtcgcgcg gcggaggcgg ctcgagcttc 240
gtgctgcgcg ctcgctcttg ggctcctcgc tgcaggagga gtgtgactat gtgcagatga 300
tcgaggtgca gcacaagcag tgcctggagg aggcccagct ggagaatgag acaataggct 360
gcagcaagat gtgggacaac ctcacctgct ggccagccac ccctcggggc caggtagttg 420
tcttggcctg tcccctcatc ttcaagctct tctcctccat tcaaggccgc aatgtaagcc 480

gcagctgcac cgacgaaggc tggacgcacc tggagcctgg cccgtacccc attgcctgtg 540
gtttggatga caaggcagcg agtttggatg agcagcagac catgttctac ggttctgtga 600
agaccggcta caccattggc tacggcctgt ccctcgccac ccttctggtc gccacagcta 660
tcctgagcct gttcaggaag ctccactgca cgcggaacta catccacatg cacctcttca 720
tatccttcat cctgagggct gccgctgtct tcatcaaaga cttggccctc ttcgacagcg 780
gggagtcgga ccagtgctcc gagggctcgg ggtacccagc acattcacca tggtgtggac 840
catcgccagg atccattttg aggattatgg tctgctcagg tgctgggaca ccatcaactc 900
ctcactgtgg tggatcataa agggccccat cctcacctcc atcttggtaa acttcatcct 960
gtttatttgc atcatccgaa tcctgcttca gaaactgcgg cccccagata tcaggaagag 1020
tgacagcagt ccatactcaa ggctagccag gtccacactc ctgctgatcc ccctgtttgg 1080
agtacactac atcatgttcg ccttctttcc ggacaatttt aagcctgaag tgaagatggt 1140
ctttgagctc gtcgtggggt ctttccaggg ttttgtggtg gctatcctct actgcttcct 1200
caatggtgag gtgcaggcgg agctgaggcg gaagtggcgg cgctggcacc tgcagggcgt 1260
cctgggctgg aaccccaaat accggcaccc gtcgggaggc agcaacggcg ccacgtgcag 1320
cacgcaggtt tccatgctga cccgcgtcag cccaggtgcc cgccgctcct ccagcttcca 1380
agccgaagtc tccctggtct gaccaccagg atcccagccc aagcggcccc tcccgcccct 1440
tcccactcgc agcagacgcc ggggacagag gcctgcc 1477

<210> 52
<211> 1097
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7503281CB1

<400> 52
aggggcgacg ctcttgtcta gccgagccgg gcagcgctgt cgtccacggt gcgcactggg 60
cgggcagcgc tccctctgcc cacctcccgc cccgtcatgg accaccagga cccctactcc 120
gtgcaggcca cagcggccat agcggcggcc atcaccttcc tcattctctt taccatcttc 180
ggcaacgctc tggtcatcct ggctgtgttg accagccgct cgctgcgcgc ccctcagaac 240
ctgttcctgg tgtcgctggc cgccgccgac atcctggtgg ccacgctcat catcccttтc 300
tcgctggcca acgagctgct gggctactgg tacttccggc gcacgtggtg cgaggtgtac 360
ctggcgctcg acgtgctctt ctgcacctcg tccatcgtgc acctgtgcgc catcagcctg 420
gaccgctact gggccgtgag ccgcgcgctg gagtacaact ccaagcgcac cccgcgccgc 480
atcaagtgca tcatcctcac tgtgtggctc atcgccgccg tcatctcgct gccgcccctc 540
atctacaagg gcgaccaggg cccccagccg cgcgggcgcc cccagtgcaa gctcaaccag 600
gaggcctggt acatcctggc ctccagcatc ggatctttct ttgctccttg cctcatcatg 660
atccttgtct acctgcgcat ctacctgatc gccaaacgca gcaaccgcag aggtcccagg 720
gccaaggggg ggcctgggca ggctacagcc tgggcgccat ctgcccgaag cactgcaagg 780
tgccccatgg cctcttccag ttcttcttct ggatcggcta ctgcaacagc tcactgaacc 840
ctgttatcta caccatcttc aaccaggact tccgccgtgc cttccggagg atcctgtgcc 900
gcccgtggac ccagacggcc tggtgagccc gcctgcgctg cccctgtggg gttggtgcgg 960
tggcgccggg gtcaccctgc ttcttgccct gctgtgtgtg gctgcctccc ctgggctttc 1020
tgctccctgc ccagatcctg taggcctcat cttaggaacc ccttgggagg ggtgggcagg 1080
ggggctgcta gcaaggg 1097

<210> 53
<211> 1501
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7503292CB1

<400> 53
ccggccgcgg gagcgggatg gaaaccagca gcccgcggcc cccgcggccc agctccaacc 60
cggggctgag cctggacgcc cggctgggcg tggacactcg cctctgggcc aaggtgctgt 120
tcaccgcgct ctacgcactc atctgggcgc tgggcgcggc gggcaatgcg ctgtccgtgc 180
acgtggtgct gaaggcgcgg gccgggcgcg cggggcgcct gcgccaccac gtgctcagcc 240
tggcgctcgc gggcctgctg ctgctgctgg tcggcgtgcc ggtggagctc tacagcttcg 300

tgtggttcca ctacccctgg gtcttcggcg acctgggctg ccgcggctac tacttcgtgc 360
acgagctgtg cgcctacgcc acggtgctga gcgtggcagg cctgagcgcc gagcgctgcc 420
tagccgtgtg ccagcccctg cgtgcccgca gcctgctgac gccacgccgg acccggtggc 480
tggtggcgct ctcgtgggcc gcctcgctcg gcctcgccct gcccatggcc gtcatcatgg 540
ggcagaagca cgaactcgag acggcggacg gggagccgga gcccgcctcg cgagtgtgca 600
cggtgctggt gagccgcacc gcgctccaag tctttatcca ggtgaatgtg ctggtgtcct 660
tcgtgctccc cttggcacta actgctttcc tgaatggggt cacagtgagc cacctgctgg 720
ccctctgctc ccaagtgccg tccacttcta ccccgggcag ctccaccccc agccgcctgg 780
agctgctgag tgaggagggt ctcctcagct tcatcgtatg gaagaagacc tttatccagg 840
gaggccagga gccatcgtgg tcatgtatgt catctgctgg ctgccgtacc atgcccgcag 900
gctcatgtac tgctacgtac ctgatgacgc gtggactgac ccactgtaca atttctacca 960
ctacttctac atggtgacca acacactttt ctacgtcagc tcagctgtga ctcctcttct 1020
ctacaacgcc gtgtcctcct ccttcagaaa actcttcctg gaagccgtca gctccctgtg 1080
tggagagcac caccccatga agcggttacc cccgaagccc cagagtccca ccctaatgga 1140
tacagcttca ggctttgggg atcccccaga aacccggacc tgaatgtaat gcaagaatga 1200
acagaacaag caaaatgacc agctgcttag tcacctggca aagcaggtga gcaacctcat 1260
cactaatcat tcaagcttcg cagccagggc gacttctatc aacccctgct ctgctgagaa 1320
ccatcaagcg cagggaagcc acgtgacccc tcctagcctc aggctccctc gtctgtgtag 1380
tggagataaa gaacagcacc catctcttag tgttgcctga gactaaagtg cttagcacag 1440
aacctggtgc gtagtagatg ctcaataaat ttttgctggc acgaaaaaaa aaaaaaaaaa 1500
a 1501

<210> 54
<211> 1613
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7503311CB1

<400> 54
ggcagcggtg gcaggggctg caggagcaag tgaccaggag caggactggg gacaggcctg 60
atcgcccctg cacgaaccag acccttcgcc gccctcacga tgactacctc tccgatcctg 120
cagctgctgc tgcggctctc actgtgcggg ctgctgctcc agagggcgga gacaggctct 180
aaggggcaga cggcgggga gctgtaccag cgctgggaac ggtaccgcag ggagtgccag 240
gagaccttgg cagccgcgga accgccttca ggcctcgcct gtaacgggtc cttcgatatg 300
tacgtctgct gggactatgc tgcacccaat gccactgccc gtgcgtcctg cccctggtac 360
ctgccctggc accaccatgt ggctgcaggt ttcgtcctcc gccagtgtgg cagtgatggc 420
caatggggac tttggagaga ccatacacaa tgtgagaacc cagagaagaa tgaggccttt 480
ctggaccaaa ggctcatctt ggagcggttg caggtcatgt acactgtcgg ctactccctg 540
tctctcgcca cactgctgct agccctgctc atcttgagtt tgttcaggcg gctacattgc 600
actagaaact atatccacat caacctgttc acgtctttca tgctgcgagc tgcggccatt 660
ctcagccgag accgtctgct acctcgacct ggcccctacc ttggggacca ggcccttgcg 720
ctgtggaacc aggccctcgc tgcctgccgc acggcccaga tcgtgaccca gtactgcgtg 780
ggtgccaact acacgtggct gctggtggag ggcgtctacc tgcacagtct cctggtgctc 840
gtgggaggct ccgaggaggg ccacttccgc tactacctgc tcctcggctg gggtgctggg 900
agcgcaacga agtcaaggcc atttggtgga ttatacggac ccccatcctc atgaccatct 960
tgattaattt cctcattttt atccgcattc ttggcattct cctgtccaag ctgaggacac 1020
ggcaaatgcg ctgccgggat taccggctga ggctggctcg ctccacgctg acgctggtgc 1080
ccctgctggg tgtccacgag gtggtgtttg ctcccgtgac agaggaacag gcccggggcg 1140
ccctgcgctt cgccaagctc ggctttgaga tcttcctcag ctccttccag ggcttcctgg 1200
tcagcgtcct ctactgcttc atcaacaagg aggtgcagtc ggagatccgc cgtggctggc 1260
accactgccg cctgcgccgc agcctgggcg aggagcaacg ccagctcccg gagcgcgcct 1320
tccgggccct gccctccggc tccggcccgg gcgaggtccc caccagccgc ggcttgtcct 1380
cggggaccct cccagggcct gggaatgagg ccagccggga gttggaaagt tactgctagg 1440
gggcgggatc cccgtgtctg ttaagttagc atggatttat tgagtgccaa ctgcgtgcca 1500
ggcccagtac ggaggacgct ggggaaatgg tgaaggaaac agaaaaaagg tccctgccct 1560
tctggagatg acaactgagt ggggaaaaca gaccgtgaac acaaaacatc aag 1613

<210> 55
<211> 1523
<212> DNA

<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510384CB1

<400> 55
gaggctggtg gagggagcca ctgctgggct caccatggac cgccggatgt gggggggcca 60
cgtcttctgc gtgttgagcc cgttaccgac cgtattgggc cacatgcacc cagaatgtga 120
cttcatcacc cagctgagag aggatgagag tgcctgtcta caagcagcag aggagatgcc 180
caacaccacc ctgggctgcc ctgcgacctg ggatgggctg ctgtgctggc caacggcagg 240
ctctggcgag tgggtcaccc tcccctgccc ggatttcttc tctcacttca gctcagagtc 300
aggggctgtg aaacgggatt gtactatcac tggctggtct gagccctttc caccttaccc 360
tgtggcctgc cctgtgcctc tggagctgct ggctgaggag gaatcttact tctccacagt 420
gaagattatc tacaccgtgg gccatagcat ctctattgta gccctcttcg tggccatcac 480
catcctggtt gctctcagga ggctccactg cccccggaac tacgtccaca cccagctgtt 540
caccactttt atcctcaagg cgggagctgt gttcctgaag gatgctgccc ttttccacag 600
cgacgacact gaccactgca gcttctccac tgtaatggcc atgggtgaag gggctgggca 660
ggtgggggag agaggaggtt ctatgcaagg tctctgtggc cgcctcccat ttcgccacca 720
tgaccaactt cagctggctg ttggcagaag ccgtctacct gaactgcctc ctggcctcca 780
cctcccccag ctcaaggaga gccttctggt ggctggttct cgctggctgg gggctgcccg 840
tgctcttcac tggcacgtgg gtgagctgca aactggcctt cgaggacatc gcgtgctggg 900
acctggacga cacctccccc tactggtgga tcatcaaagg gcccattgtc ctctcggtcg 960
gggtgaactt tgggcttttt ctcaatatta tccgcatcct ggtgaggaaa ctggagccag 1020
ctcagggcag cctccatacc cagtctcagt attggcgtct ctccaagtcg acacttttcc 1080
tgatcccact ctttggaatt cactacatca tcttcaactt cctgccagac aatgctggcc 1140
tgggcatccg cctccccctg gagctgggac tgggttcctt ccagggcttc attgttgcca 1200
tcctctactg cttcctcaac caagaggtga ggactgagat ctcacggaag tggcatggcc 1260
atgaccctga gcttctgcca gcctggagga cccgtgctaa gtggaccacg ccttcccgct 1320
cggcggcaaa ggtgctgaca tctatgtgct aggctgcctc atcacgccac tggagtccac 1380
acttgaattt gggcagctac cacgggtctg ccatgctctg gaggagcaag ggggccacat 1440
ccccacccca gctgttaccc agcccggggc aggtgcagcc cttcctccct gtctctgcat 1500
ctgactctct tttgaggtcc ctg 1523

<210> 56
<211> 6826
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7509976CB1

<400> 56
agtgtgtggg cggcggcggc ggcggctgcg cgcttggggc ccggggcgcg gggcgaggcc 60
gtggggacgt gcgagcgggg ccgcggtggg gctcgggggc gcgtccacgt ggccagaggg 120
cggccacccg gagccagcgg agggacaggc ctgtccccag gcgcggctgc cggccatgcc 180
ctctgtctgc ctcctcctgc tgctcttcct tgccgtgggg ggggccctgg gcaacaggcc 240
cttccgtgcc ttcgtggtga cagacaccac gcttacccac ctggctgtgc accgggtgac 300
tggggaggtg ttcgtgggcg cagtgaaccg agtctttaag ctggccccca acctgactga 360
gctgcgggcc catgtcacgg ggcccgtcga ggacaacgct cgctgctacc cgccccccag 420
catgcgcgtg tgtgcccacc gcctggcccc cgtggacaac atcaacaagc tgctgctcat 480
agactatgcg gcccgccgcc tggtggcctg cggcagcatc tggcagggca tctgccagtt 540
cctgcgtctg gacgacctct tcaagctggg tgagccgcac caccgcaagg agcactacct 600
gtcgggggcc caggagcccg actccatggc tggtgtcatt gtggagcagg gccaggggcc 660
cagcaagctg tttgtgggca ctgctgtcga cggcaagtcg gagtacttcc ccaccttgag 720
ctcccgcaag ctcatcagtg atgaagacag cgcggacatg ttcagtctcg tgtaccagga 780
tgagtttgtg tcctcccaga tcaagatccc ctcagacacg ctgtccttgt accctgcctt 840
tgacatctac tacatctacg gcttcgtcag cgcctccttc gtgtacttcc tgacgctgca 900
gctggacacc cagcagacgc tgttggacac agcgggcgag aaatttttca cgtccaagat 960
cgtgcgcatg tgcgcgggag actcagagtt ctactcatac gtggaattcc ccatcggctg 1020
ctcctggcgc ggcgtggagt accgcttggt gcagagcgcc cacctggcca agcctggcct 1080
gctgctggcc caggccctgg gcgtgccggc tgatgaggac gtcctcttca ccatcttctc 1140

tcagggccag aagaaccggg ccagcccacc ccggcagacc atcctctgcc tcttcaccct 1200
cagcaacatc aatgcccaca tccggcgccg catccagtcc tgctatcgtg gggagggcac 1260
tctggctctg ccctggctgc tgaacaagga gctgccctgc atcaacaccc ccatgcagat 1320
caacggcaac ttctgtgggc tggtgttgaa ccagcctctg ggaggcctgc atgtgatcga 1380
ggggctgccc ctgctggccg acagcaccga cggcatggcc agcgtggccg cctacaccta 1440
ccgccagcac tctgtggtct tcattggcac gcgcagcggc agcttgaaga aggtgcgggt 1500
cgatggcttc caggatgccc acctgtatga gacagtcccc gtggtggatg gcagccccat 1560
cctccgagac ctgctcttca gcccggacca ccggcacatc tatctcctga gtgagaagca 1620
ggtgagccag ctcccggtgg agacctgtga gcagtaccag agctgcgcag cctgcctggg 1680
ctccggggac ccgcactgtg gttggtgtgt gctgcgacac aggtgctgcc gcgaaggggc 1740
ctgtctgggc gcctctgccc cacacggctt tgctgaggag ctgagcaagt gtgtccaggt 1800
gcgggtccgg cccaacaatg tgtcagtgac gtcacctggg gtgcagctga ccgtcaccct 1860
gcacaacgtg ccagacctca gtgcgggcgt gagctgcgcc ttcgaggcgg cggcggagaa 1920
cgaggcggtc ctgctgccct ccggtgaact gctctgcccc tcaccctccc tccaggagct 1980
ccgagctctt accagggggc atggggccac ccgcactgtg cggctgcagc ttctctccaa 2040
ggagacaggc gtgaggtttg ccggtgctga ctttgtcttc tacaactgca gcgtcctcca 2100
gtcgtgcatg tcctgtgttg gcagccctta cccctgccac tggtgtaagt accgccacac 2160
gtgtaccagc cgcccccacg agtgctcctt ccaggagggc agggtccaca gccctgaggg 2220
ctgccctgag atcctgccca gtggggacct cctgatcccc gttggggtca tgcagcctct 2280
taccttgcgg gctaagaacc tacctcagcc gcagtcgggc cagaagaact atgagtgcgt 2340
ggtgcgggtg caggggcggc agcagcgggt gcctgccgtg cgcttcaaca gcagcagtgt 2400
gcagtgccag aacgcctcgt actcctatga aggtgatgag catggtgaca ccgagctgga 2460
cttctccgtg gtctgggatg gagacttccc catagacaag cctcccagct tccgagccct 2520
cctgtacaag tgctgggcgc agcggcccag ctgtggcctc tgcctcaagg ctgatccccg 2580
cttcaactgt ggctggtgca tctcagagca caggtgccag ctgcggaccc actgcccggc 2640
cccgaagacc aactggatgc acctgagcca gaagggcacc cggtgcagcc acccccgcat 2700
cacgcagatc caccctctcg tggggcccaa ggaaggaggc acccgggtca ccatcgtggg 2760
tgacaacctg ggcctcttgt cccgagaggt gggcctgcgg gtggctggcg tgcgttgcaa 2820
ctccattccg gccgagtaca tcagtgctga gaggtgagtg cggctctgtg ggtgcccggg 2880
ccgtatgtgg cctggccggc cctgacgctc tctgagccct aggatcgtgt gtgagatgga 2940
ggagtcgctg gtgcccagcc cgccgccggg gcccgtggag ctgtgtgtgg gtgactgttc 3000
agccgacttc cgcacgcagt cggagcaggt ctacagcttt gtgaccccaa cgtttgacca 3060
agtgagtccc agccgtggcc cggcgtccgg gggcacacgg cttaccatct caggcagctc 3120
tctggatgct ggcagcaggg tcacagtgac tgtgagggac agcgagtgcc agtttgtaag 3180
gagagatgcc aaggcgatcg tgtgcatctc acctctctcc accctgggcc ccagccaggc 3240
ccccatcaca cttgccattg accgggctaa catctccagc cccgggctca tctacaccta 3300
cactcaggac cccaccgtca cccgccttga gcccacctgg agcatcatca atggaagcac 3360
tgccatcact gtgagtggga cccacctgct gacggtccag gagccccggg tccgtgccaa 3420
gtaccgcggc attgagacca ccaatacatg ccaagtgatc aacgacactg ccatgctgtg 3480
taaggccccc ggcatctttc ttgggcggcc ccagcctcgg gcgcaaggcg agcaccctga 3540
tgagtttggc ttcctgctgg accacgtgca aacggcccgc tccctcaacc gctcctcctt 3600
tacctactac cctgatccca gctttgagcc gctggggccc tctggcgtgc tggacgtcaa 3660
accgggctcc cacgtggtgc tgaagggcaa gaacctgatt cccgcggcag ccggcagctc 3720
ccgcctcaac tacactgtgc tgataggagg ccagccgtgt tcgctcactg tctcggacac 3780
acaactcctg tgcgactcac ccagccagac tggccggcag cctgtcatgg tgctggtggg 3840
tggcctggag ttctggctgg gcaccctgca catctcggca gagcgggcgc tgaccctacc 3900
ggccatgatg gggctggcgg cgggggggtgg gctcctgctg ctggccatca cagccgtgct 3960
ggtggcgtac aagcgcaaga ctcaggacgc ggaccgtacc ctcaagcgtc tgcagctgca 4020
gatggacaac ctggagtccc gtgtggccct ggagtgcaag gaagcttttg cagagctgca 4080
gacggacatc aatgagctga ctaaccacat ggacgaggtg cagatccgct tcctggacta 4140
ccggacttac gccgtgcgcg tgctcttccc gggcatcgag gcccacccgg tgctcaagga 4200
gctggatacg ccacccaacg tggagaaggc cctgcgcctc ttcgggcagc tgctgcacag 4260
ccgcgcgttc gtgcttacct tcatccacac gctggaggcc cagagcagct tctccatgcg 4320
cgaccgcggc accgtggcct cgctcaccat ggtggccctg cagagccggc tcgactatgc 4380
cacggggctg ctcaagcaac tgctggccga cctcatcgag aagaacctcg agagcaagaa 4440
ccaccccaag ctgctgctac gcaggacaga gtcagtggct gagaagatgc ttaccaactg 4500
gttcacgttc ctgctgcata agtttctgaa ggagtgtgct ggggagcctc tcttcctgct 4560
ttactgtgcc atcaagcagc agatggagaa gggccccatt gatgccatca cgggcgaggc 4620
acgatactcc ctgagcgagg acaagctcat ccgtcagcag atcgactaca agacactgac 4680
ccttcactgc gtgtgtccgg agaacgaggg cagcgcccag gtcccagtga aggttctcaa 4740
ctgtgacagc atcacccagg ccaaagataa gctgctggac actgtgtaca agggcattcc 4800
gtactcccag cgtcccaaag ctgaggacat ggacctggag tggcgccagg gccgcatgac 4860
tcgcatcatc ctccaggatg aggatgtcac caccaagatc gagtgtgact ggaagaggct 4920

caactcactg gcccactacc aggtgacaga cggttccttg gtggcattgg tgcccaaaca 4980
agtgtctgcc tataacatgg ccaactcctt caccttcacc cgctccctca gccgctacga 5040
gagcttgctc cgcacggcca gcagccctga tagcctccgc tcacgggcac ccatgattac 5100
gcctgaccag gagacaggca ccaaattgtg gcacctggtg aaaaaccacg accatgccga 5160
ccatcgcgag ggggaccgtg gcagcaagat ggtctccgag atctacctga cacggctgct 5220
ggccaccaag ggcacactgc agaagttcgt ggatgacctc tttgagacag tgttcagcac 5280
agcccaccgg ggctcggccc tgcccctggc catcaagtac atgttcgact tcctggatga 5340
gcaggcggac cagcgccaga tcagcgaccc cgatgtgcgc cacacctgga agagcaactg 5400
cctgccgctg cgcttctggg tgaatgtgat caagaacccg cagttcgtgt tcgacatcca 5460
caagaacagc atcacggatg cctgcctgtc ggtggtagcc cagaccttca tggactcctg 5520
ctctacatcc gagcaccgcc tggggaagga ctcgccctcc aacaaactgc tctacgccaa 5580
ggacatcccc aactacaaga gctgggtgga gaggtattat cgagacattg caaagatggc 5640
atccatcagc gaccaggaca tggatgccta cctggtggag cagtcccgcc tccacgccag 5700
cgacttcagc gtcctgagtg cgctcaacga gctgtatttc tatgtcacca agtaccgcca 5760
ggagattctc acggctctgg accgagatgc ctcttgtcgg aagcataagt tgcggcagaa 5820
actggaacag atcatcagcc tcgtgtccag cgacagctaa ggtggtggaa tcggtgagga 5880
gggggcttct cagtcctgtg ccgtcctccc atccagggga gtggctggct caagcctggg 5940
tccccgggct gagccctgga ttgggtatcg tggggcaggt caccctggcc acgatgcccc 6000
cggcacaccc aggcccccct cattagtgcc ttgctttggg ccctgcaggg ggaggggtga 6060
cagggcgagc ccccacccca gcagcagcaa tacccccacc ctcctgccct gtgcccaggt 6120
gttgggacag tcccaccctc cctgctattt atatccctct gcctatttat tgaatcgaac 6180
ttcgcctctg tctccatctg taaatatgtg tccccccacc ggatgtcgcc accctcactc 6240
acctgcctct tcttgagctg tcctgggccc tgccacccgt ctgggctcct ttgtgtagca 6300
ttatcagcct cggtctggcc tctggcacct cacccttgcc atggctgacc ccacccattc 6360
caaggcgggg tcacggtacc agcagcactt ggggtgaggc ctccaaagct tcctcagaat 6420
tgtggctgtg ccacgctgga ccacagggtc cccctcaagc atctcggggc cctattctct 6480
ctgagcacct ggagggctgg actcaggctt gtgccagggc ctgacttggg cctgggggcc 6540
ctagaacact cctcctcctg agcctactgc caaacgtcct cagtgttgtc tgcacctgct 6600
ccgactcctt cagccgcccc attcagcgcc cgctccgtcc agtgcccgcc ctgtggggcc 6660
aaggcggccg tgccttacta ctctgtgtct tctgcctcct ctgaggaatc tggccctgtc 6720
tgacagtccc agaccccccg ttctctcctc tttagttgca tgagtttttc tttgttcatg 6780
gaatgttttt tcctgattaa atgttgggga aatgccaaaa aaaaaa 6826

<210> 57
<211> 2481
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510454CB1

<400> 57
gacaagggtc tcactttgtt gcccaggttg gtctcgaact cccaggctcg agcggtcctc 60
ctgttttggc ctcccaaagc attgggatta caggcatgca ccacaattcc tgacctacag 120
ttttcttctt atgggctttg tacatttctt gcctcctggt atttttaagg aaatgtaaga 180
gtgtgaatca ggtactgatg gttttgactt cattatgatc agcatctttg gcttccatca 240
gagtagacac tgaacgtttt catccaaccg gatgatgagt gcattagaac tacataagag 300
atgaaatcct ttctccctgg gacatgtatc cttttgtgtt ctgcttttaa tttgatgttt 360
ttcagtcttt tcaggctgaa atataatatt tgtatcattc tgagagcctg taacaccatg 420
ctttccagca atacaattat ggaaattttt ttcctctctc atattgacat tgggatttgg 480
aggaacttac tgctactcct gatgcctatt tacacctttt tgatatgtcc ccagcagaag 540
aagcccatgg gcttgctttt ccttcacttg tctgttgcta atacgatgac acttctccgc 600
aaagttattc cattggcagt aaaatctttc aacactaaaa atcttttgaa ttatactgga 660
tgtagggaat ttgaattttt atatagagta tcttggggac ttcccctatg tacgacatac 720
ctcctaagca tggtgcaggc cctccgtggg agccccagca aatccaggtg gacgtggctg 780
aaagacaaaa tgctcaaaac accactgtgc ttcttcttac actctgggtc atcaacagtc 840
tcatctacat caagcttgtg ccatttgttg acactatcaa atatggcagt gtcaccaaga 900
atctctccat aaaaatgtgt ttagctacac cacacatggg taacacaatt gctgtctctc 960
atacgagtgt tatcacattc caggacttaa tttttctggt tctcatgagt tgagccagtg 1020
gctacttggt gattttcctt cacagacacc agaaaaataa tccacatctt cacaacaaca 1080
gctgttcctc tatagcctcc catgagaccg gaaccatcac gactgcgctg ctgcttatga 1140
tttgcttcgt tgtatttaat gtgagcaact cgtgccacag catttaccta agtacggtga 1200

agaaaaggga tcagttgtgg accatctcag atttgatttc ctcatgttac cccatttttt 1260
ggtccatttt tgctcattgg tagagaaagt cttatcctga attcaaaatc tatgaagtag 1320
agaaagtcgt cttatcccat agatatgtca aagtaaactt tcaccaatat aaacttttc 1380
caaaacaaca ttctataaag agttggtatt ctgaagaaat gatgggattt aggtctgaaa 1440
aatgagatat ttctcagttc actgcatgaa atataatcta atgaccttta ccttcagtaa 1500
agacaatatt gcatagctta gtatttaatg tttgtataca tagatataat catttaatag 1560
acaagtagat agataatttt tcatgtcaga tgttataatg gacttcttgc actagtcatt 1620
caatatccat atttttctta ctttaatttg tgttcagcat gaaaaatcat ttcaaaagga 1680
gatcagggac tccaggaagc agagcgtaac tccccacttc taaactgtgg gcttcacata 1740
atgacatcct accaagaaat cagtatagca aaggaggaaa aagagtaact tcgcattgga 1800
gaaacctaac aaacactgtc tcagccaggt gatcaaggcc actgtgagca gtgatcagtc 1860
aagtcgaaag tgcatatcat atgacaggat gagaatggca ttttacctcg acatcttccc 1920
tcccaaaact aataatccta ctacatcaga caaacctcag ctgagaaaca gtttccaaaa 1980
acacctgact agtacccccc aaaaccatca aggtcatcaa gaacaatgta gtcctgagaa 2040
atgatcacag ccgggaagaa cctaaggact tggtgtcctt tggtatcctg atatggaatc 2100
ctggagcaga aaaggacatt aagtaaaaac caaggaaata gaaataaagt ataaacttaa 2160
taatatatca atattaattc attaattgtg acaaatgtaa catagtaatg taagacatta 2220
aaatggggaa aattgggtat gatgtggagg agaactctgt gtattctatt tgcaactctt 2280
ctgtaaatgt aaacctattt gaacaattaa aaattttatt ttttcaaaac aaaaaaaaaa 2340
aaacaaaaca acaacaacac aaaaacacag aggggcgcgg cgaccaaaaa tatcaaacgg 2400
cccaccgcgg gggggccgcc ccacccataa agagataaac acacacggag gtaaaaaacg 2460
ggggaaagcg gtccctctcg c 2481

<210> 58
<211> 2512
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 8017335CB1

<400> 58
atgagggtgt ccgtgccggg tccggcggcc gctgccgccc ccgcagccgg ccgcgagccc 60
tccacgcccg gcgggggcag cggaggcgga ggcgccgtcg ctgcagcctc aggcgccgcg 120
gtgccgggct ccgtgcagtt ggcgctgagc gtcctgcacg ccctgctcta cgccgcgctg 180
ttcgcctttg cctacctgca gctgtggcgg ctgctcctgt accgcgagcg gcggctgagt 240
taccagagcc tctgcctctt cctctgtctc ctgtgggcag cgctcaggac caccctcttc 300
tccgccgcct tctcgctcag cggctccctg cccttgctcc ggccgcccgc tcacctgcac 360
ttcttccccc actggctgct ctactgcttc ccctcctgtc tccagttctc cacgctctgt 420
ctcctcaacc tctacctggc ggaggttata tgtaaagtca gatgtgccac tgaacttgac 480
agacacaaaa ttctactgca tttgggcttt ataatggcaa gcctgctctt tttagtggtg 540
aacttgactt gcgcaatgct agttcatgga gatgtcccag aaaatcagtt gaagtggact 600
gtgtttgttc gagcattaat taatgatagc ctgtttattc tttgtgccat ctctttagtg 660
tgttacatat gcaaaattac aaaaatgtca tcagctaatg tctacctcga atcaaagggt 720
atgtctctgt gccagactgt cgtcgtgggc tctgtagtca ttcttctgta ctcttccaga 780
gcttgttata atttggtggt ggtcaccata tctcaggata cattagaaag tccatttaat 840
tatggctggg ataatctttc agataaggct catgtagaag acataagtgg agaagagtat 900
atagtatttg gaatggtcct ctttctgtgg gaacatgtgc cagcatggtc ggtggtactg 960
tttttccggg cacagagatt aaaccagaat ttggcacctg ctggcatgat aaatagtcac 1020
agttatagtt ccagagctta ctttttcgac aatccaagac gatatgatag tgatgatgac 1080
ctgccaagac tgggaagttc aagagaagga agtttaccaa attcgcaaag tttgggctgg 1140
tatggcacca tgactgggtg tggcagcagc agttacacag tcactcccca cctgaatgga 1200
cctatgacag atactgctcc tttgctcttt acttgtagta atttagattt gaacaatcat 1260
catagcttat atgtgacacc acaaaactga cagcatcacc aagtcatgat tcttgagttg 1320
tttttcataa atgtgtatat tcaatgtgtt taaattccat ctacataaac attccattat 1380
ctgttgcaac tgaaaacaaa atctggaagt gtggctgtgt ttggtaaata acacagctat 1440
tatttttgac ctcttcatag taaaatgaag taaaatggaa agtttggagt aggagaaaag 1500
agagattaga tcttaaggca cttgatggcc tccaaaaatc ctgactttgg aacatcaaat 1560
gcatatgtgc acttttatct ttgttctgag tcactgcagt ccccaaagtc atatgccaat 1620
gttcacactg aaatactgta ttgtacacca aactggaagg caatttttcct atgaaaatca 1680
aagccggtat attcattggt atgctctata cagatatctt aataaaaatt ttatagtgtg 1740
aacagtgcac agagttaagg cataaaaatg tatcattctt tataaaaatc tactgaaaat 1800

gtgtaatcat tgaagacagt tcttttaagc atgattttaa aatagcaact gaaattcaat 1860
cattttaaac aaatgatggt agtaatccat tagttatggc cagcagtgtt ctttggagag 1920
ccacaataat ttcaagagga aaatatacca gtgaaaattg tgtggctatt ttgagtagaa 1980
ttggtcagtt gattattttg tgtaattgag atatatgtag tagtttaagc atgattcttg 2040
aagaaagcaa tagtgacttt tgcataggga gattttggta gaaacttctt gggactaaac 2100
aagtttagag atgcatttaa gaattattca caaaatgtgt aattctaaat taaaacataa 2160
atatattttc aaaagcattt gatttctctg aagcatgata tagctggtct tacctagtga 2220
atcaggattg tcctcaggta aatgaaatca tgatacatta ttgcagtgaa ctcaagtgca 2280
atactttgta agacatataa ttcctatgat tttcacattt ttatatctta tatatgggaa 2340
aagccaaatt aaattgaatt cagattaatt ccagcattag actaaatgag caaacttaag 2400
taaatgtaca aactaggtaa gtataaaacc acaggttaac aatattggag tacttttaga 2460
attacattaa aactgtctta aatgtcctat cccaaatcta aaaaaaaaaa aa 2512

<210> 59
<211> 754
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510197CB1

<400> 59
catgaatcca ttcctgatcc ttgcctttgt gggagctgct ggcgagtttc atgacctgcc 60
tcaggcccca cccacccccc ttcctggcag acacatgccc tgccattctt gccacctctc 120
ctcttttgac tgcgctctga tattctattt cctccatctg acatatctcc ttcccatcct 180
ccttgggctc tctttaagcc tcacctgttt cacctgttcc ctcatttcac tcccaccact 240
gtcattcatc catatccgag ctgtgttgga gaagctggga agggagacca gttgctgtcc 300
cctttgacga tgatgacaag attgttgggg gctacacctg tgagaattct ctcccctacc 360
aggtgtccct gaattctggc tcccacttct gcggtggctc cctcatcagc gaacagtggg 420
tggtatcagc agctcactgc tacaagaccc gcatccaggt gagactggga gagcacaaca 480
tcaaagtcct ggaggggaat gagcagttca tcaatgcggc caagatcatc cgccacccta 540
aatacaacag ggacactctg gacaaaggac atcatgctga tcaaactctc ctcaactgcc 600
gtcatcaatt gcccgcgttg tccaccatct ctctgcccta ccgcccctcc agctgctggc 660
actgagtgcc tcatctccgg ttggggcaac actctgagcc tttgtggctg actacccaga 720
agagctgaag tgcctggatg ctccggtgct gacc 754

<210> 60
<211> 1660
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510055CB1

<400> 60
gccaaggctg gggcagggga gtcagcagag gcctcgctcg ggcgcccagt ggtcctgccg 60
cctggtctca cctcgccatg gttcgtctgc ctctgcagtg cgtcctctgg ggctgcttgc 120
tgaccgctgt ccatccagaa ccacccactg catgcagaga aaaacagtac ctaataaaca 180
gtcagtgctg ttctttgtgc cagccaggac agaaactggt gagtgactgc acagagttca 240
ctgaaacgga atgccttcct tgcggtgaaa gcgaattcct agacacctgg aacagagaga 300
cacactgcca ccagcacaaa tactgcgacc ccaacctagg gcttcgggtc cagcagaagg 360
gcacctcaga aacagacacc atctgcacct gtgaagaagg ctggcactgt acgagtgagg 420
cctgtgagag ctgtgtcctg cacggctcat gctcgcccgg ctttggggtc aagcagattg 480
ctacaggggt ttctgatacc atctgcgagc cctgcccagt cggcttcttc tccaatgtgt 540
catctgcttt cgaaaaatgt caccttgga caagctgtga gaccaaagac ctggttgtgc 600
aacaggcagg cacaaacaag actgatgttg tctgtggtga gtcctggaca atgggccctg 660
gagaaagcct aggaaggtcc ccaggatcgg ctgagagccc tggtggtgat ccccatcatc 720
ttcgggatcc tgtttgccat cctcttggtg ctggtcttta tcaaaaaggt ggccaagaag 780
ccaaccaata aggccccca ccccaagcag gaaccccagg agatcaattt tcccgacgat 840
cttcctggct ccaacactgc tgctccagtg caggagactt tacatggatg ccaaccggtc 900
acccaggagg atggcaaaga gagtcgcatc tcagtgcagg agagacagtg aggctgcacc 960

cacccaggag tgtggccacg tgggcaaaca ggcagttggc cagagagcct ggtgctgctg 1020
ctgctgtggc gtgagggtga ggggctggca ctgactgggc atagctcccc gcttctgcct 1080
gcacccctgc agtttgagac aggagacctg gcactggatg cagaaacagt tcaccttgaa 1140
gaacctctca cttcaccctg gagcccatcc agtctcccaa cttgtattaa agacagaggc 1200
agaagtttgg tggtggtggt gttggggtat ggtttagtaa tatccaccag accttccgat 1260
ccagcagttt ggtgcccaga gaggcatcat ggtggcttcc ctgcgcccag gaagccatat 1320
acacagatgc ccattgcagc attgtttgtg atagtgaaca actggaagct gcttaactgt 1380
ccatcagcag gagactggct aaatatattc taattttatt tagccagtct cctgctgatg 1440
gacagttaag caggagactg gctaaataaa attagaatat atttatacaa cagaatctca 1500
aaaacactgt tgagtaagga aaaaaaggca tgctgctgaa tgatgggtat ggaacttttt 1560
aaaaaagtac atgcttttat gtatgtatat tgcctatgga tatatgtata aatacaatat 1620
gcatcatata ttgatataaa gatgtaaaga aaaaaggggc 1660

<210> 61
<211> 2118
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7501754CB1

<400> 61
cccgcgccgc ccgcgccccg ctcgactccg gaggctcccg cagccccggc gtccgccccg 60
ctgccccctc ccccgggggc catgggggcg cccccgggct accggccctc agcttgggtg 120
catctcctcc accagctgcc ccgcgccgac ttccagctcc gcccggtgcc cagcgttttc 180
gcgccccaag agcaggaata ccagcaggcc ttgttgctgg tggcggcctt ggcgggcctg 240
ggcttgggcc tgagcctcat tttcatcgct gtctacctca tccgcttctg ctgctgccgg 300
ccccccgagc ccccgggtc caagatcccc tcgcccgggg gaggctgcgt cacctggagc 360
tgcattgtcg cccttctcgc cggctgcact ggcattggca tcggtttcta tggcaacagt 420
gagaccagtg atggggtgtc ccagctcagc tctgcgctgc tgcacgccaa ccacacactc 480
agcaccattg accacctggt gttggagacg gtggagaggc tgggcgaggc ggtgaggaca 540
gagctgacca ccctggagga ggtgctcgag ccgcgcacgg agctggtggc tgccgcccga 600
ggggctcgac ggcaggcgga ggctgcggcc cagcagctgc aggggctggc cttctggcag 660
ggagtgcccc tgagcccccc gcaggtggct gaaaatgtgt cctttgtgga ggagtacagg 720
tggctggcct acgtcctcct gctgctcctg gagctgctgg tctgcctctt caccctcctg 780
ggcctggcga agcagagcaa gtggctggtg atcgtgatga cagtcatgag tctcctggtt 840
ctcgtcctga gctggggctc catgggcctg gaggcagcca cggccgtggg cctcagtgac 900
ttctgctcca atccagaccc ttatgttctg aacctgaccc aggaggagac agggctcagc 960
tcagacatcc tgagctatta tctcctctgc aaccgggccg tctccaaccc cttccaacag 1020
aggctgactc tgtcccagcg agctctggcc aacatccact cccagctgct gggcctggag 1080
cgagaagctg tgcctcagtt cccttcagcg cagaagcctc tgctgtcctt ggaggagact 1140
ctgaatgtga cagaaggaaa tttccaccag ttggtggcac tgctacactg ccgcagcctg 1200
cacaaggact atggtgcagc cctgcggggc ctgtgcgaag acgccctgga aggcctgctc 1260
ttcctgctac tcttctccct gctgtctgca ggagcgctgg ccactgccct ctgcagcctg 1320
ccccgagcct gggccctctt cccacccagg aatccaagcg ctttgtgcag tggcagtcgt 1380
ctatctgagc ccctcctccc ggctggactg gagcctggct cccctcttcg ttccttccct 1440
ggctgccgga ggagacccca ctaacccagc ctgcctgggc tctgaccact aacactcttg 1500
gccatggaca gcctgcacag gaccgcctcc ctgctcttgg ccactgtgct cccatttctg 1560
tccttggcct tgggagtagc tgaggggca gactagggag tagggctggc aggggagggg 1620
gcagacagcc tcgcctcgca cccttcatcc ctggctgccg gtcccatcct tggagggact 1680
aagctggggg tgggggacat gagtcccccc gctgcccctg ccacatccca gtgggctctg 1740
acccccctgat ctcaactcgt ggcactaact tggaaaaggg ttgatttaaa ataaaaggga 1800
agactatttt acaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaagagggg gggggggcaa 1920
gaaatgtatc ctcccccccg gataataaac tggcggagcg tccttgggga aaaacactac 1980
tccacaacag gggcacttaa aagcccgcgg aacattggtc aacatcctac ggtagtaaat 2040
atttcccgca cacaccaaga ttgagaaaaa catgagagat agcttaacag acatggtgat 2100
cgagatttat gcagagat 2118

<210> 62
<211> 2800
<212> DNA

<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510517CB1

<400> 62
cttcactgac ccatcccgct gcacctcttg tttcccaagt ttttgaaagc tggcaactct 60
gacctcggtg tccaaaaatc gacagccact gagaccggct ttgagaagcc gaagatttgg 120
cagtttccag actgagcagg acaaggtgaa agcaggttgg aggcgggtcc aggacatctg 180
agggctgacc ctgggggctc gtgaggctgc caccgctgct gccgctacag acccagcctt 240
gcactccaag gctgcgcacc gccagccact atcatgtcca ctcccggggt caattcgtcc 300
gcctccttga gccccgaccg gctgaacagc ccagtgacca tcccggcggt gatgttcatc 360
ttcggggtgg tgggcaacct ggtggccatc gtggtgctgt gcaagtcgcg caaggagcag 420
aaggagacga ccttctacac gctggtatgt gggctggctg tcaccgacct gttgggcact 480
ttgttggtga gcccggtgac catcgccacg tacatgaagg gccaatggcc cgggggccag 540
ccgctgtgcg agtacagcac cttcattctg ctcttcttca gcctgtccgg cctcagcatc 600
atctgcgcca tgagtgtcga gcgctacctg gccatcaacc atgcctattt ctacagccac 660
tacgtggaca agcgattggc gggcctcacg ctctttgcag tctatgcgtc caacgtgctc 720
ttttgcgcgc tgcccaacat gggtctcggt agctcgcggc tgcagtaccc agacacctgg 780
tgcttcatcg actggaccac caacgtgacg gcgcacgccg cctactccta ctcgtggtgc 840
gagtattcgt caaccagtta tatcagccaa gtttggagcg agaagtcagt aaaaatccag 900
atttgcaggc catccgaatt gcttctgtga accccatcct agacccctgg atatatatcc 960
tcctgagaaa gacagtgctc agtaaagcaa tagagaagat caaatgcctc ttctgccgca 1020
ttggcgggtc ccgcagggag cgctccggac agcactgctc agacagtcaa aggacatctt 1080
ctgccatgtc aggccactct cgctccttca tctcccggga gctgaaggag atcagcagta 1140
catctcagac cctcctgcca gacctctcac tgccagacct cagtgaaaat ggccttggag 1200
gcaggaattt gcttccaggt gtgcctggca tgggcctggc ccaggaagac accacctcac 1260
tgaggacttt gcgaatatca gagacctcag actcttcaca gggtcaggac tcagagagtg 1320
tcttactggt ggatgaggct ggtgggagcg gcagggctgg gcctgcccct aaggggagct 1380
ccctgcaagt cacatttccc agtgaaacac tgaacttatc agaaaaatgt atataatagg 1440
caaggaaaga aatacagtac tgtttctgga cccttataaa atcctgtgca atagacacat 1500
acatgtcaca tttagctgtg ctcagaaggg ctatcatcat cctacaactc acattagaga 1560
acatcctggc ttttgagcac ttttcaaaca atcaagttga ctcacgtggg tcctgaggcc 1620
tgcagcacgt cggatgctac cccactatga cagaggattg tggtcacaac ttgatggctg 1680
cgaagaccta ccctccgttt ttctactaga taggaggatg gtagaagttt ggctgctgtc 1740
ataacatcca gagctttgtc gtatttggca cacagcagag gcccagatat tagaaaggct 1800
ctattccaat aaactatgag gactgcctta tggatgattt aagtgtctca ctaaagcatg 1860
aaatgtgaat ttttattgtt gtacatacga tttaaggtat ttaaagtatt ttcttctctg 1920
tgagaaggtt tattgttaat acaaggtata ataaaattat cgcaacccct ctccttccag 1980
tataaccagc tgaagttgca gatgttagat atttttcata aacaagttcg agtcaaagtt 2040
gaaaattcat agtaagattg atatctataa aatagatata aatttttaag agaaagaatt 2100
tagtattatc aaagggataa agaaaaaaat actatttaag atgtgaaaat tacagtccaa 2160
aatactgttc tttccaggct atgtataaaa tacatagtga aaattgttta gtgatattac 2220
atttatttat ccagaaaact gtgatttcag gagaacctaa catgctggtg aatattttca 2280
acttttcccc tcactaattg gtacttttaa aaacataaca taaatttttt gaagtcttta 2340
ataaataacc cataattgaa gtgtataata taaaaaattt taaaaatcta agcagcttat 2400
tgtttctctg aaagtgtgtg tagttttact ttcctaagga attaccaaga atatccttta 2460
aaatttaaaa ggatggcaag ttgcatcaga aagctttatt ttgagatgta aaaagattcc 2520
caaacgtggt tacattagcc attcatgtat gtcagaagtg cagaattggg gcacttaatg 2580
gtcaccttgt aacagttttg tgtaactccc agtgatgctg tacacatatt tgaagggtct 2640
ttctcaaaga aatattaagc atgttttgtt gctcagtgtt tttgtgaatt gcttggttgt 2700
aattaaattc tgagcctgat attgatatgg ttttaagaag cagttgtacc aagtgaaatt 2760
attttggaga ttataataaa tatatacatt caaaaaaaaa 2800

<210> 63
<211> 1750
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511014CB1

<400> 63
gccgcgcgcg ccccgcagtt tccgcgctaa gggaacgagt gcgcggaggg gacgagcggc 60
tggaccacag ccggcgcccg atcaggatct ccgcgctggg atcggtggaa cttgaggcag 120
cggcggcgcg gggcgccatg gcacaccgag cggctccgtc ttctgctcct cagagagccc 180
ggctggcggc ctgggatgac aagatgtctg gactgcaatc ctgcacagtt ttgagaggga 240
gatgacttga gtggttggct tttatctcca caacaatgtc catgaacaat tccaaacagc 300
tagtgtctcc tgcagctgcg cttctttcaa acacaacctg ccagacggaa aaccggcttt 360
ccgtattttt ttcagtaatc ttcatgacag tgggaatctt gtcaaacagc cttgccatcg 420
ccattctcat gaaggcatat cagagattta gacagaagtc caaggcatcg tttctgcttt 480
tggccagtgg cctggtaatc actgatttct ttggccatct catcaatgga gccatagcag 540
tatttgtata tgcttctgat aaagaatgga tccgctttga ccaatcaaat gtcctttgca 600
gtatttttgg tatctgcatg gtgttttctg gtctgtgccc acttcttcta ggcagtgtga 660
tggccattga gcggtgtatt ggagtcacaa aaccaatatt tcattctacg aaaattacat 720
ccaaacatgt gaaaatgatg ttaagtggtg tgtgcttgtt tgctgttttc atagctttgc 780
tgcccatcct tggacatcga gactataaaa ttcaggcgtc gaggacctgg tgtttctaca 840
acacagaaga catcaaagac tgggaagata gattttatct tctacttttt tcttttctgg 900
ggctcttagc ccttggtgtt tcattgttgt gcaatgcaat cacaggaatt acacttttaa 960
gagttaaatt taaaagtcag cagcacagac aaggcagatc tcatcatttg gaaatggtaa 1020
tccagctcct ggcgataatg tgtgtctcct gtatttgttg gagcccattt ctgggataca 1080
gaataatttt gaatgggaaa gagaaatata aagtatatga agagcaaagt gatttcttac 1140
ataggttaca atggccaaca ttggaataaa tggaaatcat tctctggaaa cctgtgaaac 1200
aacacttttt gctctccgaa tggcaacatg gaatcaaatc ttagatcctt gggtatatat 1260
tcttctacga aaggctgtcc ttaagaatct ctataagctt gccagtcaat gctgtggagt 1320
gcatgtcatc agcttacata tttgggagct tagttccatt aaaaattcct taaaggttgc 1380
tgctatttct gagtcaccag ttgcagagaa atcagcaagc acctagctta ataggacagt 1440
aaatctgtgt ggggctagaa caaaattaag acatgtttgg caatatttca gttagttaaa 1500
tacctgtagc ctaactggaa aattcaggct tcatcatgta gtttgaagat actattgtca 1560
gattcaggtt ttgaaatttg tcaaataaac aggataactg tacatttttc acttgttttt 1620
gccaatggga ggtagacaca ataaaataat gccatgggag tcacactgaa agcaattttg 1680
agcttatctg tcttattatg ctttgagtga atcatctgtt gaggtctaat gcctttactt 1740
ggcctatttg 1750

<210> 64
<211> 7106
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7506687CB1

<400> 64
gcgtgcgaat atagtaatat aacactatga ttacatgcac gcgtcgtagc tcggaattgg 60
ctcgagcagc cggcctgcca ggtgaccatg cctgctctgg gcccagctct tctccaggct 120
ctctgggccg ggtgggtcct caccctccag ccccttccac caactgcatt cactcccaat 180
ggcacgtatc tgcagcacct ggcaagggac cccacctcag gcaccctcta cctgggggct 240
accaacttcc tgttccagct gagccctggg ctgcagctgg aggccacagt gtccaccggc 300
cctgtgctag acagcaggga ctgcctgcca cctgtgatgc ctgatgagtg cccccaggcc 360
cagcctacca acaacccgaa tcagctgctc ctggtgagcc caggggccct ggtggtatgc 420
gggagcgtgc accaggggct ctgtgaacag cggcgcctgg ggcagctcga gcagctgctg 480
ctgcggccag agcggcctgg ggacacacaa tatgtggctg ccaatgatcc tgcggtcagc 540
acggtggggc tggtagccca gggcttggca ggggagcccc tcctgtttgt ggggcgagga 600
tacaccagca ggggtgtggg gggtggcatt ccacccatca caacccgggc cctgtggccg 660
cccgaccccc aagctgcctt ctcctatgag gagacagcca agctggcagt gggccgcctc 720
tccgagtaca gccaccactt cgtgagtgcc tttgcacgtg gggccagcgc ctacttcctg 780
ttcctgcggc gggacctgca ggctcagtct agagcttttc gtgcctatgt atctcgagtg 840
tgtctccggg accagcacta ctactcctat gtggagttgc ctctggcctg cgaaggtggc 900
cgctacgggc tgatccaggc tgcagctgtg gccacgtcca gggaggtggc gcatggggag 960
gtgctctttg cagctttctc ctcggctgca ccccccactg tgggccggcc cccatcggcg 1020
gctgctgggg catctggagc ctctgccctc tgtgccttcc ccctggatga ggtggaccgg 1080
cttgctaatc gcacgcgaga tgcctgctac acccgggagg gtcgtgctga ggatgggacc 1140
gaggtggcct acatcgagta tgatgtcaat tctgactgtg cacagctgcc agtggacacc 1200
ctggatgctt atccctgtgg ctcagaccac acgcccagcc ccatggccag ccgggtcccg 1260

ctggaagcca caccaattct ggagtggcca gggattcagc taacagctgt ggcagtcacc 1320
atggaagatg gacacaccat cgctttcctg ggtgatagtc aagggcagct gcacagggtc 1380
tacttgggcc cagggagcga tggccaccca tactccacac agagcatcca gcaggggtct 1440
gcagtgagca gagacctcac ctttgatggg acctttgagc acctgtatgt catgacccag 1500
agcacacttc tgaaggttcc tgtggcttcc tgtgctcagc acctggactg tgcatcttgc 1560
cttgctcaca gggacccata ctgtgggtgg tgcgtgctcc ttggcaggtg cagtcgccgt 1620
tctgagtgct cgaggggcca gggcccagag cagtggctat ggagcttcca gcctgagctg 1680
ggctgtctgc aagtggcagc catgagtcct gccaacatca gccgagagga gacgagggag 1740
gttttcctat cagtgccaga cctgccaccc ctgtggccag gggagtcata ttcctgccac 1800
tttggggaac atcagagtcc tgccctgctg actggttctg gtgtgatgtg cccctcccca 1860
gaccctagtg aggccccagt gctgccgaga ggagccgact acgtatccgt gagcgtggag 1920
ctcagatttg gcgctgttgt gatcgccaaa acttccctct ctttctatga ctgtgtggcg 1980
gtcactgaac tccgcccatc tgcgcagtgc caggcctgtg tgagcagccg ctgggggtgt 2040
aactggtgtg tctggcagca cctgtgcacc cacaaggcct cgtgtgatgc tgggcccatg 2100
gttgcaagcc atcagagccc gcttgtctcc ccagaccctc ctgcaagagg tggacccagc 2160
ccctccccac ccacagcccc caaagccctg gccacccctg ctcctgacac ccttcccgtg 2220
gagcctgggg ctccctccac agccacagct tcggacatct cacctggggc tagtccttcc 2280
ctgctcagcc cctgggggcc atgggcaggt tctggctcca tatcttcccc tggctccaca 2340
gggtcgcctc tccatgagga gccctccgct cccagccccc aaaatggacc tggaaccgct 2400
gtccctgccc ccactgactt cagaccctca gccacacctg aggacctctt ggcctccccg 2460
ctgtcaccct cagaggtagc agcagtgccc cctgcagacc ctggccccga ggctcttcat 2520
cccacagtgc ccctggacct gccccctgcc actgttcctg ccaccacttt cccaggggcc 2580
atgggctccg tgaagcccgc cctggactgg ctcacgagag aaggcggcga gctgcccgag 2640
gcggacgagt ggacgggggg tgacgcaccc gccttctcca cttccaccct cctctcagga 2700
agaggcgacc ttgggggcaa gctcctgccc ctgtgtggag agcgttcagg gctccacgtt 2760
gatgccggtc catgtggagc gggaaatccg gctgctaggc aggaacctgc acctttccca 2820
ggatggccca ggagacaatg agtgtgtgat ggagctggag ggcctcgagg tggtggttga 2880
ggcccgggtc gagtgtgagc cacctccaga tacccagtgc catgtcacct gccagcagca 2940
ccagctcagc tatgaggctc tgcagccgga gctccgtgtg gggctgtttc tgcgtcgggc 3000
cggccgtctg cgtgtggaca gtgctgaggg gctgcatgtg gtactgtatg actgttccgt 3060
gggacatgga gactgcagcc gctgccaaac tgccatgccc cagtatggct gtgtgtggtg 3120
tgaggggggag cgtccacgtt gtgtgacccg ggaggcctgt ggtgaggctg aggctgtggc 3180
cacccagtgc ccagcgcccc tcatccactc ggtggagcca ctgactgggc ctgtagacgg 3240
aggcacccgt gtcaccatca ggggctccaa cctgggccag catgtgcagg atgtgctggg 3300
catggtcacg gtggctggag tgccctgtgc tgtggatgcc caggagtacg aggtctccag 3360
cagcctcgtg tgcatcaccg gggccagtgg ggaggaggtg gccggcgcca cagcggtgga 3420
ggtgccggga agaggacgtg gtgtctcaga acacgacttt gcctaccagg atccgaaggt 3480
ccattccatc ttcccggccc gcggccccag agctgggggc acccgtctca ccctgaatgg 3540
ctccaagctc ctgactgggc ggctggagga catccgagtg gtggttggag accagccttg 3600
tcacttgctg ccggagcagc agtcagaaca actgcggtgt gagaccagcc cacgccccac 3660
gcctgccacg ctcctgtggg ctgtgtggtt tggggccacg gagcggaggc ttcaacgcgg 3720
acagttcaag tataccttgg accccaacat cacctctgct ggccccacca agagcttcct 3780
cagtggagga cgtgagatat gcgtccgtgg ccagaatctg gacgtggtac agacgccaag 3840
aatccgggtg accgtggtct cgagaatgct gcagcccagc caggggcttg gacggaggcg 3900
tcgcgtggtc ccggagacgg catgttccct tggaccctcc tgcagtagcc agcaatttga 3960
ggagccgtgc catgtcaact cctcccagct catcacgtgc cgcacacctg ccctcccagg 4020
cctgcctgag gacccctggg tccgggtgga atttatcctt gacaacctgg tctttgactt 4080
tgcaacactg aaccccacac ctttctccta tgaggccgac cccaccctgc agccactcaa 4140
ccctgaggac cccaccatgc cattccggca caagcctggg agtgtgttct ccgtggaggg 4200
ggagaacctg gaccttgcaa tgtccaagga ggaggtggtg gctatgatag gggatggccc 4260
ctgtgtggtg aagacgctga cgcggcacca cctgtactgc gagccccccg tggagcagcc 4320
cctgccacgg caccatgccc tccgagaggc acctgactct ttgcctgagt tcacggtgca 4380
gatggggaac ttgcgcttct ccctgggtca cgtgcagtat gacggcgaga gccctggggc 4440
ttttcctgtg gcagcccagg tgggcttggg ggtgggcacc tctcttctgg ctctgggtgt 4500
catcatcatt gtcctcatgt acaggaggaa gagcaagcag gccctgaggg actataagaa 4560
ggttcagatc cagctggaga atctggagag cagtgtgcgg gaccgctgca agaaggaatt 4620
cacagacctc atgactgaga tgaccgatct caccagtgac ctcctgggca gcggcatccc 4680
cttcctcgac tacaaggtgt atgcggagag gatcttcttc cctgggcacc gcgagtcgcc 4740
cttgcaccgg gacctgggtg tgcctgagag cagacggccc actgtggagc aagggctggg 4800
gcagctctct aacctgctca acagcaagct cttcctcacc aagttcatcc acacgctgga 4860
gagccagcgc acctttcag ctcgggaccg tgcctacgtg gcatctctgc tcaccgtggc 4920
actgcatggg aagcttgagt atttcactga catcctccgc actctgctca gtgacctggt 4980
tgcccagtat gtggccaaga accccaagct gatgctgcgc aggacagaga ctgtggtgga 5040

gaagctgctc accaactgga tgtccatctg tctgtatacc ttcgtgaggg actccgtagg 5100
ggagcctctg tacatgctct ttcgagggat taagcaccaa gtggataagg ggccagtgga 5160
cagtgtgaca ggcaaggcca aatacacctt gaacgacaac cgcctgctca gagaggatgt 5220
ggagtaccgt cccctgacct tgaatgcact attggctgtg gggcctgggg caggagaggc 5280
ccagggcgtg cccgtgaagg tcctagactg tgacaccatc tcccaggcaa aggagaagat 5340
gctggaccag ctttataaag gagtgcctct cacccagcgg ccagaccctc gcacccttga 5400
tgttgagtgg cggtctgggg tggccgggca cctcattctt tctgacgagg atgtcacttc 5460
tgaggtccag ggtctgtgga ggcgcctgaa cacactgcag cattacaagg tcccagatgg 5520
agcaactgtg gccctcgtcc cctgcctcac caagcatgtg ctccgggaaa accaggatta 5580
tgtccctgga gagcggaccc caatgctgga ggatgtagat gaggggggca tccggccctg 5640
gcacctggtg aagccaagtg atgagccgga gccgcccagg cctcggaggg gcagccttcg 5700
gggcggggag cgtgagcgcg ccaaggccat ccctgagatc tacctgaccc gcctgctgtc 5760
catgaagggc accctgcaga agttcgtgga tgacctgttc caggtgattc tcagcaccag 5820
ccgccccgtg ccgctcgctg tgaagtactt ctttgacctg ctggatgagc aggcccagca 5880
gcatggcatc tccgaccagg acaccatcca catctggaag accaacagct tgcctctgag 5940
gttctggatc aatataataa aaaacccgca gtttgtgttc gacgtgcaaa catctgataa 6000
catggatgcg gtgctccttg tcattgcaca gaccttcatg gacgcctgca ccctggccga 6060
ccacaagctg ggccgggact ccccgatcaa caaacttctg tatgcacggg acattccccg 6120
gtacaagcgg atggtggaaa ggtactatgc agacatcaga cagactgtcc cagccagcga 6180
ccaagagatg aactctgtcc tggctgaact gtcctggaac tactccggag acctcggggc 6240
gcgagtggcc ctgcatgaac tctacaagta catcaacaag tactatgacc agatcatcac 6300
tgccctggag gaggatggca cggcccagaa gatgcagctg ggctatcggc tccagcagat 6360
tgcagctgct gtggaaaaca aggtcacaga tctataggaa cccaggagcc acggcctgct 6420
gttgcttcag cctggcctgg gcagccctgg aagctcggag gagaggccac cttcttaggt 6480
gcctgtagtg actgacaagc agagttagtg gaaggtgact cccagtctcc tggtggctct 6540
ggcctcggcc ctgctggatc cacctcctag acccggggcc tcaaggctca tggggtagta 6600
cccagcctgc tccccgagtc cagcgaccct gtgacaccgg tctgcaggga gttggggact 6660
aagggcttcc agagagtggc tggaagagac tccaggcccc tggggagact gtactgttcc 6720
tgaacactgg ccttggccac actgggattc ggagaggaag gaggagagcc ccatgcttcc 6780
tgtctgcctc ctccaccatc cctgacctca gttgagctgc ctctggcctt gttgctgctg 6840
ccacatccta ggtctaagag ttgaacgcct ctcctaggcc actacaaact gacccctcag 6900
cagggctggc tgccacaggg ctgccctgcc tcataggtag ccatggtgag ggctatctgc 6960
tgcaggggg tcttggggag agtggtgact ccattgaccc agcttttcat taaaggataa 7020
cacactgcac tgagtctgat gtgtgagccc ggcctagccc ctggctacta ggaggacggc 7080
agctatgccc agcaggtacc aggggg 7106

<210> 65
<211> 1187
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510621CB1

<400> 65
ggaaaatgga gaagctgtgc taatagaggg gggccagaaa tccccactct agaatgctgt 60
agaatgttgg gagacaccca ggatgtgagc cagggacttt ctggaagtgt ttgttctggc 120
cccacccgac cccaggcagt ccccagctgt ctgcacagtc ggatggggag ggggcttgca 180
cagagttgga gccagaggag agagctggct catcccctac ggtaggatgg ggaaacctca 240
cagaccacat tgtcacccgg cctcagctct ccgccccggc gctcagaggg taactctcac 300
ccacctcgtc cgcttctctg aaccagagtg acccaggctg cgctccgccc cgctctccta 360
ccccgagttg gcacggaggc ccggcagcca tggcggtgga aggaggaatg aaatgtgtga 420
agttcttgct ctacgtcctc ctgctggcct tttgcgcctg tgcagtggga ctgattgccg 480
tgggtgtcgg ggcacagctt gtcctgagtc agaccataat ccaggggggct acccctggct 540
ctctgttgcc agtggtcatc atcgcagtgg gtgtcttcct cttcctggtg gcttttgtgg 600
gctgctgcgg ggcctgcaag gagaactatt gtcttatgat cacgtttgcc attgctggct 660
atgtgtttag agataaggtg atgtcagagt ttaataacaa cttccggcag cagatggaga 720
attacccgaa aaacaaccac actgcttcga tcctggacag gatgcaggca gattttaagt 780
gctgtggggc tgctaactac acagattggg agaaaatccc ttccatgtcg aagaaccgag 840
tccccgactc ctgctgcatt aatgttactg tgggctgtgg gattaatttc aacgagaagg 900
cgatccataa ggagggctgt gtggagaaga ttgggggctg gctgaggaaa aatgtgctgg 960
tggtagctgc agcagccctt ggaattgctt ttgtcgaggt tttgggaatt gtctttgcct 1020

gctgcctcgt gaagagtatc agaagtggct acgaggtgat gtaggggtct ggtctcctca 1080
gcctcctcat ctgggggagt ggaatagtat cctcatctgg gggagtggaa tagtatcctc 1140
caggtttttc aattaaacgg attatttttt cagaccgaaa aaaaaaa 1187

<210> 66
<211> 570
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7505533CB1

<400> 66
ttcggctcga gggcggcgac ggaggaggag gatggaggcg gtggtgttcg tcttctctct 60
cctcgattgt tgcgcgctca tcttcctctc ggtctacttc ataattacat tgtctgattt 120
agaatgtgat tacattaatg ctagatcatg ttgctcaaaa ttaaacaagt gggtaattcc 180
agaattgatt ggccatacca ttgtcactgt attactgctc atgtcattgc actggttcat 240
cttccttctc aacttacctg ttgccacttg gaatatatat cgaaatacac aatcgagggc 300
agctgaagtc acacatgaaa gaagccatga tcaagcttgg tttccacttg ctctgcttct 360
tcatgtatct ttatagtatg atcttagctt tgataaatga ctgaagctgg agaagccgtg 420
gttgaagtca gcctacacta cagtgcacag ttgaggagcc agagacttct taaatcatcc 480
ttagaaccgt gaccatagca gtatatattt tcctcttgga acaaaaaact atttttgctg 540
tatttttacc atataaagta tttaaaaaac 570

<210> 67
<211> 685
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511220CB1

<400> 67
ggccgagcgc ggggcacccg ggggcctcct gtataggcgg gcaccatggg ctcctgctcc 60
ggccgctgcg cgctcgtcgt cctctgcgct tttcagctgg tcgccgccct ggagaggcag 120
gtgtttgact tcctgggcta ccagtgggcg cccatcctgg ccaactttgt ccacatcatc 180
atcgtcatcc tgggactctt cggcaccatc cagtaccggc tgcgctacgt catggtgtac 240
acgctgtggg cagccgtctg ggtcacctgg aacgtcttca tcatctgctt ctacctggaa 300
gtcggtggcc tcttacagga cagcgagcta ctgaccttca gcctctcccg gcatcgctcc 360
tggtggcgtg agcgctggcc aggctgtctg catgaggagg tgccagcagt gggcctcggg 420
gccccccatg gccaggccct ggtgtcaggt gctggctgtg ccctggagcc cagctatgtg 480
gaggccctac acagtggcct gcagatcctg atcgcgcttc tgggctttgt ctgtggctgc 540
caggtggtca gcgtgtttac ggaggaagag gacagctgcc tgcgtaagtg aggaaacagc 600
tgatcctgct cctgtggcct ccagcctcag cgaccgacca gtgacaatga caggagctcc 660
caggccttgg gacgcgcccc caccc 685

<210> 68
<211> 5723
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510967CB1

<400> 68
tggccgccgg gtgtggtgag ggcgacgcgc ttgcagtcgc cgtctcttgc ttccccgtcc 60
tctgacatcg cctgcagccg agcgggcccg ttccgccgga gctgaggacc aggtattcaa 120
ataaagttaa ttgcagcttt ctgtgaaaat gtcagttttg atatcacaga gcgtcataaa 180
ttatgtagag gaagaaaaca ttcctgctct gaaagctctt cttgaaaaat gcaaagatgt 240
agatgagaga aatgagtgtg gccagactcc actgatgata gctgccgaac aaggcaatct 300

ggaaatagtg aaggaattaa ttaagaatgg agctaactgc aatctggaag atttggataa 360
ttggacagca cttatatctg catcgaaaga agggcatgtg cacatcgtag aggaactact 420
gaaatgtggg gttaacttgg agcaccgtga tatgggagga tggacagctc ttatgtgggc 480
atgttacaaa ggccgtactg acgtagtaga gttgcttctt tctcatggtg ccaatccaag 540
tgtcactggt ctgcagtaca gtgtttaccc aatcatttgg gcagcaggga gaggccatgc 600
agatatagtt catcttttac tgcaaaatgg tgctaaagtc aactgctctg ataagtatgg 660
aaccacccct ttagtttggg ctgcacgaaa gggtcatttg gaatgtgtga aacatttatt 720
ggccatggga gctgatgtgg atcaagaagg agctaattca atgactgcac ttattgtggc 780
agtgaaagga ggttacacac agtcagtaaa agaaattttg aagaggaatc caaatgtaaa 840
cttaacagat aaagatggaa atacagcttt gatgattgca tcaaaggagg gacatacgga 900
gattgtgcag gatctgctcg acgctggaac atatgtgaac atacctgaca ggagtgggga 960
tactgtgttg attggcgctg tcagaggtgg tcatgttgaa attgttcgag cgcttctcca 1020
aaaatatgct gatatagaca ttagaggaca ggataataaa actgctttgt attgggctgt 1080
tgagaaagga aatgcaacaa tggtgagaga tatcttacag tgcaatcctg acactgaaat 1140
atgcacaaag gatggtgaaa cgccacttat aaaggctacc aagatgagaa acattgaagt 1200
ggtggagctg ctgctagata aaggtgctaa agtgtctgct gtagataaga aaggagatac 1260
tcccttgcat attgctattc gtggaaggag ccggaaactg gcagaactgc ttttaagaaa 1320
tcccaaagat gggcgattac tttataggcc caacaaagca ggcgagactc cttataatat 1380
tgactgtagc catcagaaga gtattttaac tcaaatattt ggagccagac acttgtctcc 1440
tactgaaaca gacggtgaca tgcttggata tgatttatat agcagtgccc tggcagatat 1500
tctcagtgag cctaccatgc agccacccat ttgtgtgggg ttatatgcac agtggggaag 1560
tgggaaatct ttcttactca agaaactaga agacgaaatg aaaaccttcg ccggacaaca 1620
gattgagcct ctctttcagt tctcatggct catagtgttt cttaccctgc tactttgtgg 1680
agggcttggt ttattgtttg ccttcacggt ccacccaaat cttggaatag cagtgtcact 1740
gagcttcttg gctctcttat atatattctt tattgtcatt tactttggtg gacgaagaga 1800
aggagagagt tggaattggg cctgggtcct cagcactaga ttggcaagac atattggata 1860
tttggaactc ctccttaaat tgatgtttgt gaatccacct gagttgccag agcagactac 1920
taaagcttta cctgtgaggt ttttgtttac agattacaat agactgtcca gtgtaggtgg 1980
agaaacttct ctggctgaaa tgattgcaac cctctcggat gcttgtgaaa gagagtttgg 2040
ctttttggca accaggcttt ttcgagtatt caagactgaa gatactcagg gtaaaaagaa 2100
atggaaaaaa acatgttgtc tcccatcttt tgtcatcttc ctttttatca ttggctgcat 2160
tatatctgga attactcttc tggctatatt tagagttgac ccaaagcatc tgactgtaaa 2220
tgctgtcctc atatcaatcg catctgtagt gggattggcc tttgtgttga actgtcgtac 2280
atggtggcaa gtgctggact cgctcctgaa ttcccaaaga aaacgcctcc ataatgcagc 2340
ctccaaactg cacaaattga aaagtgaagg attcatgaaa gttcttaaat gtgaagtgga 2400
attgatggcc aggatggcaa aaaccattga cagcttcact cagaatcaga caaggctggt 2460
ggtcatcatc gatggattag atgcctgtga gcaggacaaa gtccttcaga tgctggacac 2520
tgtccgagtt ctgttttcaa aaggcccgtt cattgccatt tttgcaagtg atccacatat 2580
tatcataaag gcaattaacc agaacctcaa tagtgtgctt cgggattcaa atataaatgg 2640
ccatgactac atgcgcaaca tagtccactt gcctgtgttc cttaatagtc gtggactaag 2700
caatgcaaga aaatttctcg taacttcagc aacaaatgga gacgttccat gctcagatac 2760
tacagggata caggaagatg ctgacagaag agtttcacag aacagccttg gggagatgac 2820
aaaacttggt agcaagacag ccctcaatag acgggacact taccgaagaa ggcagatgca 2880
gaggaccatc actcgccaga tgtcctttga tcttacaaaa ctgctggtta ccgaggactg 2940
gttcagtgac atcagtcccc agaccatgag aagattactt aatattgttt ctgtgacagg 3000
acgattactg agagccaatc agattagttt caactgggac aggcttgcta gctggatcaa 3060
ccttactgag cagtggccat accggacttc atggctcata ttatatttgg aagagactga 3120
aggtattcca gatcaaatga cattaaaaac catctacgaa agaatatcaa agaatattcc 3180
aacaactaag gatgttgagc cacttcttga aattgatgga gatataagaa attttgaagt 3240
gtttttgtct tcaaggaccc cagttcttgt ggctcgagat gtaaaagtct ttttgccatg 3300
cactgtaaac ctagatccca aactacggga aattattgca gatgttcgtg ctgccagaga 3360
gcagatcagt attggaggac tggcgtaccc cccgctccct ctacatgagg gtcctcctag 3420
ggcgccatca gggtacagcc agcccccatc cgtgtgctct tccacgtcct tcaatgggcc 3480
cttcgcaggt ggagtggtgt caccacagcc tcacagcagc tattacagcg gcatgacggg 3540
ccctcagcat cccttctaca acaggccatt ctttgcccca taccttaca cgccaaggta 3600
ttaccctggc ggctcccaac atctcatctc acgtccatca gtaaaaacga gtttgcccag 3660
agatcagaac aatggcctag ggtcaggccc agccccaggc ccagtggtat tactgaattc 3720
actgaatgtg gatgcagtat gtgagaagct gaaacaaata gaagggctgg accagagtat 3780
gctgcctcag tattgtacca cgatcaaaaa ggcaaacata aatggccgtg tgttagctca 3840
gtgtaacatt gatgagctga agaaagagat gaatatgaat tttggagact ggcacctttt 3900
cagaagcaca gtactagaaa tgagaaacgc agaaagccac gtggtccctg aagacccacg 3960
tttcctcagt gagagcagca gtggcccagc cccgcacggt gagcctgctc gccgcgcttc 4020
ccacaacgag ctgcctcaca ccgagctctc cagccagacg ccctacacac tcaacttcag 4080

cttcgaagag ctgaacacgc ttggcctgga tgaaggtgcc cctcgtcaca gtaatctaag 4140
ttggcagtca caaactcgca gaaccccaag tctttcgagt ctcaattccc aggattccag 4200
tattgaaatt tcaaagctta ctgataaggt gcaggccgag tatagagatg cctatagaga 4260
atacattgct cagatgtccc agttagaagg gggccccggg tctacaacca ttagtggcag 4320
atcttctcca catagcacat attacatggg tcagagttca tcaggggct ctattcattc 4380
aaacctagag caagaaaagg ggaaggatag tgaaccaaag cccgatgatg ggaggaagtc 4440
ctttctaatg aagaggggag atgttatcga ttattcatca tcaggggttt ccaccaacga 4500
tgcttccccc ctggatccta tcactgaaga agatgaaaaa tcagatcagt caggcagtaa 4560
gcttctccca ggcaagaaat cttccgaaag gtcaagcctc ttccagacag atttgaagct 4620
taagggaagt gggctgcgct atcaaaaact cccaagtgac gaggatgaat ctggcacaga 4680
agaatcagat aacactccac tgctcaaaga tgacaaagac agaaaagccg aagggaaagt 4740
agagagagtg ccgaagtctc cagaacacag tgctgagccg atcagaacct tcattaaagc 4800
caaagagtat ttatcggatg cgctccttga caaaaaggat tcatcggatt caggagtgag 4860
atccagtgaa agttctccca atcactctct gcacaatgaa gtggcggatg actcccagct 4920
tgaaaaggca aatctcatag agctggaaga tgacagtcac agcggaaagc ggggaatccc 4980
acatagcctg agtggcctgc aagatccaat tatagctcgg atgtccattt gttcagaaga 5040
caagaaaagc ccttccgaat gcagcttgat agccagcagc cctgaagaaa actggcctgc 5100
atgccagaaa gcctacaacc tgaaccgaac tcccagcacc gtgactctga acaacaatag 5160
tgctccagcc aacagagcca atcaaaattt cgatgagatg gagggaatta gggagacttc 5220
tcaagtcatt ttgaggccta gttccagtcc caacccaacc actattcaga atgagaatct 5280
aaaaagcatg acacataagc gaagccaacg ttcaagttac acaaggctct ccaaagatcc 5340
tccggagctc catgcagcag cctcttctga gagcacaggc tttggagaag aaagagaaag 5400
cattctttga gaaaaacaag caaaggagaa gagtgttact gtacccttat gacagaattg 5460
tcctggattt tgactccatc cacgcccatc acctttctac attttgctga cagataacta 5520
accgatgatg aggccgaggt aaaagagaca tctgcagtgt gacagaaggg agcatgaaaa 5580
gccatggttc acacaaggca agcttctgtg ggctttgtat tagaagcttt cgaactccac 5640
taatatatct gtggctttca ttggggcctt tccccataaa atttttgag accaggggcg 5700
accggggatt aaacaacggg cca 5723

<210> 69
<211> 3044
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511298CB1

<400> 69
agcctgtgga gacgggacag ccctgtccca ctcactcttt cccctgccgc tcctgccggc 60
agctccaacc atgggaggcc gcgtctttct cgcattctgt gtctggctga ctctgccggg 120
agctgaaacc caggactcca ggggctgtgc ccggtggtgc cctcagaact cctcgtgtgt 180
caatgccacc gcctgtcgct gcaatccagg gttcagctct ttttctgaga tcatcaccac 240
cccgacggag acttgtgacg acatcaacga gtgtgcaaca ccgtcgaaag tgtcatgcgg 300
aaaattctcg gactgctgga acacagaggg gagctacgac tgcgtgtgca gcccgggata 360
tgagcctgtt tctggggcaa aaacattcaa gaatgagagc gagaacacct gtcaagatgt 420
ggacgaatgt cagcagaacc caaggctctg taaaagctac ggcacctgcg tcaacaccct 480
tggcagctat acctgccagt gcctgcctgg cttcaagttc atacctgagg atccgaaggt 540
ctgcacagat gtggacgagt gcagctccgg gcagcatcag tgtgacagct ccaccgtctg 600
cttcaacacc gtgggttcat acagctgccg ctgccgccca ggctggaagc ccagacacgg 660
aatcccgaat aaccaaaagg acactgtctg tgaagatatg actttctcca cctggacccc 720
gcccccctgga gtccacagcc agacgctttc ccgattcttc gacaaagtcc aggacctggg 780
cagagactcc aagacaagct cagccgaggt caccatccag aatgtcatca aattggtgga 840
tgaactgatg gaagctcctg gagacgtaga ggccctggcg ccacctgtcc ggcacctcat 900
agccacccag ctgctctcaa accttgaaga tatcatgagg atcctggcca agagcctgcc 960
taaaggcccc ttcacctaca tttccccttc gaacacagag ctgaccctga tgatccagga 1020
gcgggggggac aagaacgtca ctatgggtca gagcagcgca cgcatgaagc tgaattgggc 1080
tgtggcagct ggagccgagg atccaggccc cgccgtggcg ggcatcctct ccatccagaa 1140
catgacgaca ttgctggcca atgcctcctt gaacctgcat tccaagaagc aagccgaact 1200
ggaggagata tatgaaagca gcatccgtgg tgtccaactc agacgcctct ctgccgtcaa 1260
ctccatcttt ctgagccaca acaacaccaa ggaactcaac tcccccatcc ttttcgcctt 1320
ctcccacctt gagtcctccg atggggaggc gggaagagac cctcctgcca aggacgtgat 1380
gcctgggcca cggcaggagc tgctctgtgc cttctggaag agtgacagcg acaggggagg 1440

gcactgggcc accgagggct gccaggtgct gggcagcaag aacggcagca ccacctgcca 1500
atgcagccac ctgagcagct ttgcgatcct tatggctcat tatgacgtgg aggactggaa 1560
gctgaccctg atcaccaggg tgggactggc gctgtcactc ttctgcctgc tgctgtgcat 1620
cctcactttc ctgctggtgc ggcccatcca gggctcgcgc accaccatac acctgcacct 1680
ctgcatctgc ctcttcgtgg gctccaccat cttcctggcc ggcatcgaga acgaaggcgg 1740
ccaggtgggg ctgcgctgcc gcctggtggc cgggctgctg cactactgtt tcctggccgc 1800
cttctgctgg atgagcctcg aaggcctgga gctctacttt cttgtggtgc gcgtgttcca 1860
aggccagggc ctgagtacgc gctggctctg cctgatcggc tatggcgtgc ccctgctcat 1920
cgtgggcgtc tcggctgcca tctacagcaa gggctacggc cgccccagat actgctggtt 1980
ggactttgag cagggcttcc tctggagctt cttgggacct gtgaccttca tcattttgtg 2040
caatgctgtc attttcgtga ctaccgtctg gaagctcact cagaagtttt ctgaaatcaa 2100
tccagacatg aagaaattaa agaaggcgag ggcgctgacc atcacggcca tcgcgcagct 2160
cttcctgttg ggctgcacct gggtctttgg cctgttcatc ttcgacgatc ggagcttggt 2220
gctgacctat gtgtttacca tcctcaactg cctgcagggc gccttcctct acctgctgca 2280
ctgcctgctc aacaagaagg ttcgggaaga ataccggaag tgggcctgcc tagttgctgg 2340
ggggagcaag tactcagaat tcacctccac cacgtctggc actggccaca atcagacccg 2400
ggccctcagg gcatcagagt ccggcatatg aaggcgcatg gttctggacg gcccagcagc 2460
tcctgtggcc acagcagctt tgtacacgaa gaccatccat cctcccttcg tccaccactc 2520
tactccctcc accctccctc cctgatcccg tgtgccacca ggagggagtg gcagctatag 2580
tctggcacca aagtccagga cacccagtgg ggtggagtcg gagccactgg tcctgctgct 2640
ggctgcctct ctgctccacc ttgtgaccca gggtggggac aggggctggc ccagggctgc 2700
aatgcagcat gttgccctgg cacctgtggc cagtactcgg gacagactaa gggcgcttgt 2760
cccatcctgg acttttcctc tcatgtcttt gctgcagaac tgaagagact aggcgctggg 2820
gctcagcttc cctcttaagc taagactgat gtcagaggcc ccatggcgag gcccccttggg 2880
gccactgcct gaggctcacg gtacagaggc ctgccctgcc tggccgggca ggaggttctc 2940
actgttgtga aggttgtaga cgttgtgtaa tgtgttttta tctgttaaaa tttttcagtg 3000
ttgacactta aaattaaaca catgcataca gaaaaaaaaa aaaa 3044

<210> 70
<211> 4455
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7510937CB1

<400> 70
cgacggcacc tgagcgactg ccgcggcggc ggcggcggcg gcggcgcctc ggagcgggcg 60
gcccgggctg tagtgccggc gccgccgcgt cttcccggtc tcctttcccg gccgcacagg 120
gttttatagg atcacattga caaaagtacc atggagtttt atgagtcagc atattttatt 180
gttcttattc cttcaatagt tattacagta attttcctct tcttctggct tttcatgaaa 240
gaaacattat atgatgaagt tcttgcaaaa cagaaaagag aacaaaagct tattcctacc 300
aaaacagata aaaagaaagc agaaaagaaa aagaataaaa agaaagaaat ccagaatgga 360
aacctccatg aatccgactc tgagagtgta cctcgagact ttaaattatc agatgctttg 420
gcagtagaag atgatcaagt tgcacctgtt ccattgaatg tcgttgaaac ttcaagtagt 480
gttagggaaa gaaaaaagaa ggaaaagaaa caaaagcctg tgcttgaaga gcaggtcatc 540
aaagaaagtg acgcatcaaa gattcctggc aaaaaagtag aacctgtccc agttactaaa 600
cagcccaccc ctccctctga agcagctgcc tcgaagaaga aaccagggca gaagaagtct 660
aaaaatggaa gcgatgacca ggataaaaag gtggaaactc tcatggtacc atcaaaaagg 720
caagaagcat tgcccctcca ccaagagact aaacaagaaa gtggatcagg gaagaagaaa 780
gcttcatcaa agaaacaaaa gacagaaaat gtcttcgtag atgaacccct tattcatgca 840
actacttata ttcctttgat ggataatgct gactcaagtc ctgtggtaga taagagagag 900
gttattgatt tgcttaaacc tgaccaagta gaagggatcc agaaatctgg gactaaaaaa 960
ctgaagaccg aaactgacaa agaaaatgct gaagtgaagt ttaaagattt tcttctgtcc 1020
ttgaagacta tgatgttttc tgaagatgag gctctttgtg ttgtagactt gctaaaggag 1080
aagtctggtg taatacaaga tgctttaaag aagtcaagta agggagaatt gactacgctt 1140
atacatcagc ttcaagaaaa ggacaagtta ctcgctgctg tgaaggaaga tgctgctgct 1200
acaaaggatc ggtgtaagca gttaacccag gaaatgatga cagagaaaga aagaagcaat 1260
gtggttataa caaggatgaa agatcgaatt ggaacattag aaaaggaaca taatgtattt 1320
caaaacaaaa tacatgtcag ttatcaagag actcaacaga tgcagatgaa gtttcagcaa 1380
gttcgtgagc agatggaggc agagatagct cacttgaagc aggaaaatgg tatactgaga 1440
gatgcagtca gcaacactac aaatcaactg gaaagcaagc agtctgcaga actaaataaa 1500

ctacgccagg attatgctag gttggtgaat gagctgactg agaaaacagg aaagctacag 1560
caagaggaag tccaaaagaa gaatgctgag caagcagcta ctcagttgaa ggttcaacta 1620
caagaagctg agagaaggtg ggaagaagtt cagagctaca tcaggaagag aacagcggaa 1680
catgaggcag cacagcaaga tttacagagt aaatttgtgg ccaaagaaaa tgaagtacag 1740
agtctgcata gtaagcttac agataccttg gtatcaaaac aacagttgga gcaaagacta 1800
atgcagttaa tggaatcaga gcagaaaagg gtgaacaaag aagagtctct acaaatgcag 1860
gttcaggata ttttggagca gaatgaggct ttgaaagctc aaattcagca gttccattcc 1920
cagatagcag cccagacctc cgcttcagtt ctagcagaag aattacataa agtgattgca 1980
gaaaaggata agcagataaa acagactgaa gattctttag caagtgaacg tgatcgttta 2040
acaagtaaag aagaggaact taaggatata cagaatatga atttcttatt aaaagctgaa 2100
gtgcagaaat tacaggccct ggcaaatgag caggctgctg ctgcacatga attggagaag 2160
atgcaacaaa gtgtttatgt taaagatgat aaaataagat tgctggaaga gcaactacaa 2220
catgaaattt caaacaaaat ggaagaattt aagattctaa atgaccaaaa caaagcatta 2280
aaatcagaag ttcagaagct acagactctt gtttctgaac agcctaataa ggatgttgtg 2340
gaacaaatgg aaaaatgcat tcaagaaaaa gatgagaagt taaagactgt ggaagaatta 2400
cttgaaactg gacttattca ggtggcaact aaagaagagg agctgaatgc aataagaaca 2460
gaaaattcat ctctgacaaa agaagttcaa gacttaaaag ctaagcaaaa tgatcaggtt 2520
tcttttgcct ctctagttga agaacttaag aaagtgatcc atgagaaaga tggaaagatc 2580
aagtctgtag aagagcttct ggaggcagaa cttctcaaag ttgctaacaa ggagaaaact 2640
gttcaggatt tgaaacagga aataaaggct ctaaaagaag aaataggaaa tgtccagctt 2700
gaaaaggctc aacagttatc tatcacttcc aaagttcagg agcttcagaa cttattaaaa 2760
ggaaaagagg aacagatgaa taccatgaag gctgttttgg aagagaaaga gaaagaccta 2820
gccaatacag ggaagtggtt acaggatctt caagaagaaa atgaatcttt aaaagcacat 2880
gttcaggaag tagcacaaca taacttgaaa gaggcctctt ctgcatcaca gtttgaagaa 2940
cttgagattg tgttgaaaga aaaggaaaat gaattgaaga ggttagaagc catgctaaaa 3000
gagagggaga gtgatctttc tagcaaaaca cagctgttac aggatgtaca agatgaaaac 3060
aaattgttta agtcccaaat tgagcagctt aaacaacaaa actaccaaca ggcatcttct 3120
tttccccctc atgaagaatt attaaaagta atttcagaaa gagagaaaga aataagtggt 3180
ctctggaatg agttagattc tttgaaggat gcagttgaac accagaggaa gaaaaacaat 3240
gaaaggcagc aacaggtgga agctgttgag ttggaggcta aagaagttct caaaaaatta 3300
tttccaaagg tgtctgtccc ttctaatttg agttatggtg aatggttgca tggatttgaa 3360
aaaaaggcaa aagaatgtat ggctggaact tcagggtcag aggaggttaa ggttctagag 3420
cacaagttga aagaagctga tgaaatgcac acattgttac agctagagtg tgaaaaatac 3480
aaatccgtcc ttgcagaaac agaaggaatt ttacagaagc tacagagaag tgttgagcaa 3540
gaagaaaata aatggaaagt taaggtcgat gaatcacaca agactattaa acagatgcag 3600
tcatcattta catcttcaga acaagagcta gagcgattaa gaagcgaaaa taaggatatt 3660
gaaaatctga gaagagaacg agaacatttg gaaatggaac tagaaaaggc agagatggaa 3720
cgatctacct atgttacaga agtcagagag ctgaaagatc tgttgactga attgcagaaa 3780
aaacttgatg attcatattc tgaagcagta agacagaatg aagagctaaa tttgttgaag 3840
gcacagttaa atgaaacact cacaaaactt agaactgaac aaaatgaaag acagaaggta 3900
gctggtgatt tgcataaggc tcaacagtca ctggagctta tccagtcaaa aatagtaaaa 3960
gctgctggag acactactgt tattgaaaat agtgatgttt ccccagaaac ggagtcttct 4020
gagaaggaga caatgtctgt aagtctaaat cagactgtaa cacagttaca gcagttgctt 4080
caggcggtaa accaacagct cacaaaggag aaagagcact accaggtgtt agagtgaagt 4140
aattgggaaa ctgttcattt gaggataaaa aaggcattgt attatatttt gccaaattaa 4200
agccttattt atgttttcac cctttctact ttgtcagaaa cactgaacag agttttgtct 4260
tttctaatcc ttgttagact actgatttaa agaaggaaaa aaaaaagcca actctgtaga 4320
caccttcaga gtttagtttt ataataaaaa ctgtttgaat aattagacct ttacattcct 4380
gaagataaac atgtaatctt ttatcttatt ttgctcaata aaattgttca gaagaaaaaa 4440
aaaaaaaaaa aaaaa 4455

<210> 71
<211> 1949
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511852CB1

<400> 71
tacccatggc gcccgtcgcc gtctgggccg cgctggccgt cggactggag ctctgggctg 60
cggcgcacgc cttgcccgcc caggtggcat ttacacccta cgccccggag cccgggagca 120

catgccggct cagagaatac tatgaccaga cagctcagat gtgctgcagc aaatgctcgc 180
cgggccaaca tgcaaaagtc ttctgtacca agacctcgga caccgtgtgt gactcctgtg 240
aggacagcac atacacccag ctctggaact gggttcccga gtgcttgagc tgtggctccc 300
gctgtagctc tgaccaggtg gaaactcaag cctgcactcg ggaacagaac cgcatctgca 360
cctgcaggcc cggctggtac tgcgcgctga gcaagcagga ggggtgccgg ctgtgcgcgc 420
cgctgcgcaa gtgccgcccg ggcttcggcg tggccagacc aggaactgaa acatcagacg 480
tggtgtgcaa gccctgtgcc ccggggacgt tctccaacac gacttcatcc acggatattt 540
gcaggcccca ccagatctgt aacgtggtgg ccatccctgg gaatgcaagc atggatgcag 600
tctgcacgtc cacgtccccc acccggagta tggccccagg ggcagtacac ttaccccagc 660
cagtgtccac acgatcccaa cacacgcagc caactccaga acccagcact gctccaagca 720
cctccttcct gctcccaatg ggccccagcc ccccagctga agggagcact ggcgacttcg 780
ctcttccagt tgattcttcc cctggtggcc atgggaccca ggtcaatgtc acctgcatcg 840
tgaacgtctg tagcagctct gaccacagct cacagtgctc ctcccaagcc agctccacaa 900
tgggagacac agattccagc ccctcggagt ccccgaagga cgagcaggtc cccttctcca 960
aggaggaatg tgcctttcgg tcacagctgg agacgccaga gaccctgctg gggagcaccg 1020
aagagaagcc cctgcccctt ggagtgcctg atgctgggat gaagcccagt taaccaggcc 1080
ggtgtgggct gtgtcgtagc caaggtgggc tgagccctgg caggatgacc ctgcgaaggg 1140
gccctggtcc ttccaggccc ccaccactag gactctgagg ctctttctgg gccaagttcc 1200
tctagtgccc tccacagccg cagcctccct ctgacctgca ggccaagagc agaggcagcg 1260
ggttgtggaa agcctctgct gccatggcgt gtccctctcg gaaggctggc tgggcatgga 1320
cgttcggggc atgctggggc aagtccctga ctctctgtga cctgccccgc ccagctgcac 1380
ctgccagcct ggcttctgga gcccttgggt tttttgtttg tttgtttgtt tgtttgtttg 1440
tttctccccc tgggctctgc cccagctctg gcttccagaa aaccccagca tccttttctg 1500
cagaggggct ttctggagag gagggatgct gcctgagtca cccatgaaga caggacagtg 1560
cttcagcctg aggctgagac tgcgggatgg tcctggggct ctgtgcaggg aggaggtggc 1620
agccctgtag ggaacggggt ccttcaagtt agctcaggag gcttggaaag catcacctca 1680
ggccaggtgc agtggctcac gcctatgatc ccagcacttt gggaggctga ggcgggtgga 1740
tcacctgagg ttaggagttc gagaccagcc tggccaacat ggtaaaaccc catctctact 1800
aaaaatacag aaattagccg ggcgtggtgg cgggcaccta tagtcccagc tactcagaag 1860
cctgaggctg ggaaatcgtt tgaacccggg aagcggaggt tgcagggagc cgagatcacg 1920
ccactgcact cgagactggc gacagaatc 1949

<210> 72
<211> 1322
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511077CB1

<400> 72
ccggcgccgg gcgcccgata ccgggagccg ccgccatggg ggcctgcctg ggagcctgct 60
ccctgctcag ctgcgcgtcc tgcctctgcg gctctgcccc ctgcatcctg tgcagctgct 120
gccccgccag ccgcaactcc accgtgagcc gcctcatctt cacgttcttc ctcttcctgg 180
gggtgctggt gtccatcatt atgctgagcc cgggcgtgga gagtcagctc tacaagctgc 240
cctgggtgtg tgaggagggg gccgggatcc ccaccgtcct gcagggccac atcgactgtg 300
gctccctgct tggctaccgc gctgtctacc gcatgtgctt cgccacggcg gccttcttct 360
tcttttcac cctgctcatg ctctgcgtga gcagcagccg ggacccccgg gctgccatcc 420
agaatgggtt ttggttcttt aagttcctga tcctggtggg cctcaccgtg ggtgccttct 480
acatccctga cggctccttc accaacatct ggttctactt cggcgtcgtg ggctccttcc 540
tcttcatcct catccagctg gtgctgctca ttgactttgc gcactcctgg aaccagcggt 600
ggctgggcaa ggccgaggag tgcgattccc gtgcctggta cgcaggcctc ttcttcttca 660
ctctcctctt ctacttgctg tcgatcgcgg ccgtggcgct gatgttcatg tactacactg 720
agcccagcgg ctgccacgag ggcaaggtct tcatcagcct caacctcacc ttctgtgtct 780
gcgtgtccat cgctgctgtc ctgcccaagg tccagtctgc gctcctcaga ccaccggcag 840
gtgaacagcc tgatgcagac cgaggagtgc ccacctatgc tagacgccac acagcagcag 900
cagcagcagg tggcagcctg tgagggccgg gcctttgaca acgagcagga cggcgtcacc 960
tacagctact ccttcttcca cttctgcctg gtgctggcct cactgcacgt catgatgacg 1020
ctcaccaact ggtacaagcc cggtgagacc cggaagatga tcagcacgtg gaccgccgtg 1080
tgggtgaaga tctgtgccag ctgggcaggg ctgctcctct acctgtggac cctggtagcc 1140
ccactcctcc tgcgcaaccg cgacttcagc tgaggcagcc tcacagcctg ccatctggtg 1200
cctcctgcca cctggtgcct ctcggctcgg tgacagccac cctgcccccc tcctggactt 1260

cgtgccttac tgagtctcta agacttttc taataaacaa gccagtgcgt gtaacaaaaa 1320
aa 1322

<210> 73
<211> 1381
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511576CB1

<400> 73
atttcacaaa tctacaatct gtgagtatca catcctgtat agctgtaaac actggaataa 60
ggaagggctg atgactttca gaagatgaag gtaagtagaa accgttgatg ggactgagaa 120
accagagtta aaacctcttt ggagcttctg aggactcagc tggaaccaac gggcacagtt 180
ggcaacacca tcatgacatc acaacctgtt cccaatgaga ccatcatagt gctcccatca 240
aatgtcatca acttctccca agcagagaaa cccgaaccca ccaaccaggg gcaggatagc 300
ctgaagaaac atctacacgc agaaatcaaa gttattgggt ttatcatctc tggctctcta 360
tcaatcgcca cagagaaaag gttaaccaag cttttggtgc atagcagcct ggttggaagc 420
attctgagtg ctctgtctgc cctggtgggt ttcattatcc tgtctgtcaa acaggccacc 480
ttaaatcctg cctcactgca gtgtgagttg gacaaaaata atataccaac aagaagttat 540
gtttcttact tttatcatga ttcactttat accacggact gctatacagc caaagccagt 600
ctggctggaa ctctctctct gatgctgatt tgcactctgc tggaattctg cctagctgtg 660
ctcactgctg tgctgcggtg gaaacaggct tactctgact tccctgggag tgtacttttc 720
ctgcctcaca gttacattgg taattctggc atgtcctcaa aaatgactca tgactgtgga 780
tatgaagaac tattgacttc ttaagaaaaa agggagaaat attaatcaga aagttgattc 840
ttatgataat atggaaaagt taaccattat agaaaagcaa agcttgagtt tcctaaatgt 900
aagcttttaa agtaatgaac attaaaaaaa accattattt cactgtcatt taagatatgt 960
gttcattggg gatctcttga tttgcctgac attgacttca gcaaaagcac ggggctgtaa 1020
attaccattt actagattag ccaaatagtc tgaatttcca gaaaacaagg cagaatgatc 1080
attcccagaa acatttccca gaaaatgttt cccagaaaac tagacagaat gatcattcaa 1140
tggatcacag tgaagcaaag gacacaactt tttattgtac cccttaattg tcaacaggag 1200
ttaactgatt tgttgtggtg ctcagacttt tttatacagg tgctagtgtt ttatcctatg 1260
tattttaact cattagtgca taaaggcaag ccccatataa tgaagtctca gggtatatga 1320
aagtagctgg cttcaaaata aaatttttga gtgcaaaaaa aaaaaaaaaa aaaaaaaaaa 1380
g 1381

<210> 74
<211> 1027
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511492CB1

<400> 74
gaagattcca gcaccctccc ctaactccag gccagactcc tttcagctaa aggggagatc 60
tggatggcat ctacttcgta tgactattgc agagtgccca tggaagacgg ggataagcgc 120
tgtaagcttc tgctggggat aggaattctg gtgctcctga tcatcgtgat tctgggggtg 180
cccttgatta tcttcaccat caaggccaac agcgaggcct gccgggacgg ccttcgggca 240
gtgatggagt gtcgcaatgt cacccatctc ctgcaacaag agctgaccga ggcccagaag 300
ggctttcagg atgtggaggc ccaggccgcc acctgcaacc acactgtgaa gagaaaacca 360
ggtcttaagc gtgagaatcg cggacaagaa gtactacccc agctcccagg actccagctc 420
cgctgcggcg ccccagctgc tgattgtgct gctgggcctc agcgctctgc tgcagtgaga 480
tcccaggaag ctggcacatc ttggaaggtc cgtcctgctc ggcttttcgc ttgaacattc 540
ccttgatctc atcagttctg agcgggtcat ggggcaacac ggttagcggg gagagcacgg 600
ggtagccgga gaagggcctc tggagcaggt ctggaggggc catggggcag tcctgggtgt 660
ggggacacag tcgggttgac ccagggctgt ctccctccag agcctccctc cggacaagat 720
cccctctgtc ccaccgaaat ggcagggtgc ggtggggcag tccgctgtgt atggtctttt 780
gcgggggtg ctttcgggtc tgactcacaa aaacccccctt gagaaacacc taaaaaaaaa 840
aaaaaaacaa aaggggccaa aagccgaggg gccccccccga gaaaacaccc cccccagtgt 900

taaacccggg gaccgaaacc ccgcggggag ggcccccaaa aagcccggga caaatggtct 960
tgctcccccc ccgccgaagg ccggatagaa aaccagagac aatcctgtta acacccgccg 1020
ccccccc 1027

<210> 75
<211> 3040
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511141CB1

<400> 75
gccgcaggtc gggtggctca gccatggctc ctcggggcgc agcggccggc cggagcccgg 60
gaccctgcgc ggggcgctga gctcccgagc gggcagaggg cacgggcagg cggacgtcgg 120
ggcgccctcg gggaacgtgc gggcaccatg cgtccccacc tgtcgccgcc gctgcagcag 180
ctactactgc cggtgctgct cgcctgcgcc gcgcactcga ctggagccct tccccgacta 240
tgtgacgtgc tacaagtgct gtgggaagag caagaccagt gcctgcagga actctccaga 300
gagcagacag gagacctggg cacggagcag ccagtgccag gttgtgaggg gatgtgggac 360
aacataagct gctggccctc ttctgtgccg ggccggatgg tggaggtgga atgcccgaga 420
ttcctccgga tgctcaccag cagaaatggt tccttgttcc gaaactgcac acaggatggc 480
tggtcagaaa ccttccccag gcctaatctg gcctgtggcg ttaatgtgaa cgactcttcc 540
aacgagaagc gggaggctcc actgcactcg caactacatc cacatgcacc tgttcgtgtc 600
cttcatcctt cgtgccctgt ccaacttcat caaggacgcc gtgctcttct cctcagatga 660
tgtcacctac tgcgatgccc acagggcggg ctgcaagctg gtcatggtgc tgttccagta 720
ctgcatcatg gccaactact cctggctgct ggtggaaggc ctctaccttc acacactcct 780
cgccatctcc ttcttctctg aaagaaagta cctccaggga tttgtggcat tcggatgggg 840
ttctccagcc atttttgttg ctttgtgggc tattgccaga cactttctgg aagatgttgg 900
gtaagctaac ggaaggagga taacaagaat gtatctgaca tcgtccagct tttcaaacag 960
catagttact tctttggagc tatctaggaa aggccttttt ctcaaagtag aggccacaga 1020
tgagttccct ggactgatgc tcactgcttc ccaggtgtgt ttccaggtgg gccgagcagc 1080
cttggccatg cctgcactgt cctggccttc ctgtcttctt gctgcctgtc cgctctgcat 1140
gtgggtcaga tgccagacaa gagctacggg gctccaggca ggtgttgctc catggaagaa 1200
actcaaggaa gggccagtcc agcttttttct tcctcctggg atctccctcc tggatgcctc 1260
tctacccctg ggtgtttagg agccctgcag agccagactc taaagaagtc aggcattgag 1320
ggtggcagtg agcccagggg acgcacctgg gagtaggtac atgggaagca agcttaaaag 1380
aagctgggga agaggagagg cagcagggca gcagcgaggc agcggggcag catgggagtt 1440
gatttctcag gggcataatg acacaaccag gccaataagt ggatgaggtc aaatgagaca 1500
tccaagtgtc tatagtccaa atttagcccg aaataattgc ttcaaagtaa tttttgtatt 1560
gggtgaattc acttttttcaa aaaatctgga ttttcagctt gtctagaaaa aaatggagag 1620
gtcctttaac acgttccatt tttccttgtg gcaaaaataa gctggagcag agctgcggct 1680
gtcttggaca gggcacatgc tccccagttt gctcagtacc ctccaggcct gatgtcccca 1740
gatcctgagg tcacatgtca gccatccacc acttctctta ctgatgtcat cttcctggct 1800
tctgttggta gctgagtttg ccaccgtgct cgctggtgaa ttctgacagt aagctaactt 1860
ttggatctgg gagtctcccg gctctcaggt tctcgcaggg agacaggtgg ccactccctc 1920
agccccagca gtgctcctgg gtggcaggag ggggtgttct aatggtgctg ggcacaccac 1980
tgcaggggct cagtgccaca aacacaggtc cttcatacca agggccacct cagggaacat 2040
gtccttgctg gttagcccag ctcccacagc tcccgctcat aaccatgccc agctgtccct 2100
cccttaggtg ctgggacatc aatgccaacg catccatctg gtggatcatt cgtggtcctg 2160
tgatcctctc catcctgatt aatttcatcc ttttcataaa cattctaaga atcctgatga 2220
gaaaacttag aacccaagaa acaagaggaa atgaagtcag ccattataag cgcctggcca 2280
ggtccactct cctgctgatc cccctctttg gcatccacta catcgtcttc gccttctccc 2340
cagaggacgc tatggagatc cagctgtttt ttgaactagc ccttggctca ttccagggac 2400
tggtggtggc cgtcctctac tgcttcctca acggggaggt gcagctggag gttcagaaga 2460
agtggcagca atggcacctc cgtgagttcc cactgcaccc cgtggcctcc ttcagcaaca 2520
gcaccaaggc cagccacttg gagcagagcc agggcacctg caggaccagc atcatctgag 2580
aggctggagc agggtcaccc atggacagag accaagagag gtcctgcgaa ggctgggcac 2640
tgctgtggga cagccagtct tcccagcaga caccctgtgt cctccttcag ctgaagatgc 2700
ccctccccag gccttggact cttccgaagg gatgtgaggc actgtggggc aggacaaggg 2760
cctgggattg gttcgttgct cttctgggaa gagaagttca ggggtcccat aaagggaccg 2820
cgaccttact atggtgcctg gatgagaaaa atgcgtgtaa gaaaagacac aaggaaatac 2880
ctgggctgca gggaagactc cgataattcc aaagataata tggcttacac taccgaacta 2940

cgagtgggta gacccgtata ccaaattact gcctagtagt gaggtcgata taagatctgc 3000
aacctgcgtg ttattacgcc gtcgacacct gggagcggcc 3040

<210> 76
<211> 3158
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7511300CB1

<400> 76
agcctgtgga gacgggacag ccctgtccca ctcactcttt cccctgccgc tcctgccggc 60
agctccaacc atgggaggcc gcgtctttct cgcattctgt gtctggctga ctctgccggg 120
agctgaaacc caggactcca ggggctgtgc ccggtggtgc cctcagaact cctcgtgtgt 180
caatgccacc gcctgtcgct gcaatccagg gttcagctct ttttctgaga tcatcaccac 240
cccgacggag acttgtgacg acatcaacga gtgtgcaaca ccgtcgaaag tgtcatgcgg 300
aaaattctcg gactgctgga acacagaggg gagctacgac tgcgtgtgca gcccgggata 360
tgagcctgtt tctggggcaa aaacattcaa gaatgagagc gagaacacct gtcaagatgt 420
ggacgaatgt cagcagaacc caaggctctg taaaagctac ggcacctgcg tcaacaccct 480
tggcagctat acctgccagt gcctgcctgg cttcaagttc atacctgagg atccgaaggt 540
ctgcacagat gtgaatgaat gcacctccgg acaaaaaccg tgccacagct ccacccactg 600
cctcaacaac gtgggcagct atcagtgccg ctgccgcccg ggctggcaac cgattccggg 660
gtcccccaat ggcccaaaca ataccgtctg tgaagatgtg gacgagtgca gctccgggca 720
gcatcagtgt gacagctcca ccgtctgctt caacaccgtg ggttcataca gctgccgctg 780
ccgcccaggc tggaagccca gacacggaat cccgaataac caaaaggaca ctgtctgtga 840
agatatgact ttctccacct ggaccccgcc ccctggagtc cacagccaga cgctttcccg 900
attcttcgac aaagtccagg acctgggcag agactccaag acaagctcag ccgaggtcac 960
catccagaat gtcatcaaat tggtggatga actgatggaa gctcctggag acgtagaggc 1020
cctggcgcca cctgtccggc acctcatagc cacccagctg ctctcaaacc ttgaagatat 1080
catgaggatc ctggccaaga gcctgcctaa aggccccttc acctacattt ccccttcgaa 1140
cacagagctg accctgatga tccaggagcg gggggacaag aacgtcacta tgggtcagag 1200
cagcgcacgc atgaagctga attgggctgt ggcagctgga gccgaggatc caggccccgc 1260
cgtggcgggc atcctctcca tccagaacat gacgacattg ctggccaatg cctccttgaa 1320
cctgcattcc aagaagcaag ccgaactgga ggagatatat gaaagcagca tccgtggtgt 1380
ccaactcaga cgcctctctg ccgtcaactc catctttctg agccacaaca acaccaagga 1440
actcaactcc cccatccttt tcgccttctc ccaccttgag tcctccgatg gggaggcggg 1500
aagagaccct cctgccaagg acgtgatgcc tgggccacgg caggagctgc tctgtgcctt 1560
ctggaagagt gacagcgaca ggggagggca ctgggccacc gagggctgcc aggtgctggg 1620
cagcaagaac ggcagcacca cctgccaatg cagccacctg agcagctttg cgatccttat 1680
ggctcattat gacgtggagg actggaagct gaccctgatc accagggtgg gactggcgct 1740
gtcactcttc tgcctgctgc tgtgcatcct cactttcctg ctggtgcggc ccatccaggg 1800
ctcgcgcacc accatacacc tgcacctctg catctgcctc ttcgtgggct ccaccatctt 1860
cctggccggc atcgagaacg aaggcggcca ggtggggctg cgctgccgcc tggtggccgg 1920
gctgctgcac tactgtttcc tggccgcctt ctgctggatg agcctcgaag gcctggagct 1980
ctactttctt gtggtgcgcg tgttccaagg ccagggcctg agtacgcgct ggctctgcct 2040
gatcggctat ggcgtgcccc tgctcatcgt gggcgtctcg gctgccatct acagcaaggg 2100
ctacggccgc cccagatact gctggttgga ctttgagcag ggcttcctct ggagcttctt 2160
gggacctgtg accttcatca ttttgtgcaa tgctgtcatt ttcgtgacta ccgtctggaa 2220
gctcactcag aagttttctg aaatcaatcc agacatgaag aaattaaaga aggcgagggc 2280
gctgaccatc acggccatcg cgcagctctt cctgttgggc tgcacctggg tctttggcct 2340
gttcatcttc gacgatcgga gcttggtgct gacctatgtg tttaccatcc tcaactgcct 2400
gcagggcgcc ttcctctacc tgctgcactg cctgctcaac aagaaggccc tcagggcatc 2460
agagtccggc atatgaaggc gcatggttct ggacggccca gcagctcctg tggccacagc 2520
agctttgtac acgaagacca tccatcctcc cttcgtccac cactctactc cctccaccct 2580
ccctccctga tcccgtgtgc caccaggagg gagtggcagc tatagtctgg caccaaagtc 2640
caggacaccc agtggggtgg agtcggagcc actggtcctg ctgctggctg cctctctgct 2700
ccaccttgtg acccagggtg gggacagggg ctggcccagg gctgcaatgc agcatgttgc 2760
cctggcacct gtggccagta ctcgggacag actaagggcg cttgtcccat cctggacttt 2820
tcctctcatg tctttgctgc agaactgaag agactaggcg ctggggctca gcttccctct 2880
taagctaaga ctgatgtcag aggccccatg gcgaggcccc ttggggccac tgcctgaggc 2940
tcacggtaca gaggcctgcc ctgcctggcc gggcaggagg ttctcactgt tgtgaaggtt 3000

gtagacgttg tgtaatgtgt ttttatctgt taaaattttt cagtgttgac acttaaaatt 3060
aaacacatgc atacagaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3120
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 3158